e8vk
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 18, 2010
MannKind Corporation
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-50865
|
|
13-3607736 |
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.) |
|
|
|
28903 North Avenue Paine
Valencia, California
(Address of principal executive offices)
|
|
91355
(Zip Code) |
Registrants telephone number, including area code: (661) 775-5300
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions (see General Instruction A.2.
below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
TABLE OF CONTENTS
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance
Sheet Arrangement of a Registrant.
The information contained in Item 8.01 below regarding the Notes and the Indenture (each as
defined below) is incorporated by reference herein.
Item 3.02 Unregistered Sales of Equity Securities.
The information contained in Item 8.01 below regarding the sale of the Notes (as defined
below) is incorporated by reference herein.
Item 8.01 Other Events.
Senior Convertible Note Offering
On August 18, 2010, we entered into a purchase agreement (the Purchase Agreement) with
Merrill Lynch, Pierce, Fenner & Smith Incorporated (Merrill Lynch), acting as representative of
the several initial purchasers named therein, relating to the sale by us of $100 million aggregate
principal amount of 5.75% Senior Convertible Notes due 2015 (the Notes). Pursuant to the Purchase
Agreement, we granted the initial purchasers an option to purchase up to an additional $10 million
aggregate principal amount of the Notes solely to cover over-allotments, if any. The foregoing
description of the Purchase Agreement is qualified in its entirety by reference to the Purchase
Agreement, which is attached hereto as Exhibit 99.1.
We offered and sold the Notes to the initial purchasers in reliance on the exemption from
registration provided by Section 4(2) of the Securities Act of 1933, as amended (the Securities
Act). The Notes were offered and sold by the initial purchasers to qualified institutional buyers
pursuant to Rule 144A under the Securities Act. None of the Notes (including any shares of common
stock issuable upon conversion thereof) has been registered under the Securities Act or under any
state securities laws and, unless so registered, may not be offered or sold in the United States or
to U.S. persons except pursuant to an exemption from, or in a transaction not subject to, the
registration requirements of the Securities Act and applicable state securities laws.
The net proceeds to us from the sale of the Notes were approximately $95.5 million (which does
not include any additional proceeds we may receive if the initial purchasers exercise their
overallotment option), after deducting the discount to the initial purchasers of
$3.3 million and the estimated offering expenses payable by us. We
intend to use the net proceeds from the sale of the Notes to fund the costs of our clinical trials
programs and other research and development activities, to expand our manufacturing operations,
both on-going and planned, and for general corporate purposes, including working capital.
The Notes were issued under an indenture (the Indenture) entered into between us and Wells
Fargo Bank, National Association, as trustee. The Notes will be our general, unsecured, senior
obligations and will rank equally in right of payment with our other unsecured senior debt. The
Notes bear interest at the rate of 5.75% per year on the principal amount, payable semiannually in
arrears in cash on February 15 and August 15 of each year, beginning February 15, 2011. The Notes
will mature on August 15, 2015.
The Notes are convertible, at the option of the holder, at any time on or prior to the close
of business on the business day immediately preceding the stated maturity date, into shares of our
common stock at a conversion rate of 147.0859 shares per $1,000 principal amount of Notes, which is
equal to a conversion price of approximately $6.80 per share. The conversion rate is subject to
adjustment under certain circumstances described in the Indenture.
If certain fundamental changes occur, we will be obligated to pay a fundamental change
make-whole premium on any Notes converted in connection with such fundamental change by increasing
the conversion rate on such Notes. In such instances, the amount of the fundamental change
make-whole premium will be based on our common stock price and the effective date of the applicable
fundamental change.
If we undergo certain fundamental changes, except in certain circumstances, each holder of
Notes will have the option to require us to repurchase all or any portion of that holders Notes.
The fundamental change repurchase price will be 100% of the principal amount of the Notes to be
repurchased plus accrued and unpaid interest, if any.
We may elect to redeem some or all of the Notes but only if the closing price of our common
stock has equaled or exceeded 150% of the conversion price for at least 20 of the 30 consecutive
trading days ending on the trading day before our redemption notice. The redemption price will
equal 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest,
if any, to, but excluding, the redemption date, plus a make-whole payment equal to the sum of the
present values of the remaining scheduled payments of interest on the Notes to be redeemed through
and including August 15, 2015 (other than the interest accrued up to, but excluding, the redemption
date).
In addition, we will be obligated to make the make-whole payment on all Notes called for
redemption and converted during the period from the date we mailed the notice of redemption to and
including the redemption date. We may elect to pay such make-whole payment to converting holders in
cash or shares of our common stock, subject to certain limitations.
The foregoing description of the Notes and the Indenture is qualified in its entirety by
reference to the Indenture and form of Note, which are attached hereto as Exhibits 4.1 and 4.2,
respectively.
Share Lending Agreement and Common Stock Offering
In connection with the offering of the Notes, on August 18, 2010, we entered into a share
lending agreement (the Share Lending Agreement) with Bank of America, N.A. (the Share
Borrower), an affiliate of Merrill Lynch, pursuant to which we lent 9,000,000 shares of our common
stock (the Borrowed Shares) to the Share Borrower. The Share Borrower is obligated to return the
borrowed shares (or identical shares or, in certain circumstances, the cash value thereof) to us on
or about the 45th business day following the date as of which the entire principal
amount of the Notes ceases to be outstanding, subject to extension or acceleration in certain
circumstances or early termination at the Share Borrowers option.
Also on August 18, 2010,
we entered into an underwriting agreement (the Underwriting
Agreement) with Merrill Lynch and the Share Borrower. Pursuant to the Underwriting Agreement, the Borrowed Shares were
offered and sold to the public at a fixed price of $5.55 per share. We did not receive any
proceeds from the sale of the Borrowed Shares to the public, but received a nominal lending fee of
$90,000 pursuant to the Share Lending Agreement for the use by the Share Borrower of the Borrowed
Shares. The Share Borrower or its affiliate received all of the net proceeds from the sale of Borrowed Shares to the
public.
The foregoing description of the Share Lending Agreement and the Underwriting Agreement is
qualified in its entirety by reference to the Share Lending Agreement and the Underwriting
Agreement, which are attached hereto as Exhibits 99.2 and 1.1, respectively.
A copy of the opinion of Cooley LLP relating to the legality of the issuance of the Borrowed
Shares is attached hereto as Exhibit 5.1.
Letter Agreement with The Mann Group LLC
On August 18, 2010, we entered into a letter agreement confirming a previous commitment by The
Mann Group LLC to not require us to prepay amounts outstanding under the Amended and Restated
Promissory Note made by us in favor of The Mann Group LLC, dated August 10, 2010, if the prepayment
would require us to use our
working capital resources, including the proceeds from the sale of the Notes. The foregoing
description of the letter agreement is qualified in its entirety by reference to the letter
agreement, which is attached hereto as Exhibit 99.3.
Updated Company Disclosure
We are filing certain information for the purpose of updating the risk factors and description
of capital stock contained in our other filings with the Securities and Exchange Commission. A
copy of this additional disclosure is attached as Exhibit 99.4 to this Current Report and incorporated
herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
1.1 |
|
Underwriting Agreement by and among MannKind Corporation,
Merrill Lynch, Pierce, Fenner & Smith Incorporated and Bank of
America, N.A, dated August 18,
2010. |
|
4.1 |
|
Indenture related to the 5.75% Senior Convertible Notes due 2015,
dated as of August 24, 2010, by and between MannKind Corporation and Wells
Fargo Bank, National Association, as trustee. |
|
4.2 |
|
Form of 5.75% Senior Convertible Note due 2015. |
|
5.1 |
|
Opinion of Cooley LLP. |
|
23.1 |
|
Consent of Cooley LLP (included in Exhibit 5.1). |
|
99.1 |
|
Purchase Agreement by and between MannKind Corporation and Merrill
Lynch, Pierce, Fenner & Smith Incorporated, as representative
for the initial purchasers named therein, dated August 18, 2010. |
|
99.2 |
|
Share Lending Agreement by and between MannKind Corporation and Bank
of America, N.A., dated August 18, 2010. |
|
99.3 |
|
Letter Agreement dated August 18, 2010, related to Amended and
Restated Promissory Note made by MannKind Corporation in favor of The
Mann Group LLC, dated August 10, 2010. |
|
99.4 |
|
Company Disclosure. |
Forward Looking Statements
This Current Report, including the exhibits hereto, contains forward-looking statements,
including statements related to the future conversion of, redemption or payments under the Notes,
our expected use of proceeds from the Note offering, the future return of the Borrowed Shares to
us, the development and commercialization of our lead product candidate, AFREZZA, and our
other product candidates, our ability to achieve and sustain profitability, the insufficiency of
our existing capital resources to complete the commercialization of AFREZZA or the development of
any of our other product candidates, the future depletion of our capital resources and our ability
to raise additional funds, including from our arrangement with Seaside 88, LP, future competition,
our ability to enter into a strategic collaboration with respect to AFREZZA or to achieve our
objectives with respect to such a collaboration, the future performance of our suppliers, our
ability to manufacture AFREZZA or any other product candidates in commercial quantities, future
market acceptance of AFREZZA and our other product candidates, government and third party
reimbursement policies with respect to AFREZZA and our other product candidates, the potential for
future product liability claims, the potential loss of any or our key employees or scientific
advisors, the ability of our chief executive officer to devote sufficient time and attention to our
business, regulatory approval process with respect to AFREZZA and our other product candidates, our
ability to protect our proprietary rights and potential conflicts with the proprietary rights of
others, the volatility of the market price of our common stock, the control exercised by our chief
executive officer through his ownership of our common stock, and our ability to conduct future
financings, that involve risks and uncertainties. Words such as anticipates, intends, plans,
proposes, expects, will, and similar expressions are intended to identify forward-looking
statements. These forward-looking statements are based upon our current expectations. Actual
results and the timing of events could differ materially from those anticipated in such
forward-looking statements as a result of these risks and uncertainties, which include, without
limitation, risks related to market and other general economic conditions, the fact that our
management will have broad discretion in the use of the proceeds from the sale of the Notes, the
ability of the Share Borrower to return the Borrowed Shares when required to do so under the Share
Lending Agreement, the progress, timing and results of clinical trials, difficulties or delays in
seeking or obtaining regulatory approval, the manufacture of AFREZZA, competition from other
pharmaceutical or
biotechnology companies, our ability to enter into any collaborations or strategic partnerships,
intellectual property matters and stock price volatility. The foregoing list sets forth some, but
not all, of the factors that could affect our ability to achieve results described in any
forward-looking statements. For additional information about risks and uncertainties we face and a
discussion of our financial statements and footnotes, see the risk factors set forth in Exhibit
99.4 as well as the documents we file with the Securities and Exchange Commission from time to
time. You are cautioned not to place undue reliance on these forward-looking statements, which
speak only as of the date of this Current Report. All forward-looking statements are qualified in
their entirety by this cautionary statement, and we undertake no obligation and expressly disclaim
any duty to revise or update any forward-looking statements to reflect events or circumstances
after the date of this Current Report.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
MANNKIND CORPORATION
|
|
|
By: |
/s/ David Thomson
|
|
|
|
Name: |
David Thomson, Ph.D., J.D. |
|
|
|
Title: |
Corporate Vice President, General Counsel
and Secretary |
|
|
Dated: August 24, 2010
exv1w1
EXHIBIT 1.1
EXECUTION VERSION
MANNKIND CORPORATION
(A Delaware corporation)
9,000,000 Shares of Common Stock
UNDERWRITING AGREEMENT
Dated: August 18, 2010
MANNKIND CORPORATION
(A Delaware corporation)
9,000,000 Shares of Common Stock
UNDERWRITING AGREEMENT
August 18, 2010
Merrill Lynch, Pierce, Fenner & Smith
|
|
|
Incorporated, as Underwriter and as agent for Bank of America, N.A. |
One Bryant Park
New York, New York 10036
Ladies and Gentlemen:
MannKind Corporation, a Delaware corporation (the Company), subject to the terms and
conditions stated herein and pursuant to the Share Lending Agreement (the Share Lending
Agreement), dated August 18, 2010, between the Company and Bank of America, N.A. (the Borrower),
proposes to issue and lend to the Borrower, an affiliate of Merrill Lynch, Pierce, Fenner & Smith
Incorporated (Merrill Lynch), as a share loan pursuant to and upon the terms of the Share Lending
Agreement, 9,000,000 shares of Common Stock, par value $0.01 per share, of the Company (Common
Stock). The aforesaid shares of Common Stock are herein called, collectively, the Securities.
The Borrower will transfer, or delegate the right to receive (in accordance with the Share Lending
Agreement), the borrowed Securities to Merrill Lynch, which will sell the borrowed Securities to
the public as an underwriter (the Underwriter).
The Company understands that the Underwriter proposes to make a public offering of the
Securities as soon as the Underwriter deems advisable after this Agreement has been executed and
delivered.
Concurrently with the issuance of the Securities, the Company is offering (the Notes
Offering) $100,000,000 in aggregate principal amount of its 5.75% Senior Convertible Notes due
2015 (the Notes). Merrill Lynch is acting as representative of the several initial purchasers in
the Notes Offering. The Company has granted the initial purchasers in the Notes Offering an option
to purchase up to an additional $10,000,000 in aggregate principal amount of its Notes to cover
over-allotments, if any.
The Company has filed with the Securities and Exchange Commission (the Commission) a shelf
registration statement on Form S-3 (File No. 333-166404) covering the public offering and sale of
certain securities, including the Securities, under the Securities Act of 1933, as amended (the
1933 Act), and the rules and regulations promulgated thereunder (the 1933 Act Regulations),
which shelf registration statement was declared effective by the Commission on May 11, 2010. Such
registration statement, as of any time, means such registration statement as amended by any
post-effective amendments thereto to such time, including the exhibits and any schedules thereto at
such time, the documents incorporated or deemed to be incorporated by reference therein at such
time pursuant to Item
12 of Form S-3 under the 1933 Act and the documents otherwise deemed to be a part thereof as
of such time pursuant to Rule 430B under the 1933 Act Regulations (Rule 430B), is referred to
herein as the Registration Statement; provided, however, that the Registration Statement
without reference to a time means such registration statement as amended by any post-effective
amendments thereto as of the time of the first contract of sale for the Securities, which time
shall be considered the new effective date of such registration statement with respect to the
Securities within the meaning of paragraph (f)(2) of Rule 430B, including the exhibits and
schedules thereto as of such time, the documents incorporated or deemed incorporated by reference
therein at such time pursuant to Item 12 of Form S-3 under the 1933 Act and the documents otherwise
deemed to be a part thereof as of such time pursuant to the Rule 430B. Any registration statement
filed pursuant to Rule 462(b) of the 1933 Act Regulations to register a portion of the Securities
is herein referred to as the Rule 462(b) Registration Statement, and after such filing, the term
Registration Statement shall include the Rule 462(b) Registration Statement. Each preliminary
prospectus used in connection with the offering of the Securities, including the documents
incorporated or deemed to be incorporated by reference therein pursuant to Item 12 of Form S-3
under the 1933 Act, are collectively referred to herein as a preliminary prospectus. Promptly
after execution and delivery of this Agreement, the Company will prepare and file a final
prospectus relating to the Securities in accordance with the provisions of Rule 424(b) under the
1933 Act Regulations (Rule 424(b)). The final prospectus, in the form first furnished or made
available to the Underwriter for use in connection with the offering of the Securities, including
the documents incorporated or deemed to be incorporated by reference therein pursuant to Item 12 of
Form S-3 under the 1933 Act, are collectively referred to herein as the Prospectus. For purposes
of this Agreement, all references to the Registration Statement, any preliminary prospectus, the
Prospectus or any amendment or supplement to any of the foregoing shall be deemed to include the
copy filed with the Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval
system (EDGAR) or its Interactive Data Electronic Applications system (IDEA).
As used in this Agreement:
Applicable Time means 7:00 P.M., New York City time, on August 18, 2010 or such other
time as agreed by the Company and Merrill Lynch.
General Disclosure Package means any Issuer General Use Free Writing Prospectuses
issued at or prior to the Applicable Time and the prospectus (including any documents
incorporated therein by reference) that is included in the Registration Statement as of the
Applicable Time, all considered together.
Issuer Free Writing Prospectus means any issuer free writing prospectus, as defined
in Rule 433 of the 1933 Act Regulations (Rule 433), including without limitation any free
writing prospectus (as defined in Rule 405 of the 1933 Act Regulations (Rule 405))
relating to the Securities that is (i) required to be filed with the Commission by the
Company, (ii) a road show that is a written communication within the meaning of Rule
433(d)(8)(i), whether or not required to be filed with the Commission, or (iii) exempt from
filing with the Commission pursuant to Rule 433(d)(5)(i) because it contains a description
of the Securities or of the offering that does not reflect the final terms, in each case in
the form filed or required to be filed with the Commission or, if not required to be filed,
in the form retained in the Companys records pursuant to Rule 433(g).
Issuer General Use Free Writing Prospectus means any Issuer Free Writing Prospectus
that is intended for general distribution to prospective investors (other than a bona fide
electronic road show, as defined in Rule 433), as evidenced by its being specified in
Schedule A hereto.
2
Issuer Limited Use Free Writing Prospectus means any Issuer Free Writing Prospectus
that is not an Issuer General Use Free Writing Prospectus.
All references in this Agreement to financial statements and schedules and other information
which is contained, included or stated (or other references of like import) in the
Registration Statement, any preliminary prospectus or the Prospectus shall be deemed to include all
such financial statements and schedules and other information incorporated or deemed incorporated
by reference in the Registration Statement, any preliminary prospectus or the Prospectus, as the
case may be, prior to the Applicable Time; and all references in this Agreement to amendments or
supplements to the Registration Statement, any preliminary prospectus or the Prospectus shall be
deemed to include the filing of any document under the Securities Exchange Act of 1934, as amended,
and the rules and regulations promulgated thereunder (collectively, the 1934 Act), incorporated
or deemed to be incorporated by reference in the Registration Statement, the Preliminary Prospectus
or the Prospectus, as the case may be, at or after the Applicable Time.
SECTION 1. Representations and Warranties.
(a) Representations and Warranties by the Company. The Company represents and warrants to
each of the Underwriter and the Borrower as of the date hereof, the Applicable Time and the Closing
Time (as defined below), and agrees with each of the Underwriter and the Borrower, as follows:
(i) Registration Statement and Prospectuses. The Company meets the
requirements for use of Form S-3 under the 1933 Act. The Registration Statement has become
effective under the 1933 Act. No stop order suspending the effectiveness of the
Registration Statement has been issued under the 1933 Act, no order preventing or suspending
the use of any preliminary prospectus or the Prospectus has been issued and no proceedings
for any of those purposes have been instituted or are pending or, to the Companys
knowledge, contemplated. The Company has complied with each request (if any) from the
Commission for additional information.
Each of the Registration Statement and any post-effective amendment thereto, at the
time of its effectiveness and at each deemed effective date with respect to the Underwriter
pursuant to Rule 430B(f)(2) under the 1933 Act Regulations, complied in all material
respects with the requirements of the 1933 Act and the 1933 Act Regulations. Each
preliminary prospectus (including the prospectus filed as part of the Registration Statement
as originally filed or as part of any amendment thereto), at the time it was filed, complied
in all material respects with the 1933 Act Regulations and each preliminary prospectus and
the Prospectus delivered to the Underwriter and the Borrower for use in connection with this
offering was identical to the electronically transmitted copies thereof filed with the
Commission pursuant to EDGAR or IDEA, except to the extent permitted by Regulation S-T and
with respect to the 424(b) legend included in the filed version.
The documents incorporated or deemed to be incorporated by reference in the
Registration Statement and the Prospectus, when they became effective or at the time they
were or hereafter are filed with the Commission, complied and will comply in all material
respects with the requirements of the 1934 Act and the rules and regulations of the
Commission under the 1934 Act (the 1934 Act Regulations).
(ii) Accurate Disclosure. Neither the Registration Statement nor any amendment
thereto, at its effective time, at the Closing Time, contained, contains or will contain an
untrue statement of a material fact or omitted, omits or will omit to state a material fact
required to be stated therein or necessary to make the statements therein not misleading.
As of the Applicable
3
Time, neither (A) the General Disclosure Package nor (B) any individual Issuer Limited
Use Free Writing Prospectus, when considered together with the General Disclosure Package,
included an untrue statement of a material fact or omitted to state a material fact
necessary in order to make the statements therein, in the light of the circumstances under
which they were made, not misleading. Neither the Prospectus nor any amendment or
supplement thereto (including any prospectus wrapper), as of its issue date, at the time of
any filing with the Commission pursuant to Rule 424(b), at the Closing Time, included,
includes or will include an untrue statement of a material fact or omitted, omits or will
omit to state a material fact necessary in order to make the statements therein, in the
light of the circumstances under which they were made, not misleading. The documents
incorporated or deemed to be incorporated by reference in the Registration Statement, the
General Disclosure Package and the Prospectus, at the time the Registration Statement became
effective or when such documents incorporated by reference were filed with the Commission,
as the case may be, when read together with the other information in the Registration
Statement, the General Disclosure Package or the Prospectus, as the case may be, did not and
will not contain an untrue statement of a material fact or omit to state a material fact
necessary in order to make the statements therein, in the light of the circumstances under
which they were made, not misleading.
The representations and warranties in this subsection shall not apply to statements in
or omissions from the Registration Statement (or any amendment thereto), the General
Disclosure Package or the Prospectus (or any amendment or supplement thereto) made in
reliance upon and in conformity with written information furnished to the Company by any
Underwriter through Merrill Lynch expressly for use therein. For purposes of this
Agreement, the only information so furnished shall be the information in the first, second,
third, fourth and fifth sentences of the second paragraph under the caption Underwriting
in the Prospectus (collectively, the Underwriter Information).
(iii) Issuer Free Writing Prospectuses. No Issuer Free Writing Prospectus
conflicts or will conflict with the information contained in the Registration Statement or
the Prospectus, including any document incorporated by reference therein, and any
preliminary or other prospectus deemed to be a part thereof that has not been superseded or
modified. Any offer that is a written communication relating to the Securities made prior
to the initial filing of the Registration Statement by the Company or any person acting on
its behalf (within the meaning, for this paragraph only, of Rule 163(c) of the 1933 Act
Regulations) has been filed with the Commission in accordance with the exemption provided by
Rule 163 under the 1933 Act Regulations (Rule 163) and otherwise complied with the
requirements of Rule 163, including without limitation the legending requirement, to qualify
such offer for the exemption from Section 5(c) of the 1933 Act provided by Rule 163.
If at any time following issuance of an Issuer Free Writing Prospectus through the
Closing Time there occurred or occurs an event or development as a result of which such
Issuer Free Writing Prospectus conflicted or would conflict with the information contained
in the Prospectus that has not been superseded or modified, or included in the General
Disclosure Package or included or would include an untrue statement of a material fact or
omitted or would omit to state a material fact required to be stated therein or necessary in
order to make the statements therein, in the light of the circumstances prevailing at the
subsequent time, not misleading, the Company has promptly notified or will promptly notify
the Underwriter and the Borrower and has promptly amended or supplemented or will promptly
amend or supplement, at its own expense, such Issuer Free Writing Prospectus to eliminate or
correct such conflict, untrue statement or omission.
4
(iv) Incorporation of Documents by Reference. The documents incorporated by
reference in the Registration Statement, the General Disclosure Package and the Prospectus,
at the time they became effective or were filed with the Commission, as the case may be,
complied in all material respects with the requirements of the 1933 Act or the 1934 Act, as
applicable, and the rules and regulations of the Commission thereunder (the 1934 Act
Regulations), and none of such documents contained an untrue statement of a material fact
or omitted to state a material fact required to be stated therein or necessary in order to
make the statements therein, in the light of the circumstances under which they were made,
not misleading, and any further documents so filed and incorporated by reference in the
Registration Statement, the General Disclosure Package and the Prospectus, when such
documents become effective or are filed with the Commission, as the case may be, will
conform in all material respects to the requirements of the 1933 Act, the 1933 Act
Regulations, the 1934 Act, the 1934 Act Regulations, as applicable, and will not contain an
untrue statement of a material fact or omit to state a material fact required to be stated
therein or necessary to make the statements therein, in light of the circumstances under
which they are made, not misleading.
(v) Company Not Ineligible Issuer. At the time of filing the Registration
Statement and any post-effective amendment thereto, at the earliest time thereafter that the
Company or another offering participant made a bona fide offer (within the meaning of Rule
164(h)(2) of the 1933 Act Regulations) of the Securities and at the date hereof, the Company
was not and is not an ineligible issuer, as defined in Rule 405, without taking account of
any determination by the Commission pursuant to Rule 405 that it is not necessary that the
Company be considered an ineligible issuer.
(vi) Independent Accountants. Deloitte & Touche LLP is and, during the periods
covered by its reports, was an independent public accounting firm as required by the 1933
Act, the 1933 Act Regulations and the Public Accounting Oversight Board. Except as described
in the Registration Statement, the General Disclosure Package and the Prospectus and as
pre-approved in accordance with the requirements set forth in Section 10A of the 1934 Act,
Deloitte & Touche LLP has not been engaged by the Company to perform any prohibited
activities (as defined in Section 10A of the 1934 Act).
(vii) Financial Statements. The financial statements of the Company (including
all notes and schedules thereto) included or incorporated by reference in the Registration
Statement, the General Disclosure Package and the Prospectus present fairly, in all material
respects, the financial position of the Company and its consolidated subsidiaries at the
dates indicated and the statement of operations, stockholders equity and cash flows of the
Company and its consolidated subsidiaries for the periods specified; and such financial
statements and related schedules and notes thereto, and the unaudited financial information
included or incorporated by reference in the Registration Statement, the General Disclosure
Package and the Prospectus, have been prepared in conformity with generally accepted
accounting principles, consistently applied throughout the periods involved (provided that
non-year-end financial statements are subject to normal recurring year-end audit adjustments
that are not expected to be material in the aggregate and do not contain all footnotes
required by generally accepted accounting principles). The summary and selected financial
data included in the Registration Statement, the General Disclosure Package and the
Prospectus, if any, present fairly, in all material respects, the information shown therein
as at the respective dates and for the respective periods specified and have been presented
on a basis consistent with the consolidated financial statements set forth in the Prospectus
and other financial information.
5
(viii) Good Standing of the Company. The Company and each of its subsidiaries
is duly organized, validly existing and in good standing under the laws of their respective
jurisdictions of incorporation or organization and each such entity has all requisite power
and authority to carry on its business as is currently being conducted as described in the
General Disclosure Package and the Prospectus, and to own, lease and operate its properties.
The Company and each of its subsidiaries is duly qualified to do business and is in good
standing as a foreign corporation in each jurisdiction in which the nature of the business
conducted by it or location of the assets or properties owned, leased or licensed by it
requires such qualification, except for such jurisdictions where the failure to so qualify
or be in good standing, individually or in the aggregate, would not reasonably be expected
to have a material adverse effect on the assets, properties, condition, financial or
otherwise, or in the results of operations, business affairs or business prospects of the
Company and its subsidiaries considered as a whole (a Material Adverse Effect), and to the
Companys knowledge, no proceeding has been instituted in any such jurisdiction revoking,
limiting or curtailing, or seeking to revoke, limit or curtail, such power and authority or
qualification. The Company has no subsidiary other than its five wholly owned subsidiaries,
MannKind LLC, MannKind Limited, Technosphere International C.V., MannKind Netherlands B.V.
and MannKind Deutchland GmbH, and does not control, directly or indirectly, any other
corporation, partnership, joint venture, association or other business organization. Such
subsidiaries, when considered in the aggregate as a single subsidiary, do not constitute a
significant subsidiary of the Company (as such term is defined in Rule 1-02(w) of
Regulation S-X under the Securities Act) and are not otherwise material to the assets and
operations of the Company. All outstanding shares of capital stock of each of the Companys
subsidiaries have been duly authorized and validly issued, and are fully paid and
nonassessable and are owned directly by the Company or by another wholly owned subsidiary of
the Company free and clear of any security interests, liens, encumbrances, equities or
claims, other than those described in the General Disclosure Package and the Prospectus.
(ix) Capitalization. The authorized, issued and outstanding shares of capital
stock of the Company are as set forth in the General Disclosure Package and the Prospectus
in the column entitled Actual under the caption Capitalization (except for subsequent
issuances, if any, pursuant to this Agreement, the Share Lending Agreement, the purchase
agreement with The Mann Group LLC and the purchase agreement with Seaside 88, LP, pursuant
to reservations, agreements or employee benefit plans referred to in the General Disclosure
Package and the Prospectus or pursuant to the vesting, conversion or exercise of convertible
securities or options referred to in the General Disclosure Package and the Prospectus).
All of the issued and outstanding shares of Common Stock have been duly and validly issued
and are fully paid and nonassessable. There are no statutory preemptive or other similar
rights to subscribe for or to purchase or acquire any shares of Common Stock of the Company
or any of its subsidiaries or any such rights pursuant to its Certificate of Incorporation
or by-laws or any agreement or instrument to or by which the Company or any of its
subsidiaries is a party or bound.
(x) Authorization of Agreement. This Agreement has been duly authorized,
executed and delivered by the Company.
(xi) Authorization of Securities. The Securities have been duly authorized by
the Company pursuant to this Agreement and the Share Lending Agreement and, when issued and
delivered by the Company pursuant to this Agreement and the Share Lending Agreement against
payment of the Loan Fee (as defined in the Share Lending Agreement), will be validly issued
and will be fully paid and non-assessable; no holder of the Securities will be subject to
personal liability solely by reason of being such a holder; and the issuance of the
Securities pursuant to this
6
Agreement and the Share Lending Agreement will not be subject to the preemptive or
other similar rights of any securityholder of the Company.
(xii) Authorization of the Share Lending Agreement. The Share Lending Agreement
has been duly authorized, executed and delivered by the Company and is a valid and binding
agreement of the Company, enforceable against the Company in accordance with its terms,
except as the enforcement thereof may be limited by bankruptcy, insolvency (including,
without limitation, all laws relating to fraudulent transfers), reorganization, moratorium
or similar laws affecting enforcement of creditors rights generally and except as
enforcement thereof is subject to general principles of equity (regardless of whether
enforcement is considered in a proceeding in equity or at law).
(xiii) Description of Securities. The Common Stock and the Share Lending
Agreement conform in all material respects to all statements in relation thereto contained
or incorporated by reference in the Registration Statement, the General Disclosure Package
and the Prospectus and such description conforms to the rights set forth in the instruments
defining the same.
(xiv) Lock-Up Agreements. Each director and executive officer of the Company
listed on Schedule B hereto has delivered to the Underwriter his or her executed written
lock-up agreement in the form attached to this Agreement as Exhibit D hereto or in such form
as may be approved in writing by the Underwriter.
(xv) Stock Options. The exercise price of each option to acquire Common Stock
(each, a Company Stock Option) is no less than the fair market value of a share of Common
Stock as determined on the date of grant of such Company Stock Option. All grants of Company
Stock Options were validly issued and properly approved by the Board of Directors of the
Company, a committee thereof or an individual with authority duly delegated by the Board of
Directors of the Company or a committee thereof, in material compliance with (i) all
applicable laws and (ii) the terms of the plans under which such Company Stock Options were
issued and were recorded on the Companys financial statements in accordance with generally
accepted accounting principles, and no such grants involved any back dating, forward
dating, spring loading or similar practices with respect to the effective date of grant.
(xvi) Absence of Violations, Defaults and Conflicts. Neither the Company nor
any subsidiary (i) is in violation of its certificate or articles of incorporation or
organization, by-laws, certificate of formation, limited liability company agreement,
partnership agreement or other organizational documents, (ii) is in default under, and no
event has occurred which, with notice or lapse of time, or both, would constitute a default
under, or result in the creation or imposition of any lien, charge, mortgage, pledge,
security interest, claim, limitation on voting rights, equity, trust or other encumbrance,
preferential arrangement, defect or restriction of any kind whatsoever, upon, any property
or assets of the Company or any subsidiary pursuant to, any bond, debenture, note,
indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which
it is a party or by which it is bound or to which any of its properties or assets is subject
or (iii) is in violation of any statute, law, rule, regulation, ordinance, directive,
judgment, decree or order of any judicial, regulatory or other legal or governmental agency
or body, foreign or domestic having jurisdiction over the Company (each, a Governmental
Entity), except (in the case of clauses (ii) and (iii) above) for violations or defaults
that would not (individually or in the aggregate) reasonably be expected to have a Material
Adverse Effect. Neither the execution, delivery and performance of this Agreement or the
Share Lending Agreement by the Company nor the consummation of any of the transactions
contemplated hereby or thereby and in the General Disclosure Package and the Prospectus
(including, without
7
limitation, the issuance and delivery by the Company of the Securities and the receipt
by the Company of the Loan Fee (as defined in the Share Lending Agreement) as described
therein under the caption Use of Proceeds) will give rise to a right to terminate or
accelerate the due date of any payment due under, or conflict with or result in the breach
of any term or provision of, or constitute a default (or an event which with notice or lapse
of time or both would constitute a default) under, or require any consent or waiver under,
or result in the execution or imposition of any lien, charge or encumbrance upon any
properties or assets of the Company or its subsidiaries pursuant to the terms of, any
indenture, mortgage, deed of trust or other agreement or instrument to which the Company or
any of its subsidiaries is a party or by which either the Company or its subsidiaries or any
of their properties or businesses is bound, or any franchise, license, permit, judgment,
decree, order, statute, rule or regulation applicable to the Company or any of its
subsidiaries, except where it would not reasonably be expected to have a Material Adverse
Effect, or violate any provision of the charter or by-laws of the Company or any of its
subsidiaries, except for such consents or waivers which have already been obtained and are
in full force and effect.
(xvii) Incorporated Documents. There are no contracts or documents which are
required to be described in the Registration Statement or to be filed as exhibits thereto
which have not been so described and filed as required. Each description of a contract,
document or other agreement in the Registration Statement, the General Disclosure Package or
the Prospectus accurately reflects in all respects the material terms of the underlying
contract, document or other agreement. Each contract, document or other agreement described
in the Registration Statement, the General Disclosure Package or the Prospectus or
incorporated by reference is in full force and effect and is valid and enforceable by and
against the Company or any of its subsidiaries, as the case may be, in accordance with its
terms, except as the enforceability thereof may be limited by bankruptcy, insolvency,
reorganization, moratorium or similar laws affecting the enforcement of creditors rights
generally and by general equitable principles. Neither the Company nor any of its
subsidiaries, if a subsidiary is a party, nor to the Companys knowledge, any other party is
in default in the observance or performance of any term or obligation to be performed by it
under any such agreement, and no event has occurred which with notice or lapse of time or
both would constitute such a default, in any such case which default or event, individually
or in the aggregate, would reasonably be expected to have a Material Adverse Effect. No
default exists, and no event has occurred which with notice or lapse of time or both would
constitute a default, in the due performance and observance of any term, covenant or
condition, by the Company or its subsidiary, if a subsidiary is a party thereto, of any
other agreement or instrument to which the Company or any of its subsidiaries is a party or
by which the Company or its properties or business or a subsidiary or its properties or
business may be bound or affected which default or event, individually or in the aggregate,
would reasonably be expected to have a Material Adverse Effect.
(xviii) Corporate Action. All necessary corporate action has been duly and
validly taken by the Company to authorize the execution, delivery and performance of this
Agreement and the Share Lending Agreement and the issuance and delivery of the Securities by
the Company.
(xix) Absence of Labor Dispute. Neither the Company nor any of its
subsidiaries is involved in any labor dispute nor, to the knowledge of the Company, is any
such dispute threatened, which dispute would reasonably be expected to have a Material
Adverse Effect. The Company is not aware of any existing or imminent labor disturbance by
the employees of any of its principal suppliers or contractors which would reasonably be
expected to have a Material Adverse Effect. The Company is not aware of any threatened or
pending litigation between the
8
Company or its subsidiaries and any of its executive officers which, if adversely
determined, would reasonably be expected to have a Material Adverse Effect.
(xx) Related Party Transactions. No transaction has occurred between or among
the Company and any of its officers or directors, shareholders or any affiliate or
affiliates of any such officer or director or shareholder that is required to be described
in and is not described in the Registration Statement, the General Disclosure Package and
the Prospectus.
(xxi) Absence of Proceedings. There are no legal or governmental proceedings
pending to which the Company or any of its subsidiaries is a party or of which any property
of the Company or any of its subsidiaries is the subject which, if determined adversely to
the Company or any of its subsidiaries could individually or in the aggregate have a
Material Adverse Effect; and, to the knowledge of the Company, no such proceedings are
threatened or contemplated by governmental authorities or threatened by others.
(xxii) Absence of Further Requirements. Each approval, consent, order,
authorization, designation, declaration or filing of, by or with any Governmental Entity
necessary in connection with the execution and delivery by the Company of this Agreement and
the Share Lending Agreement, the consummation of the transactions herein and therein
contemplated and the issuance and delivery of the Securities required to be obtained or
performed by the Company (except such additional steps as may be necessary to qualify the
Securities by the Underwriter under the state securities or Blue Sky laws) has been obtained
or made and is in full force and effect.
(xxiii) Possession of Licenses and Permits. Except as set forth in the General
Disclosure Package and the Prospectus, the Company and each of its subsidiaries has all
requisite corporate power and authority, and all necessary authorizations, approvals,
consents, orders, licenses, certificates and permits of and from all governmental or
regulatory bodies or any other person or entity (collectively, the Permits), to own, lease
and license its assets and properties and conduct its business, all of which are valid and
in full force and effect, except where the lack of such Permits, individually or in the
aggregate, would not reasonably be expected to have a Material Adverse Effect. The Company
and each of its subsidiaries has fulfilled and performed in all material respects all of its
obligations with respect to such Permits and no event has occurred that allows, or after
notice or lapse of time would allow, revocation or termination thereof or results in any
other material impairment of the rights of the Company or such subsidiary thereunder. Except
as may be required under the 1933 Act and state and foreign Blue Sky laws, no other Permits
are required to enter into, deliver and perform this Agreement or the Share Lending
Agreement and to issue, lend and sell the Securities.
(xxiv) Title to Property. The Company and each of its subsidiaries has good
and marketable title in fee simple to all real property owned by it, and good and marketable
title to all other property owned by it, in each case free and clear of all liens,
encumbrances, claims, security interests and defects, except as are described in the General
Disclosure Package and the Prospectus or such as do not materially affect the value of such
property and do not materially interfere with the use made of such property by the Company
and its subsidiaries. All property held under lease by the Company and its subsidiaries is
held by them under valid, existing and enforceable leases, free and clear of all liens,
encumbrances, claims, security interests and defects, except such as are not material and do
not materially interfere with the use made of such property by the Company and its
subsidiaries. Subsequent to the respective dates as of which information is given in the
Registration Statement, the Prospectus, (i) there has not been any event which would
reasonably be expected to have a Material Adverse Effect; (ii) neither the
9
Company nor any of its subsidiaries has sustained any loss or interference with its
assets, businesses or properties (whether owned or leased) from fire, explosion, earthquake,
flood or other calamity, whether or not covered by insurance, or from any labor dispute or
any court or legislative or other governmental action, order or decree which would
reasonably be expected to have a Material Adverse Effect; and (iii) since the date of the
latest balance sheet included or incorporated by reference in the Registration Statement and
the Prospectus, except as otherwise disclosed in the Registration Statement and the
Prospectus, neither the Company nor its subsidiaries has (A) issued any securities (other
than securities pursuant to the Companys equity incentive plans) or incurred any liability
or obligation, direct or contingent, for borrowed money, except such liabilities or
obligations incurred in the ordinary course of business, (B) entered into any transaction
not in the ordinary course of business or (C) declared or paid any dividend or made any
distribution on any shares of its stock or redeemed, purchased or otherwise acquired or
agreed to redeem, purchase or otherwise acquire any shares of its capital stock.
(xxv) Possession of Intellectual Property. Except as set forth in the General
Disclosure Package and the Prospectus, the Company and each of its subsidiaries owns or
possesses legally-enforceable rights (including license rights) to use all patents, patent
rights, inventions, trademarks, trademark applications, trade names, service marks,
copyrights, copyright applications, licenses, know-how and other similar rights and
proprietary knowledge (collectively, Intellectual Property) necessary for the conduct of
its business. Neither the Company nor any of its subsidiaries has received any written
notice of, or is aware of, any infringement of or conflict with asserted rights of others
with respect to any Intellectual Property, except as referenced in the General Disclosure
Package and the Prospectus or that would not reasonably be expected to have a Material
Adverse Effect.
(xxvi) Environmental Laws. (A) Each of the Company and each of its
subsidiaries is in compliance in all material respects with all rules, laws and regulation
relating to the use, treatment, storage and disposal of toxic substances and protection of
health or the environment (Environmental Laws) which are applicable to its business; (B)
neither the Company nor its subsidiaries has received any notice from any governmental
authority or third party of an asserted claim under Environmental Laws; (C) each of the
Company and each of its subsidiaries has received all permits, licenses or other approvals
required of it under applicable Environmental Laws to conduct its business and is in
compliance with all terms and conditions of any such permit, license or approval; (D) to the
Companys knowledge, no facts currently exist that will require the Company or any of its
subsidiaries to make future material capital expenditures to comply with Environmental Laws;
and (E) no property which is or has been owned, leased or occupied by the Company or its
subsidiaries has been designated as a Superfund site pursuant to the Comprehensive
Environmental Response, Compensation of Liability Act of 1980, as amended (42 U.S.C. Section
9601, et. seq.) (CERCLA), or otherwise designated as a contaminated site under applicable
state or local law. Neither the Company nor any of its subsidiaries has been named as a
potentially responsible party under the CERCLA 1980.
In the ordinary course of its business, the Company periodically reviews the effect of
Environmental Laws on the business, operations and properties of the Company and its
subsidiaries, in the course of which the Company identifies and evaluates associated costs
and liabilities (including, without limitation, any capital or operating expenditures
required for clean-up, closure of properties or compliance with Environmental Laws, or any
permit, license or approval, any related constraints on operating activities and any
potential liabilities to third parties). On the basis of such review, the Company has
reasonably concluded that such associated costs and liabilities would not, singly or in the
aggregate, have a Material Adverse Effect.
10
(xxvii) Accounting Controls. The books, records and accounts of the Company
and its subsidiaries accurately and fairly reflect, in all material respects, the
transactions in, and dispositions of, the assets of, and the results of operations of, the
Company and its subsidiaries. The Company and its subsidiaries maintain a system of internal
accounting controls sufficient to provide reasonable assurances that (A) transactions are
executed in accordance with managements general or specific authorizations, (B)
transactions are recorded as necessary to permit preparation of financial statements in
accordance with generally accepted accounting principles and to maintain asset
accountability, (C) access to assets is permitted only in accordance with managements
general or specific authorization and (D) the recorded accountability for assets is compared
with the existing assets at reasonable intervals and appropriate action is taken with
respect to any differences.
(xxviii) Disclosure Controls. The Company has established and maintains
disclosure controls and procedures (as such term is defined in Rule 13a-15 under the 1934
Act), which: (A) are designed to ensure that material information relating to the Company is
made known to the Companys principal executive officer and its principal financial officer
by others within the Company, particularly during the periods in which the periodic reports
required under the 1934 Act are required to be prepared; (B) provide for the periodic
evaluation of the effectiveness of such disclosure controls and procedures at the end of the
periods in which the periodic reports are required to be prepared; and (C) are effective in
all material respects to perform the functions for which they were established. Based on the
evaluation of its disclosure controls and procedures, the Company is not aware of (1) any
significant deficiency in the design or operation of internal controls which could adversely
affect the Companys ability to record, process, summarize and report financial data or any
material weaknesses in internal controls; or (2) any fraud, whether or not material, that
involves management or other employees who have a role in the Companys internal controls.
(xxix) Off-Balance Sheet Arrangements. Except as described in the General
Disclosure Package and the Prospectus, there are no material off-balance sheet arrangements
(as defined in Item 303 of Regulation S-K) that have or are reasonably likely to have a
material current or future effect on the Companys financial condition, revenues or
expenses, changes in financial condition, results of operations, liquidity, capital
expenditures or capital resources.
(xxx) Audit Committee. The Companys Board of Directors has validly appointed
an audit committee whose composition satisfies the requirements of Rule 5605(c)(2) of the
Listing Rules of NASDAQ (the NASDAQ Rules) and the Companys Board of Directors and/or the
audit committee has adopted a charter that satisfies the requirements of Rule 5605(c)(1) of
the NASDAQ Rules. The audit committee has reviewed the adequacy of its charter within the
past twelve months..
(xxxi) Compliance with the Sarbanes-Oxley Act. There is and has been no
failure on the part of the Company or any of its directors or officers, in their capacities
as such, to comply with any applicable provision of the Sarbanes-Oxley Act of 2002,
including, without limitation, Section 402 related to loans and Sections 302 and 906 related
to certifications.
(xxxii) Payment of Taxes. The Company and each of its subsidiaries has filed
all Federal, state, local and foreign tax returns which are required to be filed through the
date hereof, which returns are true and correct in all material respects or has received
timely extensions thereof, and has paid all taxes shown on such returns and all assessments
received by it to the extent that the same are material and have become due, except in each
case where such failure to file or pay would not reasonably be expected to have a Material
Adverse Effect. There are no tax
11
audits or investigations pending which, if adversely determined, would reasonably be
expected to have a Material Adverse Effect; nor to the Companys knowledge are there any
material proposed additional tax assessments against the Company or any of its subsidiaries.
(xxxiii) Insurance. The Company and its subsidiaries are insured by insurers
of recognized financial responsibility against such losses and risks and in such amounts as
are customary in the businesses in which they are engaged or propose to engage after giving
effect to the transactions described in the General Disclosure Package and the Prospectus;
all policies of insurance and fidelity or surety bonds insuring the Company or any of its
subsidiaries or the Companys or its subsidiaries respective businesses, assets, employees,
officers and directors are in full force and effect; the Company and each of its
subsidiaries are in compliance with the terms of such policies and instruments in all
material respects; and neither the Company nor any subsidiary of the Company has any reason
to believe that it will not be able to renew its existing insurance coverage as and when
such coverage expires or to obtain similar coverage from similar insurers as may be
necessary to continue its business at a cost that is not materially greater than the current
cost of such coverage. Neither the Company nor any of its subsidiaries has been denied any
insurance coverage which it has sought or for which it has applied.
(xxxiv) Investment Company Act. The Company is not and, after giving effect to
the issuance and sale of the Securities as contemplated by this Agreement and the Share
Lending Agreement, will not be an investment company within the meaning of the Investment
Company Act of 1940, as amended.
(xxxv) Absence of Manipulation. The Company has not taken, nor will it take,
directly or indirectly, any action designed to or which might reasonably be expected to
cause or result in, or which has constituted or which might reasonably be expected to
constitute, the stabilization or manipulation of the price of the Common Stock or any
security of the Company to facilitate the sale or resale of any of the Securities.
(xxxvi) Continued Registration of Common Stock. The Company has taken no action
designed to, or likely to have the effect of, terminating the registration of the Common
Stock under the 1934 Act or the listing of the Common Stock on the Nasdaq Global Market, nor
has the Company received any notification that the Commission or the Nasdaq Global Market is
contemplating terminating such registration or listing.
(xxxvii) Foreign Corrupt Practices Act. Neither the Company nor any other
person associated with or acting on behalf of the Company including, without limitation, any
director, officer, agent or employee of the Company or its subsidiaries, has, directly or
indirectly, while acting on behalf of the Company or its subsidiaries (i) used any corporate
funds for unlawful contributions, gifts, entertainment or other unlawful expenses relating
to political activity; (ii) made any unlawful payment to foreign or domestic government
officials or employees or to foreign or domestic political parties or campaigns from
corporate funds; (iii) violated any provision of the Foreign Corrupt Practices Act of 1977,
as amended; or (iv) made any other unlawful payment.
(xxxviii) Money Laundering Laws. The operations of the Company and its
subsidiaries are in compliance in all material respects with applicable financial
recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting
Act of 1970, as amended, the money laundering statutes of all required jurisdictions, the
rules and regulations thereunder and any related or similar rules, regulations or
guidelines, issued, administered or enforced by any governmental agency having jurisdiction
over the Company (collectively, the
12
Money Laundering Laws) and no action, suit or proceeding by or before any court or
governmental agency, authority or body or any arbitrator involving the Company or any of it
subsidiaries with respect to the Money Laundering Laws is pending, or to the best knowledge
of the Company, threatened.
(xxxix) OFAC. Neither the Company nor any of its subsidiaries nor, to the
knowledge of the Company, any director, officer, agent, employee or affiliate of the Company
or any of its subsidiaries is currently subject to any U.S. sanctions administered by the
Office of Foreign Assets Control of the U.S. Treasury Department (OFAC); and the Company
will not directly or indirectly use the Loan Fee, or lend, contribute or otherwise make
available such Loan Fee to any subsidiary, joint venture partner or other person or entity,
for the purpose of financing the activities of any person known by the Company to be
currently subject to any U.S. sanctions administered by OFAC.
(xl) ERISA. The Company has fulfilled its obligations, if any, under the
minimum funding standards of Section 302 of the U.S. Employee Retirement Income Security Act
of 1974 (ERISA) and the regulations and published interpretations thereunder with respect
to each plan as defined in Section 3(3) of ERISA and such regulations and published
interpretations in which its employees are eligible to participate and each such plan is in
compliance in all material respects with the presently applicable provisions of ERISA and
such regulations and published interpretations. No Reportable Event (as defined in Section
4043 of ERISA) has occurred with respect to any Pension Plan (as defined in ERISA) for
which the Company could have any material liability.
(xli) Clinical and Pre-Clinical Studies. The clinical, pre-clinical and other
studies and tests conducted by the Company or in which the Company or its products or
product candidates have participated, or that are described in the Registration Statement,
the General Disclosure Package and the Prospectus or the results of which are referred to in
the Registration Statement, the General Disclosure Package or the Prospectus, and such
studies and tests conducted on behalf of or sponsored by the Company or that the Company
intends to rely on in support of regulatory approval by the U.S. Food and Drug
Administration (the FDA) or foreign regulatory agencies, were and, if still pending, are,
to the Companys knowledge, being conducted in all material respects in accordance with
standard accepted medical and scientific research procedures and, to the Companys
knowledge, the protocols established by the Company for such studies and tests. The
descriptions in the Registration Statement, the General Disclosure Package and the
Prospectus of the results of such studies and tests are accurate and complete in all
material respects and fairly present the data derived from such studies and tests, and
except as set forth in the Registration Statement, the General Disclosure Package and the
Prospectus, the Company has no knowledge of any other studies or tests, the results of which
the Company believes reasonably call into question the results described or referred to in
the Registration Statement, the General Disclosure Package and the Prospectus when viewed in
the context in which such results are described. Except to the extent disclosed in the
Registration Statement, the General Disclosure Package and the Prospectus, the Company has
not received any written notices or other correspondence from the FDA or any other domestic
or foreign governmental agency requiring the termination, suspension or modification (other
than such modifications as are normal in the regulations, any such modification which are
material have been disclosed to you) of any clinical or pre-clinical studies or tests that
are described in the Registration Statement, the General Disclosure Package or the
Prospectus or the results of which are referred to in the Registration Statement, the
General Disclosure Package or the Prospectus.
13
(xlii) Lending Relationship. Except as disclosed in the General Disclosure
Package and the Prospectus, the Company (i) does not have any material lending or other
relationship with any bank or lending affiliate of the Underwriter and (ii) does not intend
to use any of the proceeds from the sale of the Securities to repay any outstanding debt
owed to any affiliate of the Underwriter.
(xliii) Statistical and Market-Related Data. The statistical and market
related data included in the Registration Statement, the General Disclosure Package or the
Prospectus are based on or derived from sources that the Company believes to be reliable and
accurate.
SECTION 2. Issuance, Offering and Delivery of the Securities; Closing.
(a) Securities. On the basis of the representations and warranties herein contained, and
subject to the terms and conditions set forth herein and in the Share Lending Agreement, the
Company agrees to issue to Merrill Lynch, as delagatee of the Borrower, in exchange for payment of
the Loan Fee, and Merrill Lynch agrees to sell the Securities, and the Underwriter agrees to
purchase such Securities from Merrill Lynch on the basis of the representations, warranties and
agreements herein contained, and upon the terms, subject to the conditions thereto, set forth
herein and in the Share Lending Agreement.
(b) Closing Time. In accordance with the Share Lending Agreement, delivery of the Securities
to Merrill Lynch, as delagatee of the Borrower, shall be made at the offices of Davis Polk &
Wardwell LLP (or such other place as shall be agreed upon by Merrill Lynch, as delagatee of the
Borrower, and the Company)(the Closing Location) and shall occur at the time specified by the
Borrower (or Merrill Lynch as its agent) in a Borrowing Notice and confirmed by the Company in
accordance with the Share Lending Agreement, which shall be on or prior to 9:00 A.M. (New York City
time) on the third (fourth, if the pricing occurs after 4:30 P.M. (New York City time) on any given
day) business day after the date hereof, or such other time not later than ten business days after
such date as shall be agreed upon by Merrill Lynch, as delagatee of the Borrower, and the Company
(such time and date of payment and delivery being herein called Closing Time).
(c) Public Offering of the Securities. The Underwriter hereby advises the Company that it
intends to offer for sale to the public, as described in the Prospectus, the Securities from time
to time.
(d) Payment of Loan Fee. Payment of the Loan Fee by Merrill Lynch, as delagatee of the
Borrower, shall be made at the Closing Time by wire transfer of immediately available funds
pursuant to the order of the Company. The Underwriter agrees to make any payment due to Merrill
Lynch in respect of the Securities in the manner agreed between the Underwriter and Merrill Lynch.
(e) Denominations; Registration. The Securities to be purchased by the Underwriter hereunder
will be represented by one or more definitive global shares in book-entry form which will be
deposited by or on behalf of the Company with the Depository Trust Company or its designated
custodian. The documents to be delivered at the Closing Time by or on behalf of the parties hereto,
including the cross receipt for the Securities and any additional documents requested by the
Underwriter, and the Securities will be delivered at the Closing Location, all at such Closing
Time. A meeting will be held at the Closing Location at approximately 3:00 P.M., California time,
on the business day preceding such Closing Time, at which meeting the final drafts of the documents
to be delivered pursuant to the preceding sentence will be available for review by the parties
hereto.
14
SECTION 3. Covenants of the Company. The Company covenants with each of the
Underwriter and the Borrower as follows:
(a) Compliance with Securities Regulations and Commission Requests. The Company, subject to
Section 3(b), will comply with the requirements of Rule 430B, and will notify the Underwriter and
the Borrower promptly, and confirm the notice in writing, (i) when any post-effective amendment to
the Registration Statement shall become effective or any amendment or supplement to the Prospectus
shall have been filed, (ii) of the receipt of any comments from the Commission, (iii) of any
request by the Commission for any amendment to the Registration Statement or any amendment or
supplement to the Prospectus, including any document incorporated by reference therein or for
additional information, (iv) of the issuance by the Commission of any stop order suspending the
effectiveness of the Registration Statement or any post-effective amendment or of any order
preventing or suspending the use of any preliminary prospectus or the Prospectus, or of the
suspension of the qualification of the Securities for offering or sale in any jurisdiction, or of
the initiation or threatening of any proceedings for any of such purposes or of any examination
pursuant to Section 8(e) of the 1933 Act concerning the Registration Statement and (v) if the
Company becomes the subject of a proceeding under Section 8A of the 1933 Act in connection with the
offering of the Securities. The Company will effect all filings required under Rule 424(b), in the
manner and within the time period required by Rule 424(b) (without reliance on Rule 424(b)(8)), and
will take such steps as it deems necessary to ascertain promptly whether the form of prospectus
transmitted for filing under Rule 424(b) was received for filing by the Commission and, in the
event that it was not, it will promptly file such prospectus. The Company will make every
reasonable effort to prevent the issuance of any stop order, prevention or suspension and, if any
such order is issued, to obtain the lifting thereof at the earliest possible moment.
(b) Continued Compliance with Securities Laws. The Company will comply with the 1933 Act, the
1933 Act Regulations, the 1934 Act and the 1934 Act Regulations so as to permit the completion of
the distribution of the Securities as contemplated in this Agreement and in the General Disclosure
Package and the Prospectus. If at any time when a prospectus relating to the Securities is (or,
but for the exception afforded by Rule 172 of the 1933 Act Regulations (Rule 172), would be)
required by the 1933 Act to be delivered in connection with sales of the Securities, any event
shall occur or condition shall exist as a result of which it is necessary, in the opinion of
counsel for the Underwriter and the Borrower or for the Company, to (i) amend the Registration
Statement in order that the Registration Statement will not include an untrue statement of a
material fact or omit to state a material fact required to be stated therein or necessary to make
the statements therein not misleading, (ii) amend or supplement the General Disclosure Package or
the Prospectus in order that the General Disclosure Package or the Prospectus, as the case may be,
will not include any untrue statement of a material fact or omit to state a material fact necessary
in order to make the statements therein not misleading in the light of the circumstances existing
at the time it is delivered to a purchaser or (iii) amend the Registration Statement or amend or
supplement the General Disclosure Package or the Prospectus, as the case may be, in order to comply
with the requirements of the 1933 Act or the 1933 Act Regulations, the Company will promptly (A)
give the Underwriter and the Borrower notice of such event, (B) prepare any amendment or supplement
as may be necessary to correct such statement or omission or to make the Registration Statement,
the General Disclosure Package or the Prospectus comply with such requirements and, a reasonable
amount of time prior to any proposed filing or use, furnish the Underwriter and the Borrower with
copies of any such amendment or supplement and (C) file with the Commission any such amendment or
supplement; provided that the Company shall not file or use any such amendment or supplement to
which the Underwriter, the Borrower or counsel for the Underwriter and the Borrower shall object.
The Company will furnish to the Underwriter and the Borrower such number of copies of such
amendment or supplement as the Underwriter and the Borrower may reasonably request. The Company
has given the Underwriter and the Borrower notice of any filings made pursuant to the 1934 Act or
1934 Act Regulations within 48 hours prior to the Applicable Time; the Company will give the
Underwriter
15
and the Borrower notice of its intention to make any such filing from the Applicable Time to
the Closing Time and will furnish the Underwriter and the Borrower with copies of any such
documents a reasonable amount of time prior to such proposed filing, as the case may be, and will
not file or use any such document to which the Underwriter, the Borrower or counsel for the
Underwriter and the Borrower shall reasonably object.
(c) Delivery of Registration Statements. The Company has furnished or will deliver to the
Underwriter, the Borrower and counsel for the Underwriter and the Borrower, upon request and
without charge, signed copies of the Registration Statement as originally filed and each amendment
thereto (including exhibits filed therewith or incorporated by reference therein and documents
incorporated or deemed to be incorporated by reference therein) and signed copies of all consents
and certificates of experts. The copies of the Registration Statement and each amendment thereto
furnished to the Underwriter and the Borrower will be identical to the electronically transmitted
copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by
Regulation S-T and with respect to the 424(b) legend included in the filed version.
(d) Delivery of Prospectuses. The Company has delivered to the Underwriter and the Borrower,
without charge, as many copies of each preliminary prospectus as the Underwriter and the Borrower
reasonably requested, and the Company hereby consents to the use of such copies for purposes
permitted by the 1933 Act. The Company will furnish to the Underwriter and the Borrower, without
charge, during the period when a prospectus relating to the Securities is (or, but for the
exception afforded by Rule 172, would be) required to be delivered under the 1933 Act, such number
of copies of the Prospectus (as amended or supplemented) as the Underwriter and the Borrower may
reasonably request. The Prospectus and any amendments or supplements thereto furnished to the
Underwriter and the Borrower will be identical to the electronically transmitted copies thereof
filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T and
with respect to the 424(b) legend included in the filed version.
(e) Blue Sky Qualifications. The Company will use its best efforts, in cooperation with the
Underwriter, to qualify the Securities for offering and lending under the applicable securities
laws of such states and other jurisdictions (domestic or foreign) as the Underwriter may designate
and to maintain such qualifications in effect so long as required to complete the distribution of
the Securities; provided, however, that the Company shall not be obligated to file any general
consent to service of process or to qualify as a foreign corporation or as a dealer in securities
in any jurisdiction in which it is not so qualified or to subject itself to taxation in respect of
doing business in any jurisdiction in which it is not otherwise so subject.
(f) Rule 158. The Company will timely file such reports pursuant to the 1934 Act as are
necessary in order to make generally available to its securityholders as soon as practicable, but
in any event not later than 45 days after the end of the 12-month period beginning at the end of
the fiscal quarter of the Company during which the most recent effective date of the Registration
Statement occurs (or 90 days after the end of such 12-month period if such 12-month period
coincides with the Companys fiscal year), an earnings statement (which need not be audited) for
the purposes of, and to provide to the Underwriter the benefits contemplated by, the last paragraph
of Section 11(a) of the 1933 Act.
(g) Use of Proceeds. The Company will not receive any proceeds from the sale of the
Securities, but will receive the Loan Fee, each as set described in the General Disclosure Package
and the Prospectus under the caption Use of Proceeds.
(h) Listing. The Company will use its commercially reasonable efforts to effect and maintain
the listing of the Securities on the Nasdaq Global Market.
16
(i) Restriction on Sale of Securities. During a period of 90 days from the date of the
Prospectus (the Lock-Up Period), the Company will not, without the prior written consent of the
Underwriter and the Borrower, (i) directly or indirectly, offer, pledge, sell, contract to sell,
sell any option or contract to purchase, purchase any option or contract to sell, grant any option,
right or warrant to purchase or otherwise transfer or dispose of any shares of Common Stock or any
securities convertible into or exercisable or exchangeable for Common Stock or file any
registration statement under the 1933 Act with respect to any of the foregoing or (ii) enter into
any swap or any other agreement or any transaction that transfers, in whole or in part, directly or
indirectly, the economic consequence of ownership of the Common Stock, whether any such swap or
transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or
such other securities, in cash or otherwise. The foregoing sentence shall not apply to (A) the
Securities to be sold hereunder, (B) the Notes and any shares of Common Stock issuable upon
conversion of the Notes, (C) up to an aggregate of 8,400,000 shares of Common Stock to be sold and
issued by the Company pursuant to the Common Stock Purchase Agreement by and between the Company
and Seaside 88, LP and the Common Stock Purchase Agreement by and between the Company and The Mann
Group LLC, each dated as of August 10, 2010, (D) any shares of Common Stock issued by the Company
upon the exercise of an option or warrant or the conversion of a security outstanding on the date
hereof and referred to in the General Disclosure Package and the Prospectus, (E) any shares of
Common Stock issued or options to purchase Common Stock granted pursuant to existing employee
benefit plans of the Company referred to in the General Disclosure Package and the Prospectus, (F)
any shares of Common Stock issued pursuant to any non-employee director stock plan or dividend
reinvestment plan referred to in the General Disclosure Package and the Prospectus or (G) any
shares of Common Stock issued to one or more counterparties in connection with the consummation of
a strategic partnership, joint venture, collaboration, merger or the acquisition or license of any
business products or technology complementary to the Companys business; provided that, with
respect to this subsection (G), (1) the sum of the aggregate number of Common Stock so issued shall
not exceed 10% of the total number of shares of Common Stock outstanding as of the date hereof and
(2) prior to the issuance of such Common Stock each recipient of such Common Stock shall have
executed and delivered to the Underwriter an agreement substantially in the form of Exhibit D
hereto.
(j) Reporting Requirements. The Company, during the period when a Prospectus relating to the
Securities is (or, but for the exception afforded by Rule 172, would be) required to be delivered
under the 1933 Act, will file all documents required to be filed with the Commission pursuant to
the 1934 Act within the time periods required by the 1934 Act and 1934 Act Regulations.
Additionally, the Company shall report the use of proceeds from the issuance of the Securities as
may be required under Rule 463 under the 1933 Act.
(k) Issuer Free Writing Prospectuses. The Company agrees that, unless it obtains the prior
written consent of the Underwriter and the Borrower, it will not make any offer relating to the
Securities that would constitute an Issuer Free Writing Prospectus or that would otherwise
constitute a free writing prospectus, or a portion thereof, required to be filed by the Company
with the Commission or retained by the Company under Rule 433; provided that the Underwriter and
the Borrower will be deemed to have consented to the Issuer Free Writing Prospectuses listed on
Schedule A hereto and any road show that is a written communication within the meaning of Rule
433(d)(8)(i) that has been reviewed by the Underwriter and the Borrower. The Company represents
that it has treated or agrees that it will treat each such free writing prospectus consented to, or
deemed consented to, by the Underwriter and the Borrower as an issuer free writing prospectus, as
defined in Rule 433, and that it has complied and will comply with the applicable requirements of
Rule 433 with respect thereto, including timely filing with the Commission where required,
legending and record keeping. If at any time following issuance of an Issuer Free Writing
Prospectus there occurred or occurs an event or development as a result of which such Issuer Free
Writing Prospectus conflicted or would conflict with the information contained in the Registration
Statement or included or would include an untrue statement of a material fact or omitted or would
omit to
17
state a material fact necessary in order to make the statements therein, in the light of the
circumstances existing at that subsequent time, not misleading, the Company will promptly notify
the Underwriter and the Borrower and will promptly amend or supplement, at its own expense, such
Issuer Free Writing Prospectus to eliminate or correct such conflict, untrue statement or omission.
SECTION 4. Payment of Expenses.
(a) Expenses. The Company will pay or cause to be paid all expenses incident to the
performance of their obligations under this Agreement, including (i) the preparation, printing and
filing of the Registration Statement (including financial statements and exhibits) as originally
filed and each amendment thereto, (ii) the preparation, printing and delivery to the Underwriter
and the Borrower of copies of each preliminary prospectus, each Issuer Free Writing Prospectus and
the Prospectus and any amendments or supplements thereto and any costs associated with electronic
delivery of any of the foregoing by the Underwriter to investors, (iii) the preparation, issuance
and delivery of the certificates for the Securities to the Underwriter and the Borrower (or Merrill
Lynch, as delagatee), including any stock or other transfer taxes and any stamp or other duties
payable upon the sale, issuance or delivery of the Securities to the Underwriter and the Borrower
(or Merrill Lynch, as delagatee), (iv) the fees and disbursements of the Companys counsel,
accountants and other advisors, (v) the qualification of the Securities under securities laws in
accordance with the provisions of Section 3(e) hereof, including filing fees and the reasonable
fees and disbursements of counsel for the Underwriter and the Borrower in connection therewith and
in connection with the preparation of the Blue Sky Survey and any supplement thereto, provided such
fees and disbursements do not exceed $10,000 in the aggregate, (vi) the fees and expenses of any
transfer agent or registrar for the Securities, (vii) the costs and expenses of the Company
relating to investor presentations on any road show undertaken in connection with the marketing
of the Securities, including without limitation, expenses associated with the production of road
show slides and graphics, fees and expenses of any consultants engaged in connection with the road
show presentations, travel and lodging expenses of the representatives and officers of the Company
and any such consultants, and the cost of aircraft and other transportation chartered in connection
with the road show, (viii) the fees and expenses incurred in connection with the listing of the
Securities on the Nasdaq Global Market and (ix) the costs and expenses (including, without
limitation, any damages or other amounts payable in connection with legal or contractual liability)
associated with the reforming of any contracts for sale of the Securities made by the Underwriter
caused by a breach of the representation contained in the third sentence of Section 1(a)(ii).
Subject to the provisions of Section 4(b) below, the Underwriter and the Borrower agree to pay,
whether or not the transactions contemplated hereby are consummated or this Agreement is
terminated, all costs and expenses incident to the performance of their respective obligations
under this Agreement not payable by the Company pursuant to the preceding sentence, including,
without limitation, the fees and disbursements of any counsel for the Underwriter or the Borrower.
This Section 4(a) shall not affect or modify any separate, valid agreement relating to the
allocation of payment of expenses between the Company, on the one hand, and the Borrower, on the
other hand.
(b) Termination of Agreement. If this Agreement is terminated by the Underwriter or the
Borrower in accordance with the provisions of Section 5(a)-(d), Section 5(f)-(o), Section 9(a)(i)
or Section 9(a)(iii) hereof, the Company shall reimburse the Underwriter and the Borrower for all
of their out-of-pocket expenses, including the reasonable fees and disbursements of counsel for the
Underwriter and the Borrower.
(c) Allocation of Expenses. The provisions of this Section shall not affect any agreement
that the Company may make for the sharing of such costs and expenses.
18
SECTION 5. Conditions of the Obligations of the Underwriter and the Borrower. The
obligations of the Underwriter and the other obligations of Merrill Lynch hereunder are subject to
the accuracy of the representations and warranties of the Company contained herein or in
certificates of any officer of the Company or any of its subsidiaries delivered pursuant to the
provisions hereof, to the performance by the Company of its respective covenants and other
obligations hereunder, and to the following further conditions:
(a) Effectiveness of Registration Statement. The Registration Statement shall have been
declared effective and at the Closing Time no stop order suspending the effectiveness of the
Registration Statement or any post-effective amendment thereto has been issued under the 1933 Act,
no order preventing or suspending the use of any preliminary prospectus or the Prospectus has been
issued and no proceedings for any of those purposes have been instituted or are pending or, to the
Companys knowledge, contemplated; and the Company has complied with each request (if any) from the
Commission for additional information.
(b) Opinion and Negative Assurance Letter of Counsel for Company. At the Closing Time, the
Underwriter and the Borrower shall have received an opinion and negative assurance letter, each
dated the Closing Time, of Cooley LLP, counsel for the Company, substantially in the forms attached
as Exhibit A-1 and A-2 hereto, respectively.
(c) Opinion of Intellectual Property Counsel for Company. At the Closing Time, the
Underwriter and the Borrower shall have received an opinion, dated the Closing Time, of K&L Gates
LLP, intellectual property counsel for the Company, substantially in the form attached as Exhibit B
hereto.
(d) Certificate of the General Counsel of the Company. At the Closing Time, the Underwriter
and the Borrower shall have received a certificate, addressed to each of them, of the General
Counsel of the Company, dated the Closing Time, substantially in the form attached as Exhibit C
hereto.
(e) Opinion of Counsel for the Underwriter and the Borrower. At the Closing Time, the
Underwriter and the Borrower shall have received the favorable opinion, dated the Closing Time, of
Davis Polk & Wardwell LLP, counsel for the Underwriter and the Borrower, together with signed or
reproduced copies of such letter for each of the Underwriter and the Borrower in form and substance
satisfactory to the Underwriter and the Borrower. In giving such opinion such counsel may rely, as
to all matters governed by the laws of jurisdictions other than the law of the State of New York,
the General Corporation Law of the State of Delaware and the federal securities laws of the United
States, upon the opinions of counsel satisfactory to the Underwriter and the Borrower. Such
counsel may also state that, insofar as such opinion involves factual matters, they have relied, to
the extent they deem proper, upon certificates of officers and other representatives of the Company
and its subsidiaries and certificates of public officials.
(f) Officers Certificate. At the Closing Time, there shall not have been, since the date
hereof or since the respective dates as of which information is given in the General Disclosure
Package or the Prospectus, any material adverse change in the condition, financial or otherwise, or
in the earnings, business affairs or business prospects of the Company and its subsidiaries
considered as one enterprise, whether or not arising in the ordinary course of business, and the
Underwriter and the Borrower shall have received a certificate of the Chief Executive Officer or
the President of the Company and of the chief financial or chief accounting officer of the Company,
dated the Closing Time, to the effect that (i) there has been no such material adverse change,
(ii) the representations and warranties of the Company in this Agreement are true and correct with
the same force and effect as though expressly made at and as of the Closing Time, (iii) the Company
has complied with all agreements and satisfied all conditions on its
19
part to be performed or satisfied at or prior to the Closing Time, and (iv) no stop order
suspending the effectiveness of the Registration Statement under the 1933 Act has been issued, no
order preventing or suspending the use of any preliminary prospectus or the Prospectus has been
issued and no proceedings for any of those purposes have been instituted or are pending or, to
their knowledge, contemplated.
(g) Accountants Comfort Letter. At the time of the execution of this Agreement, the
Underwriter and the Borrower shall have received from Deloitte & Touche LLP a letter, dated such
date, in form and substance satisfactory to the Underwriter and the Borrower, together with signed
or reproduced copies of such letter for each of the Underwriter and the Borrower containing
statements and information of the type ordinarily included in accountants comfort letters to
underwriters with respect to the financial statements and certain financial information contained
in the Registration Statement, the General Disclosure Package and the Prospectus.
(h) Bring-down Comfort Letter. At the Closing Time, the Underwriter and the Borrower shall
have received from Deloitte & Touche LLP a letter, dated as of the Closing Time, to the effect that
they reaffirm the statements made in the letter furnished pursuant to subsection (g) of this
Section, except that the specified date referred to shall be a date not more than three business
days prior to the Closing Time.
(i) Nasdaq Listing. At the Closing Time, (1) a listing application for the Securities shall
have been submitted to NASDAQ and (2) NASDAQ shall not have rejected such application.
(j) Lock-up Agreements. At the date of this Agreement, the Underwriter shall have received an
agreement substantially in the form of Exhibit D hereto signed by the persons listed on Schedule B
hereto.
(k) Maintenance of Rating. Since the execution of this Agreement, there shall not have been
any decrease in or withdrawal of the rating of any securities of the Company or any of its
subsidiaries by any nationally recognized statistical rating organization (as defined for
purposes of Rule 436(g) under the 1933 Act) or any notice given of any intended or potential
decrease in or withdrawal of any such rating or of a possible change in any such rating that does
not indicate the direction of the possible change.
(l) Additional Documents. At the Closing Time, counsel for the Underwriter and the Borrower
shall have been furnished with such documents and opinions as they may reasonably require for the
purpose of enabling them to pass upon the issuance and sale of the Securities as herein
contemplated, or in order to evidence the accuracy of any of the representations or warranties, or
the fulfillment of any of the conditions, herein contained; and all proceedings taken by the
Company in connection with the issuance and sale of the Securities as herein contemplated shall be
satisfactory in form and substance to the Underwriter and the Borrower and counsel for the
Underwriter and the Borrower.
(m) Notes Offering. The Notes Offering, substantially on the terms described in the
Prospectus, shall have been consummated at the Closing Time.
(n) Delivery of Securities. The Share Lending Agreement shall have become effective and the
Company shall have delivered the Securities to Merrill Lynch, as delagatee of the Borrower, in
accordance therewith.
(o) Accounting. As of the Closing Time, the Company intends to account for the transaction
contemplated by the Share Loan Agreement as a single transaction under EITF 09-01, not representing
20
the repurchase of shares of Common Stock or another equivalent transaction but rather, consistent
with the intent of the parties, representing a loan of the Securities by the Company to the
Borrower.
(p) Termination of Agreement. If any condition specified in this Section shall not have been
fulfilled when and as required to be fulfilled, this Agreement may be terminated by the Underwriter
and the Borrower by notice to the Company at any time at or prior to Closing Time, and such
termination shall be without liability of any party to any other party except as provided in
Section 4 and except that Sections 1, 6, 7, 8, 13 and 14 shall survive any such termination and
remain in full force and effect.
SECTION 6. Indemnification.
(a) Indemnification of Underwriter and the Borrower. The Company agrees to indemnify and hold
harmless each of the Underwriter and the Borrower, their respective affiliates (as such term is
defined in Rule 501(b) under the 1933 Act (each, an Affiliate)), their respective selling agents
and each person, if any, who controls the Underwriter or the Borrower within the meaning of Section
15 of the 1933 Act or Section 20 of the 1934 Act as follows:
(i) against any and all loss, liability, claim, damage and expense whatsoever, as
incurred, arising out of any untrue statement or alleged untrue statement of a material fact
contained in the Registration Statement (or any amendment thereto), including any
information deemed to be a part thereof pursuant to Rule 430B, or the omission or alleged
omission therefrom of a material fact required to be stated therein or necessary to make the
statements therein not misleading or arising out of any untrue statement or alleged untrue
statement of a material fact included (A) in any preliminary prospectus, any Issuer Free
Writing Prospectus or the Prospectus (or any amendment or supplement thereto) or (B) in any
materials or information provided to investors by, or with the approval of, the Company in
connection with the marketing of the offering of the Stock (Marketing Materials),
including any roadshow or investor presentations made to investors by the Company (whether
in person or electronically), or the omission or alleged omission in any preliminary
prospectus, Issuer Free Writing Prospectus, Prospectus or in any Marketing Materials of a
material fact necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading;
(ii) against any and all loss, liability, claim, damage and expense whatsoever, as
incurred, to the extent of the aggregate amount paid in settlement of any litigation, or any
investigation or proceeding by any governmental agency or body, commenced or threatened, or
of any claim whatsoever based upon any such untrue statement or omission, or any such
alleged untrue statement or omission; provided that (subject to Section 6(d) below) any such
settlement is effected with the written consent of the Company;
(iii) against any and all expense whatsoever, as incurred (including the fees and
disbursements of counsel chosen by the Underwriter and the Borrower), reasonably incurred in
investigating, preparing or defending against any litigation, or any investigation or
proceeding by any governmental agency or body, commenced or threatened, or any claim
whatsoever based upon any such untrue statement or omission, or any such alleged untrue
statement or omission, to the extent that any such expense is not paid under (i) or (ii)
above;
provided, however, that this indemnity agreement shall not apply to any loss, liability, claim,
damage or expense to the extent arising out of any untrue statement or omission or alleged untrue
statement or omission made in the Registration Statement (or any amendment thereto), including any
information
deemed to be a part thereof pursuant to Rule 430B, the General Disclosure Package or the Prospectus
(or
21
any amendment or supplement thereto) in reliance upon and in conformity with the Underwriter
Information.
(b) Indemnification of Company, Directors and Officers. The Underwriter agrees to indemnify
and hold harmless the Company, its directors, each of its officers who signed the Registration
Statement, and each person, if any, who controls the Company within the meaning of Section 15 of
the 1933 Act or Section 20 of the 1934 Act, against any and all loss, liability, claim, damage and
expense described in the indemnity contained in subsection (a) of this Section, as incurred, but
only with respect to untrue statements or omissions, or alleged untrue statements or omissions,
made in the Registration Statement (or any amendment thereto), including any information deemed to
be a part thereof pursuant to Rule 430B, the General Disclosure Package or the Prospectus (or any
amendment or supplement thereto) in reliance upon and in conformity with the Underwriter
Information.
(c) Actions against Parties; Notification. Each indemnified party shall give notice as
promptly as reasonably practicable to each indemnifying party of any action commenced against it in
respect of which indemnity may be sought hereunder, but failure to so notify an indemnifying party
shall not relieve such indemnifying party from any liability hereunder to the extent it is not
materially prejudiced as a result thereof and in any event shall not relieve it from any liability
which it may have otherwise than on account of this indemnity agreement. In the case of parties
indemnified pursuant to Section 6(a) above, counsel to the indemnified parties shall be selected by
the Underwriter and the Borrower, and, in the case of parties indemnified pursuant to Section 6(b)
above, counsel to the indemnified parties shall be selected by the Company. An indemnifying party
may participate at its own expense in the defense of any such action; provided, however, that
counsel to the indemnifying party shall not (except with the consent of the indemnified party) also
be counsel to the indemnified party. In no event shall the indemnifying parties be liable for fees
and expenses of more than one counsel (in addition to any local counsel) separate from their own
counsel for all indemnified parties in connection with any one action or separate but similar or
related actions in the same jurisdiction arising out of the same general allegations or
circumstances. No indemnifying party shall, without the prior written consent of the indemnified
parties, settle or compromise or consent to the entry of any judgment with respect to any
litigation, or any investigation or proceeding by any governmental agency or body, commenced or
threatened, or any claim whatsoever in respect of which indemnification or contribution could be
sought under this Section 6 or Section 7 hereof (whether or not the indemnified parties are actual
or potential parties thereto), unless such settlement, compromise or consent (i) includes an
unconditional release of each indemnified party from all liability arising out of such litigation,
investigation, proceeding or claim and (ii) does not include a statement as to or an admission of
fault, culpability or a failure to act by or on behalf of any indemnified party.
(d) Settlement without Consent if Failure to Reimburse. If at any time an indemnified party
shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses
of counsel, such indemnifying party agrees that it shall be liable for any settlement of the nature
contemplated by Section 6(a)(ii) effected without its written consent if (i) such settlement is
entered into more than 45 days after receipt by such indemnifying party of the aforesaid request,
(ii) such indemnifying party shall have received notice of the terms of such settlement at least 30
days prior to such settlement being entered into and (iii) such indemnifying party shall not have
reimbursed such indemnified party in accordance with such request prior to the date of such
settlement.
SECTION 7. Contribution. If the indemnification provided for in Section 6 hereof is
for any reason unavailable to or insufficient to hold harmless an indemnified party in respect of
any losses, liabilities, claims, damages or expenses referred to therein, then each indemnifying
party shall contribute to the aggregate amount of such losses, liabilities, claims, damages and
expenses incurred by such
indemnified party, as incurred, (i) in such proportion as is appropriate to reflect the
relative benefits
22
received by the Company, the Underwriter and the Borrower from the offering of
the Securities pursuant to this Agreement or (ii) if the allocation provided by clause (i) is not
permitted by applicable law, in such proportion as is appropriate to reflect not only the relative
benefits referred to in clause (i) above but also the relative fault of the Company, the
Underwriter and the Borrower in connection with the statements or omissions which resulted in such
losses, liabilities, claims, damages or expenses, as well as any other relevant equitable
considerations.
The relative benefits received by the Company, on the one hand, and the Underwriter, on the
other hand, in connection with the offering of the Securities pursuant to this Agreement shall be
deemed to be in the same respective proportions as the total net proceeds of the Notes in the Notes
Offering (before deducting expenses) received by the Company, on the one hand, and the total
discount received by the Underwriter in the Notes Offering, on the other hand, bear to the
aggregate initial offering price of the Notes as set forth on the cover of the Final Offering
Memorandum.
The relative fault of any party shall be determined by reference to, among other things,
whether any such untrue or alleged untrue statement of a material fact or omission or alleged
omission to state a material fact relates to information supplied by such party and the parties
relative intent, knowledge, access to information and opportunity to correct or prevent such
statement or omission.
The Company, the Underwriter and the Borrower agree that it would not be just and equitable if
contribution pursuant to this Section 7 were determined by pro rata allocation (even if the
Underwriter and the Borrower were treated as one entity for such purpose) or by any other method of
allocation which does not take account of the equitable considerations referred to above in this
Section 7. The aggregate amount of losses, liabilities, claims, damages and expenses incurred by
an indemnified party and referred to above in this Section 7 shall be deemed to include any legal
or other expenses reasonably incurred by such indemnified party in investigating, preparing or
defending against any litigation, or any investigation or proceeding by any governmental agency or
body, commenced or threatened, or any claim whatsoever based upon any such untrue or alleged untrue
statement or omission or alleged omission.
Notwithstanding the provisions of this Section 7, the Underwriter shall not be required to
contribute any amount in excess of the purchase discount or commisisons received by the Underwriter
in connection with the Notes purchased by it and distributed to the investors in the Notes
Offering.
No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the
1933 Act) shall be entitled to contribution from any person who was not guilty of such fraudulent
misrepresentation.
For purposes of this Section 7, each person, if any, who controls the Underwriter or the
Borrower within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act and the
Underwriter and the Borrowers affiliates and selling agents shall have the same rights to
contribution as such Underwriter and Borrower, and each director of the Company, each officer of
the Company who signed the Registration Statement, and each person, if any, who controls the
Company within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act shall have
the same rights to contribution as the Company.
SECTION 8. Representations, Warranties and Agreements to Survive. All
representations, warranties and agreements contained in this Agreement or in certificates of
officers of the Company or any of its subsidiaries submitted pursuant hereto, shall remain
operative and in full force and effect regardless of (i) any investigation made by or on behalf of
the Underwriter or the Borrower or their respective affiliates or selling agents, any person
controlling the Underwriter or the Borrower, their
23
respective officers or directors, any person controlling the Company and (ii) delivery of and
payment for the Securities.
SECTION 9. Termination of Agreement.
(a) Termination. The Underwriter and the Borrower may terminate this Agreement, by notice to
the Company, at any time at or prior to the Closing Time (i) if there has been, in the judgment of
the Underwriter and the Borrower, since the time of execution of this Agreement or since the
respective dates as of which information is given in the General Disclosure Package or the
Prospectus, any material adverse change in the condition, financial or otherwise, or in the
earnings, business affairs or business prospects of the Company and its subsidiaries considered as
one enterprise, whether or not arising in the ordinary course of business, or (ii) if there has
occurred any material adverse change in the financial markets in the United States or the
international financial markets, any outbreak of hostilities or escalation thereof or other
calamity or crisis or any change or development involving a prospective change in national or
international political, financial or economic conditions, in each case the effect of which is such
as to make it, in the judgment of the Underwriter and the Borrower, impracticable or inadvisable to
proceed with the completion of the offering or to enforce contracts for the sale of the Securities,
or (iii) if trading in any securities of the Company has been suspended or materially limited by
the Commission or the Nasdaq Global Market, or (iv) if trading generally on the American Stock
Exchange or the New York Stock Exchange or in the Nasdaq Global Market has been suspended or
materially limited, or minimum or maximum prices for trading have been fixed, or maximum ranges for
prices have been required, by any of said exchanges or by order of the Commission, FINRA or any
other governmental authority, or (v) a material disruption has occurred in commercial banking or
securities settlement or clearance services in the United States or with respect to Clearstream or
Euroclear systems in Europe, or (vi) if a banking moratorium has been declared by either Federal or
New York authorities.
(b) Liabilities. If this Agreement is terminated pursuant to this Section, such termination
shall be without liability of any party to any other party except as provided in Section 4 hereof,
and provided further that Sections 1, 6, 7, 8, 13 and 14 shall survive such termination and remain
in full force and effect.
SECTION 10. Notices. All notices and other communications hereunder shall be in
writing and shall be deemed to have been duly given if mailed or transmitted by any standard form
of telecommunication. Notices to the Underwriter shall be directed to Merrill Lynch at One Bryant
Park, New York, New York 10036, attention of Syndicate Department, with a copy to ECM Legal;
notices to the Borrower shall be directed to Bank of America, N.A. at 9 West 57th
Street, New York, NY 10019, attention of John Servidio; notices to the Company shall be directed to
it at 28903 North Avenue Paine, Valencia, California 91355 (fax: (661) 755-2086), attention of
David Thomson, with a copy to Cooley LLP, 4401 Eastgate Mall, San Diego, California 92121 (fax:
(858) 550-6420), attention of D. Bradley Peck.
SECTION 11. No Advisory or Fiduciary Relationship. The Company acknowledges and
agrees that (a) the purchase and sale of the Securities pursuant to this Agreement, including the
determination of the initial public offering price of the Securities and any related discounts and
commissions, is an arms-length commercial transaction between the Company, on the one hand, and
the Underwriter, on the other hand, (b) in connection with the offering of the Securities and the
process leading thereto, each of the Underwriter and the Borrower is and has been acting solely as
a principal and is not the agent or fiduciary of the Company, any of its subsidiaries or its
respective stockholders, creditors, employees or any other party, (c) neither the Underwriter nor
the Borrower has assumed or will assume an advisory or fiduciary responsibility in favor of the
Company with respect to the offering of the Securities or the process leading thereto (irrespective
of whether such Underwriter or Borrower has advised or is currently advising the
24
Company or any of its subsidiaries on other matters) and neither the Underwriter nor the
Borrower has any obligation to the Company with respect to the offering of the Securities except
the obligations expressly set forth in this Agreement, (d) the Underwriter and the Borrower and
their respective affiliates may be engaged in a broad range of transactions that involve interests
that differ from those of the Company, and (e) the Underwriter and the Borrower have not provided
any legal, accounting, regulatory or tax advice with respect to the offering of the Securities and
the Company and has consulted its own respective legal, accounting, regulatory and tax advisors to
the extent it deemed appropriate.
SECTION 12. Parties. This Agreement shall inure to the benefit of and be binding upon
the Underwriter, the Company and their respective successors. Nothing expressed or mentioned in
this Agreement is intended or shall be construed to give any person, firm or corporation, other
than the Underwriter, the Borrower, the Company and their respective successors and the controlling
persons and officers and directors referred to in Sections 6 and 7 and their heirs and legal
representatives, any legal or equitable right, remedy or claim under or in respect of this
Agreement or any provision herein contained. This Agreement and all conditions and provisions
hereof are intended to be for the sole and exclusive benefit of the Underwriter, the Borrower, the
Company and their respective successors, and said controlling persons and officers and directors
and their heirs and legal representatives, and for the benefit of no other person, firm or
corporation. No purchaser of Securities from the Underwriter shall be deemed to be a successor by
reason merely of such purchase.
SECTION 13. Trial by Jury. The Company (on its behalf and, to the extent permitted by
applicable law, on behalf of its stockholders and affiliates) and each of the Underwriter and the
Borrower hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all
right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the
transactions contemplated hereby.
SECTION 14. GOVERNING LAW. THIS AGREEMENT AND ANY CLAIM, CONTROVERSY OR DISPUTE
ARISING UNDER OR RELATED TO THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH
THE LAWS OF, THE STATE OF NEW YORK WITHOUT REGARD TO ITS CHOICE OF LAW PROVISIONS.
SECTION 15. TIME. TIME SHALL BE OF THE ESSENCE OF THIS AGREEMENT. EXCEPT AS OTHERWISE
SET FORTH HEREIN, SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME.
SECTION 16. Partial Unenforceability. The invalidity or unenforceability of any
Section, paragraph or provision of this Agreement shall not affect the validity or enforceability
of any other Section, paragraph or provision hereof. If any Section, paragraph or provision of
this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed
to be made such minor changes (and only such minor changes) as are necessary to make it valid and
enforceable.
SECTION 17. Counterparts. This Agreement may be executed in any number of
counterparts, each of which shall be deemed to be an original, but all such counterparts shall
together constitute one and the same Agreement.
SECTION 18. Effect of Headings. The Section headings herein are for convenience only
and shall not affect the construction hereof.
SECTION 19. Entire Agreement. This Agreement, together with the schedules and
exhibits hereto, and the Share Lending Agreement contains the entire understanding of the parties
with respect to
25
the subject matter hereof and supersedes all prior agreements and understandings, oral or
written, with regard to such matters.
[Signature page follows]
26
If the foregoing is in accordance with your understanding of our agreement, please sign and
return to the Company a counterpart hereof, whereupon this instrument, along with all counterparts,
will become a binding agreement between Merrill Lynch and the Company in accordance with its terms.
|
|
|
|
|
|
Very truly yours,
MANNKIND CORPORATION
|
|
|
By |
/s/ Matthew J. Pfeffer
|
|
|
|
Title: Chief Financial Officer |
|
|
|
|
|
|
|
|
|
|
|
CONFIRMED AND ACCEPTED,
as of the date first above written:
MERRILL LYNCH, PIERCE, FENNER & SMITH
INCORPORATED
|
|
|
By |
/s/ Benjamin Perkins
|
|
|
|
Authorized Signatory |
|
|
|
|
|
|
|
|
|
|
|
|
BANK OF AMERICA, N.A.
solely as the recipient and/or beneficiary of certain representations, warranties, covenants and
indemnities set forth in the foregoing Agreement
|
|
|
|
|
|
|
|
By |
/s/ Charles J. Nelsen
|
|
|
|
Authorized Signatory |
|
|
|
|
|
SCHEDULE A
Free Writing Prospectuses
Free writing prospectus filed August 19, 2010
Sch A-1
SCHEDULE B
List of Persons Subject to Lock-up
Alfred E. Mann
Hakan S. Edstrom
Matthew J. Pfeffer
Juergen A. Martens, Ph.D.
Diane M. Palumbo
Dr. Peter C. Richardson
David Thomson, Ph.D., J.D.
Abraham E. Cohen
Ronald Consiglio
Michael Friedman
Kent Kresa
David H. MacCallum
Henry L. Nordhoff
James S. Shannon
Sch B-1
exv4w1
EXHIBIT 4.1
MANNKIND CORPORATION
AND
WELLS FARGO BANK, NATIONAL ASSOCIATION
as Trustee
INDENTURE
Dated as of August 24, 2010
5.75% Convertible Senior Notes due 2015
TABLE OF CONTENTS
|
|
|
|
|
|
|
Page |
|
ARTICLE 1
Definitions; Interpretations |
|
|
|
|
|
|
|
|
|
Section 1.01. Definitions |
|
|
1 |
|
Section 1.02. References to Interest |
|
|
12 |
|
|
|
|
|
|
ARTICLE 2
Issue, Description, Execution, Registration and Exchange of Notes |
|
|
|
|
|
|
|
|
|
Section 2.01. Designation and Amount |
|
|
12 |
|
Section 2.02. Form of Notes |
|
|
12 |
|
Section 2.03. Date and Denomination of Notes; Payments of Interest |
|
|
13 |
|
Section 2.04. Execution, Authentication and Delivery of Notes |
|
|
15 |
|
Section 2.05. Exchange and Registration of Transfer of Notes; Restrictions
on Transfer; Depositary; Automatic Exchange |
|
|
16 |
|
Section 2.06. Mutilated, Destroyed, Lost or Stolen Notes |
|
|
21 |
|
Section 2.07. Temporary Notes |
|
|
22 |
|
Section 2.08. Cancellation of Notes Paid, Etc. |
|
|
23 |
|
Section 2.09. CUSIP and ISIN Numbers |
|
|
23 |
|
Section 2.10. Additional Notes; Purchases |
|
|
24 |
|
|
|
|
|
|
ARTICLE 3
Satisfaction and Discharge |
|
|
|
|
|
|
|
|
|
Section 3.01. Satisfaction and Discharge |
|
|
24 |
|
Section 3.02. Deposited Monies To Be Held In Trust |
|
|
24 |
|
Section 3.03. Return Of Unclaimed Monies |
|
|
25 |
|
|
|
|
|
|
ARTICLE 4
Particular Covenants of the Company |
|
|
|
|
|
|
|
|
|
Section 4.01. Payment of Principal and Interest |
|
|
25 |
|
Section 4.02. Corporate Existence |
|
|
26 |
|
Section 4.03. Rule 144A Information Requirement and Reports |
|
|
26 |
|
Section 4.04. Compliance Certificate |
|
|
26 |
|
Section 4.05. Maintenance of Office or Agency |
|
|
27 |
|
Section 4.06. Paying Agents |
|
|
27 |
|
Section 4.07. Appointment to Fill Vacancy in Office of Trustee |
|
|
28 |
|
i
|
|
|
|
|
|
|
Page |
|
ARTICLE 5
Holders Lists and Reports by the Company and the Trustee |
|
|
|
|
|
|
|
|
|
Section 5.01. Company to Furnish Trustee Names and Addresses of Holders |
|
|
28 |
|
Section 5.02. Preservation Of Information; Communications With Holders |
|
|
29 |
|
Section 5.03. Reports by the Trustee |
|
|
29 |
|
|
|
|
|
|
ARTICLE 6
Default and Remedies |
|
|
|
|
|
|
|
|
|
Section 6.01. Events of Default |
|
|
30 |
|
Section 6.02. Acceleration of Maturity; Rescission and Annulment |
|
|
31 |
|
Section 6.03. Other Remedies |
|
|
33 |
|
Section 6.04. Waiver of Past Defaults |
|
|
33 |
|
Section 6.05. Control by Majority |
|
|
33 |
|
Section 6.06. Limitation On Suit |
|
|
34 |
|
Section 6.07. Unconditional Rights of Holders to Receive Payment and to Convert |
|
|
35 |
|
Section 6.08. Collection of Indebtedness and Suits For Enforcement By the Trustee |
|
|
35 |
|
Section 6.09. Trustee May File Proofs of Claim |
|
|
36 |
|
Section 6.10. Restoration of Rights and Remedies |
|
|
36 |
|
Section 6.11. Rights and Remedies Cumulative |
|
|
37 |
|
Section 6.12. Delay or Omission Not Waiver |
|
|
37 |
|
Section 6.13. Application of Money Collected |
|
|
37 |
|
Section 6.14. Undertaking For Costs |
|
|
37 |
|
Section 6.15. Waiver of Stay or Extension Laws |
|
|
38 |
|
Section 6.16. Notice of Default |
|
|
38 |
|
|
|
|
|
|
ARTICLE 7
Concerning the Trustee |
|
|
|
|
|
|
|
|
|
Section 7.01. Certain Duties and Responsibilities of Trustee |
|
|
39 |
|
Section 7.02. Certain Rights of Trustee |
|
|
40 |
|
Section 7.03. Trustee Not Responsible for Recitals or Issuance or Notes |
|
|
42 |
|
Section 7.04. May Hold Notes |
|
|
42 |
|
Section 7.05. Moneys Held in Trust |
|
|
42 |
|
Section 7.06. Compensation and Reimbursement |
|
|
42 |
|
Section 7.07. Reliance on Officers Certificate and Opinions |
|
|
44 |
|
Section 7.08. Disqualification; Conflicting Interests |
|
|
44 |
|
Section 7.09. Corporate Trustee Required; Eligibility |
|
|
44 |
|
Section 7.10. Resignation and Removal; Appointment of Successor |
|
|
44 |
|
Section 7.11. Acceptance of Appointment By Successor |
|
|
46 |
|
Section 7.12. Merger, Conversion, Consolidation or Succession to Business |
|
|
47 |
|
ii
|
|
|
|
|
|
|
Page |
|
Section 7.13. Preferential Collection of Claims Against the Company |
|
|
47 |
|
|
|
|
|
|
ARTICLE 8
Concerning the Holders |
|
|
|
|
|
|
|
|
|
Section 8.01. Evidence of Action by Holders |
|
|
48 |
|
Section 8.02. Proof of Execution by Holders |
|
|
48 |
|
Section 8.03. Who May be Deemed Owners |
|
|
49 |
|
Section 8.04. Certain Notes Owned by Company Disregarded |
|
|
49 |
|
Section 8.05. Actions Binding on Future Holders |
|
|
49 |
|
|
|
|
|
|
ARTICLE 9
Amendments; Supplements And Waivers |
|
|
|
|
|
|
|
|
|
Section 9.01. Without Consent of Holders |
|
|
50 |
|
Section 9.02. With Consent of Holders |
|
|
51 |
|
Section 9.03. Effect of Supplemental Indentures |
|
|
52 |
|
Section 9.04. Notes Affected by Supplemental Indentures |
|
|
52 |
|
Section 9.05. Execution of Supplemental Indentures |
|
|
52 |
|
|
|
|
|
|
ARTICLE 10
Consolidation; Merger; Conveyance; Transfer Or Lease |
|
|
|
|
|
|
|
|
|
Section 10.01. Company May Consolidate, Etc., Only on Certain Terms |
|
|
53 |
|
Section 10.02. Successor Substituted |
|
|
54 |
|
|
|
|
|
|
ARTICLE 11
Immunity of Incorporators, Stockholders, Officers and Directors |
|
|
|
|
|
|
|
|
|
Section 11.01. No Recourse |
|
|
54 |
|
|
|
|
|
|
ARTICLE 12
Additional Interest |
|
|
|
|
|
|
|
|
|
Section 12.01. Additional Interest |
|
|
55 |
|
|
|
|
|
|
ARTICLE 13
Conversion of Notes |
|
|
|
|
|
|
|
|
|
Section 13.01. Conversion Privilege and Conversion Rate |
|
|
56 |
|
Section 13.02. Conversion Procedure |
|
|
59 |
|
Section 13.03. Fractional Shares |
|
|
60 |
|
Section 13.04. Taxes on Conversion |
|
|
61 |
|
Section 13.05. Company to Provide Common Stock |
|
|
61 |
|
Section 13.06. Adjustment of Conversion Rate |
|
|
61 |
|
Section 13.07. When No Adjustment is Required |
|
|
68 |
|
iii
|
|
|
|
|
|
|
Page |
|
Section 13.08. Notice of Adjustment |
|
|
69 |
|
Section 13.09. Notice of Certain Transactions |
|
|
69 |
|
Section 13.10. Effect of Reclassification, Consolidation, Merger or Sale On Conversion Privilege |
|
|
69 |
|
Section 13.11. Trustees Disclaimer |
|
|
70 |
|
Section 13.12. Voluntary Increase; Nasdaq Compliance |
|
|
71 |
|
Section 13.13. Rights Plan |
|
|
71 |
|
Section 13.14. Exchange in Lieu of Conversion |
|
|
71 |
|
|
|
|
|
|
ARTICLE 14
Redemption Of Notes |
|
|
|
|
|
|
|
|
|
Section 14.01. Right to Redeem |
|
|
73 |
|
Section 14.02. Selection of Notes to be Redeemed |
|
|
74 |
|
Section 14.03. Notice of Redemption |
|
|
75 |
|
Section 14.04. Effect of Notice of Redemption |
|
|
75 |
|
Section 14.05. Deposit of Redemption Price |
|
|
76 |
|
Section 14.06. Notes Redeemed in Part |
|
|
76 |
|
|
|
|
|
|
ARTICLE 15
Repurchase Of Notes |
|
|
|
|
|
|
|
|
|
Section 15.01. Repurchase of Notes at Option of the Holder Upon a Fundamental Change |
|
|
76 |
|
Section 15.02. Effect of Fundamental Change Purchase Notice |
|
|
79 |
|
Section 15.03. Deposit of Fundamental Change Purchase Price |
|
|
79 |
|
Section 15.04. Repayment to the Company |
|
|
80 |
|
Section 15.05. Notes Purchased In Part |
|
|
80 |
|
Section 15.06. Compliance With Securities Laws Upon Purchase of Notes |
|
|
81 |
|
|
|
|
|
|
ARTICLE 16
Meeting Of Holders Of Notes |
|
|
|
|
|
|
|
|
|
Section 16.01. Purposes For Which Meetings May Be Called |
|
|
81 |
|
Section 16.02. Call Notice and Place of Meetings |
|
|
81 |
|
Section 16.03. Persons Entitled to Vote at Meetings |
|
|
82 |
|
Section 16.04. Quorum; Action |
|
|
82 |
|
Section 16.05. Determination of Voting Rights; Conduct and Adjournment of Meetings |
|
|
82 |
|
Section 16.06. Counting Votes and Recording Action of Meetings |
|
|
83 |
|
|
|
|
|
|
ARTICLE 17
Miscellaneous Provisions |
|
|
|
|
|
|
|
|
|
Section 17.01. Provisions Binding on Companys Successors |
|
|
84 |
|
iv
|
|
|
|
|
|
|
Page |
|
Section 17.02. Official Acts by Successor |
|
|
84 |
|
Section 17.03. Notices |
|
|
84 |
|
Section 17.04. Governing Law |
|
|
84 |
|
Section 17.05. Evidence of Compliance with Conditions Precedent;
Certificates and Opinions of Counsel to Trustee |
|
|
84 |
|
Section 17.06. Legal Holidays |
|
|
85 |
|
Section 17.07. No Security Interest Created |
|
|
85 |
|
Section 17.08. Benefits of Indenture |
|
|
85 |
|
Section 17.09. Table of Contents, Headings, Etc. |
|
|
85 |
|
Section 17.10. Execution in Counterparts |
|
|
86 |
|
Section 17.11. Severability |
|
|
86 |
|
Section 17.12. Waiver of Jury Trial |
|
|
86 |
|
Section 17.13. Consent to Jurisdiction |
|
|
86 |
|
Section 17.14. Force Majeure |
|
|
86 |
|
Section 17.15. Calculations |
|
|
87 |
|
Section 17.16. U.S.A. Patriot Act |
|
|
87 |
|
|
|
|
|
|
Exhibit A Form of Note |
|
|
|
|
v
INDENTURE dated as of August 24, 2010 between MannKind Corporation, a Delaware corporation, as
issuer (the Company) and Wells Fargo Bank, National Association, a national banking association,
as trustee (the Trustee).
W I T N E S S E T H:
WHEREAS, for its lawful corporate purposes, the Company has duly authorized the issue of its
5.75% Convertible Senior Notes due 2015 (the Notes), initially in an aggregate principal amount
of $100,000,000, and in order to provide the terms and conditions upon which the Notes are to be
authenticated, issued and delivered, the Company has duly authorized the execution and delivery of
this Indenture; and
WHEREAS, the Form of Note, the certificate of authentication to be borne by each Note, the
Form of Notice of Conversion, the Form of Fundamental Change Purchase Notice and the Form of
Assignment and Transfer to be borne by the Notes are to be substantially in the forms hereinafter
provided; and
WHEREAS, all acts and things necessary to make the Notes, when executed by the Company and
authenticated and delivered by the Trustee or a duly authorized authenticating agent, as in this
Indenture provided, the valid, binding and legal obligations of the Company, and to constitute
these presents a valid agreement according to its terms, have been done and performed, and the
execution of this Indenture and the issue hereunder of the Notes have in all respects been duly
authorized.
NOW, THEREFORE, THIS INDENTURE WITNESSETH:
That in order to declare the terms and conditions upon which the Notes are, and are to be,
authenticated, issued and delivered, and in consideration of the premises and of the purchase and
acceptance of the Notes by the Holders thereof, the Company covenants and agrees with the Trustee
for the equal and proportionate benefit of the respective Holders from time to time of the Notes
(except as otherwise provided below), as follows:
ARTICLE 1
Definitions; Interpretations
Section 1.01. Definitions. The terms defined in this Section 1.01 (except as herein
otherwise expressly provided or unless the context otherwise requires) for all purposes of this
Indenture and of any indenture supplemental hereto shall have the respective meanings specified in
this Section 1.01. All other terms used in this Indenture that are defined in the Trust Indenture
Act or that are by
reference therein defined in the Securities Act (except as herein otherwise expressly provided
or unless the context otherwise requires) shall have the meanings assigned to such terms in said
Trust Indenture Act and in the Securities Act as in force at the date of the execution of this
Indenture. The words herein, hereof, hereunder, and words of similar import refer to this
Indenture as a whole and not to any particular Article, Section or other subdivision. The terms
defined in this Article include the plural as well as the singular. Unless otherwise noted,
references to U.S. Dollars or $ shall mean the currency of the United States.
5-day Volume-Weighted Average Price means, with respect to any five Trading Day period, the
per share volume-weighted average price as displayed under the heading Bloomberg VWAP on
Bloomberg page MNKD.UQ <equity> AQR (or its equivalent successor if such page is not
available) in respect of such five Trading Day period from the scheduled open of trading on the
first Trading Day of such five Trading Day period until the scheduled close of trading of the
primary trading session on the last Trading Day of such five Trading Day period (or if such
volume-weighted average price is unavailable, the market value of one share of the Common Stock
during such five Trading Day period determined, using a volume-weighted average method, by a
nationally recognized independent investment banking firm retained for this purpose by the
Company). The 5-day Volume-Weighted Average Price shall be determined without regard to after
hours trading or any other trading outside of the regular trading session trading hours.
Additional Interest shall have the meaning specified in Section 12.01(a).
Additional Interest Event shall have the meaning specified in Section 12.01(a).
Affiliate of any specified Person means any other Person directly or indirectly controlling
or controlled by or under direct or indirect common control with such specified Person. For the
purposes of this definition, control, when used with respect to any specified Person means the
power to direct or cause the direction of the management and policies of such Person, directly or
indirectly, whether through the ownership of voting securities, by contract or otherwise; and the
terms controlling and controlled have meanings correlative to the foregoing.
Applicable Procedures means, with respect to any conversion, transfer or exchange of
beneficial ownership interests in a Global Note, the rules and procedures of the Depositary, to the
extent applicable to such conversion, transfer or exchange.
2
Bankruptcy Law shall have the meaning specified in Section 6.01.
Board of Directors means the Board of Directors of the Company or any duly authorized
committee of such Board.
Board Resolution means a copy of a resolution certified by the Secretary or an Assistant
Secretary of the Company to have been duly adopted by the Board of Directors, and to be in full
force and effect on the date of such certification.
Business Day means any day other than a day on which federal or state banking institutions
in the Borough of Manhattan, the City of New York, or in the city of the Corporate Trust Office of
the Trustee, are authorized or obligated by law, executive order or regulation to close.
Capital Stock of any Person means any and all shares, interests, rights to purchase,
warrants, options, participations or other equivalents of or interests in (however designated) the
equity of such Person, but excluding any debt securities convertible into such equity.
Cash or cash means such coin or currency of the United States as at any time of payment is
legal tender for the payment of public and private debts.
Change of Control means the occurrence of any of the following events from and after the
Issue Date:
(i) the acquisition by any person, including any syndicate or group deemed to be a person
under Section 13(d)(3) of the Exchange Act is or becomes the beneficial owner (as defined in Rule
13d-3 under the Exchange Act) of the beneficial ownership, directly or indirectly, through a
purchase, merger or other acquisition transaction or series of transactions of shares of the
Companys Capital Stock entitling that person to exercise 50% or more of the total voting power of
all shares of the Companys Voting Stock, other than (x) any acquisition by the Company, any
Subsidiary or any of the Companys employee benefit plans; (y) any acquisition during the lifetime
of Mann by Mann or his estate, by any trust where Mann is the trustee or grantor, by any
not-for-profit entity where the acquisition is directed by Mann or by any entity wholly-owned by
Mann or his estate; provided that the total beneficial ownership of all such Persons, together with
the Persons in (z), does not exceed 70% or more of the total voting power of all shares of the
Companys Voting Stock; and (z) any acquisition by any Person so long as the shares acquired by
such Person are acquired directly from one of the Persons listed in (y) and no consideration is
paid in connection with such acquisition;
3
(ii) the Company (A) recapitalizes, reclassifies or changes the Common Stock (other than
changes resulting from a subdivision or combination) as a result of which the Common Stock would be
converted into, or exchanged for, stock, other securities, other property or assets or (B)
exchanges its shares of Common Stock with, consolidates with, or merges with or into, another
Person or any Person exchanges its shares of common stock with, consolidates or merges with or into
the Company, or (C) conveys, transfers, sells, leases or otherwise disposes of all or substantially
all of its properties and assets to another Person, in each case other than (x) any transaction
pursuant to which holders of the Companys Capital Stock immediately prior to the transaction have
the entitlement to exercise, directly or indirectly, 50% or more of the total voting power of all
shares of the Voting Stock of the continuing or surviving entity of such transaction; or (y) any
merger solely for the purpose of changing the Companys jurisdiction of incorporation and resulting
in a reclassification, conversion or exchange of outstanding shares of Common Stock solely into
shares of common stock of the surviving entity traded or quoted on a U.S. national securities
exchange, and as a result of such merger the Notes become convertible into such shares; or
(iii) the Companys stockholders approve a plan of liquidation or dissolution.
Notwithstanding anything to the contrary set forth herein, a Change of Control will be deemed
not to have occurred if, in the case of a merger or consolidation, at least 90% of the
consideration (excluding cash payments for fractional shares and cash payments pursuant to
dissenters appraisal rights) in a transaction or transactions otherwise constituting a Change of
Control consists of shares of common stock or American depository receipts traded or quoted on a
U.S. national securities exchange, or which will be so traded or quoted when issued or exchanged in
connection with the transaction or transactions, and as a result of the transaction or transactions
the Notes become convertible solely into such consideration.
close of business means 5:00 p.m. (New York City time).
Commission means the Securities and Exchange Commission.
Common Stock means the shares of common stock of the Company, par value $0.01 per share, as
it exists on the date of this Indenture or any other shares of Capital Stock of the Company into
which the Common Stock shall be reclassified or changed.
Company means MannKind Corporation, a corporation duly organized and existing under the laws
of the State of Delaware, until a successor Person
4
shall have become such pursuant to the
applicable provisions of this Indenture, and thereafter Company shall mean such successor Person.
Company Order means a written order of the Company, signed by the Companys Chief Executive
Officer, Chief Financial Officer, President, Executive Vice President or any Vice President
(whether or not designated by a number or numbers or word or words added before or after the title
Vice President), Treasurer or Assistant Treasurer or Secretary or any Assistant Secretary, and
delivered to the Trustee.
Conversion Agent means the office or agency designated by the Company pursuant to Section
4.05 where Notes may be presented for conversion.
Conversion Date shall have the meaning specified in Section 13.02(a).
Conversion Price per share of Common Stock as of any day means the result obtained by
dividing (i) $1,000 by (ii) the then applicable Conversion Rate.
Conversion Rate means the rate at which shares of Common Stock shall be delivered upon
conversion, which rate shall be initially 147.0859 shares of Common Stock for each $1,000 principal
amount of Notes, as adjusted from time to time pursuant to the provisions of this Indenture.
Corporate Trust Office means the office of the Trustee at which, at any particular time, its
corporate trust business shall be principally administered, which office at the date hereof is
located at Wells Fargo Bank, National Association, Sixth & Marquette, MAC N9303-120, Minneapolis,
MN 55479.
Custodian means Wells Fargo Bank, National Association, as custodian for The Depository
Trust Company, with respect to the Global Notes, or any successor entity thereto.
Default means any event, act or condition that with notice or lapse of time, or both, would
constitute an Event of Default.
Defaulted Interest means any interest on any Note that is payable, but is not punctually
paid or duly provided for, on any February 15 or August 15.
Depositary means, with respect to the Global Notes, the Person specified in Section 2.05(c)
as the Depositary with respect to such Notes, until a successor shall have been appointed and
become such pursuant to the applicable provisions of this Indenture, and thereafter, Depositary
shall mean or include such successor.
DTC shall have the meaning specified in Section 2.05(c).
5
Ex-Dividend Date means, in respect of an issuance, a dividend or distribution to holders of
Common Stock, the first date on which shares of Common Stock trade on the applicable exchange or in
the applicable market, regular way, without the right to receive such issuance, dividend or
distribution in question.
Exchange Act means the Securities Exchange Act of 1934, as amended, and the rules and
regulations promulgated thereunder.
Exchange Settlement Property shall have the meaning specified in Section 13.14(b)
Expiration Date shall have the meaning specified in Section 13.06(e).
Expiration Time shall have the meaning specified in Section 13.06(e).
Event of Default shall have the meaning specified in Section 6.01.
Financial Institution shall have the meaning specified in Section 13.14(a).
Form of Assignment and Transfer shall mean the Form of Assignment and Transfer attached as
Attachment 3 to the Form of Note attached hereto as Exhibit A.
Form of Fundamental Change Purchase Notice shall mean the Form of Fundamental Change
Purchase Notice attached as Attachment 2 to the Form of Note attached hereto as Exhibit A.
Form of Note shall mean the Form of Note attached hereto as Exhibit A.
Form of Notice of Conversion shall mean the Form of Notice of Conversion attached as
Attachment 1 to the Form of Note attached hereto as Exhibit A.
Fundamental Change means the occurrence of either a Change of Control or a Termination of
Trading.
Fundamental Change Company Notice shall have the meaning specified in Section 15.01(b).
Fundamental Change Effective Date means the date on which any Fundamental Change becomes
effective.
6
Fundamental Change Make-Whole Premium shall have the meaning specified in Section 13.01(e).
Fundamental Change Purchase Date shall have the meaning specified in Section 15.01(a).
Fundamental Change Purchase Notice shall have the meaning specified in Section 15.01(c).
Fundamental Change Purchase Price of any Note, means 100% of the principal amount of the
Note to be repurchased plus unpaid interest, if any, accrued and unpaid to, but excluding, the
Fundamental Change Purchase Date; provided that if the Fundamental Change Purchase Date is after a
Regular Record Date and on or prior to the corresponding Interest Payment Date, the Fundamental
Change Purchase Price shall not include any accrued and unpaid interest.
Global Note shall have the meaning specified in Section 2.05(b).
Holder or Holder of a Note means the person in whose name a Note is registered on the Note
Registrars books.
Indenture means this instrument as originally executed or, if amended or supplemented as
herein provided, as so amended or supplemented.
Initial Purchasers means Merrill Lynch, Pierce, Fenner & Smith Incorporated, Wells Fargo
Securities, LLC, Rodman & Renshaw, LLC and Imperial Capital, LLC.
Interest Payment Date means each February 15 and August 15 of each year, beginning on
February 15, 2011; provided, however, that if any Interest Payment Date falls on a date that is not
a Business Day, such payment of interest will be postponed until the next succeeding Business Day,
and no interest or other amount will be paid as a result of such postponement.
Issue Date of any Note means the date on which the Note was originally issued or deemed
issued as set forth on the face of the Note.
Last Reported Sale Price means on any Business Day or Trading Day, the reported last sale
price per share of the Companys Common Stock (or if no last sale price is reported, the average of
the bid and ask prices per share or, if more than one in either case, the average of the average
bid and the average ask prices per share) on such date reported by the Nasdaq Global Market or, if
the Companys Common Stock (or the applicable security) is not quoted on the Nasdaq Global Market,
as reported by the principal national securities exchange on which the Companys Common Stock (or
such other security) is listed, or if no such prices are available, the Last Reported Sale Price
per share shall be the fair
7
value of a share of Common Stock (or such other security) as reasonably
determined by the Board of Directors (which determination shall be conclusive and shall be
evidenced by an Officers Certificate delivered to the Trustee).
Make-Whole Fundamental Change means any Fundamental Change as described in the definition
thereof, and determined after giving effect to any exceptions or exclusions to such definition, but
without regard to clause (ii)(x) of the definition of Change of Control and excluding a Fundamental
Change described under clause (iii) of the definition of Change of Control.
Make-Whole Fundamental Change Effective Date means the date on which any Make-Whole
Fundamental Change becomes effective.
Make-Whole Fundamental Change Notice has the meaning specified in Section 13.01(e).
Make-Whole Payment means, with respect to each $1,000 in principal amount of Notes being
redeemed on a Redemption Date, a payment in cash equal to the present values of the remaining
scheduled payments of interest that would have been made on such Notes to be redeemed had such
Notes remained Outstanding from such Redemption Date through and including August 15, 2015
(excluding interest accrued to, but excluding, such Redemption Date, which is otherwise paid
pursuant to clause (ii) of the definition of Redemption Price). The present values of such
remaining interest payments shall be computed using a discount rate equal to 2.5%; provided that in
respect of a Redemption Date that is after a Regular Record Date and on or prior to the
corresponding Interest Payment Date, the Make-Whole Payment will not include the interest payment
to be paid on such Interest Payment Date.
Mann means the individual Alfred E. Mann.
Market Disruption Event means (1) a failure by the primary exchange or quotation system on
which the Common Stock trades or is quoted to open for trading during its regular trading session
or (2) the occurrence or existence, prior to 1:00 p.m., New York City time, on any Trading Day for
the Common Stock, of an aggregate one half-hour period of any suspension or limitation imposed on
trading (by reason of movements in price exceeding limits permitted by the stock exchange or
otherwise) in the Common Stock or in any options, contracts or future contracts relating to the
Common Stock.
Maturity Date means August 15, 2015.
Note or Notes shall have the meaning specified in the first Whereas clause of this
Indenture.
8
Note Register shall have the meaning specified in Section 2.05(a).
Note Registrar shall have the meaning specified in Section 2.05(a).
Notice of Redemption has the meaning set forth in Section 14.03.
Offering Memorandum means the final offering memorandum dated August 18, 2010 relating to
the offering and sale of the Notes pursuant to the Purchase Agreement.
Officer means, with respect to the Company, the chairman of the Board of Directors, a chief
executive officer, a president, a chief financial officer, chief operating officer, any executive
vice president, any senior vice president, any vice
president, the treasurer or any assistant treasurer, the controller or any assistant
controller or the secretary or any assistant secretary.
Officers Certificate, means a certificate signed by any Officer. Each such certificate
shall include the statements provided for in Section 17.05, if and to the extent required by the
provisions thereof.
open of business means 9:00 a.m. (New York City time).
Opinion of Counsel means a written opinion, subject to customary exceptions, from legal
counsel who is reasonably acceptable to the Trustee that is delivered to the Trustee in accordance
with the terms hereof. The counsel may be an employee of or counsel to the Company or the Trustee.
Each such opinion shall include the statements provided for in Section 17.05 if and to the extent
required by the provisions thereof.
Outstanding, when used with reference to Notes, shall, subject to the provisions of Section
8.04, mean, as of any particular time, all Notes authenticated and delivered by the Trustee under
this Indenture, except:
(a) Notes theretofore canceled by the Trustee or accepted by the Trustee for
cancellation;
(b) Notes that have been paid pursuant to Section 2.08 or Notes in lieu of which, or
in substitution for which, other Notes shall have been authenticated and delivered
pursuant to the terms of Section 2.06 unless proof satisfactory to the Trustee is
presented that any such Notes are held by protected purchasers in due course; and
(c) Notes converted pursuant to Article 13.
Paying Agent means the office or agency designated by the Company pursuant to Section 4.05
where Notes may be presented for payment.
9
Person or person means any individual, corporation, partnership, limited liability
company, joint venture, association, joint-stock company, trust, unincorporated organization,
government or any agency or political subdivision thereof or any syndicate or group that would be
deemed to be a person under Section 13(d)(3) of the Exchange Act or any other entity.
Predecessor Note of any particular Note means every previous Note evidencing all or a
portion of the same debt as that evidenced by such particular Note; and, for the purposes of this
definition, any Note authenticated and delivered under Section 2.06 in lieu of or in exchange for a
mutilated, lost, destroyed or stolen Note shall be deemed to evidence the same debt as the
mutilated, lost, destroyed or stolen Note that it replaces.
Purchase Agreement means that certain Purchase Agreement, dated as of August 18, 2015, among
the Company and the Initial Purchasers.
Receiver shall have the meaning specified in Section 6.01.
Redemption Date shall have the meaning specified in Section 14.01(c).
Redemption Price shall have the meaning specified in Section 14.01(b).
Reference Property shall have the meaning specified in Section 13.10.
Regular Record Date, with respect to any Interest Payment Date, shall mean the February 1 or
August 1 (whether or not such day is a Business Day) immediately preceding such Interest Payment
Date.
Resale Restriction Termination Date shall have the meaning specified in Section 2.05(c).
Responsible Officer means any officer within the corporate trust department of the Trustee,
including any vice president, assistant vice president, assistant secretary, assistant treasurer,
trust officer or any other officer of the Trustee who customarily performs functions similar to
those performed by the Persons who at the time shall be such officers, respectively, or to whom any
corporate trust matter is referred because of such Persons knowledge of and familiarity with the
particular subject and who shall have direct responsibility for the administration of this
Indenture.
Restricted Securities shall have the meaning specified in Section 2.05(c).
Rights means any common stock or preferred stock purchase right or warrant, as the case may
be, that all or substantially all shares of Common Stock may be entitled to receive under a Rights
Plan.
10
Rights Plan means any common stock or preferred stock rights plan or any similar plan
adopted by the Company after the date hereof.
Rule 144 means Rule 144 as promulgated under the Securities Act.
Rule 144A means Rule 144A as promulgated under the Securities Act.
Securities Act means the Securities Act of 1933, as amended, and the rules and regulations
promulgated thereunder.
Special Interest shall have the meaning specified in Section 6.02.
Spin-Off shall have the meaning specified in Section 13.06(c).
Stock Price means the price paid or deemed to be paid per share of the Common Stock in
connection with a Make-Whole Fundamental Change subject to adjustment as determined pursuant to
Section 13.01(e).
Subsidiary means a corporation or other entity more than 50% of the outstanding Voting Stock
of which is owned, directly or indirectly, by the Company or by one or more other Subsidiaries of
the Company, or by the Company and one or more other Subsidiaries of the Company.
Termination of Trading means the occurrence of the Common Stock (or other common stock into
which the Notes are convertible) not being listed for trading on a United States national
securities exchange nor approved for listing on any United States system of automated dissemination
of quotations of securities prices nor traded in over-the-counter securities markets and no
American Depositary Shares or similar instruments for the Common Stock are so listed or approved
for listing in the United States.
Trading Day means any day during which trading in the Common Stock generally occurs on the
primary exchange or quotation system on which the Common Stock then trades or is quoted and there
is no Market Disruption Event, unless the Common Stock is not so traded or quotes, in which case
Trading Day means a Business Day.
transfer shall have the meaning specified in Section 2.05(c).
Trust Indenture Act means the Trust Indenture Act of 1939, as amended.
Trustee means the Person named as the Trustee in the first paragraph of this Indenture
until a successor Trustee shall have become such pursuant to the applicable provisions of this
Indenture, and thereafter Trustee shall mean or include each Person who is then a Trustee
hereunder.
11
United States means the United States of America.
Valuation Period shall have the meaning specified in Section 13.06(c).
Voting Stock of a Person means all classes of Capital Stock or other interests (including
partnership interests) of such Person then outstanding and normally entitled (without regard to the
occurrence of any contingency within the control of such person to satisfy) to vote in the election
of directors, managers or trustees thereof.
Section 1.02. References to Interest. Any reference to the payment of interest on, or in
respect of, any Note in this Indenture shall be deemed to include mention of the payment of Special
Interest (if applicable) and Additional Interest (if applicable) if, in such context, Special
Interest and Additional Interest, as
applicable, was, or would be, payable pursuant to Section 6.01 and Section 12.01,
respectively. An express mention of the payment of Special Interest (if applicable) or Additional
Interest (if applicable) in any provision hereof shall not be construed as excluding Additional
Interest or Special Interest, as applicable, in those provisions hereof where such express mention
is not made.
ARTICLE 2
Issue, Description, Execution, Registration and Exchange of Notes
Section 2.01. Designation and Amount. The Notes shall be designated as the 5.75%
Convertible Senior Notes due 2015. The aggregate principal amount of Notes that may be
authenticated and delivered under this Indenture is initially limited to $100,000,000 (as increased
by an amount equal to the aggregate principal amount of any additional Notes purchased by the
Initial Purchasers pursuant to the exercise of their option to purchase additional Notes set forth
in the Purchase Agreement), subject to Section 2.10 and except for Notes authenticated and
delivered upon registration or transfer of, or in exchange for, or in lieu of other Notes pursuant
to Section 2.05, Section 2.06 and Section 2.07.
Section 2.02. Form of Notes. The Notes and the Trustees certificate of authentication to be
borne by such Notes shall be substantially in the respective forms set forth in Exhibit A, which
are incorporated in and made a part of this Indenture.
Any of the Notes may have such letters, numbers or other marks of identification and such
notations, legends or endorsements as the officer executing the same may approve (execution thereof
to be conclusive evidence of such approval) and as are not inconsistent with the provisions of this
Indenture, or as may be required to comply with any law or with any rule or regulation made
pursuant thereto or with any rule or regulation of any securities exchange or
12
automated quotation
system on which the Notes may be listed or designated for issuance, or to conform to usage or to
indicate any special limitations or restrictions to which any particular Notes are subject.
The Global Note shall represent such principal amount of the Outstanding Notes as shall be
specified therein and shall provide that it shall represent the aggregate principal amount of
Outstanding Notes from time to time endorsed thereon and that the aggregate principal amount of
Outstanding Notes represented thereby may from time to time be increased or reduced to reflect
purchases, conversions, transfers, exchanges or issuances of additional Notes permitted hereby.
Any endorsement of the Global Note to reflect the amount of any increase or decrease in the amount
of Outstanding Notes represented thereby shall be made by the Trustee or the Custodian, at the
direction of the Trustee, in such manner and upon instructions given by the Holder of such Notes in
accordance with this Indenture. Payment of principal (including any Fundamental Change
Purchase Price or Redemption Price, as applicable) of, and accrued and unpaid interest, if
any, on, the Global Note shall be made to the Holder of such Note on the date of payment, unless a
record date or other means of determining Holders eligible to receive payment is provided for
herein.
The terms and provisions contained in the Form of Note attached as Exhibit A hereto shall
constitute, and are hereby expressly made, a part of this Indenture and, to the extent applicable,
the Company and the Trustee, by their execution and delivery of this Indenture, expressly agree to
such terms and provisions and to be bound thereby.
Section 2.03. Date and Denomination of Notes; Payments of Interest. The Notes shall be
issuable in registered form without coupons in denominations of $1,000 principal amount and
multiples thereof. Each Note shall be dated the date of its authentication and shall bear interest
from the date specified on the face of the Form of Note attached as Exhibit A hereto. Interest on
the Notes shall be computed on the basis of a 360-day year comprised of twelve 30-day months.
The Person in whose name any Note (or its Predecessor Note) is registered on the Note Register
at the close of business on any Regular Record Date with respect to any Interest Payment Date shall
be entitled to receive the interest payable on such Interest Payment Date. Interest shall be
payable at the office of the Paying Agent, which shall initially be the Corporate Trust Office of
the Trustee as the Companys Paying Agent and Note Registrar. The Company shall pay interest on any
Notes in certificated form (i) to the Person entitled thereto having an aggregate principal amount
of $2,000,000 or less, by check mailed to such Person at the address set forth in the Note Register
and (ii) to the Person entitled thereto having an aggregate principal amount of more than
$2,000,000, either by check mailed to such Person or, upon application by such Person to the Note
Registrar not later than the relevant Regular Record Date, by wire transfer in
13
immediately
available funds to such Persons account within the United States, which application and wire
transfer instructions shall remain in effect until such Person notifies, in writing, the Note
Registrar to the contrary.
Any Defaulted Interest shall forthwith cease to be payable to the Holder of such Note on the
relevant Regular Record Date by virtue of its having been such Holder, and such Defaulted Interest
shall be paid by the Company, at its election in each case, as provided in clause (1) or (2) below:
(1) The Company may elect to make payment of any Defaulted Interest to the Persons in whose
names the Notes (or their respective Predecessor Notes) are registered at the close of business on
a special record date for the payment of such Defaulted Interest, which shall be fixed in the
following manner. The Company shall notify the Trustee in writing of the amount of Defaulted
Interest proposed to be paid on each Note and the date of the proposed payment (which shall be not
less than 20 days after the receipt by the Trustee of such notice, unless the Trustee shall consent
to an earlier date), and at the same time
the Company shall deposit with the Trustee an amount of money equal to the aggregate amount to
be paid in respect of such Defaulted Interest or shall make arrangements satisfactory to the
Trustee for such deposit on or prior to the date of the proposed payment, such money when deposited
to be held in trust for the benefit of the Persons entitled to such Defaulted Interest as in this
clause provided. Thereupon the Company shall fix a special record date for the payment of such
Defaulted Interest which shall be not more than fifteen days and not less than ten days prior to
the date of the proposed payment, and not less than ten days after the receipt by the Trustee of
the notice of the proposed payment. The Company shall promptly notify the Trustee in writing of
such special record date and the Trustee, in the name and at the expense of the Company, shall
cause notice of the proposed payment of such Defaulted Interest and the special record date
therefor to be mailed, first-class postage prepaid, to each Holder at its address as it appears in
the Note Register, not less than ten days prior to such special record date. Notice of the
proposed payment of such Defaulted Interest and the special record date therefor having been so
mailed, such Defaulted Interest shall be paid to the Persons in whose names the Notes (or their
respective Predecessor Notes) are registered at the close of business on such special record date
and shall no longer be payable pursuant to the following clause (2) of this Section 2.03.
(2) The Company may make payment of any Defaulted Interest in any other lawful manner not
inconsistent with the requirements of any securities exchange or automated quotation system on
which the Notes may be listed or designated for issuance, and upon such notice as may be required
by such exchange or automated quotation system, if, after notice given by the Company to the
Trustee of the proposed payment pursuant to this clause, such manner of payment shall be deemed
practicable by the Trustee.
14
If the Company makes a distribution of property to holders of Common Stock that would be
taxable to them as a dividend for United States federal income tax purposes and the Conversion Rate
is increased, the Company may offset any withholding tax applicable to non-United States Holders
against cash payments of interest payable on the Notes.
Section 2.04. Execution, Authentication and Delivery of Notes. The Notes shall be signed in
the name and on behalf of the Company by the manual or facsimile signature of any Officer.
At any time and from time to time after the date of the execution and delivery of this
Indenture, the Company may, in accordance with the terms of this Indenture, deliver additional
Notes executed by the Company to the Trustee for authentication, together with a Company Order for
the authentication and delivery of such Notes, and the Trustee in accordance with such Company
Order shall authenticate and deliver such Notes, without any further action by the Company
hereunder.
Only such Notes as shall bear thereon a certificate of authentication substantially in the
form set forth on the Form of Note attached as Exhibit A hereto, executed manually by a Responsible
Officer of the Trustee (or an authorized officer of an authenticating agent appointed by the
Trustee), shall be entitled to the benefits of this Indenture or be valid or obligatory for any
purpose. Such certificate of authentication executed by the Trustee (or such an authenticating
agent) upon any Note executed by the Company shall be conclusive evidence that the Note so
authenticated has been duly authenticated and delivered hereunder and that the Holder is entitled
to the benefits of this Indenture.
All Notes shall be dated that date of their authentication.
In case any Officer of the Company who shall have signed any of the Notes shall cease to be
such Officer before the Notes so signed shall have been authenticated and delivered by the Trustee,
or disposed of by the Company, such Notes nevertheless may be authenticated and delivered or
disposed of as though the Person who signed such Notes had not ceased to be such Officer of the
Company; and any Note may be signed on behalf of the Company by such Person as, at the actual date
of the execution of such Note, shall be an Officer of the Company, although at the date of the
execution of this Indenture any such person was not such an Officer.
The Trustee shall have the right to decline to authenticate and deliver any Notes under this
Indenture if the Trustee, being advised by counsel, determines that such action may not lawfully be
taken or if the Trustee in good faith shall
15
determine that such action would expose the Trustee to
personal liability to existing Holders.
Section 2.05. Exchange and Registration of Transfer of Notes; Restrictions on Transfer;
Depositary; Automatic Exchange. (a) The Company shall cause to be kept at the Corporate Trust
Office a register (the register maintained in such office or in any other office or agency of the
Company being herein sometimes collectively referred to as the Note Register) in which, subject
to such reasonable regulations as it may prescribe, the Company shall provide for the registration
of Notes and of transfers of Notes. The Note Register shall be in written form or in any form
capable of being converted into written form within a reasonable period of time. The Trustee is
hereby appointed Note Registrar for the purpose of registering Notes and transfers of Notes as
herein provided. The Company may appoint a new Note Registrar without prior notice to Holders. The
Company may appoint one or more co-registrars.
Upon surrender for registration of transfer of any Note to the Note Registrar or any
co-registrar, and satisfaction of the requirements for such transfer set forth in this Section
2.05, the Company shall execute, and the Trustee shall authenticate and deliver, in the name of the
designated transferee or transferees, one or more new Notes of any authorized denominations and of
a like aggregate
principal amount and bearing such restrictive legends as may be required by this Indenture.
Notes may be exchanged for other Notes of any authorized denominations and of a like aggregate
principal amount, upon surrender of the Notes to be exchanged at any such office or agency
maintained by the Company pursuant to Section 4.05. Whenever any Notes are so surrendered for
exchange, the Company shall execute, and the Trustee shall authenticate and deliver, the Notes that
the Holder making the exchange is entitled to receive, bearing registration numbers not
contemporaneously outstanding.
All Notes presented or surrendered for registration of transfer or for exchange, purchase or
conversion shall (if so required by the Company, the Trustee, the Note Registrar or any
co-registrar) be duly endorsed, or be accompanied by a written instrument or instruments of
transfer in form satisfactory to the Company and duly executed, by the Holder thereof or its
attorney-in-fact duly authorized in writing.
No service charge shall be charged by the Company, the Trustee or the Notes Registrar to the
Holder for any exchange or registration of transfer of Notes, but the Holder may be required by the
Company, the Trustee, the Notes Registrar or otherwise to pay a sum sufficient to cover any tax,
assessments or other governmental charges that may be imposed in connection therewith as a result
of the name of the Holder of the new Notes issued upon such exchange or
16
registration of transfer of
Notes being different from the name of the Holder of the old Notes presented or surrendered for
such exchange or registration of transfer.
None of the Company, the Trustee, the Note Registrar or any co-registrar shall be required to
exchange or register a transfer of any Notes surrendered for conversion, redemption or repurchase
except for any portion of that Note that is not being repurchased, redeemed or converted, as the
case may be.
All Notes issued upon any registration of transfer or exchange of Notes in accordance with
this Indenture shall be the valid obligations of the Company, evidencing the same debt, and
entitled to the same benefits under this Indenture as the Notes surrendered upon such registration
of transfer or exchange. For greater certainty, all Notes issued upon any registration of transfer
or exchange of Notes will be issued as evidence of the same continuing indebtedness of the Company
under this Indenture and in no circumstances is the Company obligated under the Indenture to repay
the principal amount of the exchanged Notes by virtue of the registration of a transfer or
exchange.
(b) So long as the Notes are eligible for book-entry settlement with the Depositary, unless
otherwise required by law or except as provided in Section 2.05(c), all Notes shall be represented
by one or more Notes in global form (each, a Global Note) registered in the name of the
Depositary or the nominee of the Depositary. The transfer and exchange of beneficial interests in
a Global Note
that does not involve the issuance of a Note in certificated form shall be effected through
the Depositary (but not the Trustee or the Custodian) in accordance with this Indenture (including
the restrictions on transfer set forth herein) and the procedures of the Depositary therefor.
Members of, or participants in, the Depositary (Agent Members) shall have no rights under this
Indenture with respect to any Global Note held on their behalf by the Depositary, or the Trustee as
its custodian, or under the Global Note, and the Depositary may be treated by the Company, the
Trustee and any agent of the Company or the Trustee as the absolute owner of the Global Note for
all purposes whatsoever. Notwithstanding the foregoing, nothing herein shall prevent the Company,
the Trustee or any agent of the Company or the Trustee from giving effect to any written
certification, proxy or other authorization furnished by the Depositary or impair, as between the
Depositary and its Agent Members, the operation of customary practices governing the exercise of
the rights of any Holder.
(c) Every Note that bears or is required under this Section 2.05(c) to bear the legend set
forth in this Section 2.05(c) (together with any Common Stock issued upon conversion of the Notes
and required to bear a similar legend, the Restricted Securities) shall be subject to the
restrictions on transfer set forth in this Section 2.05(c) (including the legend set forth below),
and the holder of each such Restricted Security, by such holders acceptance thereof, agrees to be
bound by all such restrictions on transfer. As used in this Section 2.05(c), the term
17
transfer
encompasses any sale, pledge, transfer or other disposition whatsoever of any Restricted Security.
Until the date (the Resale Restriction Termination Date) that is the later of (1) the date
that is one year after the last date of original issuance of the Notes and (2) such later date, if
any, as may be required by applicable laws, any certificate evidencing such Note (and all
securities issued in exchange therefor or substitution thereof, and all shares of Common Stock, if
any, issued upon conversion thereof, if applicable) shall bear a legend in substantially the
following form (unless such Notes or shares of Common Stock, if any, have been transferred pursuant
to a registration statement that has become or been declared effective under the Securities Act and
that continues to be effective at the time of such transfer, pursuant to the exemption from
registration provided by Rule 144 or any similar provision then in force under the Securities Act,
or unless otherwise agreed by the Company in writing, with written notice thereof to the Trustee):
THE SALE OF THIS NOTE HAS NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS
AMENDED (THE SECURITIES ACT), AND ACCORDINGLY, THIS NOTE MAY NOT BE OFFERED, SOLD, PLEDGED OR
OTHERWISE TRANSFERRED EXCEPT AS SET FORTH IN THE FOLLOWING SENTENCE. BY ITS ACQUISITION HEREOF, OR
OF A BENEFICIAL OWNERSHIP HEREIN, THE ACQUIRER: (I) REPRESENTS THAT IT, AND ANY ACCOUNT FOR WHICH
IT IS ACTING, IS A QUALIFIED INSTITUTIONAL BUYER (WITHIN THE MEANING OF RULE 144A UNDER THE
SECURITIES ACT) AND THAT IT EXERCISES
SOLE INVESTMENT DISCRETION WITH RESPECT TO EACH SUCH ACCOUNT, AND (II) AGREES (1) THAT IT WILL
NOT WITHIN THE LATER OF (X) ONE YEAR AFTER THE LAST DATE OF ORIGINAL ISSUANCE OF NOTES (INCLUDING
THROUGH THE EXERCISE OF THE OPTION TO PURCHASE ADDITIONAL NOTES) AND (Y) 90 DAYS AFTER IT CEASES TO
BE AN AFFILIATE (WITHIN THE MEANING OF RULE 144 UNDER THE SECURITIES ACT) OF MANNKIND CORPORATION
(THE COMPANY), OFFER, RESELL, PLEDGE OR OTHERWISE TRANSFER THE NOTES EVIDENCED HEREBY, THE COMMON
STOCK ISSUABLE UPON CONVERSION OF SUCH NOTES OR ANY BENEFICIAL OWNERSHIP HEREIN, EXCEPT: (A) TO THE
COMPANY OR ANY SUBSIDIARY THEREOF; (B) UNDER A REGISTRATION STATEMENT THAT HAS BECOME EFFECTIVE
UNDER THE SECURITIES ACT; (C) TO A PERSON THE SELLER REASONABLY BELIEVES IS A QUALIFIED
INSTITUTIONAL BUYER (AS DEFINED IN RULE 144A UNDER THE SECURITIES ACT) THAT IS PURCHASING FOR ITS
OWN ACCOUNT OR FOR THE ACCOUNT OF ANOTHER QUALIFIED INSTITUTIONAL BUYER AND TO WHOM NOTICE IS GIVEN
THAT THE TRANSFER IS BEING MADE IN RELIANCE ON RULE 144A, ALL IN COMPLIANCE WITH RULE 144A (IF
AVAILABLE); OR (D) UNDER ANY OTHER AVAILABLE
18
EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE
SECURITIES ACT, INCLUDING RULE 144, IF AVAILABLE; AND (2) THAT IT WILL, PRIOR TO ANY TRANSFER OF
THIS NOTE WITHIN THE LATER OF (X) SIX MONTHS (OR, IF THE COMPANY HAS NOT SATISFIED THE CURRENT
PUBLIC INFORMATION REQUIREMENTS OF RULE 144, ONE YEAR) AFTER THE LAST DATE OF ORIGINAL ISSUANCE OF
NOTES (INCLUDING THROUGH THE EXERCISE OF THE OPTION TO PURCHASE ADDITIONAL NOTES) AND (Y) 90 DAYS
AFTER IT CEASES TO BE AN AFFILIATE (WITHIN THE MEANING OF RULE 144) OF THE COMPANY, FURNISH TO THE
TRUSTEE AND THE COMPANY SUCH CERTIFICATIONS, LEGAL OPINIONS OR OTHER INFORMATION AS THEY MAY
REQUIRE AND MAY RELY UPON TO CONFIRM THAT SUCH TRANSFER IS BEING MADE PURSUANT TO AN EXEMPTION
FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND
APPLICABLE STATE SECURITIES LAWS. IN ANY EVENT, NO AFFILIATE OF THE COMPANY MAY RESELL THIS NOTE
OTHER THAN UNDER A REGISTRATION STATEMENT THAT HAS BECOME EFFECTIVE UNDER THE SECURITIES ACT OR
PURSUANT TO AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT IN A TRANSACTION
THAT RESULTS IN SUCH NOTE NO LONGER BEING RESTRICTED SECURITIES (AS DEFINED UNDER RULE 144). NO
REPRESENTATION IS MADE AS TO THE AVAILABILITY OF ANY EXEMPTION FROM THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT. EACH PURCHASER AND TRANSFEREE OF A NOTE AND THE COMMON STOCK ISSUABLE UPON
CONVERSION OF A NOTE WILL BE DEEMED
TO HAVE REPRESENTED BY ITS PURCHASE AND HOLDING OF THE NOTE AND THE COMMON STOCK ISSUABLE UPON
CONVERSION OF THE NOTE THAT (A) ITS PURCHASE AND HOLDING OF THE NOTE AND THE COMMON STOCK ISSUABLE
UPON CONVERSION OF THE NOTE IS NOT MADE ON BEHALF OF OR WITH PLAN ASSETS OF ANY PLAN SUBJECT TO
TITLE I OF ERISA, SECTION 4975 OF THE CODE OR ANY SIMILAR LAW OR (B) ITS PURCHASE AND HOLDING OF
THE NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THE NOTE WILL NOT RESULT IN A NON-EXEMPT
PROHIBITED TRANSACTION UNDER SECTION 406 OF ERISA, SECTION 4975 OF THE CODE OR ANY SIMILAR LAW.
Any Common Stock issued upon conversion of the Notes prior to the Resale Restriction
Termination Date shall bear a similar legend.
No transfer of any Note prior to the Resale Restriction Termination Date will be registered by
the Note Registrar unless the applicable box on the Form of Assignment and Transfer has been
checked.
19
Notwithstanding anything to the contrary contained in this Indenture or the Note, such Note
(or security issued in exchange or substitution therefor) as to which such restrictions on transfer
shall have expired in accordance with their terms may, upon surrender of such Note for exchange to
the Note Registrar in accordance with the provisions of this Section 2.05, be exchanged for a new
Note or Notes, of like tenor and aggregate principal amount, which shall not bear the restrictive
legend required by this Section 2.05(c).
Notwithstanding any other provisions of this Indenture (other than the provisions set forth in
this Section 2.05(c)), a Global Note may not be transferred as a whole or in part except by the
Depositary to a nominee of the Depositary or by a nominee of the Depositary to the Depositary or
another nominee of the Depositary or by the Depositary or any such nominee to a successor
Depositary or a nominee of such successor Depositary.
The Depositary shall be a clearing agency registered under the Exchange Act. The Company
initially appoints The Depository Trust Company (DTC) to act as Depositary with respect to the
Global Note. Initially, the Global Notes shall be issued to the Depositary, registered in the name
of Cede & Co., as the nominee of the Depositary, and deposited with the Trustee as custodian for
DTC.
If (i) the Depositary notifies the Company at any time that the Depositary is unwilling or
unable to continue as depositary for the Global Notes and a successor depositary is not appointed
within 90 days, (ii) the Depositary ceases to be registered as a clearing agency under the Exchange
Act and a successor depositary is not appointed within 90 days or (iii) an Event of Default with
respect to the Notes has occurred and is continuing, upon the request of the beneficial owner of
the Notes, the Company will execute, and the Trustee, upon receipt of
an Officers Certificate and a Company Order for the authentication and delivery of Notes,
will authenticate and deliver Notes in definitive form to each such beneficial owner of the related
Notes (or a portion thereof) in an aggregate principal amount equal to the principal amount of such
Global Note, in exchange for such Global Note, and upon delivery of the Global Note to the Trustee
such Global Note shall be canceled.
Notes in certificated form issued in exchange for all or a part of the Global Note pursuant to
this Section 2.05(c) shall be registered in such names and in such authorized denominations as the
Depositary, pursuant to instructions from its direct or indirect participants or otherwise, shall
instruct the Trustee. Upon execution and authentication, the Trustee shall deliver such Notes in
certificated form to the Persons in whose names such Notes are so registered.
At such time as all interests in a Global Note have been converted, canceled, redeemed,
purchased or transferred, such Global Note shall be, upon receipt thereof, canceled by the Trustee
in accordance with standing procedures
20
and instructions existing between the Depositary and the
Custodian. At any time prior to such cancellation, if any interest in a Global Note is exchanged
for Notes in certificated form, converted, canceled, purchased or transferred to a transferee who
receives Notes in certificated form therefor or any Note in certificated form is exchanged or
transferred for part of such Global Note, the principal amount of such Global Note shall, in
accordance with the standing procedures and instructions existing between the Depositary and the
Custodian, be appropriately reduced or increased, as the case may be, and an endorsement shall be
made on such Global Note, by the Trustee or the Custodian, at the direction of the Trustee, to
reflect such reduction or increase.
None of the Company, the Trustee nor any agent of the Company or the Trustee will have any
responsibility or liability for any aspect of the records relating to or payments made on account
of beneficial ownership interests of a Global Note or maintaining, supervising or reviewing any
records relating to such beneficial ownership interests.
(d) The Company may cause the removal of the legends required by Sections 2.06(c) from any
Global Note at any time on or after the Resale Restriction Date by: (i) instructing the Trustee to
remove the such legends from such Global Note; (ii) providing to the Trustee and the Depositary
written notice to change the CUSIP number for the Notes to the applicable unrestricted CUSIP
number; and (iv) complying with any Applicable Procedures for delegending or otherwise exchanging
such Global Note for a Global Note not bearing the restrictive legend (including DTCs mandatory
exchange process, if applicable); whereupon any legends otherwise required by Section 2.06(c) shall
be removed from any Global Notes without any further action on the part of the Holders.
Section 2.06. Mutilated, Destroyed, Lost or Stolen Notes. In case any Note shall become
mutilated or be destroyed, lost or stolen, the Company in its
discretion may execute, and upon its written request the Trustee or an authenticating agent
appointed by the Trustee shall authenticate and deliver, a new Note, bearing a number not
contemporaneously outstanding, in exchange and substitution for the mutilated Note, or in lieu of
and in substitution for the Note so destroyed, lost or stolen. In every case the applicant for a
substituted Note shall furnish to the Company, to the Trustee and, if applicable, to the
authenticating agent, such security or indemnity as may be required by them to save each of them
harmless from any loss, liability, cost or expense caused by or connected with such substitution,
and, in every case of destruction, loss or theft, the applicant shall also furnish to the Company,
to the Trustee and, if applicable, to the authenticating agent, evidence to their satisfaction of
the destruction, loss or theft of such Note and of the ownership thereof.
The Trustee or the authenticating agent, if applicable, may authenticate any such substituted
Note and deliver the same upon the receipt of such security
21
or indemnity as the Trustee, the
Company and, if applicable, the authenticating agent may require. Upon the issuance of any
substitute Note, the Company or the Trustee may require the payment by the Holder of a sum
sufficient to cover any tax, assessment or other governmental charge that may be imposed in
relation thereto and any other expenses connected therewith. In case any Note that has matured or
is about to mature or has been tendered for redemption or purchase upon a Fundamental Change or is
about to be converted shall become mutilated or be destroyed, lost or stolen, the Company may, in
its sole discretion, instead of issuing a substitute Note, pay or authorize the payment of or
convert or authorize the conversion of the same (without surrender thereof except in the case of a
mutilated Note), as the case may be, if the applicant for such payment or conversion shall furnish
to the Company, to the Trustee and, if applicable, to the authenticating agent, such security or
indemnity as may be required by them to save each of them harmless for any loss, liability, cost or
expense caused by or connected with such substitution, and, in every case of destruction, loss or
theft, evidence satisfactory to the Company, the Trustee and, if applicable, any Paying Agent or
Conversion Agent evidence of their satisfaction of the destruction, loss or theft of such Note and
of the ownership thereof.
Every substitute Note issued pursuant to the provisions of this Section 2.06 by virtue of the
fact that any Note is destroyed, lost or stolen shall constitute an additional contractual
obligation of the Company, whether or not the destroyed, lost or stolen Note shall be found at any
time, and shall be entitled to all the benefits of (but shall be subject to all the limitations set
forth in) this Indenture equally and proportionately with any and all other Notes duly issued
hereunder. To the extent permitted by law, all Notes shall be held and owned upon the express
condition that the foregoing provisions are exclusive with respect to the replacement or payment or
conversion or purchase of mutilated, destroyed, lost or stolen Notes and shall preclude any and all
other rights or remedies, notwithstanding any law or statute existing or hereafter enacted to the
contrary
with respect to the replacement or payment or conversion of negotiable instruments or other
securities without their surrender.
For greater certainty, every substitute Note issued pursuant to the provisions of this Section
2.06 by virtue of the fact that any Note is mutilated, destroyed, lost or stolen will be issued as
evidence of the same continuing indebtedness of the Company under this Indenture and in no
circumstances is the Company obligated under the Indenture to repay the principal amount of the
substituted Note by virtue of such mutilation, destruction or loss.
Section 2.07. Temporary Notes. Pending the preparation of Notes in certificated form, the
Company may execute and the Trustee or an authenticating agent appointed by the Trustee shall, upon
written request of the Company, authenticate and deliver temporary Notes (printed or lithographed).
Temporary Notes shall be issuable in any authorized denomination, and substantially in the
22
form of
the Notes in certificated form but with such omissions, insertions and variations as may be
appropriate for temporary Notes, all as may be determined by the Company. Every such temporary
Note shall be executed by the Company and authenticated by the Trustee or such authenticating agent
upon the same conditions and in substantially the same manner, and with the same effect, as the
Notes in certificated form. Without unreasonable delay, the Company will execute and deliver to
the Trustee or such authenticating agent Notes in certificated form (other than any Global Note)
and thereupon any or all temporary Notes (other than any Global Note) may be surrendered in
exchange therefor, at each office or agency maintained by the Company pursuant to Section 4.05 and
the Trustee or such authenticating agent shall authenticate and deliver in exchange for such
temporary Notes an equal aggregate principal amount of Notes in certificated form. Such exchange
shall be made by the Company at its own expense and without any charge therefor. Until so
exchanged, the temporary Notes shall in all respects be entitled to the same benefits and subject
to the same limitations under this Indenture as Notes in certificated form authenticated and
delivered hereunder.
For greater certainty, each Note issued pursuant to the provisions of this Section 2.07 in
exchange for a temporary Note will be issued as evidence of the same continuing indebtedness of the
Company under this Indenture and in no circumstances is the Company obligated under the Indenture
to repay the principal amount of the temporary Note by virtue of the exchange.
Section 2.08. Cancellation of Notes Paid, Etc. All Notes surrendered for the purpose of
payment, purchase, conversion, exchange or registration of transfer, shall, if surrendered to the
Company or any Paying Agent or any Note Registrar or any Conversion Agent, be surrendered to the
Trustee and promptly canceled by it, or, if surrendered to the Trustee, shall be promptly canceled
by it, and no Notes shall be issued in lieu thereof except as expressly permitted by any of the
provisions of this Indenture. The Trustee shall dispose of canceled Notes in accordance with its
customary procedures and, after such disposition, shall deliver
a written confirmation of such disposition to the Company, at the Companys written request.
If the Company shall acquire any of the Notes, such acquisition shall not operate as satisfaction
of the indebtedness represented by such Notes unless and until the same are delivered to the
Trustee for cancellation.
Section 2.09. CUSIP and ISIN Numbers. The Company in issuing the Notes may use CUSIP and
ISIN numbers (if then generally in use), and, if so, the Trustee shall use CUSIP and ISIN
numbers in all notices issued to Holders of the Notes as a convenience to such Holders; provided
that any such notice may state that no representation is made as to the correctness of such numbers
either as printed on the Notes or on such notice and that reliance may be placed only on the other
identification numbers printed on the Notes. The
23
Company will promptly notify the Trustee in
writing of any change in the CUSIP or ISIN numbers.
Section 2.10. Additional Notes; Purchases. The Company may, without the consent of the
Holders of the Notes and notwithstanding Section 2.01, issue additional Notes hereunder with the
same terms and with the same CUSIP and ISIN number as the Notes initially issued hereunder in an
unlimited aggregate principal amount, which will form the same series with the Notes initially
issued hereunder; provided that no such additional Notes may be issued unless they would constitute
a qualified reopening (as defined in Treas. Reg. Sec. 1.1275-2(k)) or both the original Notes and
the additional Notes are issued with no more than de minimis original issue discount for U.S.
federal income tax purposes. Prior to the issuance of any such additional Notes, the Company shall
deliver to the Trustee a Company Order, an Officers Certificate to the effect that such issuance
of additional Notes complies with the provisions of the Indenture (including this Section 2.10).
The Company may also from time to time purchase the Notes in open market purchases or negotiated
transactions without prior notice to Holders. Any Notes purchased by the Company shall be deemed
to be no longer Outstanding under this Indenture.
ARTICLE 3
Satisfaction and Discharge
Section 3.01. Satisfaction and Discharge. This Indenture shall upon request of the Company
contained in an Officers Certificate cease to be of further effect, and the Trustee, at the
expense of the Company, shall execute proper instruments acknowledging satisfaction and discharge
of this Indenture, when (a) (i) the Company delivers to the Trustee all Outstanding Notes (other
than Notes replaced pursuant to Section 2.06) for cancellation; or (ii) the Company has deposited
with the Trustee or delivered to Holders of Notes, as applicable, after the Notes have become due
and payable, whether at the Maturity Date, or any Fundamental Change Purchase Date, or upon
conversion or otherwise, cash and/or (in the case of conversion) shares of Common Stock (together
with cash in
lieu of fractional shares), as applicable, sufficient to pay all of the Outstanding Notes and
all other sums payable under this Indenture by the Company; and (b) the Company has delivered to
the Trustee an Officers Certificate and an Opinion of Counsel, each stating that all conditions
precedent herein provided for relating to the satisfaction and discharge of this Indenture have
been complied with. Notwithstanding the satisfaction and discharge of this Indenture, the
obligations of the Company to the Trustee under Section 7.06 shall survive such satisfaction and
discharge.
Section 3.02. Deposited Monies To Be Held In Trust. Subject to Section 3.03 hereof, all
monies deposited with the Trustee pursuant to Section 3.01 hereof
24
shall be held in trust and
applied by it to the payment, either directly or through any Paying Agent (including the Company if
acting as its own Paying Agent), to the Holders for the payment or repurchase of which such monies
have been deposited with the Trustee, of all sums due and to become due thereon for principal,
premium, if any, and interest. All monies deposited with the Trustee pursuant to Section 3.01
hereof (and held by it or any Paying Agent) for the payment of Notes subsequently converted shall
be returned to the Company upon request of the Company.
Section 3.03. Return Of Unclaimed Monies. The Trustee and the Paying Agent shall pay to the
Company upon written request any money held by them for the payment of principal of or accrued and
unpaid interest on the Notes that remains unclaimed for two years after the date upon which such
payment shall have become due. Notwithstanding the foregoing, the Trustee and Paying Agent shall
have the right to withhold payment of such money to the Company until the Trustee or Paying Agent
at the expense of the Company publishes in a newspaper of general circulation in New York City, or
mails to each Holder, a notice stating that such money shall be repaid to the Company if unclaimed
after a date no less than 30 days from the publication of such press release or mailing. After
payment to the Company by the Trustee or Paying Agent, all liability of the Trustee and the Paying
Agent with respect to such money shall cease, and Holders entitled to the money must look to the
Company for payment as general creditors, subject to applicable law.
ARTICLE 4
Particular Covenants of the Company
Section 4.01. Payment of Principal and Interest. (a) The Company shall promptly make all
payments in respect of the Notes on the dates and in the manner provided in the Notes and this
Indenture. A payment of principal or interest shall be considered paid on the date it is due if the
Paying Agent holds by 10:00 a.m. (New York City time) on that date money or securities, deposited
by or on behalf of the Company sufficient to make the payment. The Company shall, to the fullest
extent permitted by law, pay interest in immediately available funds
on overdue principal amount and interest at the annual rate borne by the Notes compounded
semiannually, which interest shall accrue from the date such overdue amount was originally due to
the date payment of such amount, including interest thereon, has been made or duly provided for.
All such interest shall be payable on demand.
(b) Payment of the principal of and interest, if any, on the Notes shall be made at the office
or agency of the Company maintained for that purpose, which shall initially be at the Trustees
Corporate Trust Office, in such coin or currency of the United States of America as at the time of
payment is legal tender for
25
payment of public and private debts; provided, however, that, subject
to Section 2.03, the Company may pay principal and interest in respect of any Note in certificated
form by check or wire transfer payable in such money. Notwithstanding the foregoing, so long as the
Notes are registered in the name of a Depositary or its nominee, all payments thereon shall be made
by wire transfer of immediately available funds to the account of the Depositary or its nominee.
Section 4.02. Corporate Existence. Subject to Article 10 hereof, the Company will do or
cause to be done all things necessary to preserve and keep in full force and effect its corporate
existence and rights (charter and statutory); provided, however, that the Company shall not be
required to preserve any such right or franchise if the Company determines that the preservation
thereof is no longer desirable in the conduct of the business of the Company and that the loss
thereof is not disadvantageous in any material respect to the Holders.
Section 4.03. Rule 144A Information Requirement and Reports. (a) At any time the Company is
not subject to Sections 13 or 15(d) of the Exchange Act, the Company shall, so long as any of the
Notes or any shares of Common Stock issuable upon conversion thereof shall, at such time,
constitute restricted securities within the meaning of Rule 144(a)(3) under the Securities Act,
upon written request, provide to any Holder, beneficial owner or prospective purchaser of such
Notes or any shares of Common Stock issued upon conversion of such Notes, the information required
to be delivered pursuant to Rule 144A(d)(4) under the Securities Act to facilitate the resale of
such Notes or shares of Common Stock pursuant to Rule 144A under the Securities Act.
(b) The Company shall furnish to the Trustee within 15 calendar days after the Company is
required to file any documents or reports with the Commission pursuant to Sections 13 or 15(d) of
the Exchange Act (giving effect to all applicable grace periods provided under the Exchange Act
including that provided by Rule 12b-25 under the Exchange Act) copies of such documents or reports.
Any such document or report that the Company files with the Commission through the Commissions
EDGAR system shall be deemed furnished to the Trustee for purposes of this Section 4.03(b) at the
time such documents are filed or furnished via the Commissions EDGAR system, provided that the
Trustee shall have no responsibility for determining whether such filing
has taken place, nor shall the Trustee have any liability for the timeliness or content of any
filing or report hereunder.
Section 4.04. Compliance Certificate. The Company shall deliver to the Trustee, within 120
days after the end of each fiscal year of the Company
(beginning with the fiscal year ending
December 31, 2010) an Officers Certificate stating whether or not, to the knowledge of such
officer, the Company is in default in the performance and observance of any of the terms,
provisions and conditions of this Indenture and, if the Company shall be in default,
26
specifying
all such defaults and the nature and status thereof of which they may have knowledge. Within five
Business Days of an Officer of the Company coming to have actual knowledge of a Default or Event of
Default, regardless of the date, the Company shall deliver an Officers Certificate to the Trustee
specifying such Default or Event of Default and the nature and status thereof.
Section 4.05. Maintenance of Office or Agency. So long as any Notes remain Outstanding, the
Company agrees to maintain an office or agency with respect to such Notes and at such other
location or locations as may be designated as provided in this Section 4.05, where (i) Notes may
be presented for conversion (Conversion Agent), (ii) Notes may be presented for payment (Paying
Agent), (ii) Notes may be presented as herein above authorized for registration of transfer and
exchange, and (iii) notices and demands to or upon the Company in respect of the Notes and this
Indenture may be given or served, such designation to continue with respect to such office or
agency until the Company shall, by written notice signed by any officer authorized to sign an
Officers Certificate and delivered to the Trustee, designate some other office or agency for such
purposes or any of them. If at any time the Company shall fail to maintain any such required office
or agency or shall fail to furnish the Trustee with the address thereof, such presentations,
notices and demands may be made or served at the Corporate Trust Office of the Trustee, and the
Company hereby appoints the Trustee as its agent to receive all such presentations, notices and
demands. The Company initially appoints the Corporate Trust Office of the Trustee as Conversion
Agent and Paying Agent with respect to the Notes.
Section 4.06. Paying Agents. (a) If the Company shall appoint one or more paying agents for
the Notes, other than the Trustee, the Company will cause each such paying agent to execute and
deliver to the Trustee an instrument in which such agent shall agree with the Trustee, subject to
the provisions of this Section 4.06:
(i) that it will hold all sums held by it as such agent for the payment of the
principal of (and premium, if any) or interest on the Notes (whether such sums have been
paid to it by the Company or by any other obligor of such Notes) in trust for the benefit
of the Persons entitled thereto;
(ii) that it will give the Trustee notice of any failure by the Company to make any
payment of the principal of (and premium, if any) or interest on the Notes when the same
shall be due and payable;
(iii) that it will, at any time during the continuance of any failure referred to in
the preceding paragraph (a)(ii) above, upon the written request of the Trustee, forthwith
pay to the Trustee all sums so held in trust by such paying agent; and
27
(iv) that it will perform all other duties of paying agent as set forth in this
Indenture.
(b) If the Company shall act as its own paying agent with respect to any Notes, it will on or
before each due date of the principal of (and premium, if any) or interest on the Notes, set aside,
segregate and hold in trust for the benefit of the Persons entitled thereto a sum sufficient to pay
such principal (and premium, if any) or interest so becoming due on Notes until such sums shall be
paid to such Persons or otherwise disposed of as herein provided and will promptly notify the
Trustee of such action, or any failure to take such action. The Trustee shall have no liability or
responsibility for the action or inaction of any Paying Agent (that is not the Trustee).
(c) Notwithstanding anything in this Section 4.06 to the contrary, (i) the agreement to hold
sums in trust as provided in this Section 4.06 is subject to the provisions of Section 3.02 and
Section 3.03, and (ii) the Company may at any time, for the purpose of obtaining the satisfaction
and discharge of this Indenture or for any other purpose, pay, or direct any paying agent to pay,
to the Trustee all sums held in trust by the Company or such paying agent, such sums to be held by
the Trustee upon the same terms and conditions as those upon which such sums were held by the
Company or such paying agent; and, upon such payment by the Company or any paying agent to the
Trustee, the Company or such paying agent shall be released from all further liability with respect
to such money.
Section 4.07. Appointment to Fill Vacancy in Office of Trustee. The Company, whenever
necessary to avoid or fill a vacancy in the office of Trustee, will appoint, in the manner provided
in Section 7.10, a Trustee, so that there shall at all times be a Trustee hereunder.
ARTICLE 5
Holders Lists and Reports by the Company and the Trustee
Section 5.01. Company to Furnish Trustee Names and Addresses of Holders. The Company will
furnish or cause to be furnished to the Trustee (a) within 10 days after each Regular Record Date,
a list, in such form as the Trustee may reasonably require, of the names and addresses of the
Holders as of such regular record date, provided that the Company shall not be obligated to furnish
or
cause to furnish such list at any time that the list shall not differ in any respect from the
most recent list furnished to the Trustee by the Company and
(b) at such other times as the Trustee
may request in writing within 30 days after the receipt by the Company of any such request, a list
of similar form and content as of a date not more than 15 days prior to the time such list is
furnished; provided, however, that, in either case, no such list need be furnished for any Notes
for which the Trustee shall be the Note Registrar.
28
Section 5.02. Preservation Of Information; Communications With Holders.
(a) The Trustee shall preserve, in as current a form as is reasonably practicable, all
information as to the names and addresses of the Holders of Notes contained in the most recent list
furnished to it as provided in Section 5.01 and as to the names and addresses of Holders of Notes
received by the Trustee in its capacity as Note Registrar (if acting in such capacity).
(b) The Trustee may destroy any list furnished to it as provided in Section 5.01 upon receipt
of a new list so furnished.
(c) The rights of Holders to communicate with other Holders with respect to their rights under
this Indenture or under the Notes, and the corresponding rights and duties of the Trustee, shall be
as provided by the Trust Indenture Act.
(d) Every Holder, by receiving and holding the same, agrees with the Company and the Trustee
that neither the Company nor the Trustee nor any agent of either of them shall be held accountable
by reason of any disclosure of information as to names and addresses of Holders made pursuant
hereto or otherwise in accordance with the Trust Indenture Act.
Section 5.03. Reports by the Trustee.
(a) On or before July 1 in each year, commencing July 1, 2011, in which any of the Notes are
Outstanding, the Trustee shall transmit by mail, first class postage prepaid, to the Holders, as
their names and addresses appear upon the Note Register, a brief report dated as of the preceding
May 1, if and to the extent required under Section 313(a) of the Trust Indenture Act.
(b) The Trustee shall comply with Section 313(b) and 313(c) of the Trust Indenture Act.
(c) A copy of each such report shall, at the time of such transmission to Holders, be filed by
the Trustee with the Company, with each securities exchange upon which any Notes are listed (if so
listed) and also with the Securities and Exchange Commission. The Company agrees to notify the
Trustee when any Notes become listed on any securities exchange.
29
ARTICLE 6
Default and Remedies
Section 6.01. Events of Default. An Event of Default shall occur when any of the following
occurs:
(a) the Company fails to pay when due the principal of or premium, if any, on any of the Notes
at the Maturity Date, upon repurchase, redemption, acceleration or otherwise; or
(b) the Company fails to pay an installment of interest on any of the Notes for 30 days after
the date when due; or
(c) the Company fails to deliver when due all shares of Common Stock, together with cash
instead of fractional shares, and/or other property, if applicable, deliverable upon conversion of
the Notes pursuant to Article 13, which failure continues for 10 days; or
(d) the Company fails to perform or observe any other term, covenant or agreement contained in
the Notes or this Indenture for a period of 60 days after written notice of such failure, requiring
the Company to remedy the same, shall have been given to the Company by the Trustee or to the
Company and the Trustee by the Holders of at least 25% in aggregate principal amount of the
then-Outstanding Notes; or
(e) (i) the Company fails to make any payment by the end of the applicable grace period, if
any, after the maturity of any indebtedness for borrowed money in an amount in excess of
$25,000,000 or (ii) there is an acceleration of any indebtedness for borrowed money in an amount in
excess of $25,000,000 because of a default with respect to such indebtedness without such
indebtedness having been discharged or such acceleration having been cured, waived, rescinded or
annulled, in the case of either (i) or (ii) above, for a period of 30 days after written notice to
the Company by the Trustee or to the Company and the Trustee by Holders of at least 25% in
aggregate principal amount of the then-Outstanding Notes; or
(f) the Company fails to provide a Fundamental Change Company Notice in accordance with
Section 15.01; or
(g) a court having jurisdiction enters a decree or order under any Bankruptcy Law that: (i)
for relief against the Company in an involuntary case or proceeding; or adjudicates the Company
bankrupt or insolvent; or (ii) appoints a Receiver of the Company or of any substantial part of its
property; or (iii) orders the winding up or liquidation of the Company, and (iv) the decree or
order remains unstayed and in effect for a period of 90 days; or
30
(h) the Company pursuant to or within the meaning of any Bankruptcy Law:
(i) commences as a debtor a voluntary case or proceeding;
(ii) consents to the entry of an order for relief against it in an involuntary case
or proceeding or the commencement of any case against it;
(iii) consents to the appointment of a Receiver of it or for all or substantially all
of its property;
(iv) makes a general assignment for the benefit of its creditors;
(v) files a petition in bankruptcy or answer or consent seeking reorganization or
relief; or
(vi) consents to the filing of such a petition or the appointment of or taking
possession by a Receiver.
The term Bankruptcy Law means Title 11 of the United States Code (or any successor thereto)
or any similar federal or state law for the relief of debtors. The term Receiver means any
receiver, trustee, assignee, liquidator, sequestrator or similar official under any Bankruptcy Law.
Section 6.02. Acceleration of Maturity; Rescission and Annulment. If an Event of Default
with respect to Outstanding Notes (other than an Event of Default specified Section 6.01(g) or
6.01(h) hereof in respect of the Company) occurs and is continuing, the Trustee or the Holders of
at least 25% in aggregate principal amount of the then-Outstanding Notes, by written notice to the
Trustee, may declare the Notes due and payable at their principal amount plus any accrued and
unpaid interest, and thereupon the Trustee may, at its discretion, proceed to protect and enforce
the rights of the Holders by the appropriate judicial proceedings. Such declaration may be
rescinded and annulled with the written consent of the Holders of a majority in aggregate principal
amount of the then-Outstanding Notes, subject to the provisions of this Indenture.
If an Event of Default specified in Section 6.01(g) or 6.01(h) hereof occurs and is
continuing, then all unpaid principal of and accrued and unpaid interest on the Outstanding Notes
shall become immediately due and payable, without any declaration or other act on the part of the
Trustee or any Holder.
Notwithstanding the foregoing, at the election of the Company, the sole remedy for an Event of
Default specified in Section 6.01(d) relating to the failure by the Company to comply with its
reporting obligations under Section 4.03 and for any failure to comply with the requirements of
Section 314(a)(1) of the Trust
31
Indenture Act, shall (i) for the first 90 days after the occurrence
of such an Event
of Default, consist exclusively of the right to receive special interest on Notes (the
Special Interest) at an annual rate equal to 0.25% of the principal amount of the Outstanding
Notes, and (ii) for the next 90 days after the expiration of such 90 day period, consist
exclusively of the right to receive Special Interest on the Notes at an annual rate equal to 0.50%
of the principal amount of the Outstanding Notes.
The Special Interest shall be paid semi-annually in arrears, with the first semi-annual
payment due on the first Interest Payment Date following the date on which the Special Interest
began to accrue on any Notes. The Special Interest will accrue on all Outstanding Notes from and
including the date on which an Event of Default relating to a failure to comply with the reporting
obligations under Section 4.03 or a failure to comply with the requirements of Section 314(a)(1) of
the Trust Indenture Act first occurs to but not including the 180th day thereafter (or such earlier
date on which the Event of Default relating to such reporting obligations shall have been cured or
waived). On such 180th day (or earlier, if such Event of Default is cured or waived pursuant to
Section 6.04 prior to such 180th day), such Special Interest will cease to accrue and, if such
Event of Default relating to such reporting obligations has not been cured or waived prior to such
180th day the Notes shall be subject to acceleration as provided above in this Section 6.02. The
provisions described in this paragraph shall not affect the rights of the Holders in the event of
the occurrence of any other Event of Default. In the event the Company does not elect to pay
Special Interest upon an Event of Default in accordance with this paragraph, the Notes will be
subject to acceleration as provided in this Section 6.02. If the Company elects to pay Special
Interest as the sole remedy for an Event of Default specified in Section 6.01(d) relating to the
failure by the Company to comply with its obligations under Section 4.03 or any failure to comply
with the requirements of Section 314(a)(1) of the Trust Indenture Act, the Company shall notify in
writing, in the manner provided for in Section 17.03, the Holders and the Trustee of such election
at any time on or before the close of business on the date on which such Event of Default first
occurs.
The Holders of a majority in aggregate principal amount of the then-Outstanding Notes by
written notice to the Trustee may rescind and annul an acceleration and its consequences if:
(1) all existing Events of Default, other than the nonpayment of principal (including the
Redemption Price and the Fundamental Change Purchase Price, if applicable) of or interest on the
Notes which has become due solely because of the acceleration, have been remedied, cured or waived,
and
(2) the rescission would not conflict with any judgment or decree of a court of competent
jurisdiction;
32
provided, however, that in the event such declaration of acceleration has been made based on
the existence of an Event of Default under Section 6.01(e) hereof and such Event of Default has
been remedied, cured or waived in
accordance with Section 6.01(e) hereof, then, without any further action by the Holders, such
declaration of acceleration shall be rescinded automatically and the consequences of such
declaration shall be annulled. No such rescission or annulment shall affect any subsequent Default
or impair any right consequent thereon.
Section 6.03. Other Remedies. If an Event of Default with respect to Outstanding Notes
occurs and is continuing, the Trustee may pursue any available remedy by proceeding at law or in
equity to collect the payment of principal of or interest on the Notes or to enforce the
performance of any provision of the Notes.
Section 6.04. Waiver of Past Defaults. The Holders, either (a) through the written consent of
not less than a majority in aggregate principal amount of the Notes then Outstanding or (b) by the
adoption of a resolution, at a meeting of Holders of the Notes then Outstanding at which a quorum
is present, by the Holders of at least a majority in aggregate principal amount of the Outstanding
Notes represented at such meeting, may, on behalf of the Holders of all of the Notes, waive an
existing Default or Event of Default, except a Default or Event of Default:
(1) in the payment of the principal of or premium, if any, or interest on any Note;
(2) in respect of the right to convert any Note in accordance with Article 13; or
(3) in respect of the covenants or provisions hereof which, under Section 9.02 hereof, cannot
be modified or amended without the consent of the Holder of each Outstanding Note affected.
Upon any such waiver, such Default shall cease to exist, and any Event of Default arising
therefrom shall be deemed to have been cured, for every purpose of this Indenture; provided,
however, that no such waiver shall extend to any subsequent or other Default or impair any right
consequent thereon.
Section 6.05. Control by Majority. The Holders, either (a) through the written consent of not
less than a majority in aggregate principal amount of the Notes then Outstanding, or (b) by the
adoption of a resolution, at a meeting of Holders of the Notes then Outstanding at which a quorum
is present, by the Holders of at least a majority in aggregate principal amount of the Outstanding
Notes represented at such meeting, shall have the right to direct the time, method and place of
conducting any proceeding for any remedy available to the Trustee
33
or exercising any trust or power
conferred on the Trustee, subject to the provisions of this Indenture. However, the Trustee may
refuse to follow any direction that:
(a) conflicts with any law or with this Indenture,
(b) the Trustee determines may be unduly prejudicial to the rights of the Holders not joining
therein, or
(c) in the Trustees reasonable judgment may expose the Trustee to personal liability.
The Trustee may take any other action deemed proper by the Trustee which is not inconsistent
with such direction.
Section 6.06. Limitation On Suit. No Holder of any Note may pursue any remedy with respect
to this Indenture or the Notes (including instituting any proceeding, judicial or otherwise, with
respect to this Indenture or for the appointment of a receiver or trustee), except, in the case of
a Default or Event of Default in the payment of the principal of or premium on, if any, or interest
on the Notes unless:
(a) such Holder has previously given written notice to the Trustee of an Event of Default that
is continuing;
(b) the Holders of at least 25% in aggregate principal amount of the Notes then Outstanding
shall have made a written request to the Trustee, and shall have offered to the Trustee indemnity
satisfactory to the Trustee, to pursue the remedy;
(c) no direction inconsistent with such written request has been given to the Trustee by the
Holders of a majority in aggregate principal amount of the Notes then Outstanding (or such amount
as shall have acted at a meeting pursuant to the provisions of this Indenture);
(d) such Holder or Holders have offered the Trustee security or indemnity satisfactory to the
Trustee against any costs, liabilities or expenses incurred in complying with such request; and
(e) the Trustee has failed to comply with the request for 60 days after the receipt of such
request and an offer of indemnity.
A Holder of Notes may not use this Indenture to prejudice the rights of another Holder of
Notes or to obtain a preference or priority over another Holder of Notes (it being understood that
the Trustee does not have an affirmative duty to
34
ascertain whether or not such actions or
forbearances are unduly prejudicial to such Holders).
Section 6.07. Unconditional Rights of Holders to Receive Payment and to Convert. In addition
to the other rights and remedies set forth in this Article 6, the following shall apply with
respect to the Notes under this Indenture.
Notwithstanding any other provision in this Indenture, the Holder of any Note shall have the
right, which is absolute and unconditional, to receive payment
of the principal amount (including the Redemption Price and the Fundamental Change Purchase
Price, if applicable), interest, the Make-Whole Payment, if any, and Fundamental Change Make-Whole
Premium, if any, in respect of the Notes held by such Holder, on or after the respective due dates
expressed in the Notes and this Indenture, and to convert such Note in accordance with Article 13,
and to bring suit for the enforcement of any such payment on or after such respective due dates or
for the right to convert in accordance with Article 13, and shall not be impaired or affected
without the consent of such Holder.
Section 6.08. Collection of Indebtedness and Suits For Enforcement By the Trustee. The
Company covenants that if an Event of Default occurs under Section 6.01(a) or Section 6.01(b), then
the Company shall, upon demand of the Trustee, pay to it, for the benefit of the Holders of such
Notes, the whole amount then due and payable (as expressed therein or as a result of any
acceleration effected pursuant to Section 6.02 hereof) on such Notes for principal (including the
Redemption Price and Fundamental Change Purchase Price, if applicable) and premium, if any, and
interest and, to the extent that payment of such interest shall be legally enforceable, interest on
any overdue principal (including the Redemption Price and the Fundamental Change Purchase Price, if
applicable) and premium, if any, and on any overdue interest, in each case at the rate borne by the
Notes from the required payment date, and, in addition thereto, such further amount as shall be
sufficient to cover the costs and expenses of collection, including the reasonable compensation,
expenses, disbursements and advances of the Trustee, its agents and counsel.
If the Company fails to pay such amounts forthwith upon such demand, the Trustee, in its own
name and as trustee of an express trust, may institute a judicial proceeding for the collection of
the sums so due and unpaid, may prosecute such proceeding to judgment or final decree and may
enforce the same against the Company and collect the moneys adjudged or decreed to be payable in
the manner provided by law out of the property of the Company, wherever situated.
If an Event of Default occurs and is continuing, the Trustee may in its discretion proceed to
protect and enforce its rights and the rights of the Holders of Notes by such appropriate judicial
proceedings as the Trustee shall deem most
35
effectual to protect and enforce any such rights,
whether for the specific enforcement of any covenant or agreement in this Indenture or in aid of
the exercise of any power granted herein, or to enforce any other proper remedy.
Section 6.09. Trustee May File Proofs of Claim. In case of the pendency of any receivership,
insolvency, liquidation, bankruptcy, reorganization, arrangement, adjustment, composition or other
judicial proceeding relative to the Company or the property of the Company or its creditors, the
Trustee (irrespective of whether the principal of the Notes shall then be due and payable as
therein expressed or by declaration or otherwise and irrespective of whether the Trustee shall have
made any demand on the Company for the payment of overdue
principal or interest) shall be entitled and empowered, by intervention in such proceeding or
otherwise, (1) to file and prove a claim for the whole amount of principal (including the
Redemption Price and the Fundamental Change Purchase Price, if applicable) and premium, if any, and
interest owing and unpaid in respect of the Notes and to file such other papers or documents as may
be necessary or advisable in order to have the claims of the Trustee (including any claim for the
reasonable compensation, expenses, disbursements and advances of the Trustee, its agents and
counsel, and any other amounts due to the Trustee hereunder) and of the Holders of Notes allowed in
such judicial proceeding, and (2) to collect and receive any moneys or other property payable or
deliverable on any such claim and to distribute the same; and any custodian, receiver, assignee,
trustee, liquidator, sequestrator or other similar official in any such judicial proceedings is
hereby authorized by each Holder of Notes to make such payments to the Trustee and, in the event
that the Trustee shall consent to the making of such payments directly to the Holders of Notes, to
pay to the Trustee any amount due to it for the reasonable compensation, expenses, disbursements
and advances of the Trustee, its agents and counsel and any other amounts due the Trustee under
this Indenture.
Nothing contained herein shall be deemed to authorize the Trustee to authorize or consent to
or accept, or adopt on behalf of any Holder of a Note, any plan of reorganization, arrangement,
adjustment or composition affecting the Notes or the rights of any Holder thereof or to authorize
the Trustee to vote in respect of the claim of any Holder of a Note in any such proceeding.
Section 6.10. Restoration of Rights and Remedies. If the Trustee or any Holder of a Note has
instituted any proceeding to enforce any right or remedy under this Indenture and such proceeding
has been discontinued or abandoned for any reason, or has been determined adversely to the Trustee
or to such Holder, then and in every such case, subject to any determination in such proceeding,
the Company, the Trustee and the Holders of Notes shall be restored severally and respectively to
their former positions hereunder and thereafter all rights and remedies of the Trustee and the
Holders shall continue as though no such proceeding had been instituted.
36
Section 6.11. Rights and Remedies Cumulative. Except as otherwise provided with respect to
the replacement or payment of mutilated, destroyed, lost or stolen Notes in Section 2.05(d), no
right or remedy conferred in this Indenture upon or reserved to the Trustee or to the Holders of
Notes is intended to be exclusive of any other right or remedy, and every right and remedy shall,
to the extent permitted by law, be cumulative and in addition to every other right and remedy given
hereunder or hereafter existing at law or in equity or otherwise. The assertion or employment of
any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or
employment of any other appropriate right or remedy.
Section 6.12. Delay or Omission Not Waiver. No delay or omission of the Trustee or of any
Holder of any Note to exercise any right or remedy accruing
upon any Event of Default shall impair any such right or remedy or constitute a waiver of any
such Event of Default or any acquiescence therein. Every right and remedy given by this Article or
by law to the Trustee or to the Holders of Notes may be exercised from time to time, and as often
as may be deemed expedient, by the Trustee or by the Holders of Notes, as the case may be.
Section 6.13. Application of Money Collected. Any money and property collected by the
Trustee pursuant to this Article 6 shall be applied in the following order, at the date or dates
fixed by the Trustee and, in case of the distribution of such money and property on account of
principal (including the Redemption Price and the Fundamental Change Purchase Price, if applicable)
or premium, if any, or interest, upon presentation of the Notes and the notation thereon of the
payment if only partially paid and upon surrender thereof if fully paid:
FIRST: To the payment of all amounts due the Trustee, including its agents and counsel;
SECOND: To the payment of the amounts then due and unpaid for principal (including the
Redemption Price and the Fundamental Change Purchase Price, if applicable) of and premium, if any,
and interest on the Notes and coupons in respect of which or for the benefit of which such money
has been collected, ratably, without preference or priority of any kind, according to the amounts
due and payable on such Notes for principal (including the Redemption Price and the Fundamental
Change Purchase Price, if applicable) and premium, if any, and interest, respectively; and
THIRD: Any remaining amounts shall be repaid to the Company.
Section 6.14. Undertaking For Costs. All parties to this Indenture agree, and each Holder of
any Note by such Holders acceptance thereof shall be deemed to have agreed, that any court may in
its discretion require, in any suit for the enforcement of any right or remedy under this
Indenture, or in any suit against
37
the Trustee for any action taken, suffered or omitted by it as Trustee, the filing by any
party litigant in such suit of an undertaking to pay the costs of such suit, and that such court
may in its discretion assess reasonable costs, including reasonable attorneys fees, against any
party litigant in such suit, having due regard to the merits and good faith of the claims or
defenses made by such party litigant; but the provisions of this Section 6.14 shall not apply to
any suit instituted by the Company, to any suit instituted by the Trustee, to any suit instituted
by any Holder, or group of Holders, holding in the aggregate more than 10% in aggregate principal
amount of the Notes then Outstanding, or to any suit instituted by any Holder of any Note for the
enforcement of the payment of the principal (including the Redemption Price and the Fundamental
Change Purchase Price, if applicable) of or premium, if any, or interest on any Note on or after
the stated maturity expressed in such Note ( or in the case of a redemption, on or after the
Redemption Date or, in the case of exercise of a repurchase right in connection with a Fundamental
Change, on or after the Fundamental Change Purchase Date) or for the enforcement of the right to
convert any Note in accordance with Article 13.
Section 6.15. Waiver of Stay or Extension Laws. The Company covenants (to the extent that it
may lawfully do so) that it will not at any time insist upon, or plead, or in any manner whatsoever
claim to take the benefit or advantage of, any stay or extension law wherever enacted, now or at
any time hereafter in force, which may affect the covenants or the performance of this Indenture;
and the Company (to the extent that it may lawfully do so) hereby expressly waives all benefit or
advantage of any such law and covenants that it will not hinder, delay or impede the execution of
any power herein granted to the Trustee, but will suffer and permit the execution of every such
power as though no such law had been enacted.
Section 6.16. Notice of Default. If any Default or any Event of Default occurs and is
continuing and if such Default or Event of Default is actually known to a Responsible Officer of
the Trustee, the Trustee shall within 90 days of the occurrence of a Default or Event of Default,
mail to each Holder notice of all uncured Defaults or Events of Default known to the Trustee,
unless such Default or Event of Default has been cured; provided, however, that, except in the case
of a default in the payment of the principal of (including upon redemption or repurchase, as
applicable) or premium, if any, or interest on any Note, the Trustee shall be protected in
withholding such notice if the Trustee in good faith determines that the withholding of such notice
is in the best interest of such Holders.
38
ARTICLE 7
Concerning the Trustee
Section 7.01. Certain Duties and Responsibilities of Trustee.
(a) The Trustee, prior to the occurrence of an Event of Default and after the curing of all
Events of Default that may have occurred, shall undertake to perform with respect to the Notes such
duties and only such duties as are specifically set forth in this Indenture, and no implied
covenants shall be read into this Indenture against the Trustee. In case an Event of Default has
occurred (that has not been cured or waived), the Trustee shall exercise with respect to the Notes
such of the rights and powers vested in it by this Indenture, and use the same degree of care and
skill in their exercise, as a prudent person would exercise or use under the circumstances in the
conduct of his or her own affairs.
(b) No provision of this Indenture shall be construed to relieve the Trustee from liability
for its own negligent action, its own negligent failure to act, or its own willful misconduct,
except that:
(i) prior to the occurrence of an Event of Default and after the curing or waiving of
all such Events of Default that may have occurred:
(A) the duties and obligations of the Trustee shall with respect to the
Notes be determined solely by the express provisions of this Indenture,
and the Trustee shall not be liable with respect to the Notes except for
the performance of such duties and obligations as are specifically set forth in
this Indenture and subject to the terms of this Indenture, and no implied
covenants or obligations shall be read into this Indenture against the Trustee;
and
(B) in the absence of bad faith on the part of the Trustee, the Trustee may
with respect to the Notes conclusively rely, as to the truth of the statements
and the correctness of the opinions expressed therein, upon any certificates or
opinions furnished to the Trustee and conforming to the requirements of this
Indenture; but in the case of any such certificates or opinions that by any
provision hereof are specifically required to be furnished to the Trustee, the
Trustee shall be under a duty to examine the same to determine whether or not
they conform to the requirements of this Indenture;
(ii) the Trustee shall not be liable for any error of judgment made in good faith by
a Responsible Officer or Responsible Officers of
39
the Trustee, unless it shall be proved that the Trustee was negligent in ascertaining
the pertinent facts;
(iii) the Trustee shall not be liable with respect to any action taken or omitted to
be taken by it in good faith in accordance with the direction of the Holders of not less
than a majority in principal amount of the Notes at the time Outstanding relating to the
time, method and place of conducting any proceeding for any remedy available to the
Trustee, or exercising any trust or power conferred upon the Trustee under this Indenture
with respect to the Notes; and
(iv) None of the provisions contained in this Indenture shall require the Trustee to
expend or risk its own funds or otherwise incur personal financial liability in the
performance of any of its duties or in the exercise of any of its rights or powers if
there is reasonable ground for believing that the repayment of such funds or liability is
not reasonably assured to it under the terms of this Indenture or adequate indemnity
against such risk is not reasonably assured to it.
Section 7.02. Certain Rights of Trustee. Except as otherwise provided in Section 7.01:
(a) the Trustee may rely conclusively and shall be protected in acting or refraining from
acting upon any resolution, certificate, statement, instrument, opinion, report, notice, request,
consent, order, approval, bond, security or other paper or document believed by it to be genuine
and to have been signed or presented by the proper party or parties;
(b) any request, direction, order or demand of the Company mentioned herein shall be
sufficiently evidenced by a Board Resolution or an instrument signed in the name of the Company by
any authorized officer of the Company (unless other evidence in respect thereof is specifically
prescribed herein);
(c) the Trustee may consult with counsel and the written advice of such counsel or any Opinion
of Counsel shall be full and complete authorization and protection in respect of any
action taken or suffered or omitted hereunder in good faith and in reliance thereon;
(d) the Trustee shall be under no obligation to exercise any of the rights or powers vested in
it by this Indenture at the request, order or direction of any of the Holders pursuant to the
provisions of this Indenture, unless such Holders shall have offered the Trustee security or
indemnity satisfactory to the Trustee against the costs, expenses and liabilities that may be
incurred therein or thereby;
40
(e) the Trustee shall not be liable for any action taken or omitted to be taken by it in good
faith and believed by it to be authorized or within the discretion or rights or powers conferred
upon it by this Indenture;
(f) the Trustee shall not be bound to make any investigation into the facts or matters stated
in any resolution, certificate, statement, instrument, opinion, report, notice, request, consent,
order, approval, bond, security, or other papers or documents, unless requested in writing so to do
by the Holders of not less than a majority in principal amount of the Outstanding Notes affected
thereby (determined as provided in Section 8.04); provided, however, that if the payment within a
reasonable time to the Trustee of the costs, expenses or liabilities likely to be incurred by it in
the making of such investigation is, in the opinion of the Trustee, not reasonably assured to the
Trustee by the security afforded to it by the terms of this Indenture, the Trustee may require
reasonable indemnity against such costs, expenses or liabilities as a condition to so proceeding.
The reasonable expense of every such examination shall be paid by the Company or, if paid by the
Trustee, shall be repaid by the Company upon demand;
(g) the Trustee may execute any of the trusts or powers hereunder or perform any duties
hereunder either directly or by or through agents, attorneys or other professionals or consultants
and may retain such parties in furtherance of its administration hereunder and the Trustee shall
not be responsible for any misconduct or negligence on the part of any such agent, attorney or
other professional appointed with due care by it hereunder;
(h) in no event shall the Trustee be responsible or liable for special, indirect, punitive or
consequential loss or damage of any kind whatsoever (including, but not limited to, loss of profit)
irrespective of whether the Trustee has been advised of the likelihood of such loss or damage and
regardless of the form of action;
(i) the rights, privileges, protections, immunities and benefits given to the Trustee,
including, without limitation, its right to be indemnified, are extended to, and shall be
enforceable by, the Trustee in each of its capacities hereunder, and each agent, custodian and
other Person employed to act hereunder;
(j) the Trustee shall not be required to give any bond or surety in respect of the performance
of its powers and duties hereunder; and
(k) the Trustee may request that the Company deliver a certificate setting forth the names of
individuals and/or titles of officers authorized at such time to take specified actions pursuant to
this Indenture.
In addition, the Trustee shall not be deemed to have knowledge of any Default or Event of
Default except (1) any Event of Default occurring pursuant to
41
Section 6.01(a) and 6.01(b)) or (2) any Default or Event of Default of which the Trustee shall
have received written notification in the manner set forth in this Indenture or a Responsible
Officer of the Trustee shall have obtained actual knowledge. Delivery of reports, information and
documents to the Trustee under Section 4.03 is for informational purposes only and the information
and the Trustees receipt of the foregoing shall not constitute constructive notice of any
information contained therein, or determinable from information contained therein including the
Companys compliance with any of their covenants thereunder (as to which the Trustee is entitled to
rely conclusively on an Officers Certificate).
Section 7.03. Trustee Not Responsible for Recitals or Issuance or Notes.
(a) The recitals contained herein and in the Notes shall be taken as the statements of the
Company, and the Trustee assumes no responsibility for the correctness of the same.
(b) The Trustee makes no representations as to the validity or sufficiency of this Indenture
or of the Notes;
(c) The Trustee shall not be accountable for the use or application by the Company of any of
the Notes or of the proceeds of such Notes, or for the use or application of any moneys paid over
by the Trustee in accordance with any provision of this Indenture, or for the use or application of
any moneys received by any Paying Agent other than the Trustee, acting in such capacity.
Section 7.04. May Hold Notes. The Trustee or any Paying Agent or Note Registrar, in its
individual or any other capacity, may become the owner or pledgee of Notes with the same rights it
would have if it were not Trustee, Paying Agent or Note Registrar.
Section 7.05. Moneys Held in Trust. Subject to the provisions of Section 3.03, all moneys
received by the Trustee shall, until used or applied as herein provided, be held in trust for the
purposes for which they were received, but need not be segregated from other funds except to the
extent required by law. The Trustee shall be under no liability for interest on any moneys received
by it hereunder except such as it may agree to in writing with the Company to pay thereon.
Section 7.06. Compensation and Reimbursement.
(a) The Company covenants and agrees to pay to the Trustee, and the Trustee shall be entitled
to, such compensation (which shall not be limited by any provision of law in regard to the
compensation of a trustee of an express trust) as the Company and the Trustee may from time to time
agree in writing, for all
42
services rendered by it in the execution of the trusts hereby created and in the exercise and
performance of any of the powers and duties hereunder of the Trustee, and, except as otherwise
expressly provided herein, the Company will pay or reimburse the Trustee upon its request for all
reasonable expenses, disbursements and advances incurred or made by the Trustee in accordance with
any of the provisions of this Indenture (including the reasonable compensation and the expenses and
disbursements of its counsel and of all Persons not regularly in its employ), except any such
expense, disbursement or advance as may arise from its negligence or bad faith and except as the
Company and Trustee may from time to time agree in writing. The Company also covenants to indemnify
the Trustee (and its officers, agents, directors and employees) for, and to hold it harmless
against, any loss, liability or expense incurred without negligence or bad faith on the part of the
Trustee and arising out of or in connection with the acceptance or administration of this trust,
including the reasonable costs and expenses of defending itself against any claim of liability in
the premises.
(b) The obligations of the Company under this Section 7.06 to compensate and indemnify the
Trustee and to pay or reimburse the Trustee for reasonable expenses, disbursements and advances
shall constitute additional indebtedness hereunder. Such additional indebtedness shall be secured
by a lien prior to that of the Notes upon all property and funds held or collected by the Trustee
as such, except funds held in trust for the benefit of the Holders.
(c) The Company covenants and agrees to indemnify the Trustee for, and hold it harmless from
and against, any loss, liability or expense reasonably incurred by it arising out of or in
connection with the acceptance or administration of the trust or trusts hereunder or the
performance of its duties hereunder, including the reasonable costs and expenses of defending
itself against any claim or liability in connection with the exercise or performance of any of its
powers or duties hereunder except to the extent any such loss, liability or expense may be
attributable to its negligence, willful misconduct or bad faith.
(d) In addition and without prejudice to the rights provided to the Trustee under any of the
provisions of this Indenture, when the Trustee incurs expenses or renders services in connection
with an Event of Default specified in Section 6.01(g) or Section 6.01(h), the expenses (including
the reasonable charges and expenses of its counsel) and the compensation for the services are
intended to constitute expenses of administration under any applicable Federal and State
bankruptcy, insolvency or other similar law.
(e) The Companys obligations under this Section 7.06 and the lien referred to in Section
7.06(b) shall survive the resignation or removal of the Trustee, the discharge of the Companys
obligations under Article Eleven of this Indenture and/or the termination of this Indenture.
43
Section 7.07. Reliance on Officers Certificate and Opinions. Except as otherwise provided
in Section 7.01, whenever in the administration of the provisions of this Indenture the Trustee
shall deem it reasonably necessary or desirable that a matter be proved or established prior to
taking or suffering or omitting to take any action hereunder, such matter (unless other evidence in
respect thereof be herein specifically prescribed) may, in the absence of negligence or bad faith
on the part of the Trustee, be deemed to be conclusively proved and established by an Officers
Certificate and Opinion of Counsel delivered to the Trustee and such certificate or opinion, in the
absence of negligence or bad faith on the part of the Trustee, shall be full warrant to the Trustee
for any action taken, suffered or omitted to be taken by it under the provisions of this Indenture
upon the faith thereof.
Section 7.08. Disqualification; Conflicting Interests. If the Trustee has or shall acquire
any conflicting interest within the meaning of Section 310(b) of the Trust Indenture Act.
Section 7.09. Corporate Trustee Required; Eligibility. There shall at all times be a Trustee
with respect to the Notes issued hereunder which shall at all times be a corporation organized and
doing business under the laws of the United States of America or any state or territory thereof or
of the District of Columbia, or a corporation or other Person permitted to act as trustee by the
Securities and Exchange Commission, authorized under such laws to exercise corporate trust powers,
having a combined capital and surplus of at least fifty million U.S. dollars ($50,000,000), and
subject to supervision or examination by federal, state, territorial, or District of Columbia
authority.
If such corporation or other Person publishes reports of condition at least annually, pursuant
to law or to the requirements of the aforesaid supervising or examining authority, then for the
purposes of this Section 7.09, the combined capital and surplus of such corporation or other Person
shall be deemed to be its combined capital and surplus as set forth in its most recent report of
condition so published. The Company may not, nor may any Person directly or indirectly controlling,
controlled by, or under common control with the Company, serve as Trustee. In case at any time the
Trustee shall cease to be eligible in accordance with the provisions of this Section 7.09, the
Trustee shall resign immediately in the manner and with the effect specified in Section 7.10.
Section 7.10. Resignation and Removal; Appointment of Successor.
(a) The Trustee or any successor hereafter appointed may at any time resign with respect to
the Notes by giving written notice thereof to the Company. Upon receiving such notice of
resignation, the Company shall promptly appoint a successor trustee with respect to the Notes by
written instrument, in duplicate, executed by order of the Board of Directors, one copy of which
instrument shall
44
be delivered to the resigning Trustee and one copy to the successor trustee. If no successor
trustee shall have been so appointed and have accepted appointment within 30 days after the mailing
of such notice of resignation, the resigning Trustee, at the expense of the Company, may petition
any court of competent jurisdiction for the appointment of a successor trustee with respect to the
Notes, or any Holder who has been a bona fide Holder of Notes for at least six months may on behalf
of himself and all others similarly situated, petition any such court for the appointment of a
successor trustee. Such court may thereupon after such notice, if any, as it may deem proper and
prescribe, appoint a successor trustee.
(b) In case at any time any one of the following shall occur:
(i) the Trustee shall fail to comply with the provisions of Section 7.08 after
written request therefor by the Company or by any Holder who has been a bona fide Holder
of Notes for at least six months;
(ii) the Trustee shall cease to be eligible in accordance with the provisions of
Section 7.09 and shall fail to resign after written request therefor by the Company or by
any such Holder; or
(iii) the Trustee shall become incapable of acting, or shall be adjudged a bankrupt
or insolvent, or commence a voluntary bankruptcy proceeding, or a receiver of the Trustee
or of its property shall be appointed or consented to, or any public officer shall take
charge or control of the Trustee or of its property or affairs for the purpose of
rehabilitation, conservation or liquidation,
then, in any such case, the Company may remove the Trustee with respect to the Notes and
appoint a successor trustee by written instrument, in duplicate, executed by order of the Board of
Directors, one copy of which instrument shall be delivered to the Trustee so removed and one copy
to the successor trustee, or any Holder who has been a bona fide Holder of Notes for at least six
months may, on behalf of that Holder and all others similarly situated, petition any court of
competent jurisdiction for the removal of the Trustee and the appointment of a successor trustee.
Such court may thereupon after such notice, if any, as it may deem proper and prescribe, remove the
Trustee and appoint a successor trustee.
(c) The Holders of a majority in aggregate principal amount of the Notes at the time
Outstanding may at any time remove the Trustee by so notifying the Trustee and the Company in
writing and may appoint a successor Trustee with the consent of the Company.
(d) Any resignation or removal of the Trustee and appointment of a successor trustee with
respect to the Notes pursuant to any of the provisions of
45
this Section 7.10 shall become effective upon acceptance of appointment by the successor
trustee as provided in Section 7.11.
Section 7.11. Acceptance of Appointment By Successor.
(a) In case of the appointment hereunder of a successor trustee with respect to all Notes,
every such successor trustee so appointed shall execute, acknowledge and deliver to the Company and
to the retiring Trustee an instrument accepting such appointment, and thereupon the resignation or
removal of the retiring Trustee shall become effective and such successor trustee, without any
further act, deed or conveyance, shall become vested with all the rights, powers, trusts and duties
of the retiring Trustee; but, on the request of the Company or the successor trustee, such retiring
Trustee shall, upon payment of its charges, execute and deliver an instrument transferring to such
successor trustee all the rights, powers, and trusts of the retiring Trustee and shall duly assign,
transfer and deliver to such successor trustee all property and money held by such retiring Trustee
hereunder. The trustee shall have no liability or responsibility for the action or inaction of any
successor Trustee.
(b) In case of the appointment hereunder of a successor trustee with respect to some, but not
all of the Notes, the Company, the retiring Trustee and each successor trustee with respect to such
Notes shall execute and deliver an indenture supplemental hereto wherein each successor trustee
shall accept such appointment and which (i) shall contain such provisions as shall be necessary or
desirable to transfer and confirm to, and to vest in, each successor trustee all the
rights, powers, trusts and duties of the retiring Trustee with respect to the Notes to which the
appointment of such successor trustee relates, (ii) shall contain such provisions as shall be
deemed necessary or desirable to confirm that all the rights, powers, trusts and duties of the
retiring Trustee with respect to the Notes as to which the retiring Trustee is not retiring shall
continue to be vested in the retiring Trustee, and (iii) shall add to or change any of the
provisions of this Indenture as shall be necessary to provide for or facilitate the administration
of the trusts hereunder by more than one Trustee, it being understood that nothing herein or in
such supplemental indenture shall constitute such Trustees co-trustees of the same trust, that each
such Trustee shall be trustee of a trust or trusts hereunder separate and apart from any trust or
trusts hereunder administered by any other such Trustee and that no Trustee shall be responsible
for any act or failure to act on the part of any other Trustee hereunder; and upon the execution
and delivery of such supplemental indenture the resignation or removal of the retiring Trustee
shall become effective to the extent provided therein, such retiring Trustee shall with respect to
the Notes to which the appointment of such successor trustee relates have no further responsibility
for the exercise of rights and powers or for the performance of the duties and obligations vested
in the Trustee under this Indenture, and each such successor trustee, without any further act, deed
or conveyance, shall become vested with all the rights, powers, trusts and duties of
46
the retiring Trustee with respect to the Notes to which the appointment of such successor
trustee relates; but, on request of the Company or any successor trustee, such retiring Trustee
shall duly assign, transfer and deliver to such successor trustee, to the extent contemplated by
such supplemental indenture, the property and money held by such retiring Trustee hereunder with
respect to the Notes to which the appointment of such successor trustee relates.
(c) Upon request of any such successor trustee, the Company shall execute any and all
instruments for more fully and certainly vesting in and confirming to such successor trustee all
such rights, powers and trusts referred to in paragraph (a) or (b) of this Section 7.11, as the
case may be.
(d) No successor trustee shall accept its appointment unless at the time of such acceptance
such successor trustee shall be qualified and eligible under this Article 7.
(e) Upon acceptance of appointment by a successor trustee as provided in this Section 7.11,
the Company shall transmit notice of the succession of such trustee hereunder by mail, first class
postage prepaid, to the Holders, as their names and addresses appear upon the Note Register. If the
Company fails to transmit such notice within ten days after acceptance of appointment by the
successor trustee, the successor trustee shall cause such notice to be transmitted at the expense
of the Company.
Section 7.12. Merger, Conversion, Consolidation or Succession to Business. Any corporation
into which the Trustee may be merged or converted or with which it may be consolidated, or any
corporation resulting from any merger, conversion or consolidation to which the Trustee shall be a
party, or any corporation succeeding to the corporate trust business of the Trustee, shall be the
successor of the Trustee hereunder, provided that such corporation shall be qualified under the
provisions of Section 7.08 and eligible under the provisions of Section 7.09, without the execution
or filing of any paper or any further act on the part of any of the parties hereto, anything herein
to the contrary notwithstanding. In case any Notes shall have been authenticated, but not
delivered, by the Trustee then in office, any successor by merger, conversion or consolidation to
such authenticating Trustee may adopt such authentication and deliver the Notes so authenticated
with the same effect as if such successor Trustee had itself authenticated such Notes.
Section 7.13. Preferential Collection of Claims Against the Company. The Trustee shall
comply with Section 311(a) of the Trust Indenture Act, excluding any creditor relationship
described in Section 311(b) of the Trust Indenture Act. A Trustee who has resigned or been removed
shall be subject to Section 311(a) of the Trust Indenture Act to the extent included therein.
47
ARTICLE 8
Concerning the Holders
Section 8.01. Evidence of Action by Holders. Whenever in this Indenture it is provided that
the Holders of a majority or specified percentage in aggregate principal amount of the Notes may
take any action (including the making of any demand or request, the giving of any notice, consent
or waiver or the taking of any other action), the fact that at the time of taking any such action
the holders of such majority or specified percentage of such Notes have joined therein may be
evidenced by any instrument or any number of instruments of similar tenor executed by such Holders
of such Notes in person or by agent or proxy appointed in writing.
If the Company shall solicit from the Holders any request, demand, authorization, direction,
notice, consent, waiver or other action, the Company may, at its option, as evidenced by an
Officers Certificate, fix in advance a record date for such Notes for the determination of Holders
entitled to give such request, demand, authorization, direction, notice, consent, waiver or other
action, but the Company shall have no obligation to do so. If such a record date is fixed, such
request, demand, authorization, direction, notice, consent, waiver or other action may be given
before or after the record date, but only the Holders of record at the close of business on the
record date shall be deemed to be Holders for the purposes of determining whether Holders of the
requisite proportion of Outstanding Notes have authorized or agreed or consented to such request,
demand, authorization, direction, notice, consent, waiver or other action, and for that purpose the
Outstanding Notes shall be computed as of the record date; provided, however, that no such
authorization, agreement or consent by such Holders on the record date shall be deemed effective
unless it shall become effective pursuant to the provisions of this Indenture not later than six
months after the record date.
Section 8.02. Proof of Execution by Holders. Subject to the provisions of Section 7.01,
proof of the execution of any instrument by a Holder (such proof will not require notarization) or
his agent or proxy and proof of the holding by any Person of any of the Notes shall be sufficient
if made in the following manner:
(a) The fact and date of the execution by any such Person of any instrument may be proved in
any reasonable manner acceptable to the Trustee.
(b) The ownership of Notes shall be proved by the Note Register or by a certificate of the
Note Registrar thereof.
The Trustee may require such additional proof of any matter referred to in this Section 8.02
as it shall deem necessary.
48
Section 8.03. Who May be Deemed Owners. Prior to the due presentment for registration of
transfer of any Note, the Company, the Trustee, any paying agent and any Note Registrar may deem
and treat the Person in whose name such Note shall be registered upon the books of the Company as
the absolute owner of such Note (whether or not such Note shall be overdue and notwithstanding any
notice of ownership or writing thereon made by anyone other than the Note Registrar) for the
purpose of receiving payment of or on account of the principal of, premium, if any, and (subject to
Section 2.03) interest on such Note and for all other purposes; and neither the Company nor the
Trustee nor any paying agent nor any Note Registrar shall be affected by any notice to the
contrary.
Section 8.04. Certain Notes Owned by Company Disregarded. In determining whether the Holders
of the requisite aggregate principal amount of Notes have concurred in any direction, consent or
waiver under this Indenture, the Notes that are owned by the Company or any other obligor on the
Notes or by any Affiliate of the Company or any other obligor on the Notes shall be disregarded and
deemed not to be Outstanding for the purpose of any such determination, except that for the purpose
of determining whether the Trustee shall be protected in relying on any such direction, consent or
waiver, only Notes that the Trustee actually knows are so owned shall be so disregarded. The Notes
so owned that have been pledged in good faith may be regarded as Outstanding for the purposes of
this Section 8.04, if the pledgee shall establish to the satisfaction of the Trustee the pledgees
right so to act with respect to such Notes and that the pledgee is not a Person directly or
indirectly controlling or controlled by or under direct or indirect common control with the Company
or any such other obligor. In case of a dispute as to such right, any decision by the Trustee taken
upon the advice of counsel shall be full protection to the Trustee.
Section 8.05. Actions Binding on Future Holders. At any time prior to (but not after) the
evidencing to the Trustee, as provided in Section 8.01, of the taking of any action by the Holders
of the majority or percentage in aggregate principal amount of the Notes specified in this
Indenture in connection with such action, any Holder of a Note that is shown by the evidence to be
included in the Notes the Holders of which have consented to such action may, by filing written
notice with the Trustee, and upon proof of holding as provided in Section 8.02, revoke such action
so far as concerns such Note. Except as aforesaid any such action taken by the Holder of any Note
shall be conclusive and binding upon such Holder and upon all future Holders and owners of such
Note, and of any Note issued in exchange therefor, on registration of transfer thereof or in place
thereof, irrespective of whether or not any notation in regard thereto is made upon such Note. Any
action taken by the Holders of the majority or percentage in aggregate principal amount of the
Notes specified in this Indenture in connection with such action shall be conclusively binding upon
the Company, the Trustee and the Holders.
49
ARTICLE 9
Amendments; Supplements And Waivers
Section 9.01. Without Consent of Holders. The Company and the Trustee may amend or
supplement this Indenture or the Notes without notice to or consent of any Holder of a Note for any
of the following purposes:
(a) to add to the covenants of the Company for the benefit of the Holders of Notes;
(b) to surrender any right or power herein conferred upon the Company;
(c) to make provision with respect to the conversion rights of Holders of Notes pursuant to
Section 13.10 hereof;
(d) to provide for the assumption of the Companys obligations to the Holders of Notes in the
case of a merger, consolidation, conveyance, transfer or lease pursuant to Article 10 hereof;
(e) to increase the Conversion Rate; provided, however, that such increase in the Conversion
Rate shall not adversely affect the interests of the Holders of Notes in any material respect;
(f) to comply with the requirements of the Commission in order to effect or maintain the
qualification of this Indenture under the Trust Indenture Act;
(g) to cure any ambiguity, correct or supplement any provision herein which may be
inconsistent with any other provision herein or which is otherwise defective; provided, that such
action pursuant to this clause (g) does not adversely affect the interests of the Holders of Notes
in any material respect;
(h) to add or modify any other provisions which the Company and the Trustee may deem necessary
or desirable and which shall not adversely affect the interests of the Holders of Notes in any
material respect; or
(i) conform as necessary the Indenture and the form or terms of the Notes to the Description
of Notes as set forth in the Offering Memorandum.
After an amendment, supplement or waiver under this Section 9.01 becomes effective, the
Company, or, at the written request of the Company, the Trustee, shall mail to the Holders affected
thereby a notice briefly describing the amendment, supplement or waiver. Any failure of the
Company to mail such notice, or any defect therein, shall not, however, in any way impair or affect
the validity of any such amendment, supplement or waiver.
50
Section 9.02. With Consent of Holders. Except as provided below in this Section 9.02, this
Indenture or the Notes may be amended or supplemented, and noncompliance by the Company in any
particular instance with any provision of this Indenture or the Notes may be waived, in each case
(i) with the written consent of the Holders of at least a majority in aggregate principal amount of
the Notes then Outstanding or (ii) by the adoption of a resolution, at a meeting of Holders of the
Notes then Outstanding at which a quorum is present, by the Holders of a majority in aggregate
principal amount of the Outstanding Notes represented at such meeting.
Without the written consent or the affirmative vote of each Holder of an affected Note, an
amendment, supplement or waiver to this Indenture or the Notes may not:
(a) change the stated maturity of the principal of, or the time of payment of any installment
of interest on, any Note;
(b) reduce the principal amount of any Note;
(c) reduce the interest rate or interest on any Note;
(d) change the currency of payment of principal of, premium, if any, or interest on any Note;
(e) impair the right to institute suit for the enforcement of any payment with respect to, or
the conversion of, any Note;
(f) except as otherwise permitted by Section 13.10 hereof, adversely affect the right to
convert any Note as provided in Article 13 hereof;
(g) adversely affect the right of Holders to require the Company to purchase the Notes in the
event of a Fundamental Change;
(h) modify any of the provisions of this Section 9.02, Section 6.04 or Section 6.12, except to
increase any percentage contained herein or therein or to provide that certain other provisions of
this Indenture cannot be modified or waived without the consent of the Holder of each Note affected
thereby; or
(i) reduce the percentage in aggregate principal amount of the Outstanding Notes required for
the adoption of a resolution or the quorum required at any meeting of Holders of Notes at which a
resolution is adopted.
It shall not be necessary for the consent of Holders of Notes under this Section 9.02 to
approve the particular form of any proposed modification, amendment or waiver, but it shall be
sufficient if such act shall approve the substance thereof.
51
After an amendment, supplement or waiver under this Section 9.02 becomes effective, the
Company, or, at the written request of the Company, the Trustee, shall mail to the Holders affected
thereby a notice briefly describing the amendment, supplement or waiver. Any failure of the Company
to mail such notice, or any defect therein, shall not, however, in any way impair or affect the
validity of any such amendment, supplement or waiver.
Section 9.03. Effect of Supplemental Indentures. Upon the execution of any supplemental
indenture pursuant to the provisions of this Article 9 or Section 10.01 this Indenture shall be and
be deemed to be modified and amended in accordance therewith and the respective rights, limitations
of rights, obligations, duties and immunities under this Indenture of the Trustee, the Company and
the Holders of Notes affected thereby shall thereafter be determined, exercised and enforced
hereunder subject in all respects to such modifications and amendments, and all the terms and
conditions of any such supplemental indenture shall be and be deemed to be part of the terms and
conditions of this Indenture for any and all purposes.
Section 9.04. Notes Affected by Supplemental Indentures. Notes affected by a supplemental
indenture, authenticated and delivered after the execution of such supplemental indenture pursuant
to the provisions of this Article 9 or Section 10.01, may bear a notation in form approved by the
Company, provided such form meets the requirements of any securities exchange upon which such Notes
may be listed, as to any matter provided for in such supplemental indenture. If the Company shall
so determine, new securities so modified as to conform, in the opinion of the Board of Directors,
to any modification of this Indenture contained in any such supplemental indenture may be prepared
by the Company, authenticated by the Trustee and delivered in exchange for the Notes then
Outstanding.
Section 9.05. Execution of Supplemental Indentures. Upon the request of the Company,
accompanied by its Board Resolutions authorizing the execution of any such supplemental indenture,
and upon the filing with the Trustee of evidence of the consent of Holders required to consent
thereto as aforesaid (if such consent is required pursuant to this Article), the Trustee shall join
with the Company in the execution of such supplemental indenture unless such supplemental indenture
affects the Trustees own rights, duties or immunities under this Indenture or otherwise, in which
case the Trustee may in its discretion but shall not be obligated to enter into such supplemental
indenture. The Trustee, subject to the provisions of Section 7.01, will be entitled to receive and
will be fully protected in relying upon an Officers Certificate and an Opinion of Counsel stating
that any supplemental indenture executed pursuant to this Article is authorized or permitted by,
and conforms to, the terms of this Article 9, constitutes a valid, binding and legal obligation,
enforceable against the Company (subject to
52
customary qualifications) and that it is proper for the Trustee under the provisions of this
Article 9 to join in the execution thereof.
Promptly after the execution by the Company and the Trustee of any supplemental indenture
pursuant to the provisions of this Section, the Company shall transmit by mail, first class postage
prepaid, a notice, setting forth in general terms the substance of such supplemental indenture, to
the Holders of all Notes affected thereby as their names and addresses appear upon the Note
Register. Any failure of the Company to mail such notice, or any defect therein, shall not,
however, in any way impair or affect the validity of any such supplemental indenture.
ARTICLE 10
Consolidation; Merger; Conveyance; Transfer Or Lease
Section 10.01. Company May Consolidate, Etc., Only on Certain Terms. The Company may not,
without the consent of the Holders, consolidate with, merge into or convey, transfer or lease all
or substantially all of the property and assets of the Company and its Subsidiaries, taken as a
whole, to another Person unless:
(a) either (1) the Company shall be the resulting or surviving corporation or (2) the Person
(if other than the Company) formed by such consolidation or into which the Company is merged, or
the Person which acquires by transfer or lease all or substantially all of the property and assets
of the Company, shall (i) be a corporation incorporated and existing under the laws of the United
States of America or any State thereof or the District of Columbia and (ii) expressly assume, by an
indenture supplemental hereto, executed and delivered to the Trustee, in form reasonably
satisfactory to the Trustee, the obligations of the Company under the Notes and this Indenture;
(b) after giving effect to such transaction, no Event of Default, and no event which, after
notice or lapse of time or both, would become an Event of Default, shall have occurred and be
continuing; and
(c) if the Company will not be the resulting or surviving corporation, the Company shall have,
at or prior to the effective date of such consolidation, merger, conveyance, transfer or lease,
delivered to the Trustee an Officers Certificate and an Opinion of Counsel, each stating that such
consolidation, merger, conveyance, transfer or lease complies with this Article 10 and, if a
supplemental indenture is required in connection with such transaction, such supplemental indenture
complies with this Article 10, and that all conditions precedent herein provided for relating to
such transaction have been complied with.
53
Section 10.02. Successor Substituted. Upon any consolidation of the Company with, or merger
of the Company into, any other Person or any conveyance, transfer or lease of all or substantially
all of the properties and assets of the Company and its Subsidiaries, taken as a whole, in
accordance with Section 10.01, the successor Person formed by such consolidation or into which the
Company is merged or to which such conveyance, transfer or lease is made shall succeed to, and be
substituted for, and may exercise every right and power of, the Company under this Indenture with
the same effect as if such successor Person had been named as the Company herein, and thereafter,
except in the case of a lease, and except for obligations the predecessor Person may have under a
supplemental indenture, the predecessor Person shall be relieved of all obligations and covenants
under the Indenture and the Notes.
ARTICLE 11
Immunity of Incorporators, Stockholders, Officers and Directors
Section 11.01. No Recourse. No recourse under or upon any obligation, covenant or agreement
of this Indenture, or of the Notes, or for any claim based thereon or otherwise in respect thereof,
shall be had against any incorporator, stockholder, officer or director, past, present or future as
such, of the Company or of any predecessor or successor corporation, either directly or through the
Company or any such predecessor or successor corporation, whether by virtue of any constitution,
statute or rule of law, or by the enforcement of any assessment or penalty or otherwise; it being
expressly understood that this Indenture and the obligations issued hereunder are solely corporate
obligations, and that no such personal liability whatever shall attach to, or is or shall be
incurred by, the incorporators, stockholders, officers or directors as such, of the Company or of
any predecessor or successor corporation, or any of them, because of the creation of the
indebtedness hereby authorized, or under or by reason of the obligations, covenants or agreements
contained in this Indenture or in any of the Notes or implied therefrom; and that any and all such
personal liability of every name and nature, either at common law or in equity or by constitution
or statute, of, and any and all such rights and claims against, every such incorporator,
stockholder, officer or director as such, because of the creation of the indebtedness hereby
authorized, or under or by reason of the obligations, covenants or agreements contained in this
Indenture or in any of the Notes or implied therefrom, are hereby expressly waived and released as
a condition of, and as a consideration for, the execution of this Indenture and the issuance of the
Notes.
54
ARTICLE 12
Additional Interest
Section 12.01. Additional Interest. (a) If, at any time during the six-month period
beginning on, and including, the date that is six months after the last date of original issuance
of the Notes and ending on the date that is one year after the last date of the original issuance
of the Notes, the Company either (i) fails to timely file any periodic report that the Company is
required to file with the Commission under Article 13 or 15(d) of the Exchange Act, as applicable
(other than reports on Form 8-K), and such failure continues for 14 days in the aggregate, or (ii)
the Notes are not otherwise freely tradable pursuant to Rule 144 by Holders of the Notes other than
the Companys Affiliates, or under the terms of this Indenture or the Notes, then in either case
(an Additional Interest Event), the Company shall pay additional interest on the Notes (the
Additional Interest). Such Additional Interest will accrue on the Notes at the rate of 0.25% per
annum of the principal amount of Notes Outstanding for each day during the first 90-day period (or
portion thereof) for which an Additional Interest Event has occurred and is continuing, which rate
will increase by an additional 0.25% per annum of the principal amount of the Notes for each
subsequent 90-day period (or portion thereof), up to a maximum of 0.50% of the principal amount of
the Notes. Additional Interest shall be payable in arrears on each Interest Payment Date following
accrual in the same manner as regular interest on the Notes.
(b) Unless
(i) the restrictive legend on the Notes has not been removed, or
(ii) the Notes are not freely tradable pursuant to Rule 144 by Holders other than the
Companys Affiliates (without restrictions pursuant to U.S. securities law or the terms of
this Indenture or the Notes),
on or after the 365th day after the last date of original issuance of the Notes offered hereby, an
Additional Interest Event would be deemed to have occurred and the Company shall pay Additional
Interest on the Notes at an annual rate equal to 0.25% of the aggregate principal amount of the
Notes for each day during the first 90-day period (or portion thereof) for which such Additional
Interest Event is continuing, which rate will increase by an additional 0.25% per annum of the
principal amount of the Notes for each subsequent 90-day period (or portion thereof), up to a
maximum of 0.50% of the principal amount of the Notes; provided that the Company shall not be
required to pay Additional Interest on the Notes for failure to remove the restrictive legend on
the Notes unless the Company has received a request to do so by a Holder, any Initial Purchaser or
the Trustee on or after the 335th day after the last Issue Date of the original issuance of the
Notes, except that if the Company receives such a request on or after the
55
5th Business Day immediately preceding such 365th day and the restrictive legend on the Notes has
not been removed by the close of business on the 5th Business Day thereafter, Additional Interest
on the Notes will accrue from such 365th day.
(c) Notwithstanding the foregoing, the Company shall not be required to pay Additional
Interest on any date if (i) the Company has filed a shelf registration statement for the resale of
the Notes and any shares of Common Stock issued upon conversion of the Notes, (ii) such shelf
registration statement is effective and usable by Holders of the Notes identified therein as
selling securityholders for the resale of the Notes and any shares of Common Stock issued upon
conversion of the Notes, and (iii) the Holders may register the resale of their Notes under such
shelf registration statement on terms customary for the resale of convertible securities offered in
reliance on Rule 144A.
(d) Under no circumstances will the combined rate of Additional Interest or Special Interest
exceed 1.00% per annum.
(e) The Company shall provide written notice to the Trustee prior to paying any Additional
Interest.
ARTICLE 13
Conversion of Notes
Section 13.01. Conversion Privilege and Conversion Rate. (a) The conversion rights pursuant
to this Article 13 shall commence on the Issue Date of the Notes and expire at the close of
business on the Business Day immediately preceding the Maturity Date unless previously redeemed or
repurchased, subject to the provisions of this Indenture and, in the case of conversion of any
Global Note, to any Applicable Procedures; provided, however, that if the Company has elected to
redeem the Notes pursuant to Article 14 hereof, Holders may convert their Notes only until the
close of business on the Business Day prior to the Redemption Date unless the Company fails to pay
the Redemption Price in which case the conversion right shall terminate at the close of business on
the Business Day prior to the date such failure is cured and such Note is redeemed. If a Note is
submitted or presented for purchase pursuant to Article 15, subject to the last paragraph of
Section 13.02(b), such conversion right shall terminate at the close of business on the Business
Day prior to the Fundamental Change Purchase Date for such Note (unless the Company shall fail to
make the Fundamental Change Purchase Price payment when due in accordance with Article 15, in which
case the conversion right shall terminate at the close of business on the Business Day prior to the
date such failure is cured and such Note is repurchased).
56
(b) Provisions of this Indenture that apply to conversion of all of a Note also apply to
conversion of a portion of a Note.
(c) A Holder of Notes is not entitled to any rights of a holder of Common Stock until such
Holder has converted its Notes into Common Stock, and only to the extent such Notes are deemed to
have been converted into Common Stock pursuant to this Article 13.
(d) The Conversion Rate shall be adjusted in certain instances as provided in Section 13.01(e)
and Section 13.06.
(e) If a Make-Whole Fundamental Change shall have occurred, the Company shall calculate and
pay a Fundamental Change Make-Whole Premium to the Holders of the Notes who convert their Notes
during the period beginning the date of the Make-Whole Fundamental Change Notice until the close of
business on the tenth Business Day immediately following the Make-Whole Fundamental Change
Effective Date by increasing the Conversion Rate for such Notes. The Fundamental Make-Whole Change
Premium will be in addition to, and not in substitution for, any cash, securities or other assets
otherwise due to Holders of Notes upon conversion. The number of additional shares of Common Stock
per $1,000 principal amount of Notes constituting the Fundamental Change Make-Whole Premium shall
be determined by reference to the table set forth on Schedule A hereto, based on the Make-Whole
Fundamental Change Effective Date and the Stock Price; provided that if the Stock Price or
Make-Whole Fundamental Change Effective Date are not set forth on the table: (i) if the actual
Stock Price on the Make-Whole Fundamental Change Effective Date is between two Stock Prices on the
table or the actual Fundamental Change Effective Date is between two Make-Whole Fundamental Change
Effective Dates on the table, the Fundamental Change Make-Whole Premium will be determined by a
straight-line interpolation between the Fundamental Change Make-Whole Premiums set forth for the
two Stock Prices and the two Make-Whole Fundamental Change Effective Dates on the table based on a
365-day year, as applicable, (ii) if the Stock Price on the Fundamental Change Effective Date
exceeds $50.00 per share, subject to adjustment as set forth herein, no Fundamental Change
Make-Whole Premium will be paid, and (iii) if the Stock Price on the Make-Whole Fundamental Change
Effective Date is less than $5.97 per share, subject to adjustment as set forth herein, no
Fundamental Change Make-Whole Premium will be paid. If holders of Common Stock receive only cash in
the Make-Whole Fundamental Change, the Stock Price shall be the cash amount paid per share of
Common Stock in connection with such Make-Whole Fundamental Change. Otherwise, the Stock Price
shall be equal to the average Last Reported Sale Price of the Common Stock over the 10 Trading Day
period ending on the Trading Day immediately preceding, and excluding, the applicable Fundamental
Change Effective Date. The Company, or, at the request of the Company, the Trustee, shall mail
written notice of the anticipated effective date of any Make-Whole Fundamental Change
57
to the Holders (with a copy to the Trustee if applicable) as practicable following the date
the Company publicly announces such Make-Whole Fundamental Change, but in no event less than 20
days prior to the anticipated Make-Whole Fundamental Change Effective Date (the Make-Whole
Fundamental Change Notice). At the Companys request, the Trustee shall give such Make-Whole
Fundamental Change Notice in the Companys name and at the Companys request; provided that, unless
otherwise agreed by the Trustee, the Company makes such request at least three (3) Business Days
prior to the date of such notice.
The Stock Prices set forth in the first column of the table on Schedule A will be adjusted as
of any date on which the Conversion Rate of the Notes is adjusted other than an adjustment pursuant
to the Fundamental Change Make-Whole Premium described above. The adjusted Stock Prices will equal
the Stock Prices applicable immediately prior to such adjustment multiplied by a fraction, the
numerator of which is the Conversion Rate immediately prior to the adjustment giving rise to the
Stock Price adjustment and the denominator of which is the Conversion Rate as so adjusted. The
number of additional shares set forth in the table above will be adjusted in the same manner as the
Conversion Rate as set forth in Section 13.06 hereof, other than as a result of an adjustment to
the Conversion Rate by adding the Fundamental Change Make-Whole Premium as described above.
Notwithstanding the foregoing, in no event will the Conversion Rate exceed 167.5041 per $1,000
principal amount as a result of this Section 13.01, subject to proportional adjustment in the same
manner as the Conversion Rate as set forth in Section 13.06 hereof.
The Fundamental Change Make-Whole Premium shall be delivered upon the later of the settlement
date for the conversion and promptly following the Fundamental Change Effective Date.
If a Holder converts its Notes prior to the Fundamental Change Effective Date, and the
Make-Whole Fundamental Change does not occur, such Holder shall not be entitled to the Fundamental
Change Make-Whole Premium in connection with such conversion.
(f) By delivering the number of shares of Common Stock issuable on conversion to the Trustee,
plus a cash payment for any fractional share, the Company will be deemed to have satisfied its
obligation to pay the principal amount of the Notes so converted and its obligation to pay accrued
and unpaid interest attributable to the period from the most recent Interest Payment Date through
the Conversion Date (which amount will be deemed satisfied and extinguished).
58
Section 13.02. Conversion Procedure. (a) To convert a Note in certificated form, a Holder
must (1) complete and manually sign the Notice of Conversion on the back of the Note, or facsimile
of such Notice of Conversion, and deliver such Notice of Conversion to the Conversion Agent, which
shall become irrevocable upon receipt by the Conversion Agent, (2) surrender the Note to the
Conversion Agent, (3) furnish appropriate endorsements and transfer documents if required by the
Note Registrar or the Conversion Agent, (4) pay an amount equal to the interest payable on the next
Interest Payment Date to which the Holder is not entitled as required by Section 13.02(c) and (5)
pay all transfer or similar taxes, if required pursuant to Section 13.04. Anything herein to the
contrary notwithstanding, in the case of Global Notes, Notices of Conversion may be delivered and
such Notes may be surrendered for conversion in accordance with clauses (3), (4) and (5) of this
Section 13.02(a) and the Applicable Procedures as in effect from time to time. The date on which
the Holder satisfies all the requirements set forth in this Section 13.02(a) is the Conversion
Date.
(b) Each conversion shall be deemed to have been effected as to any Notes surrendered for
conversion on the Conversion Date and the person in whose name the shares of Common Stock shall be
issuable upon conversion shall be deemed to be the holder of record of such Common Stock as of the
close of business on such Conversion Date, and the Company shall deliver the consideration due in
respect of any conversion on the third Business Day immediately following the relevant Conversion
Date; provided, however, that no surrender of a Note on any Conversion Date when the stock transfer
books of the Company shall be closed shall be effective to constitute the person or persons
entitled to receive the shares of Common Stock upon conversion as the record holder or holders of
such shares of Common Stock on such date, but such surrender shall be effective to constitute the
person or persons entitled to receive such shares of Common Stock as the record holder or holders
thereof for all purposes at the close of business on the next succeeding day on which such stock
transfer books are open. Upon conversion of a Note, such person shall no longer be the Holder of
such Note. Except as set forth in this Indenture, no payment or adjustment will be made for
dividends or distributions declared or made on shares of Common Stock issued upon conversion of a
Note prior to the issuance of such shares.
A Holder that has delivered a Fundamental Change Purchase Notice pursuant to Section 15.01
with respect to a Note may not surrender such Note for conversion until such Holder has withdrawn
the Fundamental Change Purchase Notice in accordance with Section 15.01(c).
(c) Holders of Notes surrendered for conversion (in whole or in part) during the period from
the close of business on any Regular Record Date to the open of business on the next succeeding
Interest Payment Date will receive the semiannual interest payable on the principal amount of such
Notes being
59
surrendered for conversion on the corresponding Interest Payment Date notwithstanding the
conversion. Upon surrender of any such Notes for conversion, such Notes shall also be accompanied
by payment in funds to the Conversion Agent acceptable to the Company of an amount equal to the
interest payable on such corresponding Interest Payment Date (but excluding any overdue interest on
the principal amount of such Note so converted if any overdue interest exists at the time such
Holder surrenders such Note for conversion); provided, however, that no such payment need be made
(i) if the Company has specified a Redemption Date that is after such Regular Record Date and on or
prior to the next succeeding Interest Payment Date, (ii) if the Company has specified a Fundamental
Change Purchase Date that is after such Regular Record Date and on or prior to the next succeeding
Interest Payment Date, or (iii) if conversion occurs after the last Regular Record Date prior to
the Maturity Date,. Except as otherwise provided in this Section 13.02(c) and Section 14.01(c), no
payment or adjustment will be made for accrued interest on a converted Note and any such accrued
interest shall be deemed satisfied and extinguished.
(d) Subject to Section 13.02(c), nothing in this Section 13.02 shall affect the right of a
Holder in whose name any Note is registered at the close of business on a Regular Record Date to
receive the interest payable on such Note on the related Interest Payment Date in accordance with
the terms of this Indenture and the Notes. If a Holder converts more than one Note at the same
time, the number of shares of Common Stock issuable upon the conversion (and the amount of any cash
in lieu of fractional shares pursuant to Section 13.03) shall be based on the aggregate principal
amount of all Notes so converted.
(e) In the case of any Note which is converted in part only, upon such conversion the Company
shall execute and the Trustee shall authenticate and deliver to the Holder thereof, without service
charge, a new Note or Notes of authorized denominations in an aggregate principal amount equal to,
and in exchange for, the unconverted portion of the principal amount of such Note. A Note may be
converted in part, but only if the principal amount of such part is an integral multiple of $1,000
and the principal amount of such Note to remain Outstanding after such conversion is equal to
$1,000 or any integral multiple of $1,000 in excess thereof.
Section 13.03. Fractional Shares. No fractional shares of Common Stock shall be issued upon
conversion of any Note or Notes. If more than one Note shall be surrendered for conversion at one
time by the same Holder, the number of full shares which shall be issued upon conversion thereof
shall be computed on the basis of the aggregate principal amount of the Notes (or specified
portions thereof) so surrendered. Instead of any fractional share of Common Stock which would
otherwise be issued upon conversion of any Note or Notes (or specified portions thereof), the
Company shall pay a cash adjustment in respect of such fraction (calculated to the nearest
one-100th of a share) in an amount equal to the same
60
fraction of the Last Reported Sale Price of the Common Stock as of the Trading Day preceding
the Conversion Date.
Section 13.04. Taxes on Conversion. Except as provided in the next sentence, the Company
will pay any and all documentary, stamp or similar issue or transfer tax due and duties on the
issuance of shares of Common Stock upon conversion of Notes pursuant hereto. A Holder delivering a
Note for conversion shall be liable for and will be required to pay any tax or duty which may be
payable in respect of any transfer involved in the issue and delivery of shares of Common Stock in
a name other than that of the Holder of the Note or Notes to be converted, and no such issue or
delivery shall be made unless the Person requesting such issue has paid to the Company the amount
of any such tax or duty, or has established to the satisfaction of the Company that such tax or
duty has been paid.
Section 13.05. Company to Provide Common Stock. (a) The Company shall, prior to issuance of
any Notes hereunder, and from time to time as may be necessary, reserve, out of its authorized but
unissued Common Stock, a sufficient number of shares of Common Stock to permit the conversion of
all Outstanding Notes into shares of Common Stock.
(b) All shares of Common Stock delivered upon conversion of the Notes shall be newly issued
shares, shall be duly authorized, validly issued, fully paid and nonassessable and shall be free
from preemptive or similar rights and free of any lien or adverse claim as the result of any action
by the Company.
Section 13.06. Adjustment of Conversion Rate. The Conversion Rate shall be adjusted from
time to time by the Company as follows:
(a) If the Company issues shares of Common Stock as a dividend or distribution on shares of
Common Stock, or effects a share split or share combination, the Conversion Rate will be adjusted
based on the following formula:
where,
|
|
|
|
|
CR0
|
|
=
|
|
the applicable Conversion Rate in effect
immediately prior to the open of business on the
Ex-Dividend Date for such dividend or
distribution, or immediately prior to the open of
business on the effective date of such share split
or share combination, as the case may be; |
61
|
|
|
|
|
CR
|
|
=
|
|
the applicable Conversion Rate in effect
immediately after the open of business on the
Ex-Dividend Date for such dividend or
distribution, or immediately after the open of
business on the effective date of such share split
or share combination, as the case may be; |
|
|
|
|
|
OS0
|
|
=
|
|
the number of shares of Common Stock outstanding
immediately prior to such dividend, distribution,
share split or share combination, as the case may
be; and |
|
|
|
|
|
OS
|
|
=
|
|
the number of shares of Common Stock outstanding
immediately after giving effect to such dividend,
distribution, share split or share combination, as
the case may be. |
Any adjustments made pursuant to this Section 13.06(a) shall become effective immediately on
or after (x) the open of business on the Ex-Dividend Date for such dividend or distribution or (y)
the effective date of such split or combination, as applicable. If any dividend or distribution
described in this Section 13.06(a) is declared but not so paid or made, the new Conversion Rate
shall again be adjusted to the Conversion Rate that would then be in effect if such dividend or
distribution had not been declared.
(b) If the Company distributes to all holders of Common Stock any rights or warrants entitling
them to purchase, for a period of not more than 45 days after the Ex-Dividend Date for the
distribution, shares of Common Stock at a price per share less than the average of the Last
Reported Sale Prices of the Common Stock for the 10 consecutive Trading-Day period ending on the
Trading Day immediately preceding the declaration date for such distribution, the Conversion Rate
will be adjusted based on the following formula:
where,
|
|
|
|
|
CR0
|
|
=
|
|
the Conversion Rate in effect immediately prior
to the open of business on the Ex-Dividend Date
for such distribution; |
|
|
|
|
|
CR
|
|
=
|
|
the new Conversion Rate in effect immediately
after the open of business on the Ex-Dividend
Date for such distribution; |
|
|
|
|
|
OS0
|
|
=
|
|
the number of shares of Common Stock
outstanding immediately prior to the open of
business on the Ex-Dividend Date for such
distribution; |
62
|
|
|
|
|
X
|
|
=
|
|
the total number of shares of Common Stock
issuable pursuant to such rights or warrants;
and |
|
|
|
|
|
Y
|
|
=
|
|
the number of shares of Common Stock equal to
the aggregate price payable to exercise such
rights or warrants divided by the average of
the Last Reported Sale Prices of the Common
Stock over the 10 consecutive Trading-Day
period ending on the Trading Day immediately
preceding the declaration date for such
distribution. |
For purposes of this Section 13.06(b), in determining whether any rights or warrants entitle
the Holders to subscribe for or purchase shares of Common Stock at less than the average of the
Last Reported Sale Prices of the Common Stock for the applicable 10 consecutive Trading-Day period,
there shall be taken into account any consideration received by the Company for such rights or
warrants and any amount payable on exercise thereof, with the value of such consideration if other
than cash, to be determined by the Board of Directors. If any right or warrant described in this
Section 13.06(b) is not exercised prior to the expiration of the exercisability thereof, the new
Conversion Rate shall be readjusted to the Conversion Rate that would then be in effect if such
right or warrant had not been so issued. Any adjustment made pursuant to this Section 13.06(b)
shall become effective immediately after the Ex-Dividend Date for the applicable distribution.
(c) If the Company distributes shares of its Capital Stock, evidences of its indebtedness or
other assets or property of the Company to all holders of the Common Stock, excluding
(i) dividends or distributions (including share splits) as to which an adjustment is
effected in Section 13.06(a) or Section 13.06(b);
(ii) dividends or distributions covered by Section 13.06(d);
(iii) dividends or distributions that constitute Reference Property following an
event pursuant to Section 13.10; and
(iv) Spin-Offs to which the provisions set forth below in this Section 13.06(c) shall
apply,
then the applicable Conversion Rate will be adjusted based on the following formula:
63
where,
|
|
|
|
|
CR0
|
|
=
|
|
the applicable Conversion Rate in effect
immediately prior to the open of business on the
Ex-Dividend Date for such distribution; |
|
|
|
|
|
CR
|
|
=
|
|
the applicable Conversion Rate in effect
immediately after the open of business on the
Ex-Dividend Date for such distribution; |
|
|
|
|
|
SP0
|
|
=
|
|
the average of the Last Reported Sale Prices of
the Common Stock over the 10 consecutive
Trading-Day period ending on, and including, the
Trading Day immediately preceding the Ex-Dividend
Date for such distribution; and |
|
|
|
|
|
FMV
|
|
=
|
|
the fair market value (as determined in good faith
by the Board of Directors) of the shares of
Capital Stock, evidences of indebtedness, assets
or property distributed with respect to each
outstanding share of Common Stock as of the open
of business on the Ex-Dividend Date for such
distribution. |
If the then fair market value of the portion of the shares of Capital Stock, evidences of
indebtedness or other assets or property so distributed applicable to one share of Common Stock is
equal to or greater than the average of the Last Reported Sales Prices of the Common Stock over the
10 consecutive Trading-Day period ending on the Trading Day immediately preceding the Ex-Dividend
Date for such distribution, in lieu of the foregoing adjustment, adequate provisions shall be made
so that each Holder of a Note shall have the right to receive on conversion in respect of each Note
held by such Holder, in addition to any amounts to which such Holder is entitled to receive, the
amount and kind of securities and assets such Holder would have received had such Holder already
owned a number of shares of Common Stock equal to the applicable Conversion Rate immediately prior
to the open of business on the Ex-Dividend Date for the distribution of the securities or assets.
With respect to an adjustment pursuant to this Section 13.06(c) where there has been a payment
of a dividend or other distribution on the Common Stock of shares of the Capital Stock of any class
or series, or similar equity interest, of or relating to a Subsidiary or other business unit that
are, or, when issued, will be, traded or quoted on any national or regional securities exchange or
other market (a Spin-Off), the applicable Conversion Rate will instead be adjusted based on the
following formula:
where,
64
|
|
|
|
|
CR0
|
|
=
|
|
the applicable Conversion Rate in effect
immediately prior to the tenth Trading Day
immediately following the effective date for such
Spin-Off; |
|
|
|
|
|
CR
|
|
=
|
|
the applicable Conversion Rate in effect
immediately after the open of business on the
tenth Trading Day immediately following the
effective date for such Spin-Off; |
|
|
|
|
|
FMV
|
|
=
|
|
the average of the Last Reported Sale Prices of
the Capital Stock or similar equity interest
distributed to holders of Common Stock applicable
to one share of Common Stock over the first 10
consecutive Trading-Day period immediately
following the effective date for such Spin-Off
(such period, the Valuation Period); and |
|
|
|
|
|
MP0
|
|
=
|
|
the average of the Last Reported Sale Prices of
Common Stock over the Valuation Period. |
Such adjustment shall occur immediately after the tenth Trading Day immediately following, and
including, the effective date of such Spin-Off; provided that, for purposes of determining the
Conversion Rate in respect of any conversion during the 10 Trading Days following the effective
date of any Spin-Off, references within this Section 13.06(c) related to Spin-Offs to 10 Trading
Days shall be deemed replaced with such lesser number of Trading Days as have elapsed between the
effective date of such Spin-Off and the relevant Conversion Date.
If any such dividend or distribution described in this Section 13.06(c) is declared but not
paid or made, the new Conversion Rate shall be readjusted to be the Conversion Rate that would then
be in effect if such dividend or distribution had not been declared.
(d) If any cash dividend or distribution is made to all holders of Common Stock, the
Conversion Rate will be adjusted based on the following formula:
where,
|
|
|
|
|
CR0
|
|
=
|
|
the applicable Conversion Rate in effect
immediately prior to the open of business on the
Ex-Dividend Date for such distribution; |
65
|
|
|
|
|
CR
|
|
=
|
|
the applicable Conversion Rate in effect
immediately after the open of business on the
Ex-Dividend Date for such distribution; |
|
|
|
|
|
SP0
|
|
=
|
|
the average of the Last Reported Sale Prices of
the Common Stock over the 10 consecutive
Trading-Day period ending on, and including, the
Trading Day immediately preceding the Ex-Dividend
Date for such distribution; and |
|
|
|
|
|
C
|
|
=
|
|
the amount in cash per share of Common Stock the
Company distributes to holders of Common Stock. |
An adjustment to the Conversion Rate made pursuant to this Section 13.06(d) shall become
effective immediately after the open of business on the Ex-Dividend Date for the applicable
dividend or distribution. If any dividend or distribution described in this Section 13.06(d) is
declared but not so paid or made, the new Conversion Rate shall be readjusted to the Conversion
Rate that would then be in effect if such dividend or distribution had not been declared.
If the amount in cash per share of Common Stock so paid or distributed is equal to or greater
than the average of the Last Reported Sales Prices of the Common Stock over the 10 consecutive
Trading-Day period ending on the Trading Day immediately preceding the Ex-Dividend Date for such
cash dividend or distribution, in lieu of the foregoing adjustment, adequate provisions shall be
made so that each Holder of a Note shall have the right to receive on conversion in respect of each
Note held by such Holder, in addition to any amounts to which such Holder is entitled to receive,
the amount in cash such Holder would have received had such Holder already owned a number of shares
of Common Stock equal to the applicable Conversion Rate immediately prior to the record date for
such cash dividend or distribution.
(e) If the Company or any of its Subsidiaries makes a payment in respect of a tender or
exchange offer for Common Stock (other than tender offers or exchange offers not subject to Rule
13e-4 of the Exchange Act or odd lot tender offers), to the extent that the cash and value of any
other consideration included in the payment per share of Common Stock exceeds the Last Reported
Sale Price of the Common Stock on the Trading Day next succeeding the last date on which tenders or
exchanges may be made pursuant to such tender or exchange offer (the Expiration Date), the
Conversion Rate shall be increased based on the following formula:
where,
66
|
|
|
|
|
CR0
|
|
=
|
|
the applicable Conversion Rate in effect
immediately prior to the open of business on the
Trading Day next succeeding the Expiration Date; |
|
|
|
|
|
CR
|
|
=
|
|
the applicable Conversion Rate in effect
immediately after the open of business on the
Trading Day next succeeding the Expiration Date; |
|
|
|
|
|
AC
|
|
=
|
|
the aggregate value of all cash and any other
consideration (as determined by the Board of
Directors) paid or payable for shares purchased in
such tender offer or exchange offer; |
|
|
|
|
|
OS0
|
|
=
|
|
the number of shares of Common Stock outstanding
immediately prior to time (the Expiration Time)
such tender or exchange offer expires (prior to
giving effect to such tender offer or exchange
offer); |
|
|
|
|
|
OS
|
|
=
|
|
the number of shares of Common Stock outstanding
immediately after the expiration time (after
giving effect to such tender offer or exchange
offer); and |
|
|
|
|
|
SP
|
|
=
|
|
the average of the Last Reported Sale Prices of
Common Stock over the 10 consecutive Trading-Day
period commencing on, and including, the Trading
Day next succeeding the Expiration Date. |
The adjustment to the Conversion Rate under this Section 13.06(e) shall become effective
immediately following the tenth Trading Day next succeeding the date such tender offer or exchange
offer expires; provided that, for purposes of determining the Conversion Rate, in respect of any
conversion during the 10 Trading Days following the date that any tender or exchange offer expires,
references within this Section 13.06(e) to 10 Trading Days shall be deemed replaced with such
lesser number of Trading Days as have elapsed between the date such tender or exchange offer
expires and the relevant Conversion Date. If the Company or one of its Subsidiaries is obligated to
purchase Common Stock pursuant to any such tender or exchange offer but are permanently prevented
by applicable law from effecting any such purchase or all such purchases are rescinded, the new
Conversion Rate shall be readjusted to be the Conversion Rate that would be in effect if such
tender or exchange offer had not been made.
(f) Notwithstanding the foregoing, if a Conversion Rate adjustment becomes effective on any
Ex-Dividend Date pursuant to Section 13.06(a) through Section 13.06(e), and a Holder that has
converted its Notes on or after such Ex-Dividend Date and on or prior to the related record date
would be treated as the record holder of the Common Stock as of the related Conversion Date based
on an adjusted Conversion Rate for such Ex-Dividend Date, then, notwithstanding
67
Section 13.06(a) through Section 13.06(e), the Conversion Rate adjustment relating to such
Ex-Dividend Date will not be made for such converting Holder. Instead, such Holder shall be treated
as if such Holder were the record owner of the Common Stock on an unadjusted basis and participate
in the related dividend, distribution or other event giving rise to such adjustment.
Section 13.07. When No Adjustment is Required. (a) No adjustment in the Conversion Rate
shall be required unless such adjustment would require an increase or decrease of at least 1% in
the Conversion Rate as last adjusted; provided, however, that any adjustments which would be
required to be made but for this Section 13.07(a) shall be carried forward and taken into account
in any subsequent adjustment and any carry forward amount shall be paid to the Holder upon
conversion regardless of the 1% threshold. All calculations under this Article 13 shall be made to
the nearest cent or to the nearest one-hundredth of a share.
(b) Without limiting the foregoing provisions of Section 13.06, no adjustment will be made
thereunder, nor shall an adjustment be made to the ability of a Holder to convert, for any
distribution described therein if the Holder will otherwise participate in the distribution without
conversion of such Holders Notes as if such Holder held a number of shares of Common Stock equal
to the applicable Conversion Rate, multiplied by the principal amount (expressed in thousands) of
Notes held by such Holder, without having to convert its Notes. Further, if the application of the
foregoing formulas in Section 13.06 would result in a decrease in the Conversion Rate, no
adjustment to the Conversion Rate will be made (except on account of share combinations).
(c) No adjustment to the Conversion Rate will be made unless as specifically set forth in
Section 13.06 and Section 13.01(e). Without limiting the foregoing, no adjustment to the Conversion
Rate need be made:
(i) upon the issuance of any shares of Common Stock pursuant to any present or future
plan providing for the reinvestment of dividends or interest payable on securities of the
Company and the investment of additional optional amounts in shares of Common Stock under
any plan;
(ii) upon the issuance of any shares of Common Stock or options or rights to purchase
shares of Common Stock pursuant to any present or future employee, director or consultant
benefit plan or program or employee stock purchase plan of, or assumed by, the Company or
any of its Subsidiaries;
(iii) upon the issuance of any shares of Common Stock pursuant to any option,
warrant, right, or exercisable, exchangeable or convertible
68
security not described in clause (ii) above and outstanding as of the Issue Date;
(iv) for a change in the par value of the Common Stock; or
(v) for accrued and unpaid interest (including any Special Interest and Additional
Interest, if applicable).
Section 13.08. Notice of Adjustment. Whenever the Conversion Rate or conversion privilege is
required to be adjusted pursuant to this Indenture, the Company shall promptly mail to Holders a
notice of the adjustment and file with the Trustee an Officers Certificate briefly stating the
facts requiring the adjustment, the adjusted Conversion Rate and the manner of computing it.
Failure to mail such notice or any defect therein shall not affect the validity of any such
adjustment. Unless and until the Trustee shall receive an Officers Certificate setting forth an
adjustment of the Conversion Rate, the Trustee may assume without inquiry that the Conversion Rate
has not been adjusted and that the last Conversion Rate of which it has knowledge remains in
effect.
Section 13.09. Notice of Certain Transactions. In the event that there is a dissolution or
liquidation of the Company, the Company shall mail to Holders and file with the Trustee a notice
stating the proposed effective date. The Company shall mail such notice at least 20 days before
such proposed effective date. Failure to mail such notice or any defect therein shall not affect
the validity of any transaction referred to in this Section 13.09.
Section 13.10. Effect of Reclassification, Consolidation, Merger or Sale On Conversion
Privilege. If any of the following events occur:
(a) any recapitalization, reclassification or change of the outstanding shares of Common Stock
(other than a changes resulting from a subdivision or combination),
(b) any consolidation, merger, or combination involving the Company with another corporation,
or
(c) any sale, conveyance or lease to any other corporation of all or substantially all of the
property and assets of the Company,
(d) any statutory share exchange,
in each case as a result of which holders of Common Stock shall be entitled to receive stock, other
securities or other property or assets (including cash or any combination thereof) (the Reference
Property) with respect to or in exchange for such Common Stock, the Holders of the Notes then
Outstanding will be entitled thereafter to convert those Notes into the kind and amount of shares
of
69
stock, other securities or other property or assets (including cash or any combination thereof)
which they would have owned or been entitled to receive upon such transaction had such notes been
converted into Common Stock immediately prior to such transaction. In the event holders of Common
Stock have the opportunity to elect the form of consideration to be received in such transaction,
the reference property will be deemed to be the weighted average of the types and amounts of
consideration received by the holders of Common Stock that affirmatively make such election. The
Company shall notify the Holders of the weighted average as soon as practicable after such
determination is made. The Company may not become a party to any such transaction unless its terms
are consistent with the preceding. None of the foregoing provisions shall affect the right of a
Holder of Notes to convert its Notes into shares of Common Stock prior to the effective date of
such transaction.
The above provisions of this Section 13.10 shall similarly apply to successive
recapitalizations, reclassifications, mergers, consolidations, statutory share exchanges,
combinations, sales and conveyances.
If this Section 13.10 applies to any event or occurrence, Section 13.06 hereof shall not
apply.
The Company shall not become a party to any such transaction unless its terms are consistent
with the foregoing. None of the foregoing provisions shall affect the right of a Holder to convert
the Notes as set forth in Section 13.01 prior to the effective time of such transaction.
Section 13.11. Trustees Disclaimer. (a) The Trustee shall have no duty to determine, or
liability in connection therewith, when an adjustment under this Article 13 should be made, how it
should be made or what such adjustment should be, but may accept as conclusive evidence of that
fact or the correctness of any such adjustment, and shall be protected in relying upon, an
Officers Certificate, including the Officers Certificate with respect thereto which the Company
is obligated to file with the Trustee pursuant to Section 13.08. Unless and until the Trustee
receives such Officers Certificate delivered pursuant to Section 13.08, the Trustee may assume
without inquiry that no such adjustment has been made and the last Conversion Rate of which the
Trustee has knowledge remains in effect. The Trustee makes no representation as to the validity or
value of any securities or assets issued upon conversion of Notes, and the Trustee shall not be
responsible for the Companys failure to comply with any provisions of this Article 13.
(b) The Trustee shall not be under any responsibility to determine the correctness of any
provisions contained in any supplemental indenture executed pursuant to Section 13.10, but may
accept as conclusive evidence of the correctness thereof, and shall be fully protected in relying
upon, the Officers
70
Certificate and Opinion of Counsel, with respect thereto which the Company are
obligated to file with the Trustee pursuant to Section 13.10 and Section 10.01, respectively.
Section 13.12. Voluntary Increase; Nasdaq Compliance. Subject to Section 9.01(e), the
Company from time to time may increase the Conversion Rate, to the extent permitted by law and
subject to any applicable stockholder approval requirements pursuant to the listing standards of
the Nasdaq Stock Market or such other United States securities exchange on which the Common Stock
is traded, by any amount for any period of at least 20 days. The Company may make such increase in
the Conversion Rate (in addition to others provided in this Indenture) as the Board of Directors
deems advisable to avoid or diminish any income tax to holders of Common Stock resulting from a
dividend or distribution of stock, or rights to acquire stock, or similar event, and the Company
provides 15 days prior written notice of any increase in the Conversion Rate to the Trustee and
the Holders: provided, however, that in no event may the Company increase the Conversion Rate such
that it causes the Conversion Price to be less than the par value of a share of Common Stock.
The Company may not
take any voluntary actions that would result in an adjustment to the
Conversion Rate pursuant to Section 13.06 without complying, if applicable, with the
stockholder approval rules of the NASDAQ Global Market and any similar rule of any stock exchange
on which the Common Stock is listed at the relevant time. In accordance with such listing
standards, this restriction shall apply at any time when the Notes are Outstanding, regardless of
whether the Company then has a class of securities listed on the NASDAQ Global Market.
Section 13.13. Rights Plan. To the extent that the Company has a Rights Plan in effect upon
conversion of the Notes into Common Stock, the Holder will receive upon conversion of the Notes in
respect of which the Company has elected to deliver Common Stock, if applicable, the Rights under
the Rights Plan, unless prior to any conversion, the Rights have separated from the Common Stock,
in which case, and only in such case, the Conversion Rate will be adjusted at the time of
separation as if the Company distributed to all holders of Common Stock shares of the Companys
Capital Stock, evidences of indebtedness or assets as described in Section 13.06(c) above, subject
to readjustment in the event of the expiration, termination or redemption of such Rights. In lieu
of any such adjustment, the Company may amend such applicable Rights Plan to provide that upon
conversion of the Notes the Holders will receive, in addition to the Common Stock issuable upon
such conversion, the Rights which would have attached to such Common Stock if the Rights had not
become separated from the Common Stock under such applicable Rights Plan.
Section 13.14.
Exchange in Lieu of Conversion. (a) Notwithstanding anything in this
Indenture to the contrary, when a Holder surrenders Notes for
71
conversion, the Company may, at its
election, direct the Conversion Agent to surrender, on or prior to the second Business Day
immediately following the
Conversion Date (assuming for purposes of this Section 13.14 that the date such Holder
surrenders such Notes for conversion is the Conversion Date for such Notes), such Notes to a
financial institution designated by the Company (a Financial Institution) for exchange in lieu of
conversion.
(b) In order to accept any such Notes surrendered for conversion, the Financial Institution
must agree to deliver, in exchange for such Notes, shares of Common Stock (and cash in lieu of
fractional shares) equal to the consideration due upon conversion under Section 13.01(a), together
with any cash payments (or common stock in lieu thereof) representing the Make-Whole Payment
pursuant to Section 14.01 or any additional shares of Common Stock representing the Fundamental
Change Make-Whole Premium pursuant to Section 13.01(e) (the Exchange Settlement Property).
(c) By the close of business on the second Business Day immediately following the Conversion
Date, the Company must notify the Holder surrendering Notes for conversion that it has directed the
Financial Institution to make an exchange in lieu of conversion and the Financial Institution shall
be required to notify the Conversion Agent whether it will deliver the Exchange Settlement Property
upon exchange.
(d) If the Financial Institution accepts any such Notes, it shall deliver the Exchange
Settlement Property to the Conversion Agent and the Conversion Agent shall deliver such Exchange
Settlement Property to the applicable Holder no later than the third Business Day following the
Conversion Date. Any Notes exchanged by the Financial Institution shall remain Outstanding.
(e) If the Financial Institution agrees to accept any Notes for exchange but does not timely
deliver the related consideration, or if the Financial Institution does not accept the Notes for
exchange, the Company shall deliver such conversion consideration as if the Company had not made an
exchange election.
The Companys designation of the Financial Institution to which the Notes may be submitted for
exchange does not require the Financial Institution to accept any Notes. The Company shall not pay
any consideration to, or otherwise enter into any agreement with, the financial institution
designated as the Financial Institution for or with respect to such designation.
72
ARTICLE 14
Redemption Of Notes
Section 14.01. Right to Redeem. (a) No sinking fund is provided for the Notes. On or after
the original Issue Date of the Notes, the Notes may be redeemed for cash in whole or in part at the
option of the Company if the Last Reported Sale Price of the Common Stock is greater than or equal
to 150% of the Conversion Price on at least 20 Trading Days during any 30 consecutive Trading
Day period ending on the date on which the Company mailed the Notice of Redemption.
(b) The price at which the Notes are redeemable (the Redemption Price) shall be equal to (i)
100% of the principal amount of Notes to be redeemed, plus (ii) accrued and unpaid interest
(including any Special Interest and Additional Interest), if any, to, but excluding, the Redemption
Date, plus (iii) the Make-Whole Payment. The Trustee shall have no duty to determine or calculate
the Make-Whole Payment, which shall be determined by the Company in accordance with the provisions
of this Indenture, and the Trustee shall not be under any responsibility to determine the
correctness of any such determination and/or calculation and may conclusively rely on the
correctness thereof.
(c) Upon any redemption in accordance with this Article 14, the Company will pay to converting
Holders, in addition to the shares of Common Stock due upon conversion (and cash in lieu of
fractional shares), the Make-Whole Payment on all Notes called for redemption and converted during
the period from the date the Company mailed the Notice of Redemption to the date of redemption (the
Redemption Date); provided, however, that such Make-Whole Payment shall not exclude interest
accrued to, but excluding, the Redemption Date. In the case of a Make-Whole Payment to converting
Holders only in accordance with this Section 14.01(c), the Company may elect to pay such Make-Whole
Payment in cash or shares of Common Stock, or any combination thereof. If the Company elects to
pay any portion of such Make-Whole Payment in shares of Common Stock, the Company shall specify a
percentage of such Make-Whole Payment in the Notice of Redemption to be paid in Common Stock. The
number of shares of Common Stock to be delivered in respect of such portion of such Make-Whole
Payment shall be determined by dividing such portion by 97.5% of the 5-day Volume-Weighted Average
Price per share for the five Trading Days immediately succeeding the Trading Day on which the
Company provides such Notice of Redemption. The Company shall not issue fractional shares for any
additional payment upon conversion but shall instead make a cash adjustment for any fractional
share payment. Notwithstanding the foregoing, the Company shall not pay any portion of any
Make-Whole Payment in shares of Common Stock if (i) the resale of any such shares of Common Stock
by any Person that is not an Affiliate of the Company shall require registration under the
Securities Act or (ii)
73
the issuance of such shares of Common Stock shall require a shareholder
approval pursuant to listing standards of the Nasdaq Stock Market.
(d) The Company may not redeem any Notes unless all accrued and unpaid interest (including
Special Interest and Additional Interest, if applicable) thereon has been or is simultaneously paid
for all interest periods ending prior to the Redemption Date.
(e) If the Redemption Date is after a Regular Record Date but on or prior to the corresponding
Interest Payment Date then notwithstanding the foregoing the Company shall (i) pay accrued and
unpaid interest on such Interest
Payment Date to the Holder of record on such Regular Record Date, the Make-Whole Payment will
equal the present value of all remaining interest payments starting with the next Interest Payment
Date for which interest has not been provided for, calculated as set forth in the definition of
Make-Whole Payment, and (x) in respect of any Notes redeemed on such Redemption Date, the
Redemption Price payable on such Notes shall not include such payment, or (y) in respect of any
Notes converted after such Regular Record Date and prior to the open of business on such Interest
Payment Date, the converting Holder shall not be required to pay funds equal to the interest
payable to the Holder of record on such Regular Record Date, as set forth under Section 13.02; and
(ii) pay any Make-Whole Payment on the Redemption Date to the Holders of the Notes to be redeemed
or Holders who convert their Notes called for redemption pursuant to Section 14.01(c), in each case
regardless of whether such Holders are the Holders of record on such Regular Record Date. However,
such Make-Whole Payment shall not include interest to be paid to the Holders of record on such
Interest Payment Date.
Section 14.02. Selection of Notes to be Redeemed. If less than all the Notes are to be
redeemed, the Trustee shall select the Notes to be redeemed by lot, or on a pro rata basis or by
any other method the Trustee considers fair and appropriate (so long as such method is not
prohibited by the rules of the Nasdaq Global Select Market or any other stock exchange on which the
Common Stock is then listed, as applicable). The Trustee shall make the selection within seven
Business Days from its receipt of the notice from the Company delivered pursuant to Section 14.03
from Outstanding Notes not previously called for redemption.
Notes and portions of Notes the Trustee selects shall be in principal amounts of $1,000 or in
integral multiples of $1,000 in excess thereof. Provisions of this Indenture that apply to Notes
called for redemption in whole also apply to Notes called for redemption in part. The Trustee
shall notify the Company promptly of the Notes or portions of Notes to be redeemed.
If any portion of a Holders Notes are selected for partial redemption and such Holder
converts a portion of its Notes, the converted portion of such Notes
74
shall be deemed (so far as may
be) to be from the portion selected for redemption. Notes which have been converted during a
selection of Notes to be redeemed may be treated by the Trustee as Outstanding for the purpose of
such selection.
Section 14.03. Notice of Redemption. At least 30 days but not more than 60 days before a
Redemption Date, the Company, or at the Companys request, the Trustee, shall mail a notice of
redemption by first-class mail, postage prepaid, to the Trustee, the Paying Agent and each Holder
of Notes to be redeemed (the Notice of Redemption); provided, however, that the Company may not
deliver any such notice to any Holder of Notes at any time when there exists any accrued and unpaid
Defaulted Interest.
The Notice of Redemption shall specify the Notes (including CUSIP numbers) to be redeemed and
shall state:
(i) the Redemption Date;
(ii) the Redemption Price;
(iii) the applicable Conversion Rate and any adjustments thereto;
(iv) the name and address of the Paying Agent and Conversion Agent;
(v) the amount of the Make-Whole Payment;
(vi) the percentage, if any, of such Make-Whole Payment to be paid in Common Stock
for Notes called for redemption and converted during the period from the date the Company
mailed the Notice of Redemption to and including the Redemption Date, pursuant to Section
14.01(c); and
(vii) the procedures a Holder must follow to exercise rights under Article 15.
At the Companys written request delivered at least 45 days prior to the Redemption Date
(unless a shorter period is agreed to by the Trustee), the Trustee shall give the Notice of
Redemption to each Holder of Notes to be redeemed in the Companys name and at the Companys
expense.
Section 14.04. Effect of Notice of Redemption. Once Notice of Redemption is given, Notes
called for redemption become due and payable on the Redemption Date and at the Redemption Price
stated in the notice except for Notes that are converted in accordance with the terms of this
Indenture. Upon surrender to the Paying Agent, such Notes shall be paid at the Redemption Price
stated in the notice.
75
Section 14.05. Deposit of Redemption Price. Prior to 10:00 a.m. (New York City time) on or
prior to the Redemption Date, the Company shall deposit with the Trustee or with the Paying Agent
(or, if the Company or a Subsidiary of the Company or an Affiliate of either of them is acting as
the Paying Agent, shall segregate and hold in trust as provided in Section 7.06) an amount of money
(in
immediately available funds if deposited on such Redemption Date) and shares of Common Stock,
if any, sufficient to pay the aggregate Redemption Price of all the Notes or portions thereof which
are to be redeemed as of the Redemption Date.
If the Paying Agent holds money and shares of Common Stock, if any, sufficient to pay the
Redemption Price with respect to the Notes to be redeemed on the Redemption Date in accordance with
the terms of this Indenture, then, immediately on and after the Redemption Date, interest on such
Notes shall cease to accrue, whether or not the Notes are delivered to the Paying Agent, and all
other rights of the Holders of such Notes shall terminate, other than the right to receive the
Redemption Price upon delivery of such Notes.
Section 14.06. Notes Redeemed in Part. (a) Any Note which is to be redeemed only in part
shall be surrendered at the office of the Paying Agent (with, if the Company or the Trustee so
requires, due endorsement by, or a written instrument of transfer in form satisfactory to the
Company and the Trustee duly executed by, the Holder thereof or such Holders attorney duly
authorized in writing) and the Company shall execute and, upon Company Order, the Trustee shall
authenticate and deliver to the Holder of such Note, without service charge, a new Note or Notes,
of any authorized denomination as requested by such Holder in aggregate principal amount equal to,
and in exchange for, the portion of the principal amount of the Note so surrendered that is not
redeemed.
(b) In the event of any redemption of any Note in part, the Company shall not be required to
(i) issue, register the transfer of or exchange, pursuant to Section 2.05 or Section 2.06, any
Notes during a period beginning at the open of business 15 days before the mailing of a Notice of
Redemption and ending at the close of business on the day of such mailing or (ii) register the
transfer of or exchange, pursuant to Section 2.05, any Notes so selected for redemption, in whole
or in part, except the portion of such Notes not being redeemed.
ARTICLE 15
Repurchase Of Notes
Section 15.01. Repurchase of Notes at Option of the Holder Upon a Fundamental Change. (a) If
a Fundamental Change occurs prior to the Maturity Date, each Holder of a Note shall have the right,
at the option of the Holder, to require the Company to repurchase all or any portion of the Notes
of such Holder equal to $1,000 principal amount (or an integral multiple thereof) at the
76
Fundamental Change Purchase Price, on the date specified by the Company that is not less than 20
days and not more than 35 days after the date of the Fundamental Change Company Notice pursuant to
Section 15.01(b) (the Fundamental Change Purchase Date). If the Fundamental Change Purchase Date
is after a Regular Record Date and on or prior to the corresponding Interest Payment Date,
the Company shall pay accrued and unpaid interest to the Holder of a Note of record at the
close of business on such Regular Record Date.
(b) On or before the tenth day after the Fundamental Change Effective Date, the Company, or,
at the request of the Company, the Trustee, shall mail a written notice of the occurrence of the
Fundamental Change, and of the repurchase right arising therefrom, to the Trustee, Paying Agent and
to each Holder (and to beneficial owners as required by applicable law) (the Fundamental Change
Company Notice). Simultaneously with providing such Fundamental Change Company Notice, the Company
shall publish a notice containing the information that is required in the Fundamental Change
Company Notice in a newspaper of general circulation in The City of New York or publish information
on a website of the Company or through such other public medium the Company may use at that time.
The Fundamental Change Company Notice shall set forth the Holders right to require the Company to
purchase the Notes and specify:
(i) the events causing such Fundamental Change;
(ii) the date of such Fundamental Change;
(iii) the last date by which the Fundamental Repurchase Notice must be delivered to
elect the repurchase option pursuant to this Section 15.01;
(iv) the Fundamental Change Purchase Price;
(v) the Fundamental Change Purchase Date;
(vi) the name and address of each Paying Agent and Conversion Agent, if applicable;
(vii) that the Notes with respect to which a Fundamental Change Notice has been
delivered by a Holder may be converted only if the Holder withdraws the Fundamental Change
Purchase Notice in accordance with the terms of this Indenture; and
(viii) the procedures that the Holder must follow to require the Company to
repurchase its Notes under this Section 15.01.
77
At the Companys request, the Trustee shall give such Fundamental Change Company Notice in the
Companys name and at the Companys expense; provided that, unless otherwise agreed by the Trustee,
the Company makes such request at least five (5) Business Days prior to the date by which such
Fundamental Change Company Notice must be given to the Holders in accordance with this Section
15.01; provided, further, that the text of such Fundamental Change Company Notice shall be prepared
by the Company. If any
of the Notes is in the form of a Global Note, then the Company shall modify such notice to the
extent necessary to accord with the Applicable Procedures relating to the purchase of Global Notes.
No failure of the Company to give the foregoing notices or defect therein shall limit any
Holders right to exercise its right to cause the Company to repurchase such Holders Notes
pursuant to this Section 15.01.
(c) A Holder may exercise its rights specified in this Section 15.01 upon delivery of (1) the
Note to be repurchased, duly endorsed for transfer, together with (2) a written purchase notice and
the form entitled Fundamental Change Purchase Notice on the reverse of the Note duly completed
and which may be delivered by letter, overnight courier, hand delivery, facsimile transmission or
in any other written form onto the Paying Agent (in the case of Notes held in book-entry form, in
accordance with DTCs Applicable Procedures) of the exercise of such rights (a Fundamental Change
Purchase Notice) to the Paying Agent at any time on or before the close of business on the
Fundamental Change Purchase Date, subject to extension to comply with applicable law.
(i) The Fundamental Change Purchase Notice shall state: (A) the certificate number
(if such Note is held in certificated form) of the Note which the Holder will deliver to
be repurchased (or, if the Note is held in global form, any other items required to comply
with the Applicable Procedures), (B) the portion of the principal amount of the Note which
the Holder will deliver to be repurchased and (C) that such Note shall be repurchased as
of the Fundamental Change Purchase Date pursuant to the terms and conditions specified in
the Notes and in this Indenture.
(ii) The delivery of a Note for which a Fundamental Change Purchase Notice has been
timely delivered to any Paying Agent, on or before the Business Day immediately preceding
the Fundamental Change Purchase Date (together with all necessary endorsements) at the
office of such Paying Agent shall be a condition to the receipt by the Holder of the
Fundamental Change Purchase Price therefor (or, if the Note is held in global form, any
items required to comply with the Applicable Procedures).
78
(iii) The Company shall only be obliged to purchase, pursuant to this Section 15.01,
a portion of a Note if the principal amount of such portion is $1,000 or an integral
multiple of $1,000 (provisions of this Indenture that apply to the purchase of all of a
Note also apply to the purchase of such portion of such Note).
(iv) A Paying Agent shall promptly notify the Company of the receipt by it of any
Fundamental Change Purchase Notice.
(v) Anything herein to the contrary notwithstanding, in the case of Global Notes, any
Fundamental Change Purchase Notice may be delivered and such Notes may be surrendered or
delivered for purchase in accordance with the Applicable Procedures as in effect from time
to time.
(vi) A Holder may withdraw any Fundamental Change Purchase Notice in whole or in part
by written notice of withdrawal delivered to the Paying Agent or in accordance with DTCs
Applicable Procedures prior to the close of business on the Business Day prior to the
Fundamental Change Purchase Date. Such notice of withdrawal shall state: (A) the principal
amount of the withdrawn Note , (B) the certificate number (if such Note is held in
certificated form) of the withdrawn Note (or, if the Note is held in global form, any
other items required to comply with the Applicable Procedures), and (C) the principal
amount, if any, which remains subject to the Fundamental Change Purchase Notice.
(d) The Company shall deposit cash at the time and in the manner as provided in Section 15.03,
sufficient to pay the aggregate Fundamental Change Purchase Price of all Notes to be purchased
pursuant to this Section 15.01.
Section 15.02. Effect of Fundamental Change Purchase Notice. Upon receipt by any Paying
Agent of a properly completed Fundamental Change Purchase Notice from a Holder, the Holder of the
Note in respect of which such Fundamental Change Purchase Notice was given shall thereafter be
entitled to receive the Fundamental Change Purchase Price with respect to such Note. Such
Fundamental Change Purchase Price shall be paid to such Holder promptly following the later of (1)
the Fundamental Change Purchase Date (provided that the conditions in Section 15.01 have been
satisfied) and (2) the time of book-entry transfer or delivery of such Note to a Paying Agent by
the Holder thereof in the manner required by Section 15.01(c), subject to extension to comply with
applicable law.
Section 15.03. Deposit of Fundamental Change Purchase Price. (a) On or before the applicable
Fundamental Change Purchase Date, the Company shall deposit with the Paying Agent (or if the
Company or an Affiliate of the Company is acting as the Paying Agent, shall segregate and hold in
trust as provided in
79
Section 7.06) an amount of money (in immediately available funds if deposited
on or after such Fundamental Change Purchase Date), sufficient to pay the aggregate Fundamental
Change Purchase Price of all the Notes or portions thereof that are to be purchased as of the
Fundamental Change Purchase Date. Payment by the Paying Agent of the Fundamental Change Purchase
Price following receipt of the Fundamental Change Purchase Price from the Company shall be made
promptly following the later of the Fundamental Change Purchase Date or the time of book-entry
transfer or delivery of such Notes.
(b) If the Paying Agent holds, on the Fundamental Change Purchase Date, in accordance with the
terms hereof, money or securities sufficient to pay
the Fundamental Change Purchase Price of any Note for which a Fundamental Change Purchase
Notice has been tendered then, immediately following the applicable Fundamental Change Purchase
Date, whether or not book-entry transfer of the Note is made or whether or not the Note is
delivered to the Paying Agent, each such Note shall cease to be Outstanding, interest, including
any additional interest, if any, shall cease to accrue, and all other rights of the Holder in
respect of the Note shall terminate (other than the right to receive the Fundamental Change
Purchase Price upon delivery or transfer of the Note as aforesaid).
(c) If a Fundamental Change Purchase Date falls after a Regular Record Date and on or before
the related Interest Payment Date, then interest on the Notes payable on such Interest Payment Date
will be payable to the Holders in whose names the Notes are registered at the close of business on
such Regular Record Date.
Section 15.04. Repayment to the Company. To the extent that the aggregate amount of cash
deposited by the Company pursuant to Section 15.03 exceeds the aggregate Fundamental Change
Purchase Price of the Notes or portions thereof that the Company is obligated to purchase, then
promptly after the Fundamental Change Purchase Date the Paying Agent shall return any such excess
cash to the Company.
Section 15.05. Notes Purchased In Part. Any Note that is to be purchased only in part shall
be surrendered at the office of a Paying Agent, and promptly after the Fundamental Change Purchase
Date, the Company shall execute and the Trustee shall authenticate and deliver to the Holder of
such Note, without service charge, a new Note or Notes, of such authorized denomination or
denominations as may be requested by such Holder (which must be equal to $1,000 principal amount or
any integral thereof), in aggregate principal amount equal to, and in exchange for, the portion of
the principal amount of the Note so surrendered that is not purchased.
80
Section 15.06. Compliance With Securities Laws Upon Purchase of Notes. In connection with
any offer to purchase of Notes under Section 15.01, the Company shall (a) comply with Rule 13e-4
and Rule 14e-1 (or any successor to either such Rule), and any other tender offer rules, if
applicable, under the Exchange Act, (b) file the related Schedule TO (or any successor or similar
schedule, form or report) if required under the Exchange Act, and (c) otherwise comply with all
applicable federal and state securities laws in connection with such offer to purchase or purchase
of Notes, all so as to permit the rights of the Holders and obligations of the Company under
Section 15.01 through Section 15.05 to be exercised in the time and in the manner specified
therein. To the extent that compliance with any such laws, rules and regulations would result in a
conflict with any of the terms hereof, this Indenture is hereby modified to the extent required for
the Company to comply with such laws, rules and regulations.
ARTICLE 16
Meeting Of Holders Of Notes
Section 16.01. Purposes For Which Meetings May Be Called. A meeting of Holders of Notes may
be called at any time and from time to time pursuant to this Article 16 to make, give or take any
request, demand, authorization, direction, notice, consent, waiver or other action provided by this
Indenture to be made, given or taken by Holders of Notes.
Notwithstanding anything contained in this Article 16, the Trustee may, during the pendency of
a Default or an Event of Default, call a meeting of Holders of Notes in accordance with its
standard practices.
Section 16.02. Call Notice and Place of Meetings. (a) The Trustee may at any time call a
meeting of Holders of Notes for any purpose specified in Section 16.01 hereof, to be held at such
time and at such place in The City of New York. Notice of every meeting of Holders of Notes,
setting forth the time and the place of such meeting, in general terms the action proposed to be
taken at such meeting and the percentage of the principal amount of the then-Outstanding Notes
which shall constitute a quorum at such meeting, shall be given, in the manner provided in the
Indenture, not less than 21 nor more than 180 days prior to the date fixed for the meeting.
(b) In case at any time the Company, pursuant to a resolution of the Board of Directors, or
the Holders of at least 10% in principal amount of the Notes then Outstanding shall have requested
the Trustee to call a meeting of the Holders of Notes for any purpose specified in Section 16.01
hereof, by written request setting forth in reasonable detail the action proposed to be taken at
the meeting, and the Trustee shall not have made the first publication of the notice of such
meeting within 21 days after receipt of such request or shall not thereafter
81
proceed to cause the
meeting to be held as provided herein, then the Company or the Holders of Notes in the amount
specified, as the case may be, may determine the time and the place in The City of New York for
such meeting and may call such meeting for such purposes by giving notice thereof as provided in
Section 16.02(a).
Section 16.03. Persons Entitled to Vote at Meetings. To be entitled to vote at any meeting
of Holders of Notes, a Person shall be (a) a Holder of one or more Outstanding Notes or (b) a
Person appointed by an instrument in writing as proxy for a Holder or Holders of one or more
Outstanding Notes by such Holder or Holders. The only Persons who shall be entitled to be present
or to speak at any meeting of Holders shall be the Persons entitled to vote at such meeting and
their counsel, any representatives of the Trustee and its counsel and any representatives of the
Company and its counsel.
Section 16.04. Quorum; Action. The Persons entitled to vote a majority in principal amount
of the then-Outstanding Notes shall constitute a quorum. In
the absence of a quorum within 30 minutes of the time appointed for any such meeting, the
meeting shall, if convened at the request of Holders of Notes, be dissolved. In any other case, the
meeting may be adjourned for a period of not less than 10 days as determined by the chairman of the
meeting prior to the adjournment of such meeting. In the absence of a quorum at any such adjourned
meeting, such adjourned meeting may be further adjourned for a period of not less than 10 days as
determined by the chairman of the meeting prior to the adjournment of such adjourned meeting.
Notice of the reconvening of any adjourned meeting shall be given as provided in Section 16.02(a)
hereof, except that such notice need be given only once and not less than five days prior to the
date on which the meeting is scheduled to be reconvened.
At a meeting or an adjourned meeting duly reconvened and at which a quorum is present as
aforesaid, any resolution and all matters (except as limited by the third paragraph of Section 9.02
hereof) shall be effectively passed and decided if passed or decided by the Persons entitled to
vote not less than a majority in principal amount of Notes then Outstanding represented and voting
at such meeting.
Any resolution passed or decisions taken at any meeting of Holders of Notes duly held in
accordance with this Section 16.04 shall be binding on all the Holders of Notes, whether or not
present or represented at the meeting.
Section 16.05. Determination of Voting Rights; Conduct and Adjournment of Meetings. (a)
Notwithstanding any other provisions of this Indenture, the Trustee may make such reasonable
regulations as it may deem advisable for any meeting of Holders of Notes in regard to proof of the
holding of Notes and of the appointment of proxies and in regard to the appointment and
82
duties of
inspectors of votes, the submission and examination of proxies, certificates and other evidence of
the right to vote, and such other matters concerning the conduct of the meeting as it shall deem
appropriate.
(b) The Trustee shall, by an instrument in writing, appoint a temporary chairman (which may be
the Trustee) of the meeting, unless the meeting shall have been called by the Company or by Holders
of Notes as provided in Section 16.02 hereof, in which case the Company or the Holders of Notes
calling the meeting, as the case may be, shall in like manner appoint a temporary chairman. A
permanent chairman and a permanent secretary of the meeting shall be elected by vote of the Persons
entitled to vote a majority in principal amount of the Outstanding Notes represented at the
meeting.
(c) At any meeting, each Holder of a Note or proxy shall be entitled to one vote for each
$1,000 principal amount of Notes held or represented by him; provided, however, that no vote shall
be cast or counted at any meeting in respect of any Note challenged as not Outstanding and ruled by
the chairman of the meeting to be not Outstanding. The chairman of the meeting shall have no right
to vote, except as a Holder of a Note or proxy.
(d) Any meeting of Holders of Notes duly called pursuant to Section 16.02 hereof at which a
quorum is present may be adjourned from time to time by Persons entitled to vote a majority in
principal amount of the then-Outstanding Notes represented at the meeting, and the meeting may be
held as so adjourned without further notice.
Section 16.06. Counting Votes and Recording Action of Meetings. The vote upon any resolution
submitted to any meeting of Holders of Notes shall be by written ballots on which shall be
subscribed the signatures of the Holders of Notes or of their representatives by proxy and the
principal amounts and serial numbers of the Outstanding Notes held or represented by them. The
permanent chairman of the meeting shall appoint two inspectors of votes who shall count all votes
cast at the meeting for or against any resolution and who shall make and file with the secretary of
the meeting their verified written reports in duplicate of all votes cast at the meeting. A record,
at least in duplicate, of the proceedings of each meeting of Holders of Notes shall be prepared by
the secretary of the meeting and there shall be attached to said record the original reports of the
inspectors of votes on any vote by ballot taken thereat and affidavits by one or more Persons
having knowledge of the facts setting forth a copy of the notice of the meeting and showing that
said notice was given as provided in Section 16.02 hereof and, if applicable, Section 16.04 hereof.
Each copy shall be signed and verified by the affidavits of the permanent chairman and secretary of
the meeting and one such copy shall be delivered to the Company and another to the Trustee to be
preserved by the Trustee, the latter to have attached thereto the ballots voted
83
at the meeting. Any
record so signed and verified shall be conclusive evidence of the matters therein stated.
ARTICLE 17
Miscellaneous Provisions
Section 17.01. Provisions Binding on Companys Successors. All the covenants, stipulations,
promises and agreements of the Company contained in this Indenture shall bind its successors and
assigns whether so expressed or not.
Section 17.02. Official Acts by Successor. Any act or proceeding by any provision of this
Indenture authorized or required to be done or performed by any board, committee or officer of the
Company shall and may be done and performed with like force and effect by the like board, committee
or officer of any corporation or other entity that shall at the time be the lawful sole successor
of the Company.
Section 17.03. Notices. Except as otherwise expressly provided herein, any notice, request
or demand that by any provision of this Indenture is required or permitted to be given, made or
served by the Trustee or by the Holders or by any other Person pursuant to this Indenture to or on
the Company may be given or
served by being deposited in first class mail, postage prepaid, addressed (until another
address is filed in writing by the Company with the Trustee), as follows: 28903 North Avenue Paine,
Valencia, CA 91355. Any notice, election, request or demand by the Company or any Holder or by any
other Person pursuant to this Indenture to or upon the Trustee shall be deemed to have been
sufficiently given or made, for all purposes, if given or made in writing at the Corporate Trust
Office of the Trustee. Except as otherwise expressly provided herein, any notice or communication
to a Holder of a Note may be given or served by being deposited in first class mail, postage
prepaid, addressed at the Holders address as it appears in the Note Register.
Section 17.04. Governing Law. THIS INDENTURE AND EACH NOTE SHALL BE DEEMED TO BE A CONTRACT
MADE UNDER THE LAWS OF NEW YORK, AND FOR ALL PURPOSES SHALL BE CONSTRUED IN ACCORDANCE WITH THE
LAWS OF NEW YORK, WITHOUT REGARD TO CONFLICTS OF LAWS PRINCIPLES THEREOF.
Section 17.05. Evidence of Compliance with Conditions Precedent; Certificates and Opinions of
Counsel to Trustee. Upon any application or demand by the Company to the Trustee to take any
action under any of the provisions of this Indenture, the Company shall furnish to the Trustee an
Officers Certificate and an Opinion of Counsel stating that such action is permitted by the
84
terms
of this Indenture; provided that no such Opinion of Counsel shall be required in connection with
the issuance of Notes on the Issue Date.
Each Officers Certificate and Opinion of Counsel provided for by or on behalf of the Company
in this Indenture and delivered to the Trustee with respect to compliance with this Indenture
(other than the Officers Certificates provided for in Section 4.04) shall include (a) a statement
that the Person making such certification is familiar with the requested action and this Indenture;
(b) a brief statement as to the nature and scope of the examination or investigation upon which the
statement contained in such certificate is based; (c) a statement that, in the judgment of such
person, he or she has made such examination or investigation as is necessary to enable him or her
to express an informed judgment as to whether or not such action is permitted by this Indenture;
and (d) a statement as to whether or not, in the judgment of such Person, such action is permitted
by this Indenture.
Notwithstanding anything to the contrary in this Section 17.05, if any provision in this
Indenture specifically provides that the Trustee shall or may receive an Opinion of Counsel in
connection with any action to be taken by the Trustee or the Company hereunder, the Trustee shall
be entitled to, or entitled to request, such Opinion of Counsel.
Section 17.06. Legal Holidays. In any case where any Interest Payment Date, Redemption Date,
Fundamental Change Purchase Date, Conversion Date or Maturity Date is not a Business Day, then any
action to be taken on such date
need not be taken on such date, but may be taken on the next succeeding Business Day with the
same force and effect as if taken on such date, and no interest shall accrue for the period from
and after such date.
Section 17.07. No Security Interest Created. Nothing in this Indenture or in the Notes,
expressed or implied, shall be construed to constitute a security interest under the Uniform
Commercial Code or similar legislation, as now or hereafter enacted and in effect, in any
jurisdiction.
Section 17.08. Benefits of Indenture. Nothing in this Indenture or in the Notes, expressed
or implied, shall give to any Person, other than the parties hereto, any Paying Agent, any
Conversion Agent, any authenticating agent, any Note Registrar and their successors hereunder or
the Holders of the Notes, any benefit or any legal or equitable right, remedy or claim under this
Indenture.
Section 17.09. Table of Contents, Headings, Etc. The table of contents and the titles and
headings of the articles and sections of this Indenture have been inserted for convenience of
reference only, are not to be considered a part hereof, and shall in no way modify or restrict any
of the terms or provisions hereof.
85
Section 17.10. Execution in Counterparts. This Indenture may be executed in any number of
counterparts, each of which shall be an original, but such counterparts shall together constitute
but one and the same instrument.
Section 17.11. Severability. In the event any provision of this Indenture or in the Notes
shall be invalid, illegal or unenforceable, then (to the extent permitted by law) the validity,
legality or enforceability of the remaining provisions shall not in any way be affected or
impaired.
Section 17.12. Waiver of Jury Trial. EACH OF THE COMPANY AND THE TRUSTEE HEREBY IRREVOCABLY
WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN
ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS INDENTURE, THE NOTES OR THE TRANSACTION
CONTEMPLATED HEREBY.
Section 17.13. Consent to Jurisdiction. (a) The Company hereby irrevocably and
unconditionally submits, for itself and its property, to the nonexclusive jurisdiction of any New
York State court or federal court of the United States sitting in the State and City of New York,
County and Borough of Manhattan, and any appellate court from any thereof, in any action or
proceeding arising out of or relating to this Indenture or the Notes, or for recognition or
enforcement of any judgment, and each of the parties hereto hereby irrevocably and unconditionally
agrees that all claims in respect of any such action or proceeding may be heard and determined in
such state court sitting in the State and City of New York, County and Borough of Manhattan or, to
the extent permitted by law, in such federal court sitting in the State and City of New York,
County and Borough of Manhattan. Each of the parties hereto agrees that a final judgment in
any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by
suit on the judgment or in any other manner provided by law.
(b) The Company hereby irrevocably and unconditionally waives, to the fullest extent it may
legally and effectively do so, any objection which it may now or hereafter have to the laying of
venue of any suit, action or proceeding arising out of or relating to this Indenture or the Notes
in any New York State or federal court. Each of the parties hereto hereby irrevocably waives, to
the fullest extent permitted by law, the defense of an inconvenient forum to the maintenance of
such action or proceeding in any such court.
Section 17.14. Force Majeure. In no event shall the Trustee be responsible or liable for any
failure or delay in the performance of its obligations hereunder arising out of or caused by,
directly or indirectly, forces beyond its control, including, without limitation, strikes, work
stoppages, accidents, acts of war or terrorism, civil or military disturbances, nuclear or natural
catastrophes or
86
acts of God, and interruptions, loss or malfunctions of utilities, communications
or computer (software and hardware) services; it being understood that the Trustee shall use
reasonable efforts that are consistent with accepted practices in the banking industry to resume
performance as soon as practicable under the circumstances.
Section 17.15. Calculations. Except as explicitly stated herein, the Company shall be
responsible for making all calculations required pursuant to this Indenture and the Notes,
including, without limitation, calculations with respect to determinations of the Conversion Price
and Conversion Rate applicable to the Notes. The Company shall make all such calculations in good
faith and, absent manifest error, the Companys calculations shall be binding on the Holders. The
Company shall provide a written schedule of such calculations to the Trustee, and the Trustee shall
be entitled to conclusively rely upon the accuracy of the Companys calculations without
responsibility for independent verification thereof. The Trustee shall forward a copy of such
calculations to any Holder upon such Holders written request.
Section 17.16. U.S.A. Patriot Act. The parties hereto acknowledge that in accordance with
Section 326 of the U.S.A. Patriot Act, the Trustee, like all financial institutions and in order to
help fight the funding of terrorism and money laundering, is required to obtain, verify, and record
information that identifies each person or legal entity that establishes a relationship or opens an
account with the Trustee. The parties to this Indenture agree that they will provide the Trustee
with such information as it may request in order for the Trustee to satisfy the requirements of the
U.S.A. Patriot Act.
[SIGNATURE PAGE FOLLOWS]
87
IN WITNESS WHEREOF, the parties hereto have caused this Indenture to be duly executed as of
the date first written above.
|
|
|
|
|
|
MANNKIND CORPORATION, as Issuer
|
|
|
By: |
/s/
Matthew J. Pfeffer |
|
|
|
Name: |
Matthew J. Pfeffer |
|
|
|
Title: |
Corporate Vice President and Chief Financial
Officer |
|
|
|
WELLS FARGO BANK, NATIONAL ASSOCIATION, as Trustee
|
|
|
By: |
/s/
Maddy Hall |
|
|
|
Name: |
Maddy Hall |
|
|
|
Title: |
Vice President |
|
|
88
Schedule A
Make Whole Premium Upon a Fundamental Change
(Number of Additional Shares)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock Price |
|
|
$5.97 |
|
$6.50 |
|
$7.00 |
|
$8.00 |
|
$10.00 |
|
$15.00 |
|
$20.00 |
|
$25.00 |
|
$30.00 |
|
$50.00 |
August 24, 2010
|
|
|
20.4182 |
|
|
|
20.4182 |
|
|
|
20.4182 |
|
|
|
20.4182 |
|
|
|
18.3976 |
|
|
|
12.2848 |
|
|
|
9.2714 |
|
|
|
7.3218 |
|
|
|
6.1493 |
|
|
|
3.7299 |
|
August 15, 2011
|
|
|
20.4182 |
|
|
|
20.4182 |
|
|
|
20.4182 |
|
|
|
19.8839 |
|
|
|
15.8641 |
|
|
|
10.6240 |
|
|
|
7.9606 |
|
|
|
6.4456 |
|
|
|
5.2813 |
|
|
|
3.1875 |
|
August 15, 2012
|
|
|
20.4182 |
|
|
|
19.7954 |
|
|
|
18.4232 |
|
|
|
16.1445 |
|
|
|
12.9562 |
|
|
|
8.6237 |
|
|
|
6.4758 |
|
|
|
5.1902 |
|
|
|
4.3654 |
|
|
|
2.6155 |
|
August 15, 2013
|
|
|
20.4182 |
|
|
|
14.3658 |
|
|
|
13.3212 |
|
|
|
11.6771 |
|
|
|
9.3477 |
|
|
|
6.2018 |
|
|
|
4.6676 |
|
|
|
3.7430 |
|
|
|
3.1215 |
|
|
|
1.8779 |
|
August 15, 2014
|
|
|
20.4182 |
|
|
|
7.7914 |
|
|
|
7.2466 |
|
|
|
6.2954 |
|
|
|
5.0676 |
|
|
|
3.3901 |
|
|
|
2.5466 |
|
|
|
2.0406 |
|
|
|
1.7032 |
|
|
|
1.0287 |
|
August 15, 2015
|
|
|
20.4182 |
|
|
|
6.7603 |
|
|
|
0.0000 |
|
|
|
0.0000 |
|
|
|
0.0000 |
|
|
|
0.0000 |
|
|
|
0.0000 |
|
|
|
0.0000 |
|
|
|
0.0000 |
|
|
|
0.0000 |
|
89
EXHIBIT A
[FORM OF FACE OF NOTE]
[INCLUDE IF A GLOBAL NOTE]
[UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST
COMPANY, A NEW YORK CORPORATION (DTC), TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER,
EXCHANGE, OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH
OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE
& CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY
TRANSFER, PLEDGE, OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL
INASMUCH AS THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.]
[INCLUDE IF A RESTRICTED SECURITY]
THE SALE OF THIS NOTE HAS NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS
AMENDED (THE SECURITIES ACT), AND ACCORDINGLY, THIS NOTE MAY NOT BE OFFERED, SOLD, PLEDGED OR
OTHERWISE TRANSFERRED EXCEPT AS SET FORTH IN THE FOLLOWING SENTENCE. BY ITS ACQUISITION HEREOF, OR
OF A BENEFICIAL OWNERSHIP HEREIN, THE ACQUIRER: (I) REPRESENTS THAT IT, AND ANY ACCOUNT FOR WHICH
IT IS ACTING, IS A QUALIFIED INSTITUTIONAL BUYER (WITHIN THE MEANING OF RULE 144A UNDER THE
SECURITIES ACT) AND THAT IT EXERCISES SOLE INVESTMENT DISCRETION WITH RESPECT TO EACH SUCH ACCOUNT,
AND (II) AGREES (1) THAT IT WILL NOT WITHIN THE LATER OF (X) ONE YEAR AFTER THE LAST DATE OF
ORIGINAL ISSUANCE OF NOTES (INCLUDING THROUGH THE EXERCISE OF THE OPTION TO PURCHASE ADDITIONAL
NOTES) AND (Y) 90 DAYS AFTER IT CEASES TO BE AN AFFILIATE (WITHIN THE MEANING OF RULE 144 UNDER THE
SECURITIES ACT) OF MANNKIND CORPORATION (THE COMPANY), OFFER, RESELL, PLEDGE OR OTHERWISE
TRANSFER THE NOTES EVIDENCED HEREBY, THE COMMON STOCK ISSUABLE UPON CONVERSION OF SUCH NOTES OR ANY
BENEFICIAL OWNERSHIP HEREIN, EXCEPT: (A) TO THE COMPANY OR ANY SUBSIDIARY THEREOF; (B) UNDER A
REGISTRATION STATEMENT THAT HAS BECOME EFFECTIVE UNDER THE SECURITIES ACT; (C) TO A PERSON THE
SELLER REASONABLY BELIEVES IS A QUALIFIED
A-1
INSTITUTIONAL BUYER (AS DEFINED IN RULE 144A UNDER THE SECURITIES ACT) THAT IS PURCHASING FOR
ITS OWN ACCOUNT OR FOR THE ACCOUNT OF ANOTHER QUALIFIED INSTITUTIONAL BUYER AND TO WHOM NOTICE IS
GIVEN THAT THE TRANSFER IS BEING MADE IN RELIANCE ON RULE 144A, ALL IN COMPLIANCE WITH RULE 144A
(IF AVAILABLE); OR (D) UNDER ANY OTHER AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF
THE SECURITIES ACT, INCLUDING RULE 144, IF AVAILABLE; AND (2) THAT IT WILL, PRIOR TO ANY TRANSFER
OF THIS NOTE WITHIN THE LATER OF (X) SIX MONTHS (OR, IF THE COMPANY HAS NOT SATISFIED THE CURRENT
PUBLIC INFORMATION REQUIREMENTS OF RULE 144, ONE YEAR) AFTER THE LAST DATE OF ORIGINAL ISSUANCE OF
NOTES (INCLUDING THROUGH THE EXERCISE OF THE OPTION TO PURCHASE ADDITIONAL NOTES) AND (Y) 90 DAYS
AFTER IT CEASES TO BE AN AFFILIATE (WITHIN THE MEANING OF RULE 144) OF THE COMPANY, FURNISH TO THE
TRUSTEE AND THE COMPANY SUCH CERTIFICATIONS, LEGAL OPINIONS OR OTHER INFORMATION AS THEY MAY
REQUIRE AND MAY RELY UPON TO CONFIRM THAT SUCH TRANSFER IS BEING MADE PURSUANT TO AN EXEMPTION
FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND
APPLICABLE STATE SECURITIES LAWS. IN ANY EVENT, NO AFFILIATE OF THE COMPANY MAY RESELL THIS NOTE
OTHER THAN UNDER A REGISTRATION STATEMENT THAT HAS BECOME EFFECTIVE UNDER THE SECURITIES ACT OR
PURSUANT TO AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT IN A TRANSACTION
THAT RESULTS IN SUCH NOTE NO LONGER BEING RESTRICTED SECURITIES (AS DEFINED UNDER RULE 144). NO
REPRESENTATION IS MADE AS TO THE AVAILABILITY OF ANY EXEMPTION FROM THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT. EACH PURCHASER AND TRANSFEREE OF A NOTE AND THE COMMON STOCK ISSUABLE UPON
CONVERSION OF A NOTE WILL BE DEEMED TO HAVE REPRESENTED BY ITS PURCHASE AND HOLDING OF THE NOTE AND
THE COMMON STOCK ISSUABLE UPON CONVERSION OF THE NOTE THAT (A) ITS PURCHASE AND HOLDING OF THE NOTE
AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THE NOTE IS NOT MADE ON BEHALF OF OR WITH PLAN
ASSETS OF ANY PLAN SUBJECT TO TITLE I OF ERISA, SECTION 4975 OF THE CODE OR ANY SIMILAR LAW OR (B)
ITS PURCHASE AND HOLDING OF THE NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THE NOTE WILL
NOT RESULT IN A NON-EXEMPT PROHIBITED TRANSACTION UNDER SECTION 406 OF ERISA, SECTION 4975 OF THE
CODE OR ANY SIMILAR LAW.
A-2
MANNKIND CORPORATION
5.75% Convertible Senior Note due 2015
CUSIP No.
ISIN No.
MannKind Corporation, a corporation duly organized and validly existing under the laws of the
state of Delaware (herein called the Company, which term includes any successor corporation or
other entity under the Indenture referred to on the reverse hereof), for value received hereby
promises to pay to CEDE & CO., or registered assigns, the principal sum of [ ] (which amount may
from time to time be increased or decreased to such other principal amounts as permitted by the
Indenture by adjustments made on the records of the Trustee or the Custodian of the Depositary as
set forth in Schedule A hereto, in accordance with the rules and procedures of the Depositary) on
August 15, 2015, and interest thereon as set forth below.
This Note shall bear interest at the rate of 5.75% per year from August 24, 2010, or from the
most recent date to which interest had been paid or provided for to, but excluding, the next
scheduled Interest Payment Date until August 15, 2015. Interest is payable semi-annually in
arrears on each February 15 and August 15 (or if any such day is not a Business Day, the
immediately following Business Day), commencing February 15, 2011, to Holders of record at the
close of business on the preceding February 1 and August 1 (whether or not such day is a Business
Day), respectively.
Interest not paid when due and any interest on principal or interest not paid when due will be
paid to Holders on a special record date, which will be the 15th day preceding the day fixed by the
Company for the payment of such interest, whether or not such day is a Business Day. At least 15
days before a special record date, the Company will send to each Holder and to the Trustee a notice
that sets forth the special record date, the payment date and the amount of interest to be paid.
Payment of the principal of, and accrued and unpaid interest on, this Note shall be made at
the office or agency of the Company maintained for that purpose in such lawful money of the United
States of America as at the time of payment shall be legal tender for the payment of public and
private debts; provided, however, that interest on any Notes in certificated form (i) to the Person
entitled thereto having an aggregate principal amount of $2,000,000 or less, by check mailed to
such Person at the address set forth in the Note Register and (ii) to the
A-3
Person entitled thereto having an aggregate principal amount of more than $2,000,000, either
by check mailed to such Person or, upon application by such Person to the Note Registrar not later
than the relevant Regular Record Date, by wire transfer in immediately available funds to such
Persons account within the United States, which application and wire transfer instructions shall
remain in effect until such Person notifies, in writing, the Note Registrar to the contrary.
Reference is made to the further provisions of this Note set forth on the reverse hereof,
including, without limitation, provisions giving the Holder of this Note the right to convert this
Note into shares of Common Stock (together with cash in lieu of fractional shares) on the terms and
subject to the limitations set forth in the Indenture. Such further provisions shall for all
purposes have the same effect as though fully set forth at this place.
THIS NOTE SHALL BE DEEMED TO BE A CONTRACT MADE UNDER THE LAWS OF NEW YORK, AND FOR ALL
PURPOSES SHALL BE CONSTRUED IN ACCORDANCE WITH THE LAWS OF NEW YORK, WITHOUT REGARD TO CONFLICTS OF
LAWS PRINCIPLES THEREOF.
This Note shall not be valid or become obligatory for any purpose until the certificate of
authentication hereon shall have been manually signed by the Trustee or a duly authorized
authenticating agent under the Indenture.
[Remainder of page intentionally left blank]
A-4
IN WITNESS WHEREOF, the Company has caused this Note to be duly executed.
|
|
|
|
|
|
MANNKIND CORPORATION
|
|
|
By: |
|
|
|
|
Name: |
|
|
|
|
Title: |
|
|
|
Dated:
|
|
|
|
|
|
TRUSTEES CERTIFICATE OF AUTHENTICATION
WELLS FARGO BANK, NATIONAL ASSOCIATION
as Trustee, certifies that this is one of the Notes described
in the within-named Indenture.
|
|
|
By: |
|
|
|
|
Authorized Signatory |
|
|
|
|
|
|
A-5
[FORM OF REVERSE OF NOTE]
MANNKIND CORPORATION
5.75% Convertible Senior Note due 2015
This Note is one of a duly authorized issue of the Notes of the Company, designated as its
5.75% Convertible Senior Notes due 2015 (herein called the Notes), all issued or to be issued
under and pursuant to an Indenture dated as of August 24, 2010 (herein called the Indenture),
between the Company and Wells Fargo Bank, National Association (herein called the Trustee), to
which Indenture and all indentures supplemental thereto reference is hereby made for a description
of the rights, limitations of rights, obligations, duties and immunities thereunder of the Trustee,
the Company and the Holders of the Notes. Additional Notes may be issued in an unlimited aggregate
principal amount, subject to certain conditions specified in the Indenture.
In case an Event of Default, as defined in the Indenture, shall have occurred and be
continuing, the principal of and accrued and unpaid interest, if any, on all Notes may be declared,
by either the Trustee or Holders of not less than 25% in aggregate principal amount of Notes then
outstanding, and upon said declaration shall become, due and payable, in the manner, with the
effect and subject to the conditions and certain exceptions set forth in the Indenture.
Subject to the terms and conditions of the Indenture, the Company will make all payments and
deliveries in respect of the Redemption Price, the Fundamental Change Purchase Price and the
principal amount on the Maturity Date, as the case may be, to the Holder who surrenders a Note to a
Paying Agent to collect such payments in respect of the Note. The Company will pay cash amounts in
money of the United States that at the time of payment is legal tender for payment of public and
private debts.
The Indenture contains provisions permitting the Company and the Trustee in certain
circumstances, without the consent of the Holders of the Notes, and in other circumstances, with
the consent of the Holders of not less than a majority in aggregate principal amount of the Notes
at the time outstanding, evidenced as in the Indenture provided, to execute supplemental indentures
modifying the terms of the Indenture and the Notes as described therein. It is also provided in
the Indenture that, subject to certain exceptions, the Holders of a majority in aggregate principal
amount of the Notes at the time outstanding may on behalf of the Holders of all of the Notes waive
any past Default or Event of Default under the Indenture and its consequences.
No reference herein to the Indenture and no provision of this Note or of the Indenture shall
alter or impair the obligation of the Company, which is absolute and unconditional, to pay the
principal of and accrued and unpaid
interest, if any, on this Note at the place, at the respective times, at the rate and in the
lawful money herein prescribed or to satisfy its obligation to convert the Notes.
The Notes are issuable in registered form without coupons in denominations of $1,000 principal
amount and multiples thereof. At the office or agency of the Company referred to on the face
hereof, and in the manner and subject to the limitations provided in the Indenture, Notes may be
exchanged for a like aggregate principal amount of Notes of other authorized denominations, without
payment of any service charge but, if required by the Company or Trustee, with payment of a sum
sufficient to cover any tax, assessments or other governmental charges that may be imposed in
connection therewith as a result of the name of the Holders of the new Notes issued upon such
exchange of Notes being different from the name of the Holder of the old Notes surrendered for such
exchange.
The Notes are not subject to redemption through the operation of any sinking fund.
The Company may redeem the Notes in whole or in part for cash, subject to certain conditions
described in the Indenture, at any time prior to the Maturity Date. The Redemption Price will
equal 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest,
if any, to, but excluding, the Redemption Date plus the Make-Whole Payment, as defined in the
Indenture.
Upon the occurrence of a Fundamental Change, the Company will offer to purchase any and all of
the Notes. The Holder has the right, at such Holders option, to accept such offer and require the
Company to purchase for cash all of such Holders Notes or any portion thereof (in principal
amounts of $1,000 or multiples thereof) on the Fundamental Change Purchase Date at a price equal to
the Fundamental Change Purchase Price.
Subject to the provisions of the Indenture, the Holder hereof has the right, at its option,
prior to the close of business on the Business Day immediately preceding the Maturity Date, to
convert any Notes or portion thereof that is $1,000 or a multiple thereof, into shares of Common
Stock (together with cash in lieu of fractional shares) at a Conversion Rate specified in the
Indenture, as adjusted from time to time as provided in the Indenture.
Terms used in this Note and defined in the Indenture are used herein as therein defined.
2
ABBREVIATIONS
The following abbreviations, when used in the inscription of the face of this Note, shall be
construed as though they were written out in full according to applicable laws or regulations:
TEN COM = as tenants in common
UNIF GIFT MIN ACT = Uniform Gifts to Minors Act
CUST = Custodian
TEN ENT = as tenants by the entireties
JT TEN = joint tenants with right of survivorship and not as tenants in common
Additional abbreviations may also be used though not in the above list.
3
SCHEDULE A
MANNKIND CORPORATION
5.75% Convertible Senior Notes due 2015
The initial principal amount of this Global Note is $100,000,000. The following increases or
decreases in this Global Note have been made:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Principal Amount of |
|
Signature of |
|
|
|
|
|
|
this Global Note |
|
authorized |
|
|
Amount of decrease |
|
Amount of increase |
|
following such |
|
signatory of |
|
|
in Principal Amount |
|
in Principal Amount |
|
decrease or |
|
Trustee or |
Date of Exchange |
|
of this Global Note |
|
of this Global Note |
|
increase |
|
Custodian |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4
ATTACHMENT 1
[FORM OF NOTICE OF CONVERSION]
5.75% Convertible Senior Note due 2015
To: MannKind Corporation
The undersigned registered owner of this Note hereby exercises the option to convert this
Note, or the portion hereof (that is $1,000 principal amount or a multiple thereof) below
designated, and the Company, at its election, may deliver shares of Common Stock (together with
cash in lieu of fractional shares) in accordance with the terms of the Indenture referred to in
this Note, and directs that any shares of Common Stock issuable and deliverable upon such
conversion, and any Notes representing any unconverted principal amount hereof, be issued and
delivered to the registered Holder hereof unless a different name has been indicated below. If any
shares of Common Stock or any portion of this Note not converted are to be issued in the name of a
Person other than the undersigned, the undersigned will pay all transfer taxes payable with respect
thereto. Any amount required to be paid to the undersigned on account of interest accompanies this
Note.
|
|
|
|
|
|
|
Signature(s) must be guaranteed |
|
|
by an eligible Guarantor Institution |
|
|
(banks, stock brokers, savings and |
|
|
loan associations and credit unions) |
|
|
with membership in an approved |
|
|
signature guarantee medallion program |
|
|
pursuant to Securities and Exchange
Commission Rule 17Ad-15 if |
|
|
shares of Common Stock are to be issued, or |
|
|
Notes to be delivered, other than |
|
|
to and in the name of the registered Holder. |
|
|
|
|
|
Fill in for registration of shares if |
|
|
to be issued, and Notes if to |
|
|
be delivered, other than to and in the |
|
|
name of the registered Holder: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(City, State and Zip Code)
|
|
|
Please print name and address |
|
|
|
|
|
|
|
|
|
Principal amount to be converted (if less than all): |
|
|
|
|
$ ,000 |
|
|
|
|
|
NOTICE: The above signature(s) of the Holder(s) |
|
|
|
|
hereof must correspond with the name as written upon |
|
|
|
|
the face of the Note in every particular without |
|
|
|
|
alteration or enlargement or any change whatever. |
|
|
|
|
|
|
Social Security or Other Taxpayer
|
|
|
|
|
Identification Number |
|
|
ATTACHMENT 2
[FORM OF FUNDAMENTAL CHANGE PURCHASE NOTICE]
5.75% Convertible Senior Note due 2015
To: MannKind Company
The undersigned registered owner of this Note hereby acknowledges receipt of a notice from MannKind
Corporation (the Company) as to the occurrence of a Fundamental Change with respect to the
Company, offering to purchase the Notes and specifying the Fundamental Change Purchase Date. The
undersigned registered owner of this Note hereby accepts the Companys offer to purchase the Notes
and instructs the Company to pay to the registered Holder hereof in accordance with the applicable
provisions of the Indenture referred to in this Note (1) the entire principal amount of this Note,
or the portion thereof (that is $1,000 principal amount or a multiple thereof) below designated,
and (2) if such Fundamental Change Purchase Date does not fall during the period after a Regular
Record Date and on or prior to the corresponding Interest Payment Date, accrued and unpaid interest
thereon to, but excluding, such Fundamental Change Purchase Date.
In the case of certificated Notes, the certificate numbers of the Notes to be purchased are as
set forth below:
|
|
|
|
|
|
|
Signature(s)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Social Security or Other Taxpayer
|
|
|
|
|
Identification Number |
|
|
|
|
|
|
|
|
|
Principal amount to be repaid (if less than all): |
|
|
|
|
$ ,000 |
|
|
|
|
|
|
|
|
|
NOTICE: The above signature(s) of the Holder(s) |
|
|
|
|
hereof must correspond with the name as written upon |
|
|
|
|
the face of the Note in every particular without |
|
|
|
|
alteration or enlargement or any change whatever. |
|
|
ATTACHMENT 3
[FORM OF ASSIGNMENT AND TRANSFER]
For value received hereby sell(s), assign(s) and transfer(s) unto
(Please insert social security or Taxpayer Identification Number of assignee) the
within Note, and hereby irrevocably constitutes and appoints attorney to
transfer the said Note on the books of the Company, with full power of substitution in the
premises.
In connection with any transfer of the within Note occurring prior to the Resale Restriction
Termination Date, as defined in the Indenture governing such Note, the undersigned confirms that
such Note is being transferred:
o To MannKind Corporation or a subsidiary thereof; or
o Pursuant to the registration statement that has become or been declared effective under the
Securities Act of 1933, as amended; or
o Pursuant to and in compliance with Rule 144A under the Securities Act of 1933, as amended; or
o Pursuant to and in compliance with Rule 144 under the Securities Act of 1933, as amended; or
o Pursuant to another available exemption from registration under the Securities Act of 1933, as
amended.
|
|
|
|
|
Dated: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Signature(s) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Signature Guarantee |
|
|
Signature(s) must be guaranteed by an
eligible Guarantor Institution (banks, stock
brokers, savings and loan associations and
credit unions) with membership in an approved
signature guarantee medallion program pursuant
to Securities and Exchange Commission
Rule 17Ad-15 if Notes are to be delivered, other
than to and in the name of the registered Holder.
NOTICE: The signature on the assignment must correspond with the name as written upon the face of
the Note in every particular without alteration or enlargement or any change whatever.
exv4w2
EXHIBIT 4.2
[FORM OF FACE OF NOTE]
[INCLUDE IF A GLOBAL NOTE]
[UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST
COMPANY, A NEW YORK CORPORATION (DTC), TO THE COMPANY OR ITS AGENT FOR REGISTRATION OF TRANSFER,
EXCHANGE, OR PAYMENT, AND ANY CERTIFICATE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH
OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE
& CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY
TRANSFER, PLEDGE, OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL
INASMUCH AS THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.]
[INCLUDE IF A RESTRICTED SECURITY]
THE SALE OF THIS NOTE HAS NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS
AMENDED (THE SECURITIES ACT), AND ACCORDINGLY, THIS NOTE MAY NOT BE OFFERED, SOLD, PLEDGED OR
OTHERWISE TRANSFERRED EXCEPT AS SET FORTH IN THE FOLLOWING SENTENCE. BY ITS ACQUISITION HEREOF, OR
OF A BENEFICIAL OWNERSHIP HEREIN, THE ACQUIRER: (I) REPRESENTS THAT IT, AND ANY ACCOUNT FOR WHICH
IT IS ACTING, IS A QUALIFIED INSTITUTIONAL BUYER (WITHIN THE MEANING OF RULE 144A UNDER THE
SECURITIES ACT) AND THAT IT EXERCISES SOLE INVESTMENT DISCRETION WITH RESPECT TO EACH SUCH ACCOUNT,
AND (II) AGREES (1) THAT IT WILL NOT WITHIN THE LATER OF (X) ONE YEAR AFTER THE LAST DATE OF
ORIGINAL ISSUANCE OF NOTES (INCLUDING THROUGH THE EXERCISE OF THE OPTION TO PURCHASE ADDITIONAL
NOTES) AND (Y) 90 DAYS AFTER IT CEASES TO BE AN AFFILIATE (WITHIN THE MEANING OF RULE 144 UNDER THE
SECURITIES ACT) OF MANNKIND CORPORATION (THE COMPANY), OFFER, RESELL, PLEDGE OR OTHERWISE
TRANSFER THE NOTES EVIDENCED HEREBY, THE COMMON STOCK ISSUABLE UPON CONVERSION OF SUCH NOTES OR ANY
BENEFICIAL OWNERSHIP HEREIN, EXCEPT: (A) TO THE COMPANY OR ANY SUBSIDIARY THEREOF; (B) UNDER A
REGISTRATION STATEMENT THAT HAS BECOME EFFECTIVE UNDER THE SECURITIES ACT; (C) TO A PERSON THE
SELLER REASONABLY BELIEVES IS A QUALIFIED INSTITUTIONAL BUYER (AS DEFINED IN RULE 144A UNDER THE
SECURITIES ACT) THAT IS PURCHASING FOR ITS OWN ACCOUNT OR FOR THE ACCOUNT OF ANOTHER QUALIFIED
INSTITUTIONAL BUYER AND TO WHOM NOTICE IS GIVEN THAT THE TRANSFER IS BEING
1
MADE IN RELIANCE ON RULE 144A, ALL IN COMPLIANCE WITH RULE 144A (IF AVAILABLE); OR (D) UNDER
ANY OTHER AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT, INCLUDING
RULE 144, IF AVAILABLE; AND (2) THAT IT WILL, PRIOR TO ANY TRANSFER OF THIS NOTE WITHIN THE LATER
OF (X) SIX MONTHS (OR, IF THE COMPANY HAS NOT SATISFIED THE CURRENT PUBLIC INFORMATION REQUIREMENTS
OF RULE 144, ONE YEAR) AFTER THE LAST DATE OF ORIGINAL ISSUANCE OF NOTES (INCLUDING THROUGH THE
EXERCISE OF THE OPTION TO PURCHASE ADDITIONAL NOTES) AND (Y) 90 DAYS AFTER IT CEASES TO BE AN
AFFILIATE (WITHIN THE MEANING OF RULE 144) OF THE COMPANY, FURNISH TO THE TRUSTEE AND THE COMPANY
SUCH CERTIFICATIONS, LEGAL OPINIONS OR OTHER INFORMATION AS THEY MAY REQUIRE AND MAY RELY UPON TO
CONFIRM THAT SUCH TRANSFER IS BEING MADE PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT
SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND APPLICABLE STATE SECURITIES
LAWS. IN ANY EVENT, NO AFFILIATE OF THE COMPANY MAY RESELL THIS NOTE OTHER THAN UNDER A
REGISTRATION STATEMENT THAT HAS BECOME EFFECTIVE UNDER THE SECURITIES ACT OR PURSUANT TO AN
EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT IN A TRANSACTION THAT RESULTS IN
SUCH NOTE NO LONGER BEING RESTRICTED SECURITIES (AS DEFINED UNDER RULE 144). NO REPRESENTATION IS
MADE AS TO THE AVAILABILITY OF ANY EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES
ACT. EACH PURCHASER AND TRANSFEREE OF A NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF A
NOTE WILL BE DEEMED TO HAVE REPRESENTED BY ITS PURCHASE AND HOLDING OF THE NOTE AND THE COMMON
STOCK ISSUABLE UPON CONVERSION OF THE NOTE THAT (A) ITS PURCHASE AND HOLDING OF THE NOTE AND THE
COMMON STOCK ISSUABLE UPON CONVERSION OF THE NOTE IS NOT MADE ON BEHALF OF OR WITH PLAN ASSETS OF
ANY PLAN SUBJECT TO TITLE I OF ERISA, SECTION 4975 OF THE CODE OR ANY SIMILAR LAW OR (B) ITS
PURCHASE AND HOLDING OF THE NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THE NOTE WILL NOT
RESULT IN A NON-EXEMPT PROHIBITED TRANSACTION UNDER SECTION 406 OF ERISA, SECTION 4975 OF THE CODE
OR ANY SIMILAR LAW.
2
MANNKIND CORPORATION
5.75% Convertible Senior Note due 2015
CUSIP No.
ISIN No.
MannKind Corporation, a corporation duly organized and validly existing under the laws of the
state of Delaware (herein called the Company, which term includes any successor corporation or
other entity under the Indenture referred to on the reverse hereof), for value received hereby
promises to pay to CEDE & CO., or registered assigns, the principal sum of [ ] (which amount may
from time to time be increased or decreased to such other principal amounts as permitted by the
Indenture by adjustments made on the records of the Trustee or the Custodian of the Depositary as
set forth in Schedule A hereto, in accordance with the rules and procedures of the Depositary) on
August 15, 2015, and interest thereon as set forth below.
This Note shall bear interest at the rate of 5.75% per year from August 24, 2010, or from the
most recent date to which interest had been paid or provided for to, but excluding, the next
scheduled Interest Payment Date until August 15, 2015. Interest is payable semi-annually in
arrears on each February 15 and August 15 (or if any such day is not a Business Day, the
immediately following Business Day), commencing February 15, 2011, to Holders of record at the
close of business on the preceding February 1 and August 1 (whether or not such day is a Business
Day), respectively.
Interest not paid when due and any interest on principal or interest not paid when due will be
paid to Holders on a special record date, which will be the 15th day preceding the day fixed by the
Company for the payment of such interest, whether or not such day is a Business Day. At least 15
days before a special record date, the Company will send to each Holder and to the Trustee a notice
that sets forth the special record date, the payment date and the amount of interest to be paid.
Payment of the principal of, and accrued and unpaid interest on, this Note shall be made at
the office or agency of the Company maintained for that purpose in such lawful money of the United
States of America as at the time of payment shall be legal tender for the payment of public and
private debts; provided, however, that interest on any Notes in certificated form (i) to the Person
entitled thereto having an aggregate principal amount of $2,000,000 or less, by check mailed to
such Person at the address set forth in the Note Register and (ii) to the Person entitled thereto
having an aggregate principal amount of more than $2,000,000, either by check mailed to such Person
or, upon application by such
3
Person to the Note Registrar not later than the relevant Regular Record Date, by wire transfer
in immediately available funds to such Persons account within the United States, which application
and wire transfer instructions shall remain in effect until such Person notifies, in writing, the
Note Registrar to the contrary.
Reference is made to the further provisions of this Note set forth on the reverse hereof,
including, without limitation, provisions giving the Holder of this Note the right to convert this
Note into shares of Common Stock (together with cash in lieu of fractional shares) on the terms and
subject to the limitations set forth in the Indenture. Such further provisions shall for all
purposes have the same effect as though fully set forth at this place.
THIS NOTE SHALL BE DEEMED TO BE A CONTRACT MADE UNDER THE LAWS OF NEW YORK, AND FOR ALL
PURPOSES SHALL BE CONSTRUED IN ACCORDANCE WITH THE LAWS OF NEW YORK, WITHOUT REGARD TO CONFLICTS OF
LAWS PRINCIPLES THEREOF.
This Note shall not be valid or become obligatory for any purpose until the certificate of
authentication hereon shall have been manually signed by the Trustee or a duly authorized
authenticating agent under the Indenture.
[Remainder of page intentionally left blank]
4
IN WITNESS WHEREOF, the Company has caused this Note to be duly executed.
|
|
|
|
|
|
MANNKIND CORPORATION
|
|
|
By: |
|
|
|
|
Name: |
|
|
|
|
Title: |
|
|
|
Dated:
TRUSTEES CERTIFICATE OF AUTHENTICATION
WELLS FARGO BANK, NATIONAL ASSOCIATION
as Trustee, certifies that this is one of the Notes described
in the within-named Indenture.
5
[FORM OF REVERSE OF NOTE]
MANNKIND CORPORATION
5.75% Convertible Senior Note due 2015
This Note is one of a duly authorized issue of the Notes of the Company, designated as its
5.75% Convertible Senior Notes due 2015 (herein called the Notes), all issued or to be issued
under and pursuant to an Indenture dated as of August 24, 2010 (herein called the Indenture),
between the Company and Wells Fargo Bank, National Association (herein called the Trustee), to
which Indenture and all indentures supplemental thereto reference is hereby made for a description
of the rights, limitations of rights, obligations, duties and immunities thereunder of the Trustee,
the Company and the Holders of the Notes. Additional Notes may be issued in an unlimited aggregate
principal amount, subject to certain conditions specified in the Indenture.
In case an Event of Default, as defined in the Indenture, shall have occurred and be
continuing, the principal of and accrued and unpaid interest, if any, on all Notes may be declared,
by either the Trustee or Holders of not less than 25% in aggregate principal amount of Notes then
Outstanding, and upon said declaration shall become, due and payable, in the manner, with the
effect and subject to the conditions and certain exceptions set forth in the Indenture.
Subject to the terms and conditions of the Indenture, the Company will make all payments and
deliveries in respect of the Redemption Price, the Fundamental Change Purchase Price and the
principal amount on the Maturity Date, as the case may be, to the Holder who surrenders a Note to a
Paying Agent to collect such payments in respect of the Note. The Company will pay cash amounts in
money of the United States that at the time of payment is legal tender for payment of public and
private debts.
The Indenture contains provisions permitting the Company and the Trustee in certain
circumstances, without the consent of the Holders of the Notes, and in other circumstances, with
the consent of the Holders of not less than a majority in aggregate principal amount of the Notes
at the time Outstanding, evidenced as in the Indenture provided, to execute supplemental indentures
modifying the terms of the Indenture and the Notes as described therein. It is also provided in
the Indenture that, subject to certain exceptions, the Holders of a majority in aggregate principal
amount of the Notes at the time Outstanding may on behalf of the Holders of all of the Notes waive
any past Default or Event of Default under the Indenture and its consequences.
No reference herein to the Indenture and no provision of this Note or of the Indenture shall
alter or impair the obligation of the Company, which is absolute and unconditional, to pay the
principal of and accrued and unpaid
interest, if any, on this Note at the place, at the respective times, at the rate and in the
lawful money herein prescribed or to satisfy its obligation to convert the Notes.
The Notes are issuable in registered form without coupons in denominations of $1,000 principal
amount and multiples thereof. At the office or agency of the Company referred to on the face
hereof, and in the manner and subject to the limitations provided in the Indenture, Notes may be
exchanged for a like aggregate principal amount of Notes of other authorized denominations, without
payment of any service charge but, if required by the Company or Trustee, with payment of a sum
sufficient to cover any tax, assessments or other governmental charges that may be imposed in
connection therewith as a result of the name of the Holders of the new Notes issued upon such
exchange of Notes being different from the name of the Holder of the old Notes surrendered for such
exchange.
The Notes are not subject to redemption through the operation of any sinking fund.
The Company may redeem the Notes in whole or in part for cash, subject to certain conditions
described in the Indenture, at any time prior to the Maturity Date. The Redemption Price will
equal 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest,
if any, to, but excluding, the Redemption Date plus the Make-Whole Payment, as defined in the
Indenture.
Upon the occurrence of a Fundamental Change, the Company will offer to purchase any and all of
the Notes. The Holder has the right, at such Holders option, to accept such offer and require the
Company to purchase for cash all of such Holders Notes or any portion thereof (in principal
amounts of $1,000 or multiples thereof) on the Fundamental Change Purchase Date at a price equal to
the Fundamental Change Purchase Price.
Subject to the provisions of the Indenture, the Holder hereof has the right, at its option,
prior to the close of business on the Business Day immediately preceding the Maturity Date, to
convert any Notes or portion thereof that is $1,000 or a multiple thereof, into shares of Common
Stock (together with cash in lieu of fractional shares) at a Conversion Rate specified in the
Indenture, as adjusted from time to time as provided in the Indenture.
Terms used in this Note and defined in the Indenture are used herein as therein defined.
2
ABBREVIATIONS
The following abbreviations, when used in the inscription of the face of this Note, shall be
construed as though they were written out in full according to applicable laws or regulations:
TEN COM = as tenants in common
UNIF GIFT MIN ACT = Uniform Gifts to Minors Act
CUST = Custodian
TEN ENT = as tenants by the entireties
JT TEN = joint tenants with right of survivorship and not as tenants in common
Additional abbreviations may also be used though not in the above list.
3
SCHEDULE A
MANNKIND CORPORATION
5.75% Convertible Senior Notes due 2015
The initial principal amount of this Global Note is $100,000,000. The following increases or
decreases in this Global Note have been made:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Principal Amount of |
|
Signature of |
|
|
|
|
|
|
this Global Note |
|
authorized |
|
|
Amount of decrease |
|
Amount of increase |
|
following such |
|
signatory of |
|
|
in Principal Amount |
|
in Principal Amount |
|
decrease or |
|
Trustee or |
Date of Exchange |
|
of this Global Note |
|
of this Global Note |
|
increase |
|
Custodian |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4
ATTACHMENT 1
[FORM OF NOTICE OF CONVERSION]
5.75% Convertible Senior Note due 2015
To: MannKind Corporation
The undersigned registered owner of this Note hereby exercises the option to convert this
Note, or the portion hereof (that is $1,000 principal amount or a multiple thereof) below
designated, and the Company, at its election, may deliver shares of Common Stock (together with
cash in lieu of fractional shares) in accordance with the terms of the Indenture referred to in
this Note, and directs that any shares of Common Stock issuable and deliverable upon such
conversion, and any Notes representing any unconverted principal amount hereof, be issued and
delivered to the registered Holder hereof unless a different name has been indicated below. If any
shares of Common Stock or any portion of this Note not converted are to be issued in the name of a
Person other than the undersigned, the undersigned will pay all transfer taxes payable with respect
thereto. Any amount required to be paid to the undersigned on account of interest accompanies this
Note.
|
|
|
|
|
Dated: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Signature(s) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Signature Guarantee |
|
|
Signature(s) must be guaranteed
by an eligible Guarantor Institution
(banks, stock brokers, savings and
loan associations and credit unions)
with membership in an approved
signature guarantee medallion program
pursuant to Securities and Exchange
Commission Rule 17Ad-15 if
shares of Common Stock are to be issued, or
Notes to be delivered, other than
to and in the name of the registered Holder.
Fill in for registration of shares if
to be issued, and Notes if to
be delivered, other than to and in the
name of the registered Holder:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(City, State and Zip Code)
|
|
|
Please print name and address |
|
|
|
|
|
|
|
Principal amount to be converted (if less than all): |
|
|
$ ,000 |
|
|
|
|
|
NOTICE: The above signature(s) of the Holder(s)
hereof must correspond with the name as written upon
the face of the Note in every particular without
alteration or enlargement or any change whatever. |
|
|
|
|
|
|
|
|
Social Security or Other Taxpayer |
|
|
Identification Number |
ATTACHMENT 2
[FORM OF FUNDAMENTAL CHANGE PURCHASE NOTICE]
5.75% Convertible Senior Note due 2015
To: MannKind Company
The undersigned registered owner of this Note hereby acknowledges receipt of a notice from MannKind
Corporation (the Company) as to the occurrence of a Fundamental Change with respect to the
Company, offering to purchase the Notes and specifying the Fundamental Change Purchase Date. The
undersigned registered owner of this Note hereby accepts the Companys offer to purchase the Notes
and instructs the Company to pay to the registered Holder hereof in accordance with the applicable
provisions of the Indenture referred to in this Note (1) the entire principal amount of this Note,
or the portion thereof (that is $1,000 principal amount or a multiple thereof) below designated,
and (2) if such Fundamental Change Purchase Date does not fall during the period after a Regular
Record Date and on or prior to the corresponding Interest Payment Date, accrued and unpaid interest
thereon to, but excluding, such Fundamental Change Purchase Date.
In the case of certificated Notes, the certificate numbers of the Notes to be purchased are as
set forth below:
|
|
|
|
|
Dated: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Signature(s) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Social Security or Other Taxpayer
Identification Number |
|
|
|
|
|
|
|
|
|
Principal amount to be repaid (if less than all): |
|
|
|
|
$ ,000 |
|
|
|
|
|
|
|
|
|
NOTICE: The above signature(s) of the Holder(s)
hereof must correspond with the name as written upon
the face of the Note in every particular without
alteration or enlargement or any change whatever. |
ATTACHMENT 3
[FORM OF ASSIGNMENT AND TRANSFER]
For value received hereby sell(s), assign(s) and transfer(s) unto
(Please insert social security or Taxpayer Identification Number of assignee) the
within Note, and hereby irrevocably constitutes and appoints attorney to
transfer the said Note on the books of the Company, with full power of substitution in the
premises.
In connection with any transfer of the within Note occurring prior to the Resale Restriction
Termination Date, as defined in the Indenture governing such Note, the undersigned confirms that
such Note is being transferred:
o To MannKind Corporation or a subsidiary thereof; or
o Pursuant to the registration statement that has become or been declared effective under the
Securities Act of 1933, as amended; or
o Pursuant to and in compliance with Rule 144A under the Securities Act of 1933, as amended; or
o Pursuant to and in compliance with Rule 144 under the Securities Act of 1933, as amended; or
o Pursuant to another available exemption from registration under the Securities Act of 1933, as
amended.
|
|
|
|
|
Dated: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Signature(s) |
|
|
|
|
|
|
|
|
|
|
Signature Guarantee |
|
|
Signature(s) must be guaranteed by an
eligible Guarantor Institution (banks, stock
brokers, savings and loan associations and
credit unions) with membership in an approved
signature guarantee medallion program pursuant
to Securities and Exchange Commission
Rule 17Ad-15 if Notes are to be delivered, other
than to and in the name of the registered Holder.
NOTICE: The signature on the assignment must correspond with the name as written upon the face of
the Note in every particular without alteration or enlargement or any change whatever.
exv5w1
EXHIBIT 5.1
D. BRADLEY PECK
(858) 550-6012
bpeck@cooley.com
August 18, 2010
MannKind Corporation
28903 North Avenue Paine
Valencia, CA 91355
Ladies and Gentlemen:
You have requested our opinion with respect to certain matters in connection with the issuance by
MannKind Corporation, a Delaware corporation (the Company), of up to 9,000,000 shares of the
Companys common stock, par value $0.01 (the Shares), pursuant to a Registration Statement on
Form S-3 (No. 333-166404) (the Registration Statement), filed with the Securities and Exchange
Commission (the Commission) under the Securities Act of 1933, as amended (the Act), the
prospectus included within the Registration Statement (the Base Prospectus), the preliminary
prospectus supplement dated August 16, 2010 and the final prospectus supplement dated August 18,
2010, each filed with the Commission pursuant to Rule 424(b) of the Rules and Regulations of the
Act (the Prospectus Supplements). The Base Prospectus and Prospectus Supplements are
collectively referred to as the Prospectus. The Shares are to be issued by the Company as
described in the Registration Statement and the Prospectus.
In connection with this opinion, we have examined and relied upon the Registration Statement and
Prospectus, the Companys Amended and Restated Certificate of Incorporation, as amended, its
Amended and Restated Bylaws, and the originals or copies certified to our satisfaction of such
records, documents, certificates, memoranda and other instruments as in our judgment are necessary
or appropriate to enable us to render the opinion expressed below.
In rendering this opinion, we have assumed the genuineness and authenticity of all signatures on
original documents; the conformity to originals of all documents submitted to us as copies; the
accuracy, completeness and authenticity of certificates of public officials; and the due
authorization, execution and delivery of all documents where authorization, execution and delivery
are prerequisites to the effectiveness of such documents.
On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when
sold in accordance with the Registration Statement and Prospectus, will be validly issued, fully
paid and nonassessable.
4401 EASTGATE MALL, SAN DIEGO, CA 92121 T: (858) 550-6000 F: (858) 550-6420 WWW.COOLEY.COM
MannKind Corporation
August 18, 2010
Page Two
We consent to the reference to our firm under the caption Legal Matters in the Prospectus and to
the filing of this opinion as an exhibit to the Registration Statement.
|
|
|
|
|
Sincerely,
Cooley LLP
|
|
|
By: |
/s/ D. Bradley Peck
|
|
|
|
D. Bradley Peck |
|
|
|
|
|
|
|
exv99w1
EXECUTION VERSION
MANNKIND CORPORATION
(A Delaware corporation)
$100,000,000
Convertible Senior Notes
PURCHASE AGREEMENT
Dated: August 18, 2010
MANNKIND CORPORATION
(A Delaware corporation)
$100,000,000
Convertible Senior Notes
PURCHASE AGREEMENT
August 18, 2010
Merrill Lynch, Pierce, Fenner & Smith Incorporated
as Representative of the several Initial Purchasers
One Bryant Park
New York, New York 10036
Ladies and Gentlemen:
MannKind Corporation, a Delaware corporation (the Company), confirms its agreement with
Merrill Lynch, Pierce, Fenner & Smith Incorporated (Merrill Lynch) and each of the other Initial
Purchasers named in Schedule A hereto (collectively, the Initial Purchasers, which term shall
also include any initial purchaser substituted as hereinafter provided in Section 11 hereof), for
whom Merrill Lynch is acting as representative (in such capacity, the Representative), with
respect to (i) the sale by the Company and the purchase by the Initial Purchasers, acting severally
and not jointly, of the respective principal amounts set forth in said Schedule A of $100,000,000
aggregate principal amount of the Companys Convertible Senior Notes (the Initial Securities) and
(ii) the grant by the Company to the Initial Purchasers, acting severally and not jointly, of the
option to purchase all or any part of an additional $10,000,000 aggregate principal amount of its
Convertible Senior Notes (the Option Securities and, together with the Initial Securities, the
Securities) to cover overallotments. The Securities are to be issued pursuant to an indenture
dated as of August 24, 2010 (the Indenture) between the Company and Wells Fargo Bank, National
Association, as trustee (the Trustee).
The Company understands that the Initial Purchasers propose to make an offering of the
Securities on the terms and in the manner set forth herein and agrees that the Initial Purchasers
may resell, subject to the conditions set forth herein, all or a portion of the Securities to
purchasers (Subsequent Purchasers) at any time after this Agreement has been executed and
delivered. The Securities are to be offered and sold through the Initial Purchasers without being
registered under the Securities Act of 1933, as amended (the 1933 Act), in reliance upon
exemptions therefrom. Pursuant to the terms of the Securities and the Indenture, investors that
acquire Securities may only resell or otherwise transfer such Securities if such Securities are
hereafter registered under the 1933 Act or if an exemption from the registration requirements of
the 1933 Act is available (including the exemption afforded by Rule 144A (Rule 144A) of the rules
and regulations promulgated under the 1933 Act (the 1933 Act Regulations) by the Securities and
Exchange Commission (the Commission)).
The Company has prepared and delivered to each Initial Purchaser copies of a preliminary
offering memorandum dated August 16, 2010 (the Preliminary Offering Memorandum) and has prepared
and will deliver to each Initial Purchaser, on the date hereof or the next succeeding day, copies
of a final offering memorandum dated August 18, 2010 (the Final Offering Memorandum), each
for use by such Initial Purchaser in connection with its solicitation of purchases of, or offering
of, the Securities. Offering Memorandum means, with respect to any date or time referred to in
this Agreement, the most recent offering memorandum (whether the Preliminary Offering Memorandum or
the Final Offering Memorandum, or any amendment or supplement to either such document), including
exhibits thereto and any documents incorporated therein by reference, which has been prepared and
delivered by the Company to the Initial Purchasers in connection with their solicitation of
purchases of, or offering of, the Securities. The Company will prepare a final term sheet
reflecting the final terms of the Securities, in the form set forth in Schedule B hereto (the
Final Term Sheet), and will deliver such Final Term Sheet to the Initial Purchasers in connection
with their solicitation of purchases of, or offering of, the Securities. The Company agrees that,
unless it obtains the prior written consent of the Representative, it will not make any offer
relating to the Securities by any written materials other than the Offering Memorandum and the
Issuer Written Information. Issuer Written Information means (i) any writing intended for general
distribution to investors as evidenced by its being specified in Schedule C hereto, including the
Final Term Sheet, and (ii) any road show that is a written communication within the meaning of
the 1933 Act. General Disclosure Package means the Preliminary Offering Memorandum and any
Issuer Written Information specified on Schedule C hereto and issued at or prior to 7:00 A.M., New
York City time, on August 19, 2010 or such other time as agreed by the Company and Merrill Lynch
(such date and time, the Applicable Time).
All references in this Agreement to financial statements and schedules and other information
which is contained, included or stated in the Offering Memorandum (or other references of
like import) shall be deemed to include all such financial statements and schedules and other
information which are incorporated by reference in the Offering Memorandum; and all references in
this Agreement to amendments or supplements to the Offering Memorandum shall be deemed to include
the filing of any document under the Securities Exchange Act of 1934 (the 1934 Act) which is
incorporated by reference in the Offering Memorandum.
Concurrently with the offering of the Initial Securities, the Company is offering 9,000,000
shares of the Companys common stock, par value $0.01 per share (the Common Stock) pursuant to a
share lending agreement with an affiliate of the Representative, pursuant to which the Company will
lend shares of its Common Stock to such affiliate (the Share Lending Agreement) (the offering of
such shares of Common Stock together with the lending of such shares pursuant to the Share Lending
Agreements are referred to collectively as the Transactions).
SECTION 1. Representations and Warranties.
(a) Representations and Warranties by the Company. The Company represents and warrants to
each Initial Purchaser as of the date hereof, the Applicable Time, the Closing Time (as defined
below) and any Date of Delivery (as defined below), and agrees with each Initial Purchaser, as
follows:
(i) General Disclosure Package; Rule 144A Eligibility. The Company hereby
confirms that it has authorized the use of the General Disclosure Package, including the
Preliminary Offering Memorandum and the Final Term Sheet, and the Final Offering Memorandum
in connection with the offer and sale of the Securities by the Initial Purchasers. The
Securities are eligible for resale pursuant to Rule 144A and will not be, at the Closing
Time, of the same class as securities listed on a national securities exchange registered
under Section 6 of the 1934 Act, or quoted in a U.S. automated interdealer quotation system.
(ii) No Registration Required; No General Solicitation. Subject to compliance
by the Initial Purchasers with the representations and warranties of the Initial Purchasers
and the
2
procedures set forth in Section 6 hereof, it is not necessary in connection with the
offer, sale and delivery of the offered Securities to the Initial Purchasers and to each
Subsequent Purchaser in the manner contemplated by this Agreement and the Offering
Memorandum to register the Securities under the 1933 Act or to qualify the Indenture under
the Trust Indenture Act of 1939, as amended (the 1939 Act). None of the Company, its
Affiliates or any person acting on its or any of their behalf (other than the Initial
Purchasers, as to whom the Company makes no representation) has engaged, in connection with
the offering of the offered Securities, in any form of general solicitation or general
advertising within the meaning of Rule 502(c) under the 1933 Act Regulations.
(iii) Accurate Disclosure. As of the Applicable Time, neither (A) the General
Disclosure Package nor (B) any Issuer Written Information, when considered together with the
General Disclosure Package, included an untrue statement of a material fact or omitted to
state a material fact necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading. The Final Offering Memorandum, as
of its date, at the Closing Time or at any Date of Delivery, did not, does not and will not
contain an untrue statement of a material fact or omit to state a material fact necessary in
order to make the statements therein, in the light of the circumstances under which they
were made, not misleading. The documents incorporated or deemed to be incorporated by
reference in the General Disclosure Package and the Final Offering Memorandum, when such
documents incorporated by reference were filed with the Commission, when read together with
the other information in the General Disclosure Package or the Final Offering Memorandum, as
the case may be, did not, does not and will not contain an untrue statement of a material
fact or omit to state a material fact necessary in order to make the statements therein, in
the light of the circumstances under which they were made, not misleading.
Each Issuer Written Information, if any, as of its issue date and at all subsequent
times through the Closing Dates or until any earlier date that the Company notified or
notifies the Representative as described in the next sentence, did not, does not and will
not include any information that conflicted, conflicts or will conflict with the information
contained in the General Disclosure Package or the Final Offering Memorandum, including any
document incorporated by reference therein.
If at any time following issuance of an Issuer Written Information through the Closing
Dates there occurred or occurs an event or development as a result of which such Issuer
Written Information conflicted or would conflict with the information contained in the
Offering Memorandum that has not been superseded or modified, or included in the General
Disclosure Package or included or would include an untrue statement of a material fact or
omitted or would omit to state a material fact required to be stated therein or necessary in
order to make the statements therein, in the light of the circumstances prevailing at the
subsequent time, not misleading, the Company has promptly notified or will promptly notify
the Representative and has promptly amended or supplemented or will promptly amend or
supplement, at its own expense, such Issuer Written Information to eliminate or correct such
conflict, untrue statement or omission.
The representations and warranties in this subsection shall not apply to statements in
or omissions from the General Disclosure Package or the Final Offering Memorandum made in
reliance upon and in conformity with written information furnished to the Company by any
Initial Purchaser through Merrill Lynch expressly for use therein. For purposes of this
Agreement, the only information so furnished shall be the information in the first paragraph
under the heading
3
Plan of DistributionPrice Stabilization, Short Positions in the Offering Memorandum
(collectively, the Initial Purchaser Information).
(iv) Incorporation of Documents by Reference. The documents incorporated by
reference in the Offering Memorandum, at the time they became effective or were filed with
the Commission, as the case may be, complied in all material respects with the requirements
of the 1933 Act or the 1934 Act, as applicable, and the rules and regulations of the
Commission thereunder (the 1934 Act Regulations), and none of such documents contained an
untrue statement of a material fact or omitted to state a material fact required to be
stated therein or necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading, and any further documents so filed
and incorporated by reference in the Offering Memorandum, when such documents become
effective or are filed with the Commission, as the case may be, will conform in all material
respects to the requirements of the 1933 Act, the 1933 Act Regulations, the 1934 Act, the
1934 Act Regulations, as applicable, and will not contain an untrue statement of a material
fact or omit to state a material fact required to be stated therein or necessary to make the
statements therein, in light of the circumstances under which they are made, not misleading.
(v) Independent Accountants. Deloitte & Touche LLP is and, during the periods
covered by its reports, was an independent public accounting firm as required by the 1933
Act, the 1933 Act Regulations and the Public Accounting Oversight Board. Except as described
in the General Disclosure Package and the Final Offering Memorandum and as pre-approved in
accordance with the requirements set forth in Section 10A of the 1934 Act, Deloitte & Touche
LLP has not been engaged by the Company to perform any prohibited activities (as defined
in Section 10A of the 1934 Act).
(vi) Financial Statements. The financial statements of the Company (including
all notes and schedules thereto) included or incorporated by reference in the General
Disclosure Package and the Final Offering Memorandum present fairly, in all material
respects, the financial position of the Company and its consolidated subsidiaries at the
dates indicated and the statement of operations, stockholders equity and cash flows of the
Company and its consolidated subsidiaries for the periods specified; and such financial
statements and related schedules and notes thereto, and the unaudited financial information
included or incorporated by reference in the Offering Memorandum, have been prepared in
conformity with generally accepted accounting principles, consistently applied throughout
the periods involved (provided that non-year-end financial statements are subject to normal
recurring year-end audit adjustments that are not expected to be material in the aggregate
and do not contain all footnotes required by generally accepted accounting principles). The
summary and selected financial data included in the General Disclosure Package and the Final
Offering Memorandum, if any, present fairly, in all material respects, the information shown
therein as at the respective dates and for the respective periods specified and have been
presented on a basis consistent with the consolidated financial statements set forth in the
Offering Memorandum and other financial information.
(vii) Good Standing of the Company. The Company and each of its subsidiaries
is duly organized, validly existing and in good standing under the laws of their respective
jurisdictions of incorporation or organization and each such entity has all requisite power
and authority to carry on its business as is currently being conducted as described in the
General Disclosure Package and the Final Offering Memorandum, and to own, lease and operate
its properties. The Company and each of its subsidiaries is duly qualified to do business
and is in good standing as a foreign corporation in each jurisdiction in which the nature of
the business conducted by it or location of the assets or properties owned, leased or
licensed by it requires
4
such qualification, except for such jurisdictions where the failure to so qualify or be
in good standing, individually or in the aggregate, would not reasonably be expected to have
a material adverse effect on the assets, properties, condition, financial or otherwise, or
in the results of operations, business affairs or business prospects of the Company and its
subsidiaries considered as a whole (a Material Adverse Effect), and to the Companys
knowledge, no proceeding has been instituted in any such jurisdiction revoking, limiting or
curtailing, or seeking to revoke, limit or curtail, such power and authority or
qualification. The Company has no subsidiary other than its five wholly owned subsidiaries,
MannKind LLC, MannKind Limited, Technosphere International C.V., MannKind Netherlands B.V.
and MannKind Deutchland GmbH, and does not control, directly or indirectly, any other
corporation, partnership, joint venture, association or other business organization. Such
subsidiaries, when considered in the aggregate as a single subsidiary, do not constitute a
significant subsidiary of the Company (as such term is defined in Rule 1-02(w) of
Regulation S-X under the Securities Act) and are not otherwise material to the assets and
operations of the Company. All outstanding shares of capital stock of each of the Companys
subsidiaries have been duly authorized and validly issued, and are fully paid and
nonassessable and are owned directly by the Company or by another wholly owned subsidiary of
the Company free and clear of any security interests, liens, encumbrances, equities or
claims, other than those described in the General Disclosure Package and the Final Offering
Memorandum.
(viii) Capitalization. The authorized, issued and outstanding shares of
capital stock of the Company are as set forth in the General Disclosure Package and the
Final Offering Memorandum in the column entitled Actual under the caption Capitalization
(except for subsequent issuances, if any, pursuant to this Agreement, the Share Lending
Agreement, the purchase agreement with The Mann Group LLC and the purchase agreement with
Seaside 88, LP, pursuant to reservations, agreements or employee benefit plans referred to
in the General Disclosure Package and the Final Offering Memorandum or pursuant to the
vesting, conversion or exercise of convertible securities or options referred to in the
General Disclosure Package and the Final Offering Memorandum). All of the issued and
outstanding shares of Common Stock have been duly and validly issued and are fully paid and
nonassessable. There are no statutory preemptive or other similar rights to subscribe for or
to purchase or acquire any shares of Common Stock of the Company or any of its subsidiaries
or any such rights pursuant to its Certificate of Incorporation or by-laws or any agreement
or instrument to or by which the Company or any of its subsidiaries is a party or bound.
(ix) Authorization of Agreement. This Agreement has been duly authorized,
executed and delivered by the Company.
(x) Authorization of the Indenture. The Indenture has been duly authorized by
the Company and, when duly executed and delivered by the Company and the Trustee, will
constitute a valid and binding agreement of the Company, enforceable against the Company in
accordance with its terms, except as the enforcement thereof may be limited by bankruptcy,
insolvency (including, without limitation, all laws relating to fraudulent transfers),
reorganization, moratorium or similar laws affecting enforcement of creditors rights
generally and except as enforcement thereof is subject to general principles of equity
(regardless of whether enforcement is considered in a proceeding in equity or at law).
(xi) Authorization of the Securities and the Common Stock. The Securities have
been duly authorized and, at the Closing Time, will have been duly executed by the Company
and, when authenticated, issued and delivered in the manner provided for in the Indenture
and delivered against payment of the purchase price therefor as provided in this Agreement,
will
5
constitute valid and binding obligations of the Company, enforceable against the
Company in accordance with their terms, except as the enforcement thereof may be limited by
bankruptcy, insolvency (including, without limitation, all laws relating to fraudulent
transfers), reorganization, moratorium or similar laws affecting enforcement of creditors
rights generally and except as enforcement thereof is subject to general principles of
equity (regardless of whether enforcement is considered in a proceeding in equity or at
law), and will be in the form contemplated by, and entitled to the benefits of, the
Indenture. The shares of Common Stock issuable upon conversion of the Securities have been
duly authorized and reserved for issuance upon such conversion by all necessary corporate
action and such shares, when issued upon such conversion, will be validly issued and will be
fully paid and non-assessable; no holder of such shares will be subject to personal
liability solely by reason of being such a holder; and the issuance of such shares upon such
conversion will not be subject to the preemptive or other similar rights of any
securityholder of the Company.
(xii) Authorization of the Share Lending Agreement. The Share Lending Agreement
has been duly authorized, executed and delivered by the Company and is a valid and binding
agreement of the Company, enforceable against the Company in accordance with its terms,
except as the enforcement thereof may be limited by bankruptcy, insolvency (including,
without limitation, all laws relating to fraudulent transfers), reorganization, moratorium
or similar laws affecting enforcement of creditors rights generally and except as
enforcement thereof is subject to general principles of equity (regardless of whether
enforcement is considered in a proceeding in equity or at law).
(xiii) Description of the Securities, the Common Stock and the Indenture. The
Securities and the Indenture will conform in all material respects to the respective
statements relating thereto contained in the General Disclosure Package and the Final
Offering Memorandum. The Common Stock conforms in all material respects to all statements
in relation thereto contained or incorporated by reference in the General Disclosure Package
and the Final Offering Memorandum and such description conforms to the rights set forth in
the instruments defining the same.
(xiv) Lock-Up Agreements. Each director and executive officer of the Company
listed on Schedule D hereto has delivered to the Representative his or her executed written
lock-up agreement in the form attached to this Agreement as Exhibit C hereto or in such form
as may be approved in writing by the Representative.
(xv) Stock Options. The exercise price of each option to acquire Common Stock
(each, a Company Stock Option) is no less than the fair market value of a share of Common
Stock as determined on the date of grant of such Company Stock Option. All grants of Company
Stock Options were validly issued and properly approved by the Board of Directors of the
Company, a committee thereof or an individual with authority duly delegated by the Board of
Directors of the Company or a committee thereof, in material compliance with (i) all
applicable laws and (ii) the terms of the plans under which such Company Stock Options were
issued and were recorded on the Companys financial statements in accordance with generally
accepted accounting principles, and no such grants involved any back dating, forward
dating, spring loading or similar practices with respect to the effective date of grant.
(xvi) Absence of Violations, Defaults and Conflicts. Neither the Company nor
any subsidiary (i) is in violation of its certificate or articles of incorporation or
organization, by-laws, certificate of formation, limited liability company agreement,
partnership agreement or other organizational documents, (ii) is in default under, and no
event has occurred which, with notice or
6
lapse of time, or both, would constitute a default under, or result in the creation or
imposition of any lien, charge, mortgage, pledge, security interest, claim, limitation on
voting rights, equity, trust or other encumbrance, preferential arrangement, defect or
restriction of any kind whatsoever, upon, any property or assets of the Company or any
subsidiary pursuant to, any bond, debenture, note, indenture, mortgage, deed of trust, loan
agreement or other agreement or instrument to which it is a party or by which it is bound or
to which any of its properties or assets is subject or (iii) is in violation of any statute,
law, rule, regulation, ordinance, directive, judgment, decree or order of any judicial,
regulatory or other legal or governmental agency or body, foreign or domestic having
jurisdiction over the Company (each, a Governmental Entity), except (in the case of
clauses (ii) and (iii) above) for violations or defaults that would not (individually or in
the aggregate) reasonably be expected to have a Material Adverse Effect. Neither the
execution, delivery and performance of this Agreement or the Share Lending Agreement by the
Company nor the consummation of any of the transactions contemplated hereby or thereby and
in the General Disclosure Package and the Final Offering Memorandum (including, without
limitation, the issuance and sale by the Company of the Securities and the use of proceeds
from the sale of the Securities as described therein under the caption Use of Proceeds)
will give rise to a right to terminate or accelerate the due date of any payment due under,
or conflict with or result in the breach of any term or provision of, or constitute a
default (or an event which with notice or lapse of time or both would constitute a default)
under, or require any consent or waiver under, or result in the execution or imposition of
any lien, charge or encumbrance upon any properties or assets of the Company or its
subsidiaries pursuant to the terms of, any indenture, mortgage, deed of trust or other
agreement or instrument to which the Company or any of its subsidiaries is a party or by
which either the Company or its subsidiaries or any of their properties or businesses is
bound, or any franchise, license, permit, judgment, decree, order, statute, rule or
regulation applicable to the Company or any of its subsidiaries, except where it would not
reasonably be expected to have a Material Adverse Effect, or violate any provision of the
charter or by-laws of the Company or any of its subsidiaries, except for such consents or
waivers which have already been obtained and are in full force and effect.
(xvii) Incorporated Documents. Each description of a contract, document or
other agreement in the General Disclosure Package or the Final Offering Memorandum
accurately reflects in all respects the material terms of the underlying contract, document
or other agreement. Each contract, document or other agreement described in the General
Disclosure Package or the Final Offering Memorandum or incorporated by reference is in full
force and effect and is valid and enforceable by and against the Company or any of its
subsidiaries, as the case may be, in accordance with its terms, except as the enforceability
thereof may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws
affecting the enforcement of creditors rights generally and by general equitable
principles. Neither the Company nor any of its subsidiaries, if a subsidiary is a party, nor
to the Companys knowledge, any other party is in default in the observance or performance
of any term or obligation to be performed by it under any such agreement, and no event has
occurred which with notice or lapse of time or both would constitute such a default, in any
such case which default or event, individually or in the aggregate, would reasonably be
expected to have a Material Adverse Effect. No default exists, and no event has occurred
which with notice or lapse of time or both would constitute a default, in the due
performance and observance of any term, covenant or condition, by the Company or its
subsidiary, if a subsidiary is a party thereto, of any other agreement or instrument to
which the Company or any of its subsidiaries is a party or by which the Company or its
properties or business or a subsidiary or its properties or business may be bound or
affected which default or event, individually or in the aggregate, would reasonably be
expected to have a Material Adverse Effect.
7
(xviii) Corporate Action. All necessary corporate action has been duly and
validly taken by the Company to authorize the execution, delivery and performance of this
Agreement and the Share Lending Agreement and the issuance and sale of the Securities by the
Company.
(xix) Absence of Labor Dispute. Neither the Company nor any of its
subsidiaries is involved in any labor dispute nor, to the knowledge of the Company, is any
such dispute threatened, which dispute would reasonably be expected to have a Material
Adverse Effect. The Company is not aware of any existing or imminent labor disturbance by
the employees of any of its principal suppliers or contractors which would reasonably be
expected to have a Material Adverse Effect. The Company is not aware of any threatened or
pending litigation between the Company or its subsidiaries and any of its executive officers
which, if adversely determined, would reasonably be expected to have a Material Adverse
Effect.
(xx) Related Party Transactions. All material transactions occurring or that
have occurred between or among the Company and any of its officers or directors,
shareholders or any affiliate or affiliates of any such officer or director or shareholder
are described in the General Disclosure Package and the Final Offering Memorandum.
(xxi) Absence of Proceedings. There are no legal or governmental proceedings
pending to which the Company or any of its subsidiaries is a party or of which any property
of the Company or any of its subsidiaries is the subject which, if determined adversely to
the Company or any of its subsidiaries could individually or in the aggregate have a
Material Adverse Effect; and, to the knowledge of the Company, no such proceedings are
threatened or contemplated by governmental authorities or threatened by others.
(xxii) Absence of Further Requirements. Each approval, consent, order,
authorization, designation, declaration or filing of, by or with any Governmental Entity
necessary in connection with the execution and delivery by the Company of this Agreement and
the Share Lending Agreement and the consummation of the transactions herein and therein
contemplated required to be obtained or performed by the Company (except such additional
steps as may be necessary to qualify the Securities by the Initial Purchasers under the
state securities or Blue Sky laws) has been obtained or made and is in full force and
effect.
(xxiii) Possession of Licenses and Permits. Except as set forth in the General
Disclosure Package and the Final Offering Memorandum, the Company and each of its
subsidiaries has all requisite corporate power and authority, and all necessary
authorizations, approvals, consents, orders, licenses, certificates and permits of and from
all governmental or regulatory bodies or any other person or entity (collectively, the
Permits), to own, lease and license its assets and properties and conduct its business,
all of which are valid and in full force and effect, except where the lack of such Permits,
individually or in the aggregate, would not reasonably be expected to have a Material
Adverse Effect. The Company and each of its subsidiaries has fulfilled and performed in all
material respects all of its obligations with respect to such Permits and no event has
occurred that allows, or after notice or lapse of time would allow, revocation or
termination thereof or results in any other material impairment of the rights of the Company
or such subsidiary thereunder. Except as may be required under the 1933 Act and state and
foreign Blue Sky laws, no other Permits are required to enter into, deliver and perform this
Agreement or the Share Lending Agreement and to issue and sell the Securities.
(xxiv) Title to Property. The Company and each of its subsidiaries has good
and marketable title in fee simple to all real property owned by it, and good and marketable
title to all other property owned by it, in each case free and clear of all liens,
encumbrances, claims, security
8
interests and defects, except as are described in the General Disclosure Package and
the Final Offering Memorandum or such as do not materially affect the value of such property
and do not materially interfere with the use made of such property by the Company and its
subsidiaries. All property held under lease by the Company and its subsidiaries is held by
them under valid, existing and enforceable leases, free and clear of all liens,
encumbrances, claims, security interests and defects, except such as are not material and do
not materially interfere with the use made of such property by the Company and its
subsidiaries. Subsequent to the respective dates as of which information is given in the
Offering Memorandum, (i) there has not been any event which would reasonably be expected to
have a Material Adverse Effect; (ii) neither the Company nor any of its subsidiaries has
sustained any loss or interference with its assets, businesses or properties (whether owned
or leased) from fire, explosion, earthquake, flood or other calamity, whether or not covered
by insurance, or from any labor dispute or any court or legislative or other governmental
action, order or decree which would reasonably be expected to have a Material Adverse
Effect; and (iii) since the date of the latest balance sheet included or incorporated by
reference in the Offering Memorandum, except as otherwise disclosed in the Offering
Memorandum, neither the Company nor its subsidiaries has (A) issued any securities (other
than securities pursuant to the Companys equity incentive plans) or incurred any liability
or obligation, direct or contingent, for borrowed money, except such liabilities or
obligations incurred in the ordinary course of business, (B) entered into any transaction
not in the ordinary course of business or (C) declared or paid any dividend or made any
distribution on any shares of its stock or redeemed, purchased or otherwise acquired or
agreed to redeem, purchase or otherwise acquire any shares of its capital stock.
(xxv) Possession of Intellectual Property. Except as set forth in the General
Disclosure Package and the Final Offering Memorandum, the Company and each of its
subsidiaries owns or possesses legally-enforceable rights (including license rights) to use
all patents, patent rights, inventions, trademarks, trademark applications, trade names,
service marks, copyrights, copyright applications, licenses, know-how and other similar
rights and proprietary knowledge (collectively, Intellectual Property) necessary for the
conduct of its business. Neither the Company nor any of its subsidiaries has received any
written notice of, or is aware of, any infringement of or conflict with asserted rights of
others with respect to any Intellectual Property, except as referenced in the General
Disclosure Package and the Final Offering Memorandum or that would not reasonably be
expected to have a Material Adverse Effect.
(xxvi) Environmental Laws. (A) Each of the Company and each of its
subsidiaries is in compliance in all material respects with all rules, laws and regulation
relating to the use, treatment, storage and disposal of toxic substances and protection of
health or the environment (Environmental Laws) which are applicable to its business; (B)
neither the Company nor its subsidiaries has received any notice from any governmental
authority or third party of an asserted claim under Environmental Laws; (C) each of the
Company and each of its subsidiaries has received all permits, licenses or other approvals
required of it under applicable Environmental Laws to conduct its business and is in
compliance with all terms and conditions of any such permit, license or approval; (D) to the
Companys knowledge, no facts currently exist that will require the Company or any of its
subsidiaries to make future material capital expenditures to comply with Environmental Laws;
and (E) no property which is or has been owned, leased or occupied by the Company or its
subsidiaries has been designated as a Superfund site pursuant to the Comprehensive
Environmental Response, Compensation of Liability Act of 1980, as amended (42 U.S.C. Section
9601, et. seq.) (CERCLA), or otherwise designated as a contaminated site under applicable
state or local law. Neither the Company nor any of its subsidiaries has been named as a
potentially responsible party under the CERCLA 1980.
9
In the ordinary course of its business, the Company periodically reviews the effect of
Environmental Laws on the business, operations and properties of the Company and its
subsidiaries, in the course of which the Company identifies and evaluates associated costs
and liabilities (including, without limitation, any capital or operating expenditures
required for clean-up, closure of properties or compliance with Environmental Laws, or any
permit, license or approval, any related constraints on operating activities and any
potential liabilities to third parties). On the basis of such review, the Company has
reasonably concluded that such associated costs and liabilities would not, singly or in the
aggregate, have a Material Adverse Effect.
(xxvii) Accounting Controls. The books, records and accounts of the Company
and its subsidiaries accurately and fairly reflect, in all material respects, the
transactions in, and dispositions of, the assets of, and the results of operations of, the
Company and its subsidiaries. The Company and its subsidiaries maintain a system of internal
accounting controls sufficient to provide reasonable assurances that (A) transactions are
executed in accordance with managements general or specific authorizations, (B)
transactions are recorded as necessary to permit preparation of financial statements in
accordance with generally accepted accounting principles and to maintain asset
accountability, (C) access to assets is permitted only in accordance with managements
general or specific authorization and (D) the recorded accountability for assets is compared
with the existing assets at reasonable intervals and appropriate action is taken with
respect to any differences.
(xxviii) Disclosure Controls. The Company has established and maintains
disclosure controls and procedures (as such term is defined in Rule 13a-15 under the 1934
Act), which: (A) are designed to ensure that material information relating to the Company is
made known to the Companys principal executive officer and its principal financial officer
by others within the Company, particularly during the periods in which the periodic reports
required under the 1934 Act are required to be prepared; (B) provide for the periodic
evaluation of the effectiveness of such disclosure controls and procedures at the end of the
periods in which the periodic reports are required to be prepared; and (C) are effective in
all material respects to perform the functions for which they were established. Based on the
evaluation of its disclosure controls and procedures, the Company is not aware of (1) any
significant deficiency in the design or operation of internal controls which could adversely
affect the Companys ability to record, process, summarize and report financial data or any
material weaknesses in internal controls; or (2) any fraud, whether or not material, that
involves management or other employees who have a role in the Companys internal controls.
(xxix) Off-Balance Sheet Arrangements. Except as described in the General
Disclosure Package and the Final Offering Memorandum, there are no material off-balance
sheet arrangements (as defined in Item 303 of Regulation S-K) that have or are reasonably
likely to have a material current or future effect on the Companys financial condition,
revenues or expenses, changes in financial condition, results of operations, liquidity,
capital expenditures or capital resources.
(xxx) Audit Committee. The Companys Board of Directors has validly appointed
an audit committee whose composition satisfies the requirements of Rule 5605(c)(2) of the
Listing Rules of NASDAQ (the NASDAQ Rules) and the Companys Board of Directors and/or the
audit committee has adopted a charter that satisfies the requirements of Rule 5605(c)(1) of
the NASDAQ Rules. The audit committee has reviewed the adequacy of its charter within the
past twelve months.
10
(xxxi) Compliance with the Sarbanes-Oxley Act. There is and has been no
failure on the part of the Company or any of its directors or officers, in their capacities
as such, to comply with any applicable provision of the Sarbanes-Oxley Act of 2002,
including, without limitation, Section 402 related to loans and Sections 302 and 906 related
to certifications.
(xxxii) Payment of Taxes. The Company and each of its subsidiaries has filed
all Federal, state, local and foreign tax returns which are required to be filed through the
date hereof, which returns are true and correct in all material respects or has received
timely extensions thereof, and has paid all taxes shown on such returns and all assessments
received by it to the extent that the same are material and have become due, except in each
case where such failure to file or pay would not reasonably be expected to have a Material
Adverse Effect. There are no tax audits or investigations pending which, if adversely
determined, would reasonably be expected to have a Material Adverse Effect; nor to the
Companys knowledge are there any material proposed additional tax assessments against the
Company or any of its subsidiaries.
(xxxiii) Insurance. The Company and its subsidiaries are insured by insurers
of recognized financial responsibility against such losses and risks and in such amounts as
are customary in the businesses in which they are engaged or propose to engage after giving
effect to the transactions described in the General Disclosure Package and the Final
Offering Memorandum; all policies of insurance and fidelity or surety bonds insuring the
Company or any of its subsidiaries or the Companys or its subsidiaries respective
businesses, assets, employees, officers and directors are in full force and effect; the
Company and each of its subsidiaries are in compliance with the terms of such policies and
instruments in all material respects; and neither the Company nor any subsidiary of the
Company has any reason to believe that it will not be able to renew its existing insurance
coverage as and when such coverage expires or to obtain similar coverage from similar
insurers as may be necessary to continue its business at a cost that is not materially
greater than the current cost of such coverage. Neither the Company nor any of its
subsidiaries has been denied any insurance coverage which it has sought or for which it has
applied.
(xxxiv) Investment Company Act. The Company is not and, after giving effect to
the offering and sale of the Securities and the application of proceeds thereof as described
in the General Disclosure Package and the Final Offering Memorandum and the transactions
contemplated by the Share Lending Agreement, will not be an investment company within the
meaning of the Investment Company Act of 1940, as amended.
(xxxv) Absence of Manipulation. The Company has not taken, nor will it take,
directly or indirectly, any action designed to or which might reasonably be expected to
cause or result in, or which has constituted or which might reasonably be expected to
constitute, the stabilization or manipulation of the price of the Common Stock or any
security of the Company to facilitate the sale or resale of any of the Securities.
(xxxvi) Continued Registration of Common Stock. The Company has taken no action
designed to, or likely to have the effect of, terminating the registration of the Common
Stock under the 1934 Act or the listing of the Common Stock on the Nasdaq Global Market, nor
has the Company received any notification that the Commission or the Nasdaq Global Market is
contemplating terminating such registration or listing.
(xxxvii) Foreign Corrupt Practices Act. Neither the Company nor any other
person associated with or acting on behalf of the Company including, without limitation, any
director, officer, agent or employee of the Company or its subsidiaries, has, directly or
indirectly, while
11
acting on behalf of the Company or its subsidiaries (i) used any corporate funds for
unlawful contributions, gifts, entertainment or other unlawful expenses relating to
political activity; (ii) made any unlawful payment to foreign or domestic government
officials or employees or to foreign or domestic political parties or campaigns from
corporate funds; (iii) violated any provision of the Foreign Corrupt Practices Act of 1977,
as amended; or (iv) made any other unlawful payment.
(xxxviii) Money Laundering Laws. The operations of the Company and its
subsidiaries are in compliance in all material respects with applicable financial
recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting
Act of 1970, as amended, the money laundering statutes of all required jurisdictions, the
rules and regulations thereunder and any related or similar rules, regulations or
guidelines, issued, administered or enforced by any governmental agency having jurisdiction
over the Company (collectively, the Money Laundering Laws) and no action, suit or
proceeding by or before any court or governmental agency, authority or body or any
arbitrator involving the Company or any of it subsidiaries with respect to the Money
Laundering Laws is pending, or to the best knowledge of the Company, threatened.
(xxxix) OFAC. Neither the Company nor any of its subsidiaries nor, to the
knowledge of the Company, any director, officer, agent, employee or affiliate of the Company
or any of its subsidiaries is currently subject to any U.S. sanctions administered by the
Office of Foreign Assets Control of the U.S. Treasury Department (OFAC); and the Company
will not directly or indirectly use the proceeds of the offering, or lend, contribute or
otherwise make available such proceeds to any subsidiary, joint venture partner or other
person or entity, for the purpose of financing the activities of any person known by the
Company to be currently subject to any U.S. sanctions administered by OFAC.
(xl) ERISA. The Company has fulfilled its obligations, if any, under the
minimum funding standards of Section 302 of the U.S. Employee Retirement Income Security Act
of 1974 (ERISA) and the regulations and published interpretations thereunder with respect
to each plan as defined in Section 3(3) of ERISA and such regulations and published
interpretations in which its employees are eligible to participate and each such plan is in
compliance in all material respects with the presently applicable provisions of ERISA and
such regulations and published interpretations. No Reportable Event (as defined in Section
4043 of ERISA) has occurred with respect to any Pension Plan (as defined in ERISA) for
which the Company could have any material liability.
(xli) Clinical and Pre-Clinical Studies. The clinical, pre-clinical and other
studies and tests conducted by the Company or in which the Company or its products or
product candidates have participated, or that are described in the General Disclosure
Package and the Final Offering Memorandum or the results of which are referred to in the
General Disclosure Package or the Final Offering Memorandum, and such studies and tests
conducted on behalf of or sponsored by the Company or that the Company intends to rely on in
support of regulatory approval by the U.S. Food and Drug Administration (the FDA) or
foreign regulatory agencies, were and, if still pending, are, to the Companys knowledge,
being conducted in all material respects in accordance with standard accepted medical and
scientific research procedures and, to the Companys knowledge, the protocols established by
the Company for such studies and tests. The descriptions in the General Disclosure Package
and the Final Offering Memorandum of the results of such studies and tests are accurate and
complete in all material respects and fairly present the data derived from such studies and
tests, and except as set forth in the General Disclosure Package and the Final Offering
Memorandum, the Company has no knowledge of any
12
other studies or tests, the results of which the Company believes reasonably call into
question the results described or referred to in the General Disclosure Package and the
Final Offering Memorandum when viewed in the context in which such results are described.
Except to the extent disclosed in the General Disclosure Package and the Final Offering
Memorandum, the Company has not received any written notices or other correspondence from
the FDA or any other domestic or foreign governmental agency requiring the termination,
suspension or modification (other than such modifications as are normal in the regulations,
any such modification which are material have been disclosed to you) of any clinical or
pre-clinical studies or tests that are described in the General Disclosure Package or the
Final Offering Memorandum or the results of which are referred to in the General Disclosure
Package or the Final Offering Memorandum.
(xlii) Lending Relationship. Except as disclosed in the General Disclosure
Package and the Final Offering Memorandum, the Company (i) does not have any material
lending or other relationship with any bank or lending affiliate of any Initial Purchaser
and (ii) does not intend to use any of the proceeds from the sale of the Securities to repay
any outstanding debt owed to any affiliate of any Initial Purchaser.
(xliii) Statistical and Market-Related Data. The statistical and market
related data included in the General Disclosure Package or the Final Offering Memorandum are
based on or derived from sources that the Company believes to be reliable and accurate.
(b) Officers Certificates. Any certificate signed by any officer of the Company or any of
its subsidiaries delivered to the Representative or to counsel for the Initial Purchasers shall be
deemed a representation and warranty by the Company to each Initial Purchaser as to the matters
covered thereby.
SECTION 2. Sale and Delivery to Initial Purchasers; Closing.
(a) Initial Securities. On the basis of the representations and warranties herein contained
and subject to the terms and conditions herein set forth, the Company agrees to sell to each
Initial Purchaser, severally and not jointly, and each Initial Purchaser, severally and not
jointly, agrees to purchase from the Company, at the price set forth in Schedule A, the aggregate
principal amount of Initial Securities set forth in Schedule A, plus any additional principal
amount of Initial Securities which such Initial Purchaser may become obligated to purchase pursuant
to the provisions of Section 11 hereof, subject to such adjustments as Merrill Lynch in its
discretion shall make to ensure that any sales or purchases are in authorized denominations.
(b) Option Securities. In addition, on the basis of the representations and warranties herein
contained and subject to the terms and conditions herein set forth, the Company hereby grants an
option to the Initial Purchasers, severally and not jointly, to purchase the Option Securities, at
the price set forth in Schedule A. The option hereby granted will expire 13 days after the Closing
Time and may be exercised in whole or in part from time to time only for the purpose of covering
overallotments made in connection with the offering and distribution of the Initial Securities upon
notice by the Representative to the Company setting forth the amount of Option Securities as to
which the several Initial Purchasers are then exercising the option and the time and date of
payment and delivery for such Option Securities. Any such time and date of delivery (a Date of
Delivery) shall be determined by the Representative, but shall not be later than seven full
business days after the exercise of said option, nor in any event prior to the Closing Time. If
the option is exercised as to all or any portion of the Option Securities, each of the Initial
Purchasers, acting severally and not jointly, will purchase that proportion of the total principal
amount of Option Securities then being purchased which the amount of Initial Securities set forth
in Schedule A opposite the name of such Initial Purchaser bears to the total principal amount of
Initial
13
Securities, subject in each case to such adjustments as Merrill Lynch in its discretion shall
make to ensure that any sales or purchases are in authorized denominations.
(c) Payment. Payment of the purchase price for, and delivery of certificates for, the Initial
Securities shall be made at the offices of Davis Polk & Wardwell LLP, or at such other place as
shall be agreed upon by the Representative and the Company, at 9:00 A.M. (New York City time) on
the third (fourth, if the pricing occurs after 4:30 P.M. (New York City time) on any given day)
business day after the date hereof (unless postponed in accordance with the provisions of
Section 11), or such other time not later than ten business days after such date as shall be agreed
upon by the Representative and the Company (such time and date of payment and delivery being herein
called Closing Time).
In addition, in the event that any or all of the Option Securities are purchased by the
Initial Purchasers, payment of the purchase price for, and delivery of certificates for, such
Option Securities shall be made at the above-mentioned offices, or at such other place as shall be
agreed upon by the Representative and the Company, on each Date of Delivery as specified in the
notice from the Representative to the Company.
Payment shall be made to the Company by wire transfer of immediately available funds to a bank
account designated by the Company, against delivery to the Representative for the respective
accounts of the Initial Purchasers of certificates for the Securities to be purchased by them. It
is understood that each Initial Purchaser has authorized the Representative, for its account, to
accept delivery of, receipt for, and make payment of the purchase price for, the Initial Securities
and the Option Securities, if any, which it has agreed to purchase. Merrill Lynch, individually
and not as representative of the Initial Purchasers, may (but shall not be obligated to) make
payment of the purchase price for the Initial Securities or the Option Securities, if any, to be
purchased by any Initial Purchaser whose funds have not been received by the Closing Time or the
relevant Date of Delivery, as the case may be, but such payment shall not relieve such Initial
Purchaser from its obligations hereunder.
(d) Denominations; Registration. Certificates for the Initial Securities and the Option
Securities, if any, shall be in such denominations ($1,000 or integral multiples thereof) and
registered in such names as the Representative may request in writing at least one full business
day before the Closing Time or the relevant Date of Delivery, as the case may be. The Initial
Securities and the Option Securities, if any, will be made available for examination and packaging
by the Representative in The City of New York not later than 10:00 A.M. (New York City time) on the
business day prior to the Closing Time or the relevant Date of Delivery, as the case may be.
SECTION 3. Covenants of the Company. The Company covenants with each Initial
Purchaser as follows:
(a) Delivery of Offering Memorandum. The Company has delivered to each Initial Purchaser,
without charge, as many copies of the Preliminary Offering Memorandum (as amended or supplemented)
thereto and documents incorporated by reference therein as such Initial Purchaser reasonably
requested, and the Company hereby consents to the use of such copies. The Company will furnish to
each Initial Purchaser, without charge, such number of copies of the Final Offering Memorandum
thereto and documents incorporated by reference therein as such Initial Purchaser may reasonably
request.
(b) Notice and Effect of Material Events. If at any time prior to the completion of resales
of the Securities by the Initial Purchasers, any event shall occur or condition shall exist as a
result of which it is necessary, in the opinion of counsel for the Initial Purchasers or for the
Company, to amend or supplement the General Disclosure Package or the Final Offering Memorandum in
order that the General
14
Disclosure Package or the Final Offering Memorandum, as the case may be, will not include any
untrue statement of a material fact or omit to state a material fact necessary in order to make the
statements therein not misleading in the light of the circumstances existing at the time it is
delivered to a Subsequent Purchaser, the Company will promptly (A) give the Representative notice
of such event and (B) prepare any amendment or supplement as may be necessary to correct such
statement or omission and, a reasonable amount of time prior to any proposed use or distribution,
furnish the Representative with copies of any such amendment or supplement; provided that the
Company shall not use or distribute any such amendment or supplement to which the Representative or
counsel for the Initial Purchasers shall object. The Company will furnish to the Initial
Purchasers such number of copies of such amendment or supplement as the Initial Purchasers may
reasonably request.
(c) Reporting Requirements. Until the completion of resales of the Securities by the Initial
Purchasers, the Company will file all documents required to be filed with the Commission pursuant
to the 1934 Act within the time periods required by the 1934 Act and the 1934 Act Regulations. The
Company has given the Representative notice of any filings made pursuant to the 1934 Act or 1934
Act Regulations within 48 hours prior to the Applicable Time; the Company will give the
Representative notice of its intention to make any such filing from the Applicable Time to the
Closing Time and will furnish the Representative with copies of any such documents a reasonable
amount of time prior to such proposed filing, as the case may be, and will not file or use any such
document to which the Representative or counsel for the Initial Purchasers shall reasonably object.
(d) Blue Sky Qualifications. The Company will use its best efforts, in cooperation with the
Initial Purchasers, to qualify the Securities for offering and sale under the applicable securities
laws of such states and other jurisdictions (domestic or foreign) as the Representative may
designate and to maintain such qualifications in effect so long as required to complete the
distribution of the Securities; provided, however, that the Company shall not be obligated to file
any general consent to service of process or to qualify as a foreign corporation or as a dealer in
securities in any jurisdiction in which it is not so qualified or to subject itself to taxation in
respect of doing business in any jurisdiction in which it is not otherwise so subject.
(e) Use of Proceeds. The Company will use the net proceeds received by it from the sale of
the Securities in the manner specified in the General Disclosure Package and the Final Offering
Memorandum under the caption Use of Proceeds.
(f) DTCC. The Company will cooperate with the Initial Purchasers and use its best efforts to
permit the offered Securities to be eligible for clearance and settlement through the facilities of
The Depository Trust & Clearing Corporation (DTCC).
(g) Listing. The Company will use its reasonable best efforts to effect and maintain the
listing of the Common Stock issuable upon conversion of the Securities on the Nasdaq Global Market.
(h) Restriction on Sale of Securities. During a period of 90 days from the date of the Final
Offering Memorandum (the Lock-Up Period), the Company will not, without the prior written consent
of Merrill Lynch, (i) directly or indirectly, offer, pledge, sell, contract to sell, sell any
option or contract to purchase, purchase any option or contract to sell, grant any option, right or
warrant to purchase or otherwise transfer or dispose of any shares of Common Stock or any
securities convertible into or exercisable or exchangeable for Common Stock or file any
registration statement under the 1933 Act with respect to any of the foregoing or (ii) enter into
any swap or any other agreement or any transaction that transfers, in whole or in part, directly or
indirectly, the economic consequence of ownership of the Common Stock, whether any such swap or
transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or
such other securities, in cash or otherwise. The foregoing sentence
15
shall not apply to (A) the
Securities to be sold hereunder, (B) the shares of Common Stock to be lent pursuant to the Share
Lending Agreement, (C) up to an aggregate of 8,400,000 shares of Common Stock to be sold and issued
by the Company pursuant to the Common Stock Purchase Agreement by and between the Company and
Seaside 88, LP and the Common Stock Purchase Agreement by and between the Company and The Mann
Group LLC, each dated as of August 10, 2010, (D) any shares of Common Stock issued by the Company
upon the exercise of an option or warrant or the conversion of a security outstanding on the date
hereof and referred to in the General Disclosure Package and the Final Offering Memorandum, (E) any
shares of Common Stock issued or options to purchase Common Stock granted pursuant to existing
employee benefit plans of the Company referred to in the General Disclosure Package and the Final
Offering Memorandum, (F) any shares of Common Stock issued pursuant to any non-employee director
stock plan or dividend reinvestment plan referred to in the General Disclosure Package and the
Final Offering Memorandum or (G) any shares of Common Stock issued to one or more counterparties in
connection with the consummation of a strategic partnership, joint venture, collaboration, merger
or the acquisition or license of any business products or technology complimentary to the Companys
business; provided that, with respect to this subsection (G), (1) the sum of the aggregate number
of Common Stock so issued shall not exceed 10% of the total number of shares of Common Stock
outstanding as of the date hereof and (2) prior to the issuance of such Common Stock each recipient
of such Common Stock shall have executed and delivered to Merrill Lynch an agreement substantially
in the form of Exhibit D hereto.
SECTION 4. Payment of Expenses.
(a) Expenses. The Company will pay or cause to be paid all expenses incident to the
performance of their obligations under this Agreement, including (i) preparation, issuance and
delivery of the Securities to the Initial Purchasers and the Common Stock issuable upon conversion
thereof and any charges of DTCC in connection therewith, (ii) the fees and disbursements of the
Companys counsel, accountants and other advisors, (iii) the qualification of the Securities under
securities laws in accordance with the provisions of Section 3(d) hereof, including filing fees and
the reasonable fees and disbursements of counsel for the Initial Purchasers in connection therewith
and in connection with the preparation of the Blue Sky Survey and any supplement thereto, provided
such fees and disbursements do not exceed $10,000 in the aggregate, (iv) the preparation, printing
and delivery to the Initial Purchasers of copies of each Preliminary Offering Memorandum, any
Issuer Written Information, the Final Term Sheet and the Final Offering Memorandum and any
amendments or supplements thereto and any costs associated with electronic delivery of any of the
foregoing by the Initial Purchasers to
investors, (v) all fees and expenses of the Trustee and any expenses of any transfer agent or
registrar for the Securities or the Common Stock issuable upon conversion of the Securities, (vi)
the costs and expenses of the Company relating to investor presentations on any road show
undertaken in connection with the marketing of the Securities, including without limitation,
expenses associated with the production of road show slides and graphics, fees and expenses of any
consultants engaged in connection with the road show presentations, travel and lodging expenses of
the representatives and officers of the Company and any such consultants, and the cost of aircraft
and other transportation chartered in connection with the road show, (vii) the fees and expenses
incurred in connection with the listing of the Common Stock issuable upon conversion of the
Securities on the Nasdaq Global Market and (viii) the costs and expenses (including, without
limitation, any damages or other amounts payable in connection with legal or contractual liability)
associated with the reforming of any contracts for sale of the Securities made by the Initial
Purchasers caused by a breach of the representation contained in the first sentence of Section
1(a)(iii). Subject to the provisions of Section 4(b) below, the Initial Purchasers agree to pay,
whether or not the transactions contemplated hereby are consummated or this Agreement is
terminated, all costs and expenses incident to the performance of the obligations of the Initial
Purchasers under this Agreement not payable by the Company pursuant to the preceding sentence,
including, without limitation, the fees and disbursements of counsel for the Initial Purchasers.
16
(b) Termination of Agreement. If this Agreement is terminated by the Representative prior to
the Closing Time in accordance with the provisions of Section 5(a)-(c), Section 5(e)-(k), Section
5(m), Section 10(a)(i) or (iii) or Section 11 hereof, the Company shall reimburse the Initial
Purchasers (except, in the case of a termination in accordance with the provisions of Section 11
hereof, any defaulting Initial Purchaser) for all of their out-of-pocket expenses, including the
reasonable fees and disbursements of counsel for the Initial Purchasers.
SECTION 5. Conditions of Initial Purchasers Obligations. The obligations of the
several Initial Purchasers hereunder are subject to the accuracy of the representations and
warranties of the Company contained herein or in certificates of any officer of the Company or any
of its subsidiaries, to the performance by the Company of its covenants and other obligations
hereunder, and to the following further conditions:
(a) Opinion and Negative Assurance Letter of Counsel for Company. At the Closing Time, the
Representative shall have received an opinion and negative assurance letter, each dated the Closing
Time, of Cooley LLP, counsel for the Company, substantially in the forms attached as Exhibit A-1
and A-2 hereto, respectively.
(b) Opinion of Intellectual Property Counsel for Company. At the Closing Time, the
Representative shall have received an opinion, dated the Closing Time, of K&L Gates LLP,
intellectual property counsel for the Company, substantially in the form attached as Exhibit B
hereto.
(c) Certificate of the General Counsel of the Company. At the Closing Time, the
Representative shall have received a certificate, addressed to the Representative, of the General
Counsel of the Company, dated the Closing Time, substantially in the form attached as Exhibit C
hereto.
(d) Opinion of Counsel for Initial Purchasers. At the Closing Time, the Representative shall
have received the favorable opinion, dated the Closing Time, of Davis Polk & Wardwell LLP, counsel
for the Initial Purchasers, together with signed or reproduced copies of such letter for each of
the other Initial Purchasers in form and substance satisfactory to the Representative. In giving
such opinion such counsel may rely, as to all matters governed by the laws of jurisdictions other
than the law of the State of New York, the General Corporation Law of the State of Delaware and the
federal securities laws of the United States, upon the opinions of counsel satisfactory to the
Representative. Such counsel may also
state that, insofar as such opinion involves factual matters, they have relied, to the extent
they deem proper, upon certificates of officers and other representatives of the Company and its
subsidiaries and certificates of public officials.
(e) Officers Certificate. At the Closing Time, there shall not have been, since the date
hereof or since the respective dates as of which information is given in the General Disclosure
Package or the Final Offering Memorandum, any material adverse change in the condition, financial
or otherwise, or in the earnings, business affairs or business prospects of the Company and its
subsidiaries considered as one enterprise, whether or not arising in the ordinary course of
business, and the Representative shall have received a certificate of the Chief Executive Officer
or the President of the Company and of the chief financial or chief accounting officer of the
Company, dated the Closing Time, to the effect that (i) there has been no such material adverse
change, (ii) the representations and warranties of the Company in this Agreement are true and
correct with the same force and effect as though expressly made at and as of the Closing Time and
(iii) the Company has complied with all agreements and satisfied all conditions on its part to be
performed or satisfied at or prior to the Closing Time.
(f) Accountants Comfort Letter. At the time of the execution of this Agreement, the
Representative shall have received from Deloitte & Touche LLP a letter, dated such date, in form
and
17
substance satisfactory to the Representative, together with signed or reproduced copies of such
letter for each of the other Initial Purchasers containing statements and information of the type
ordinarily included in accountants comfort letters to underwriters with respect to the financial
statements and certain financial information contained in the Offering Memorandum.
(g) Bring-down Comfort Letter. At the Closing Time, the Representative shall have received
from Deloitte & Touche LLP a letter, dated as of the Closing Time, to the effect that they reaffirm
the statements made in the letter furnished pursuant to subsection (f) of this Section, except that
the specified date referred to shall be a date not more than three business days prior to the
Closing Time.
(h) Approval of Listing. At the Closing Time, the Nasdaq Stock Market shall not have rejected
the Companys Application for Listing of Additional Shares covering the Common Stock issuable upon
conversion of the Securities.
(i) Lock-up Agreements. At the date of this Agreement, the Representative shall have received
an agreement substantially in the form of Exhibit D hereto signed by the persons listed on Schedule
D hereto.
(j) Maintenance of Rating. Since the execution of this Agreement, there shall not have been
any decrease in or withdrawal of the rating of any securities of the Company or any of its
subsidiaries by any nationally recognized statistical rating organization (as defined for
purposes of Rule 436(g) under the 1933 Act) or any notice given of any intended or potential
decrease in or withdrawal of any such rating or of a possible change in any such rating that does
not indicate the direction of the possible change.
(k) Transactions. At the Closing Time, the Transactions shall have been consummated on the
terms and conditions described in the General Disclosure Package and the Offering Memorandum.
(l) Conditions to Purchase of Option Securities. In the event that the Initial Purchasers
exercise their option provided in Section 2(b) hereof to purchase all or any portion of the Option
Securities, the representations and warranties of the Company contained herein and the statements
in any certificates furnished by the Company and any of its subsidiaries hereunder shall be true
and correct as of each Date of Delivery and, at the relevant Date of Delivery, the Representative
shall have received:
(i) Officers Certificate. A certificate, dated such Date of Delivery, of the
President or a Vice President of the Company and of the chief financial or chief accounting
officer of the Company confirming that the certificate delivered at the Closing Time
pursuant to Section 5(e) hereof remains true and correct as of such Date of Delivery.
(ii) Opinion and Negative Assurance Letter of Counsel for Company. If
requested by the Representative, an opinion and negative assurance letter of Cooley LLP,
counsel for the Company, together with the favorable opinion of K&L Gates LLP, special
intellectual property counsel for the Company, each dated such Date of Delivery and relating
to the Option Securities to be purchased on such Date of Delivery, and otherwise to the same
effect as the applicable opinion or negative assurance letter required by Section 5(a) or
5(b) hereof, as the case may be.
(iii) Opinion of Counsel for Initial Purchasers. If requested by the
Representative, the favorable opinion of Davis Polk & Wardwell LLP, counsel for the Initial
Purchasers, dated such Date of Delivery, relating to the Option Securities to be purchased
on such Date of Delivery and otherwise to the same effect as the opinion required by Section
5(d) hereof.
18
(iv) Bring-down Comfort Letter. If requested by the Representative, a letter
from Deloitte & Touche LLP, in form and substance satisfactory to the Representative and
dated such Date of Delivery, substantially in the same form and substance as the letter
furnished to the Representative pursuant to Section 5(f) hereof, except that the specified
date in the letter furnished pursuant to this paragraph shall be a date not more than three
business days prior to such Date of Delivery.
(m) Additional Documents. At the Closing Time and at each Date of Delivery (if any), counsel
for the Initial Purchasers shall have been furnished with such documents and opinions as they may
reasonably require for the purpose of enabling them to pass upon the issuance and sale of the
Securities as herein contemplated, or in order to evidence the accuracy of any of the
representations or warranties, or the fulfillment of any of the conditions, herein contained; and
all proceedings taken by the Company in connection with the issuance and sale of the Securities as
herein contemplated shall be satisfactory in form and substance to the Representative and counsel
for the Initial Purchasers.
(n) Termination of Agreement. If any condition specified in this Section shall not have been
fulfilled when and as required to be fulfilled, this Agreement, or, in the case of any condition to
the purchase of Option Securities on a Date of Delivery which is after the Closing Time, the
obligations of the several Initial Purchasers to purchase the relevant Option Securities, may be
terminated by the Representative by notice to the Company at any time at or prior to Closing Time
or such Date of Delivery, as the case may be, and such termination shall be without liability of
any party to any other party except as provided in Section 4 and except that Sections 1, 7, 8, 9,
14, 15 and 16 shall survive any such termination and remain in full force and effect.
SECTION 6. Subsequent Offers and Resales of the Securities.
(a) Offer and Sale Procedures. Each of the Initial Purchasers and the Company hereby
establish and agree to observe the following procedures in connection with the offer and sale of
the Securities:
(i) Offers and Sales. Offers and sales of the Securities shall be made to such
persons and in such manner as is contemplated by the Offering Memorandum. Each Initial
Purchaser severally agrees that it will not offer, sell or deliver any of the Securities in
any jurisdiction outside the United States except under circumstances that will result in
compliance with the applicable laws thereof, and that it will take at its own expense
whatever action is required to
permit its purchase and resale of the Securities in such jurisdictions. The Company
has not entered into any contractual arrangement, other than this Agreement, with respect to
the distribution of the Securities or the Common Stock issuable upon conversion of the
Securities and the Company will not enter into any such arrangement except as contemplated
thereby.
(ii) No General Solicitation. No general solicitation or general advertising
(within the meaning of Rule 502(c) under the 1933 Act Regulations) will be used in the
United States in connection with the offering or sale of the Securities.
(iii) Legends. Each of the Securities will bear, to the extent applicable, the
legend contained in Notice to Investors in the General Disclosure Package and the Final
Offering Memorandum for the time period and upon the other terms stated therein.
(iv) Minimum Principal Amount. No sale of the Securities to any one Subsequent
Purchaser will be for less than U.S. $1,000 principal amount and no Security will be issued
in a smaller principal amount. If the Subsequent Purchaser is a non-bank fiduciary acting
on behalf of
19
others, each person for whom it is acting must purchase at least U.S. $1,000
principal amount of the Securities.
(b) Covenants of the Company. The Company covenants with each Initial Purchaser as follows:
(i) Integration. The Company agrees that it will not and will cause its
Affiliates not to, directly or indirectly, solicit any offer to buy, sell or make any offer
or sale of, or otherwise negotiate in respect of, securities of the Company of any class if,
as a result of the doctrine of integration referred to in Rule 502 under the 1933 Act
Regulations, such offer or sale would render invalid (for the purpose of (i) the sale of the
offered Securities by the Company to the Initial Purchasers, (ii) the resale of the offered
Securities by the Initial Purchasers to Subsequent Purchasers or (iii) the resale of the
offered Securities by such Subsequent Purchasers to others) the exemption from the
registration requirements of the 1933 Act provided by Section 4(2) thereof or by Rule 144A
thereunder or otherwise.
(ii) Rule 144A Information. The Company agrees that, in order to render the
offered Securities eligible for resale pursuant to Rule 144A, while any of the offered
Securities remain outstanding, it will make available, upon request, to any holder of
offered Securities or prospective purchasers of Securities the information specified in Rule
144A(d)(4), unless the Company furnishes information to the Commission pursuant to Section
13 or 15(d) of the 1934 Act.
(iii) Restriction on Repurchases. Until the expiration of one year after the
original issuance of the offered Securities, the Company will not, and will cause its
Affiliates not to, resell any offered Securities which are restricted securities (as such
term is defined under Rule 144(a)(3)), whether as beneficial owner or otherwise (except as
agent acting as a securities broker on behalf of and for the account of customers in the
ordinary course of business in unsolicited brokers transactions).
(c) Representations, Warranties and Agreements of the Initial Purchasers. Each Initial
Purchaser severally and not jointly represents and warrants to, and agrees with, the Company that
it is a Qualified Institutional Buyer and an accredited investor within the meaning of Rule
501(a) under the 1933 Act Regulations. Each Initial Purchaser understands that the offered
Securities have not been and will not be registered under the 1933 Act and may not be offered or
sold within the United States except pursuant to an exemption from, or in a transaction not subject
to, the registration requirements of the
1933 Act. Each Initial Purchaser severally represents and agrees that it has not offered or
sold, and will not offer or sell, any offered Securities constituting part of its allotment within
the United States except in accordance with Rule 144A or another applicable exemption from the
registration requirements of the 1933 Act. Accordingly, neither it nor any person acting on its
behalf has made or will make offers or sales of the Securities in the United States by means of any
form of general solicitation or general advertising (within the meaning of Regulation D) in the
United States. Each Initial Purchaser will take reasonable steps to inform, and cause each of its
affiliates (as such term is defined in Rule 501(b) under the 1933 Act Regulations (each, an
Affiliate)) to take reasonable steps to inform, persons acquiring Securities from such Initial
Purchaser or Affiliate, as the case may be, in the United States that the Securities (A) have not
been and will not be registered under the 1933 Act, (B) are being sold to them without registration
under the 1933 Act in reliance on Rule 144A or in accordance with another exemption from
registration under the 1933 Act, as the case may be, and (C) may not be offered, sold or otherwise
transferred except (1) to the Company, (2) outside the United States in accordance with Regulation
S or (3) inside the United States in accordance with (x) Rule 144A to a person whom the seller
reasonably believes is a Qualified Institutional Buyer that is purchasing such Securities for its
own account or for the account of a Qualified Institutional Buyer to whom notice is given that the
offer, sale
20
or transfer is being made in reliance on Rule 144A or (y) pursuant to another available
exemption from registration under the 1933 Act.
SECTION 7. Indemnification.
(a) Indemnification of Initial Purchasers. The Company agrees to indemnify and hold harmless
each Initial Purchaser, its Affiliates, its selling agents and each person, if any, who controls
any Initial Purchaser within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934
Act as follows:
(i) against any and all loss, liability, claim, damage and expense whatsoever, as
incurred, arising out of any untrue statement or alleged untrue statement of a material fact
included in any Preliminary Offering Memorandum, the Final Offering Memorandum, the
information contained in the Final Term Sheet, any Issuer Written Information or any other
information used by or on behalf of the Company in connection with the offer or sale of the
Securities (or any amendment or supplement to the foregoing) or the omission or alleged
omission therefrom of a material fact necessary in order to make the statements therein, in
the light of the circumstances under which they were made, not misleading;
(ii) against any and all loss, liability, claim, damage and expense whatsoever, as
incurred, to the extent of the aggregate amount paid in settlement of any litigation, or any
investigation or proceeding by any governmental agency or body, commenced or threatened, or
of any claim whatsoever based upon any such untrue statement or omission, or any such
alleged untrue statement or omission; provided that (subject to Section 7(d) below) any such
settlement is effected with the written consent of the Company;
(iii) against any and all expense whatsoever, as incurred (including the fees and
disbursements of counsel chosen by Merrill Lynch), reasonably incurred in investigating,
preparing or defending against any litigation, or any investigation or proceeding by any
governmental agency or body, commenced or threatened, or any claim whatsoever based upon any
such untrue statement or omission, or any such alleged untrue statement or omission, to the
extent that any such expense is not paid under (i) or (ii) above;
provided, however, that this indemnity agreement shall not apply to any loss, liability, claim,
damage or expense to the extent arising out of any untrue statement or omission or alleged untrue
statement or omission made in any Preliminary Offering Memorandum, the Final Offering Memorandum (or any
amendment or supplement to the foregoing) in reliance upon and in conformity with the Initial
Purchaser Information.
(b) Indemnification of Company, Directors and Officers. Each Initial Purchaser severally
agrees to indemnify and hold harmless the Company, its directors, its officers and each person, if
any, who controls the Company within the meaning of Section 15 of the 1933 Act or Section 20 of the
1934 Act, against any and all loss, liability, claim, damage and expense described in the indemnity
contained in subsection (a) of this Section, as incurred, but only with respect to untrue
statements or omissions, or alleged untrue statements or omissions, made in any Preliminary
Offering Memorandum, the Final Offering Memorandum (or any amendment or supplement to the
foregoing) in reliance upon and in conformity with the Initial Purchaser Information.
(c) Actions against Parties; Notification. Each indemnified party shall give notice as
promptly as reasonably practicable to each indemnifying party of any action commenced against it in
respect of which indemnity may be sought hereunder, but failure to so notify an indemnifying party
shall
21
not relieve such indemnifying party from any liability hereunder to the extent it is not
materially prejudiced as a result thereof and in any event shall not relieve it from any liability
which it may have otherwise than on account of this indemnity agreement. In the case of parties
indemnified pursuant to Section 7(a) above, counsel to the indemnified parties shall be selected by
Merrill Lynch, and, in the case of parties indemnified pursuant to Section 7(b) above, counsel to
the indemnified parties shall be selected by the Company. An indemnifying party may participate at
its own expense in the defense of any such action; provided, however, that counsel to the
indemnifying party shall not (except with the consent of the indemnified party) also be counsel to
the indemnified party. In no event shall the indemnifying parties be liable for fees and expenses
of more than one counsel (in addition to any local counsel) separate from their own counsel for all
indemnified parties in connection with any one action or separate but similar or related actions in
the same jurisdiction arising out of the same general allegations or circumstances. No
indemnifying party shall, without the prior written consent of the indemnified parties, settle or
compromise or consent to the entry of any judgment with respect to any litigation, or any
investigation or proceeding by any governmental agency or body, commenced or threatened, or any
claim whatsoever in respect of which indemnification or contribution could be sought under this
Section 7 or Section 8 hereof (whether or not the indemnified parties are actual or potential
parties thereto), unless such settlement, compromise or consent (i) includes an unconditional
release of each indemnified party from all liability arising out of such litigation, investigation,
proceeding or claim and (ii) does not include a statement as to or an admission of fault,
culpability or a failure to act by or on behalf of any indemnified party.
(d) Settlement without Consent if Failure to Reimburse. If at any time an indemnified party
shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses
of counsel, such indemnifying party agrees that it shall be liable for any settlement of the nature
contemplated by Section 7(a)(ii) effected without its written consent if (i) such settlement is
entered into more than 45 days after receipt by such indemnifying party of the aforesaid request,
(ii) such indemnifying party shall have received notice of the terms of such settlement at least 30
days prior to such settlement being entered into and (iii) such indemnifying party shall not have
reimbursed such indemnified party in accordance with such request prior to the date of such
settlement.
SECTION 8. Contribution. If the indemnification provided for in Section 7 hereof is
for any reason unavailable to or insufficient to hold harmless an indemnified party in respect of
any losses, liabilities, claims, damages or expenses referred to therein, then each indemnifying
party shall contribute to the aggregate amount of such losses, liabilities, claims, damages and
expenses incurred by such indemnified party, as incurred, (i) in such proportion as is appropriate
to reflect the relative benefits received by the Company, on the one hand, and the Initial
Purchasers, on the other hand, from the
offering of the Securities pursuant to this Agreement or (ii) if the allocation provided by
clause (i) is not permitted by applicable law, in such proportion as is appropriate to reflect not
only the relative benefits referred to in clause (i) above but also the relative fault of the
Company, on the one hand, and of the Initial Purchasers, on the other hand, in connection with the
statements or omissions which resulted in such losses, liabilities, claims, damages or expenses, as
well as any other relevant equitable considerations.
The relative benefits received by the Company, on the one hand, and the Initial Purchasers, on
the other hand, in connection with the offering of the Securities pursuant to this Agreement shall
be deemed to be in the same respective proportions as the total net proceeds from the offering of
the Securities pursuant to this Agreement (before deducting expenses) received by the Company, on
the one hand, and the total discount received by the Initial Purchasers, on the other hand, bear to
the aggregate initial offering price of the Securities as set forth on the cover of the Final
Offering Memorandum.
The relative fault of the Company, on the one hand, and the Initial Purchasers, on the other
hand, shall be determined by reference to, among other things, whether any such untrue or alleged
untrue
22
statement of a material fact or omission or alleged omission to state a material fact
relates to information supplied by the Company or by the Initial Purchasers and the parties
relative intent, knowledge, access to information and opportunity to correct or prevent such
statement or omission.
The Company and the Initial Purchasers agree that it would not be just and equitable if
contribution pursuant to this Section 8 were determined by pro rata allocation (even if the Initial
Purchasers were treated as one entity for such purpose) or by any other method of allocation which
does not take account of the equitable considerations referred to above in this Section 8. The
aggregate amount of losses, liabilities, claims, damages and expenses incurred by an indemnified
party and referred to above in this Section 8 shall be deemed to include any legal or other
expenses reasonably incurred by such indemnified party in investigating, preparing or defending
against any litigation, or any investigation or proceeding by any governmental agency or body,
commenced or threatened, or any claim whatsoever based upon any such untrue or alleged untrue
statement or omission or alleged omission.
Notwithstanding the provisions of this Section 8, no Initial Purchaser shall be required to
contribute any amount in excess of the purchase discount or commissions received by such Initial
Purchasers in connection with the Securities purchased by it and distributed to the public.
No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the
1933 Act) shall be entitled to contribution from any person who was not guilty of such fraudulent
misrepresentation.
For purposes of this Section 8, each person, if any, who controls an Initial Purchaser within
the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act and each Initial
Purchasers Affiliates and selling agents shall have the same rights to contribution as such
Initial Purchaser, and each director of the Company, each officer of the Company, and each person,
if any, who controls the Company within the meaning of Section 15 of the 1933 Act or Section 20 of
the 1934 Act shall have the same rights to contribution as the Company. The Initial Purchasers
respective obligations to contribute pursuant to this Section 8 are several in proportion to the
aggregate principal amount of Initial Securities set forth opposite their respective names in
Schedule A hereto and not joint.
SECTION 9. Representations, Warranties and Agreements to Survive. All
representations, warranties and agreements contained in this Agreement or in certificates of
officers of the Company or any of its subsidiaries submitted pursuant hereto, shall remain
operative and in full force and effect regardless of (i) any investigation made by or on behalf of
any Initial Purchaser or its Affiliates or selling
agents, any person controlling any Initial Purchaser, its officers or directors or any person
controlling the Company and (ii) delivery of and payment for the Securities.
SECTION 10. Termination of Agreement.
(a) Termination. The Representative may terminate this Agreement, by notice to the Company,
at any time at or prior to the Closing Time (i) if there has been, in the judgment of the
Representative, since the time of execution of this Agreement or since the respective dates as of
which information is given in the General Disclosure Package or the Final Offering Memorandum, any
material adverse change in the condition, financial or otherwise, or in the earnings, business
affairs or business prospects of the Company and its subsidiaries considered as one enterprise,
whether or not arising in the ordinary course of business, or (ii) if there has occurred any
material adverse change in the financial markets in the United States or the international
financial markets, any outbreak of hostilities or escalation thereof or other calamity or crisis or
any change or development involving a prospective change in national or international political,
financial or economic conditions, in each case the effect of which is such as to make it, in the
judgment of the Representative, impracticable or inadvisable to
23
proceed with the completion of the
offering or to enforce contracts for the sale of the Securities, or (iii) if trading in any
securities of the Company has been suspended or materially limited by the Commission or the Nasdaq
Global Market, or (iv) if trading generally on the New York Stock Exchange or in the Nasdaq Global
Market has been suspended or materially limited, or minimum or maximum prices for trading have been
fixed, or maximum ranges for prices have been required, by any of said exchanges or by order of the
Commission, FINRA or any other governmental authority, or (v) a material disruption has occurred in
commercial banking or securities settlement or clearance services in the United States, or (vi) if
a banking moratorium has been declared by either Federal or New York authorities.
(b) Liabilities. If this Agreement is terminated pursuant to this Section, such termination
shall be without liability of any party to any other party except as provided in Section 4 hereof,
and provided further that Sections 1, 7, 8, 9, 14, 15 and 16 shall survive such termination and
remain in full force and effect.
SECTION 11. Default by One or More of the Initial Purchasers. If one or more of the
Initial Purchasers shall fail at the Closing Time or a Date of Delivery to purchase the Securities
which it or they are obligated to purchase under this Agreement (the Defaulted Securities), the
Representative shall have the right, within 24 hours thereafter, to make arrangements for one or
more of the non-defaulting Initial Purchasers, or any other initial purchasers, to purchase all,
but not less than all, of the Defaulted Securities in such amounts as may be agreed upon and upon
the terms herein set forth; if, however, the Representative shall not have completed such
arrangements within such 24-hour period, then:
(i) if the amount of Defaulted Securities does not exceed 10% of the aggregate
principal amount of the Securities to be purchased on such date, each of the non-defaulting
Initial Purchasers shall be obligated, severally and not jointly, to purchase the full
amount thereof in the proportions that their respective obligations hereunder bear to the
obligations of all non-defaulting Initial Purchasers, or
(ii) if the amount of Defaulted Securities exceeds 10% of the aggregate principal
amount of the Securities to be purchased on such date, this Agreement or, with respect to
any Date of Delivery which occurs after the Closing Time, the obligation of the Initial
Purchasers to purchase, and the Company to sell, the Option Securities to be purchased and
sold on such Date of Delivery, shall terminate without liability on the part of any
non-defaulting Initial Purchaser.
No action taken pursuant to this Section shall relieve any defaulting Initial Purchaser from
liability in respect of its default.
In the event of any such default which does not result in a termination of this Agreement or,
in the case of a Date of Delivery which is after the Closing Time, which does not result in a
termination of the obligation of the Initial Purchasers to purchase and the Company to sell the
relevant Option Securities, as the case may be, either the (i) Representative or (ii) the Company
shall have the right to postpone Closing Time or the relevant Date of Delivery, as the case may be,
for a period not exceeding seven days in order to effect any required changes in the General
Disclosure Package or the Final Offering Memorandum or in any other documents or arrangements. As
used herein, the term Initial Purchaser includes any person substituted for an Initial Purchaser
under this Section 11.
SECTION 12. Notices. All notices and other communications hereunder shall be in
writing and shall be deemed to have been duly given if mailed or transmitted by any standard form
of telecommunication. Notices to the Initial Purchasers shall be directed to Merrill Lynch at One
Bryant Park, New York, New York 10036, attention of Syndicate Department, with a copy to ECM Legal;
notices to the Company shall be directed to it at 28903 North Avenue Paine, Valencia, California
91355
24
(fax: (661) 755-2086), attention of David Thomson, with a copy to Cooley LLP, 4401 Eastgate
Mall, San Diego, California 92121 (fax: (858) 550-6420), attention of D. Bradley Peck.
SECTION 13. No Advisory or Fiduciary Relationship. The Company acknowledges and
agrees that (a) the purchase and sale of the Securities pursuant to this Agreement, including the
determination of the initial offering price of the Securities and any related discounts and
commissions, is an arms-length commercial transaction between the Company, on the one hand, and
the several Initial Purchasers, on the other hand, (b) in connection with the offering of the
Securities and the process leading thereto, each Initial Purchaser is and has been acting solely as
a principal and is not the agent or fiduciary of the Company, any of its subsidiaries or their
respective stockholders, creditors, employees or any other party, (c) no Initial Purchaser has
assumed or will assume an advisory or fiduciary responsibility in favor of the Company with respect
to the offering of the Securities or the process leading thereto (irrespective of whether such
Initial Purchaser has advised or is currently advising the Company or any of its subsidiaries on
other matters) and no Initial Purchaser has any obligation to the Company with respect to the
offering of the Securities except the obligations expressly set forth in this Agreement, (d) the
Initial Purchasers and their respective affiliates may be engaged in a broad range of transactions
that involve interests that differ from those of the Company and (e) the Initial Purchasers have
not provided any legal, accounting, regulatory or tax advice with respect to the offering of the
Securities and the Company has consulted its own respective legal, accounting, regulatory and tax
advisors to the extent it deemed appropriate.
SECTION 14. Parties. This Agreement shall each inure to the benefit of and be binding
upon the Initial Purchasers and the Company and their respective successors. Nothing expressed or
mentioned in this Agreement is intended or shall be construed to give any person, firm or
corporation, other than the Initial Purchasers and the Company and their respective successors and
the controlling persons and officers and directors referred to in Sections 7 and 8 and their heirs
and legal representatives, any legal or equitable right, remedy or claim under or in respect of
this Agreement or any provision herein contained. This Agreement and all conditions and provisions
hereof are intended to be for the sole and exclusive benefit of the Initial Purchasers and the
Company and their respective successors, and said controlling persons and officers and directors
and their heirs and legal representatives, and for the benefit of no other person, firm or
corporation. No purchaser of Securities from any Initial Purchaser shall be deemed to be a
successor by reason merely of such purchase.
SECTION 15. Trial by Jury. The Company (on its behalf and, to the extent permitted by
applicable law, on behalf of its stockholders and affiliates) and each of the Initial Purchasers
hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to
trial by jury in any legal proceeding arising out of or relating to this Agreement or the
transactions contemplated hereby.
SECTION 16. GOVERNING LAW. THIS AGREEMENT AND ANY CLAIM, CONTROVERSY OR DISPUTE
ARISING UNDER OR RELATED TO THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH
THE LAWS OF, THE STATE OF NEW YORK WITHOUT REGARD TO ITS CHOICE OF LAW PROVISIONS.
SECTION 17. TIME. TIME SHALL BE OF THE ESSENCE OF THIS AGREEMENT. EXCEPT AS OTHERWISE
SET FORTH HEREIN, SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME.
SECTION 18. Partial Unenforceability. The invalidity or unenforceability of any
Section, paragraph or provision of this Agreement shall not affect the validity or enforceability
of any other Section, paragraph or provision hereof. If any Section, paragraph or provision of
this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed
to be made such minor changes (and only such minor changes) as are necessary to make it valid and
enforceable.
25
SECTION 19. Counterparts. This Agreement may be executed in any number of
counterparts, each of which shall be deemed to be an original, but all such counterparts shall
together constitute one and the same Agreement.
SECTION 20. Effect of Headings. The Section headings herein are for convenience only
and shall not affect the construction hereof.
SECTION 21. Entire Agreement. This Agreement, together with the schedules and
exhibits hereto, contains the entire understanding of the parties with respect to the subject
matter hereof and supersedes all prior agreements and understandings, oral or written, with regard
to such matters.
[Signature page follows]
26
If the foregoing is in accordance with your understanding of our agreement, please sign and return
to the Company a counterpart hereof, whereupon this instrument, along with all counterparts, will
become a binding agreement among the Initial Purchasers and the Company in accordance with its
terms.
|
|
|
|
|
|
Very truly yours,
MANNKIND CORPORATION
|
|
|
By |
/s/ Matthew J. Pfeffer
|
|
|
|
Title: Chief Financial Officer |
|
|
|
|
|
|
|
|
CONFIRMED AND ACCEPTED,
as of the date first above written:
|
|
MERRILL LYNCH, PIERCE, FENNER & SMITH
INCORPORATED
|
|
By |
/s/ Benjamin Perkins
|
|
|
Authorized Signatory |
|
|
|
|
|
For itself and as Representative of the other Initial Purchasers named in Schedule A hereto.
SCHEDULE A
The initial offering price of the Securities shall be 100% of the principal amount thereof, plus
accrued interest, if any, from the date of issuance.
The purchase price to be paid by the Initial Purchasers for the Securities shall be 96.7% of the
principal amount thereof.
The interest rate on the Securities shall be 5.75% per annum.
|
|
|
|
|
|
|
Principal |
|
|
|
Amount of |
|
Name of Initial Purchaser |
|
Securities |
|
Merrill Lynch, Pierce, Fenner & Smith
Incorporated |
|
$ |
64,000,000 |
|
Wells Fargo Securities, LLC |
|
|
17,000,000 |
|
Rodman & Renshaw, LLC |
|
|
12,500,000 |
|
Imperial Capital, LLC |
|
|
6,500,000 |
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
100,000,000 |
|
|
|
|
|
Sch A-1
SCHEDULE B
Final Term Sheet
Dated August 18, 2010
MannKind Corporation
5.75% Senior Convertible Notes due 2015
The information in this pricing term sheet supplements MannKind Corporations preliminary
offering memorandum, dated August 16, 2010 (the Preliminary Offering Memorandum), and supersedes
the information in the Preliminary Offering Memorandum to the extent inconsistent with the
information in the Preliminary Offering Memorandum. In all other respects, this term sheet is
qualified in its entirety by reference to the Preliminary Offering Memorandum. Terms used herein
but not defined herein shall have the respective meanings as set forth in the Preliminary Offering
Memorandum. All references to dollar amounts are references to U.S. dollars. Unless the context
otherwise requires, references to MannKind or the company, we, us, and our in this
pricing term sheet mean MannKind Corporation and not its subsidiaries.
|
|
|
Issuer: |
|
MannKind Corporation (Nasdaq: MNKD) (the Issuer) |
|
|
|
Title of securities: |
|
5.75% Senior Convertible Notes due 2015 (the notes) |
|
|
|
Aggregate principal amount offered: |
|
$100,000,000 aggregate principal amount of notes |
|
|
|
Over-allotment option: |
|
$10,000,000 |
|
|
|
Use of proceeds: |
|
We estimate that the net proceeds to us from this offering |
|
|
will be approximately $95.5 million (or approximately |
|
|
$105.2 million if the initial purchasers exercise their |
|
|
over-allotment option in full), after deducting the |
|
|
discount to the initial purchasers and our estimated |
|
|
offering expenses payable by us. We intend to use the net |
|
|
proceeds from this offering to fund the costs of our |
|
|
clinical trials programs and other research and development |
|
|
activities, to expand our manufacturing operations, both |
|
|
on-going and planned, and for general corporate purposes, |
|
|
including working capital. |
|
|
|
Maturity date: |
|
August 15, 2015 |
|
|
|
Interest rate: |
|
5.75% per annum, accruing from the settlement date |
|
|
|
Issue price: |
|
100% |
|
|
|
Interest payment dates: |
|
Each February 15 and August 15, beginning on February 15, 2011 |
|
|
|
Initial conversion rate: |
|
147.0859 common shares per $1,000 principal amount of notes |
|
|
|
Nasdaq consolidated closing bid price on |
|
$5.97 |
August 18, 2010: |
|
|
|
|
|
Conversion premium: |
|
22.5% above the concurrent offering price (as defined below) |
|
|
|
Initial conversion price: |
|
Approximately $6.80 per common share of the Issuer |
|
|
|
Initial purchasers: |
|
Sole book-running manager: BofA Merrill Lynch |
|
|
Lead manager: Wells Fargo Securities, LLC |
Sch B-1
|
|
|
|
|
Co-managers: Rodman & Renshaw, LLC and Imperial Capital, LLC |
|
|
|
Trade date:
|
|
August 18, 2010 |
|
|
|
Settlement date:
|
|
August 24, 2010 |
|
|
|
CUSIP/ISIN:
|
|
Restricted CUSIP Number: 56400PAB8 |
|
|
Restricted ISIN Number: US56400PAB85 |
|
|
|
Concurrent offering and share
lending
agreement
|
|
Concurrently with this offering of the notes, we are
offering, in a transaction registered under the Securities
Act, and by means of a separate prospectus and prospectus
supplement, 9,000,000 shares of our common stock at an
offering price of $5.55 (the concurrent offering price),
all of which are being borrowed by Bank of America, N.A.,
or BANA, an affiliate of Merrill Lynch, Pierce, Fenner &
Smith Incorporated, the underwriter in the common stock
offering, pursuant to a share lending agreement between us
and BANA. BANA, or its affiliate, will receive all of the
proceeds from the common stock offering. We will not
receive any proceeds of that offering, but will receive a
nominal one-time lending fee for each share we loan. |
|
|
|
|
|
The delivery of shares of our common stock under the share
lending agreement is contingent upon the closing of this
offering, and the closing of this offering is contingent
upon the delivery of the shares to be lent to BANA pursuant
to the share lending agreement. We expect that delivery of
our common stock will be made on or about the closing date
of the notes offered hereby. |
|
|
|
Adjustment to conversion rate upon
a make-whole fundamental change:
|
|
The following table shows what the fundamental change
make-whole premium would be for each hypothetical stock
price and effective date set forth below, expressed as
additional shares of common stock per $1,000 principal
amount of notes: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock Price |
|
|
|
$5.97 |
|
|
$6.50 |
|
|
$7.00 |
|
|
$8.00 |
|
|
$10.00 |
|
|
$15.00 |
|
|
$20.00 |
|
|
$25.00 |
|
|
$30.00 |
|
|
$50.00 |
|
August 24, 2010 |
|
|
20.4182 |
|
|
|
20.4182 |
|
|
|
20.4182 |
|
|
|
20.4182 |
|
|
|
18.3976 |
|
|
|
12.2848 |
|
|
|
9.2714 |
|
|
|
7.3218 |
|
|
|
6.1493 |
|
|
|
3.7299 |
|
August 15, 2011 |
|
|
20.4182 |
|
|
|
20.4182 |
|
|
|
20.4182 |
|
|
|
19.8839 |
|
|
|
15.8641 |
|
|
|
10.6240 |
|
|
|
7.9606 |
|
|
|
6.4456 |
|
|
|
5.2813 |
|
|
|
3.1875 |
|
August 15, 2012 |
|
|
20.4182 |
|
|
|
19.7954 |
|
|
|
18.4232 |
|
|
|
16.1445 |
|
|
|
12.9562 |
|
|
|
8.6237 |
|
|
|
6.4758 |
|
|
|
5.1902 |
|
|
|
4.3654 |
|
|
|
2.6155 |
|
August 15, 2013 |
|
|
20.4182 |
|
|
|
14.3658 |
|
|
|
13.3212 |
|
|
|
11.6771 |
|
|
|
9.3477 |
|
|
|
6.2018 |
|
|
|
4.6676 |
|
|
|
3.7430 |
|
|
|
3.1215 |
|
|
|
1.8779 |
|
August 15, 2014 |
|
|
20.4182 |
|
|
|
7.7914 |
|
|
|
7.2466 |
|
|
|
6.2954 |
|
|
|
5.0676 |
|
|
|
3.3901 |
|
|
|
2.5466 |
|
|
|
2.0406 |
|
|
|
1.7032 |
|
|
|
1.0287 |
|
August 15, 2015 |
|
|
20.4182 |
|
|
|
6.7603 |
|
|
|
0.0000 |
|
|
|
0.0000 |
|
|
|
0.0000 |
|
|
|
0.0000 |
|
|
|
0.0000 |
|
|
|
0.0000 |
|
|
|
0.0000 |
|
|
|
0.0000 |
|
The actual stock price and effective date may not be set forth on the table, in which case:
|
|
|
if the actual stock price on the effective date is between two stock prices on the table
or the actual effective date is between two effective dates on the table, the fundamental
change make-whole premium will be determined by a straight-line interpolation between the
fundamental change make-whole premiums set forth for the two stock prices and the two
effective dates on the table based on a 365-day year, as applicable; |
Sch B-2
|
|
|
if the stock price on the effective date exceeds $50.00 per share, subject to adjustment
as described below, no fundamental change make-whole premium will be paid; and |
|
|
|
|
if the stock price on the effective date is less than $5.97 per share, subject to
adjustment as described below, no fundamental change make-whole premium will be paid. |
Notwithstanding the foregoing, in no event will the conversion rate exceed 167.5041 per $1,000
principal amount of notes, subject to adjustments in the same manner as the conversion rate.
General
This communication is intended for the sole use of the person to whom it is provided by the sender.
This material is confidential and is for your information only and is not intended to be used by
anyone other than you. This information does not purport to be a complete description of the notes
or the offering.
This communication does not constitute an offer to sell or the solicitation of an offer to buy any
notes in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation
in such jurisdiction.
The offer and sale of the notes and the common stock issuable upon conversion thereof have not been
registered, and will not be registered, under the Securities Act, and the notes may not be offered
or sold within the United States or to, or for the account or benefit of, U.S. persons except
pursuant to an exemption from, or in a transaction not subject to, the registration requirements of
the Securities Act. Accordingly, the notes are being offered and sold only to qualified
institutional buyers (as defined in Rule 144A under the Securities Act).
ANY DISCLAIMERS OR OTHER NOTICES THAT MAY APPEAR BELOW ARE NOT APPLICABLE TO THIS COMMUNICATION AND
SHOULD BE DISREGARDED. SUCH DISCLAIMERS OR OTHER NOTICES WERE AUTOMATICALLY GENERATED AS A RESULT
OF THIS COMMUNICATION BEING SENT VIA BLOOMBERG OR ANOTHER EMAIL SYSTEM.
Sch B-3
SCHEDULE C
Issuer Written Information
Final Term Sheet in the form set forth on Schedule B
Sch C-1
SCHEDULE D
List of Persons Subject to Lock-up
Alfred E. Mann
Hakan S. Edstrom
Matthew J. Pfeffer
Juergen A. Martens, Ph.D.
Diane M. Palumbo
Dr. Peter C. Richardson
David Thomson, Ph.D., J.D.
Abraham E. Cohen
Ronald Consiglio
Michael Friedman
Kent Kresa
David H. MacCallum
Henry L. Nordhoff
James S. Shannon
Sch D-1
exv99w2
EXHIBIT
99.2
EXECUTION VERSION
SHARE LENDING AGREEMENT
Dated as of August 18, 2010
Among
MANNKIND CORPORATION (Lender),
and
BANK OF AMERICA, N.A. (Borrower).
This Share Lending Agreement (this Agreement) sets forth the terms and conditions under
which Borrower may borrow from Lender shares of Lenders Common Stock.
The parties hereto agree as follows:
Section 1. Certain Definitions. The following capitalized terms shall have the following
meanings:
Borrowing Notice means a written notice from Borrower to Lender specifying the number of
Loaned Shares (not to exceed the Maximum Number of Shares) and the date and time for the
commencement of the Loan, which time and date shall not be earlier than 9:00 a.m. New York City on
the second Business Day following receipt by Lender of the Borrowing Notice, and shall not be later
than 9:00 a.m. on the Closing Date.
Business Day means a day on which (i) regular trading occurs in the principal trading market
for the Common Stock and (ii) the Clearing Organization is open.
Cash means any coin or currency of the United States as at the time shall be legal tender
for payment of public and private debts.
Clearing Organization means The Depository Trust Company, or, if agreed to by Borrower and
Lender, a Securities Intermediary at which Borrower and Lender both maintain accounts.
Closing Date means the closing date of the initial issuance of the Convertible Notes.
Common Stock means shares of Common Stock, par value $0.01 per share, of Lender; provided
that, if the Common Stock shall be exchanged or converted into any stock, other securities or other
property or assets or any
combination thereof (excluding cash) (the Reference Property) as the result of (a) any
recapitalization, reclassification or change of the Common Stock (other than changes resulting from
a subdivision or combination of the Common Stock), (b) any consolidation, merger or combination
involving Lender, (c) any sale, conveyance or lease to another corporation of all or substantially
all of Lenders property and assets or (d) any statutory share exchange (any of clauses (a), (b),
(c) or (d), a Merger Event), then, effective upon the effectiveness of such transaction, one
share of Common Stock shall be deemed to be the amount and type of such Reference Property received
in exchange for or upon conversion of one share of Common Stock (including any share as
reclassified). For purposes of the foregoing, where a share of Common Stock may be converted or
exchanged into more than a single type of Reference Property based upon any form of stockholder
election, such consideration will be deemed to be the weighted average of the types and amounts of
Reference Property received by the holders of the Common Stock that affirmatively make such an
election.
Convertible Notes means the $100,000,000 aggregate principal amount of 5.75% Senior
Convertible Notes due 2015 issued by Lender, or up to $115,000,000 aggregate principal amount to
the extent the option to purchase additional Convertible Notes is exercised in full as set forth in
the underwriting agreement relating to the Convertible Notes.
Disrupted Day means any Business Day on which any of the following occurs: (i) any
suspension of or limitation imposed on trading relating to the Common Stock or futures or options
contracts relating to the Common Stock by the principal U.S. exchange on which the Common Stock is
traded, or any exchange or quotation system where trading has a material effect on the overall
market for such futures or options contracts, (ii) any event that disrupts or impairs (as
determined by Borrower in its commercially reasonable judgment) the ability of market participants
in general to effect transactions in or obtain market values for the Common Stock or any such
futures or options contracts, or (iii) the closure on any Business Day of any such exchange or
quotation system prior to its scheduled closing time.
Exchange Act means the Securities Exchange Act of 1934, as amended.
Lenders Designated Account means the securities account of Lender maintained on the books
of Borrower, as Securities Intermediary (account number 6ZJ-10064), established simultaneously with
the execution of this Agreement.
Loaned Shares means shares of Common Stock initially transferred to Borrower pursuant to
Section 2; provided that upon the termination of any portion of the Loan, the number of Loaned
Shares shall be reduced by the number of Loaned Shares transferred by Borrower to Lender; provided
further that in respect of any such share of Common Stock initially transferred to Borrower by
Lender and subsequently transferred by Borrower to another transferee, Loaned Shares means an
equivalent number of shares of identical Common Stock. If, as a result
2
of a stock split (excluding, for the avoidance of doubt, any share dividend) or reverse stock
split, the number of outstanding shares of Common Stock is increased or decreased, then the number
of Loaned Shares shall be proportionately increased or decreased, as the case may be. If, pursuant
to the definition of Common Stock, a share of Common Stock is deemed to be stock, other securities
or other property or assets as specified therein, then each Loaned Share shall correspondingly
change to include Reference Property. For purposes of return of Loaned Shares by Borrower pursuant
to Section 4 or purchase or sale of securities pursuant to Section 10, such term shall mean
securities of the same issuer, class and quantity as the Loaned Shares as adjusted pursuant to the
two preceding sentences.
Maximum Number of Shares means 9,000,000 shares of Common Stock.
Relevant Price on any Business Day means, with respect to the Common Stock, the dollar
volume weighted average price per share of Common Stock for such Business Day based on transactions
executed during such Business Day, as reported on Bloomberg Screen MNKD.UQ <Equity> VAP
<Go>. (or any successor thereto); or, in the event such price is not so reported on such
Business Day for any reason, as reasonably determined by the Borrower.
Securities Act means the Securities Act of 1933, as amended.
Securities Intermediary means a securities intermediary as defined by Section 8-102(a)(14)
of the UCC.
UCC means the Uniform Commercial Code, as in effect in the State of New York, as in effect
from time to time. Any reference to particular sections of the UCC shall be deemed to embrace
successor renumbered provisions thereof.
Section 2. Loan of Shares; Transfers of Loaned Shares.
(a) Subject to the terms and conditions of this Agreement, Lender hereby agrees to make
available for borrowing by Borrower, on or prior to the closing date of the initial issuance of
Convertible Notes (the Closing Date), a number of shares of Common Stock up to the Maximum Number
of Shares.
(b) Subject to the terms and conditions of this Agreement, Borrower may by delivery of a
Borrowing Notice to Lender on or prior to the Closing Date, seek to initiate a transaction in which
Lender will lend shares of Common Stock to Borrower through the issuance by Lender of such Loaned
Shares to Borrower upon the terms, and subject to the conditions, set forth in this Agreement (such
issuance and loan, the Loan). The Loan shall be confirmed by a schedule and receipt listing the
Loaned Shares provided by Lender to Borrower (the Confirmation). Such Confirmation shall
constitute conclusive evidence with
3
respect to the Loan, including the number of shares of Common Stock that are the subject of
the Loan.
(c) Notwithstanding anything to the contrary in this Agreement, Borrower shall not be
permitted to borrow or have any right to take delivery of, or otherwise receive or be deemed to
have received, any shares of Common Stock hereunder to the extent (but only to the extent) that
after such receipt of such Common Stock (i) the beneficial ownership (within the meaning of
Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder) of Common
Stock by Borrower or any affiliate of Borrower or other person subject to aggregation with Borrower
under such Section 13(d) and such rules (Borrower and any such affiliate or other person,
collectively, Borrower Group) would exceed 4.5%, as determined by Borrower in its sole
discretion, (ii) Borrower would be subject to Section 16(b) of the Exchange Act, (iii) Borrower or
any affiliate or associate of Borrower would be an interested stockholder of Lender, as all
such terms are defined in Section 203 of the Delaware General Corporation Law or (iv) Borrower,
Borrower Group (as defined below) or any person whose ownership position would be aggregated with
Borrower or Borrower Group (Borrower, Borrower Group or any such person, a Borrower Person) under
any federal, state or local laws, regulations or regulatory orders applicable to ownership of
Common Stock (Applicable Laws), owns, beneficially owns, constructively owns, holds the power to
vote or otherwise meets a relevant definition of ownership in excess of a number of shares of
Common Stock equal to (a) the number of shares of Common Stock that would give rise to a reporting
or registration obligation or other requirement (including obtaining prior approval by a state or
federal regulator) of a Borrower Person under Applicable Laws, and with respect to which such
requirements have not been met or the relevant approval has not been received or that would give
rise to any consequences under the constitutive documents of Lender or any contract or agreement to
which Lender is a party, in each case minus (b) 1% of the number of shares of Common Stock
outstanding on the date of determination, in each case as determined by Borrower in its sole
discretion (each of clauses (i) to (iv) above, an Ownership Limitation), and if the Loan breaches
any Ownership Limitation, the Loan shall be void and have no effect to the extent (but only to the
extent) of such breach. If any delivery owed to Borrower hereunder is not made, in whole or in
part, as a result of an Ownership Limitation, Lenders obligation to make such delivery shall not
be extinguished and Lender shall make such delivery as promptly as practicable after, but in no
event later than one Business Day after, Borrower gives notice to Lender that such delivery would
not result in any Ownership Limitation being breached. If, notwithstanding the foregoing, any
delivery of Common Stock is erroneously made to Borrower or Borrower otherwise receives or is
deemed to have received Common Stock in excess of the foregoing limitation contrary to the first
sentence of this clause (c), such Common Stock shall remain the property of Lender and Borrower
shall be deemed to hold the same as bailee of Lender and shall have no voting, dispositive control
or pecuniary interest with respect thereto.
4
(d) Lender shall transfer to Borrower a number of shares of Common Stock equal to the number
of Loaned Shares specified in the Borrowing Notice on or before the time and date specified in the
Borrowing Notice for the commencement of the Loan in the manner set forth under Section 11 below.
Section 3. Loan Fee. Borrower agrees to pay Lender a single loan fee per Loan (a Loan Fee)
equal to $0.01 per Loaned Share. The Loan Fee shall be paid by Borrower on or before the time of
transfer of the Loaned Shares pursuant to Section 2(d) on a delivery-versus-payment basis through
the facilities of the Clearing Organization. In addition to all other consideration provided
pursuant to this Agreement or otherwise, Lender agrees that the Loan Fee will constitute
consideration for the issuance of the Loaned Shares to be issued by Lender.
Section 4. Loan Terminations.
(a) Borrower may terminate all or any portion of the Loan on any Business Day by giving
written notice thereof to Lender and transferring the corresponding number of Loaned Shares to
Lender (with an amount of cash determined by Borrower in its reasonable discretion in lieu of
fractional Loaned Shares), without any consideration being payable in respect thereof by Lender to
Borrower.
(b) Subject to Section 10, the Loan shall terminate on the date this Agreement terminates
pursuant to Section 13 (the Facility Termination Date) and all outstanding Loaned Shares shall be
delivered by Borrower to Lender (with an amount of cash determined by Borrower in its reasonable
discretion in lieu of fractional Loaned Shares), without any consideration being payable in respect
thereof by Lender to Borrower, no later than the fifth Business Day following the Facility
Termination Date.
(c) Subject to Section 10, if the Loan or any portion thereof is terminated upon the
occurrence of a Default as set forth in Section 9, the Loaned Shares shall be delivered by Borrower
to Lender, without any consideration being payable in respect thereof by Lender to Borrower, no
later than the third Business Day following the termination date of such Loan, as provided in
Section 9.
(d) If, pursuant to a Merger Event, the Common Stock is changed, reclassified, exchanged for,
or converted into, Reference Property, then:
(i) if such Reference Property consists entirely of cash, the Loan shall terminate on
the date of effectiveness of any such change, reclassification, exchange or conversion and
Borrower shall, on or prior to the fifth Business Day following such effective date, pay,
in full satisfaction of any obligation to return Loaned Shares hereunder, cash in an
amount equal to the product of (A) the number of Loaned Shares outstanding immediately
prior to such effective date and (B) the amount of
5
cash per share of Common Stock received by holders of Common Stock in such event; and
(ii) if such Reference Property consists of both cash and securities or other
property, (A) the Loan shall not terminate as a result of any such event, (B) the amount
of Loaned Shares shall be adjusted as set forth in the definition thereof, and (C)
Borrower shall, on the fifth Business Day following the effective date of any such
exchange or conversion, pay cash in an amount equal to the product of (1) the number of
Loaned Shares outstanding immediately prior to such effective date (without, for the
avoidance of doubt, giving effect to any adjustment) and (2) the amount of cash per share
of Common Stock received by holders of Common Stock in such event.
(e) For the avoidance of doubt, Borrower may deliver shares of Common Stock that are subject
to restrictions under the Securities Act to Lender in respect of any part of its obligation to
return Loaned Shares hereunder.
Section 5. Distributions.
(a) If (i) Lender pays a cash dividend or makes a cash distribution in respect of all of its
outstanding Common Stock, and (ii) as of the record date for such cash dividend or distribution the
Loan or any portion thereof remains outstanding, Borrower shall pay to Lender, within three
Business Days after the payment of such dividend or distribution, an amount in cash equal to the
product of (x) the amount per share of such dividend or distribution and (y) the number of Loaned
Shares outstanding as of the record date of such dividend or distribution.
(b) If at any time when the Loan or any portion thereof is outstanding under this Agreement,
Lender makes a distribution in respect of all of its outstanding Common Stock (other than a
distribution upon liquidation or a reorganization in bankruptcy) in property or securities,
including any options, warrants, rights or privileges in respect of securities and including any
distribution of Common Stock (a NonCash Distribution), then as of the date such Non-Cash
Distribution is paid, such Non-Cash Distribution shall be deemed to be included in the Loan and
each Loaned Share shall be deemed to include the per share of Common Stock kind and amount of
such Non-Cash Distribution; provided that in lieu of the Non-Cash Distribution being included in
the Loan and the Loaned Shares, Borrower may deliver to Lender, within three business days after
the payment of such Non-Cash Distribution, the market value of the product of (x) the amount per
share of Common Stock of such Non-Cash Distribution and (y) the number of Loaned Shares outstanding
as of the record date of such Non-Cash Distribution, as determined by the Borrower in accordance
with market practice for the property or securities constituting the Non-Cash Distribution;
provided further that if Borrower returns any Loaned Shares to Lender following a record date for
such a Non-Cash Distribution but prior to the payment of such Non-Cash Distribution, Borrower shall
deliver to Lender, at Borrowers election,
6
either (A) an amount of such Non-Cash Distribution equal to the product of (x) the amount per
share of Common Stock of such Non-Cash Distribution and (y) the number of Loaned Shares so returned
or (B) the market value of the property and securities described in clause (A) as determined by
Borrower in accordance with market practice for the property or securities constituting the
Non-Cash Distribution, in either case within three Business Days after the payment of such Non-Cash
Distribution.
Section 6. Rights in Respect of Loaned Shares. Subject to the terms of this Agreement, and
except as otherwise agreed by Borrower and Lender, Borrower, insofar as it is the record owner of
Loaned Shares, shall have all of the incidents of ownership in respect of any such Loaned Shares
until such Loaned Shares are required to be delivered to Lender in accordance with the terms of
this Agreement, including the right to transfer the Loaned Shares to others with all such incidents
of ownership. Borrower agrees that it or any of its affiliates that are the record or beneficial
owner of any Loaned Shares (x) held by Borrower or any of its affiliates prior to any sale thereof
under a registration statement by Borrower or its affiliate or (y) held by Borrower or its
affiliate specifically for the purpose of hedging this Agreement and facilitating the hedging of an
investment in Convertible Notes by holders thereof as determined by Borrower in its sole discretion
(other than, for the avoidance of doubt, any Common Stock that is held in the account of, and
beneficially owned by, any unaffiliated third party, where such third party has the power to direct
the vote of such Common Stock), will not vote or provide any consent or take any similar action
with respect to such Loaned Shares on any matter submitted to a vote of Lenders stockholders
during the term of the Loan.
Section 7. Representations and Warranties.
(a) Each of Borrower and Lender represents and warrants to the other that as of the date
hereof:
(i) it has full power to execute and deliver this Agreement, to enter into the Loan
contemplated hereby and to perform its obligations hereunder;
(ii) it has taken all necessary action to authorize such execution, delivery and
performance;
(iii) this Agreement constitutes its legal, valid and binding obligation enforceable
against it in accordance with its terms, subject to applicable bankruptcy, insolvency,
fraudulent conveyance, reorganization, moratorium and similar laws affecting creditors
rights and remedies generally, and subject, as to enforceability, to general principles of
equity, including principles of commercial reasonableness, good faith and fair dealing
(regardless of whether enforcement is sought in a proceeding at law or in equity) and
except that rights to indemnification and contribution
7
hereunder may be limited by federal or state securities laws or public policy
relating thereto;
(iv) the execution, delivery and performance of this Agreement does not and will not
violate, contravene, or constitute a default under, (A) its certificate of incorporation,
bylaws or other governing documents, (B) any laws, rules or regulations of any
governmental authority to which it is subject, (C) any contracts, agreements or instrument
to which it is a party or (D) any judgment, injunction, order or decree by which it is
bound, except, in the case of each of clauses (B), (C) and (D), for any such violation,
contravention or default that would not reasonably be expected to (I) have a material
adverse effect on the financial condition, business, properties or results of operations
of Lender and its subsidiaries, or Borrower and its affiliates, as applicable, taken as a
whole or (II) materially impair Borrowers or Lenders, as applicable, ability to perform
its obligations under this Agreement; and
(v) this Agreement is not unsuitable for it in the light of such partys financial
situation, investment objectives and needs and it is entering into this Agreement in
reliance upon such tax, accounting, regulatory, legal and financial advice as it deems
necessary and not upon any view expressed by the other.
(b) Lender represents and warrants to Borrower, as of the date hereof, and as of the date the
Loaned Shares are transferred to Borrower pursuant to Section 2(d) hereof, and agrees with
Borrower, that:
(i) The Loaned Shares and all other outstanding shares of Common Stock of Lender have
been duly authorized and, upon the issuance and delivery of the Loaned Shares to Borrower
in accordance with the terms and conditions hereof, and subject to the contemporaneous or
prior receipt of the applicable Loan Fee by Lender, the Loaned Shares will be duly
authorized, validly issued, fully paid non-assessable shares of Common Stock; and the
stockholders of Lender have no preemptive rights with respect to the Loaned Shares.
(ii) Lender acknowledges that Borrower is not making any representations or
warranties or taking any position or expressing any view with respect to the treatment of
the Agreement or transactions contemplated hereby under any accounting standards including
ASC Topic 260, Earnings Per Share, ASC Topic 815, Derivatives and Hedging, ASC Topic 480,
Distinguishing Liabilities from Equity and ASC 815-40, Derivatives and Hedging
Contracts in Entitys Own Equity (or any successor issue statements) or under FASBs
Liabilities & Equity Project.
(iii) To Lenders knowledge, no state or local (including non-U.S. jurisdictions)
law, rule, regulation or regulatory order applicable to
8
the Common Stock (excluding banking laws, rules, regulations or regulatory orders and
any other law, rule, regulation or regulatory order that is applicable to Borrower due to
the nature of Borrowers business) in any jurisdiction in which Lender or any subsidiary
thereof is organized, conducts business, operates or is licensed on the date hereof would
give rise to any reporting, consent, registration or other requirement (including without
limitation a requirement to obtain prior approval from any person or entity) solely as a
result of Borrower or its affiliates owning or holding (however defined) shares of Common
Stock.
(iv) It is entering into the Agreement in good faith and not as part of a plan or
scheme to evade compliance with federal securities laws including, without limitation,
Rule 10b-5 under the Exchange Act or any other antifraud or anti-manipulation provisions
of the federal or applicable state securities laws.
(c) Lender represents and warrants to Borrower, as of the date hereof and as of the date the
Loaned Shares are transferred to Borrower pursuant to Section 2(d) hereof, that the outstanding
shares of Common Stock are listed on The NASDAQ Global Market (the NASDAQ) and, as of the date
any Loaned Shares are transferred to Borrower pursuant to Section 2(d) hereof, (1) a listing
application for the Loaned Shares shall have been submitted to NASDAQ and (2) NASDAQ shall not have
rejected such application.
(d) Borrower and Lender agree that the Loan shall be accounted for, as of the date of this
Agreement (and, for the avoidance of doubt, without giving effect to any change in generally
accepted accounting principles, or the application thereof, that is made after the date of this
Agreement and that applies to Lender retroactively), as a single transaction under EITF 09-01, not
representing the repurchase of shares of Common Stock or another equivalent transaction but rather,
consistent with the intent of the parties, representing a loan of shares of Common Stock by Lender
to Borrower.
(e) The representations and warranties of Borrower and Lender under this Section 7 shall
remain in full force and effect at all times during the term of this Agreement and shall survive
the termination of this Agreement for any reason.
Section 8. Covenants.
(a) Borrower covenants and agrees with Lender that it will not transfer or dispose of any
Loaned Shares transferred to Borrower by Lender hereunder of which it is the record owner except
pursuant to a registration statement that is effective under the Securities Act; provided that
Borrower may transfer any such Loaned Shares to any of its affiliates without a registration
statement so long as such affiliate transferee does not transfer or dispose of such Loaned Shares
to any non-affiliated transferee except pursuant to a registration statement that is effective
under the Securities Act.
9
(b) Lender agrees and acknowledges that Borrower has represented to Lender that Borrower is a
financial institution within the meaning of Section 101(22) of the Bankruptcy Code. The parties
hereto further agree and acknowledge (A) that this Agreement is intended to be a securities
contract, as such term is defined in Section 741(7) of the Bankruptcy Code, with respect to which
each payment and delivery hereunder is a settlement payment, or margin payment, as such terms
are defined in Section 741(8) and Section 741(5) of the Bankruptcy Code, and a transfer, as such
term is defined in Section 101(54) of the Bankruptcy Code, and (B) that Borrower is intended to be
entitled to the protections afforded by, among other sections, Sections 362(b)(6), 546(e) and 555
of the Bankruptcy Code.
(c) Lender covenants and agrees that, at least ten days prior to effecting any repurchase of
shares of Common Stock, Lender shall give Borrower a written notice of the estimated number of its
outstanding shares of Common Stock after giving effect to such repurchase (a Repurchase Notice)
if, following such repurchase, the Outstanding Borrow Percentage, as determined on the day of such
repurchase after giving effect thereto, shall have increased by more than 0.5% since the
immediately preceding Repurchase Notice (or, in the case of the first such Repurchase Notice, the
number of outstanding shares of Common Stock as of the date hereof). The Outstanding Borrow
Percentage as of any day is the fraction (A) the numerator of which is the number of Loaned Shares
outstanding on such day and (B) the denominator of which is the number of shares of Common Stock
outstanding on such day, including such Loaned Shares.
(d) Lender covenants and agrees that, unless otherwise agreed to by Borrower in writing,
Lender shall not, and shall not permit any of its direct or indirect subsidiaries, or any entity or
person controlled by Lender, to, directly or indirectly, purchase shares of Common Stock if, after
giving effect to such purchase, the number of outstanding Loaned Shares shall be in excess of 9.0%
of the number of outstanding shares of Common Stock at such time.
(e) Borrower covenants and agrees that it shall not, and shall not permit any of its direct or
indirect subsidiaries to, directly or indirectly acquire record or beneficial ownership of shares
of Common Stock (other than the Loaned Shares) if, as a result of such acquisition, it or any of
its affiliates would become a beneficial owner of 9.0% or more of the number of outstanding shares
of Common Stock at such time.
(f) Lender covenants and agrees that, on the date hereof, Lender shall provide to Borrower a
properly executed Internal Revenue Service Form W-9.
(g) Borrower covenants and agrees with Lender that, insofar as Borrower or any of its
affiliates is the record owner of any Loaned Shares, such Loaned Shares shall be used for the
purpose of (x) directly or indirectly facilitating the sale of the Convertible Notes and hedging
activities (including short sales of Loaned Shares or entry into cash-settled swap agreements with
10
regard to the Common Stock) (all such facilitation and hedging activities, the Hedging
Activities) relating to the Convertible Notes by the holders thereof or (y) performing Borrowers
obligations under this Agreement during any Scheduled Unwind Period.
(h) Lender covenants and agrees with Borrower that it shall have no interest whatsoever in any
of the proceeds that Borrower or its affiliates may receive in connection with the Hedging
Activities and that Borrower or its affiliates shall be entitled to all such proceeds, if any.
(i) Lender covenants and agrees that upon the occurrence of any event described in clause (a)
(d) in the definition of Common Stock that results in right of holders of Common Stock to
receive more than one type of consideration based upon any form of stockholder election, Lender
shall notify Borrower promptly (but in any case prior to the effective date of such event) of the
weighted average of the types and amounts of Reference Property received by the holders of the
Common Stock that affirmatively make such an election.
Section 9. Events of Default.
(a) The Loan may, at the option of Lender by a written notice to Borrower, be terminated (i)
immediately upon the occurrence of any of the events set forth in Section 9(a)(iii) or Section
9(a)(iv) below and (ii) two Business Days following such notice upon the occurrence of any of the
other events set forth below (each, a Borrower Default):
(i) Borrower fails to deliver Loaned Shares to Lender as required by Section 4,
subject to Section 10;
(ii) Borrower fails to deliver or pay to Lender when due any cash, securities or
other property as required by Section 5;
(iii) the filing by or on behalf of Borrower of a voluntary petition or an answer
seeking reorganization, arrangement, readjustment of its debts or for any other relief
under any bankruptcy, reorganization, receivership, compromise, arrangement, insolvency,
readjustment of debt, dissolution, moratorium, delinquency, winding-up or liquidation or
similar act or law, of any state, federal or other applicable foreign jurisdictions, now
or hereafter existing (Bankruptcy Law), or any action by Borrower for, or consent or
acquiescence to, the appointment of a receiver trustee, conservatory, custodian or similar
official of Borrower, or of all or a substantial part of its property; or the making by
Borrower of a general assignment for the benefit of creditors; or the admission by
Borrower in writing of its inability to pay its debts as they become due;
(iv) the filing of any involuntary petition against Borrower in bankruptcy or seeking
reorganization, arrangement, readjustment of its
11
debts or for any other relief under any Bankruptcy Law and an order for relief by a
court having jurisdiction in the premises shall have been issued or entered therein; or
any other similar relief shall be granted under any applicable federal or state law or law
of any other applicable foreign jurisdictions; or a decree or order of a court having
jurisdiction in the premises for the appointment of a receiver, liquidator, sequestrator,
trustee or other officer having similar powers over Borrower or over all or a part of its
property shall have been entered; or the involuntary appointment of an interim receiver,
trustee or other custodian of Borrower or of all or a substantial part of its property; or
the issuance of a warrant of attachment, execution or similar process against any
substantial part of the property of Borrower; and continuance of any such event for 15
consecutive calendar days unless dismissed, bonded to the satisfaction of the court having
jurisdiction in the premises or discharged;
(v) Borrower fails to provide any indemnity as required by Section 12;
(vi) Borrower notifies Lender of its inability to or intention not to perform
Borrowers obligations hereunder or otherwise disaffirms, rejects or repudiates any of its
obligations hereunder; or
(vii) any representation made by Borrower under this Agreement in connection with the
Loan hereunder shall be incorrect or untrue in any material respect during the term of the
Loan or Borrower fails to comply in any material respect with any of its covenants under
this Agreement.
(b) The Loan may, at the option of Borrower by a written notice to Lender, be terminated two
Business Days following such notice by Borrower upon the occurrence of any of the events set forth
below (each, a Lender Default):
(i) the filing by or on behalf of Lender of a voluntary petition or an answer seeking
reorganization, arrangement, readjustment of its debts or for any other relief under any
Bankruptcy Law, or any action by Lender for, or consent or acquiescence to, the
appointment of a receiver, trustee, custodian or similar official of Lender, or of all or
a substantial part of its property; or the making by Lender of a general assignment for
the benefit of creditors; or the admission by Lender in writing of its inability to pay
its debts as they become due; or
(ii) the filing of any involuntary petition against Lender in bankruptcy or seeking
reorganization, arrangement, readjustment of its debts or for any other relief under any
Bankruptcy Law and an order for relief by a court having jurisdiction in the premises
shall have been issued or entered therein; or any other similar relief shall be granted
under any
12
applicable federal or state law or law of any other applicable foreign jurisdictions;
or a decree or order of a court having jurisdiction in the premises for the appointment of
a receiver, liquidator, sequestrator, trustee or other officer having similar powers over
Lender or over all or a part of its property shall have been entered; or the involuntary
appointment of an interim receiver, trustee or other custodian of Lender or of all or a
substantial part of its property; or the issuance of a warrant of attachment, execution or
similar process against any substantial part of the property of Lender; and continuance of
any such event for 45 consecutive calendar days unless dismissed, bonded to the
satisfaction of the court having jurisdiction in the premises or discharged.
Section 10. Borrowers Right to Extend; Lenders Remedies.
(a) Except to the extent a Loan is terminated pursuant to Section 9 as a result of a Borrower
Default, Borrower may, following the termination of any portion of the Loan pursuant to Section 4,
delay the date on which the related Loaned Shares are due to Lender (the Settlement Due Date as
so delayed to the extent applicable), with respect to some or all of such Loaned Shares, if
Borrower determines in good faith upon the advice of counsel that such extension is necessary or
appropriate to enable Borrower or any of its affiliates to effect purchases of Common Stock to
deliver to Lender pursuant to this Agreement in a manner that (x) is, or would be, in compliance
with legal and regulatory requirements (i) applicable to Borrower or such affiliates in purchasing
such shares of Common Stock or (ii) if Borrower were deemed to be Lender or an affiliated purchaser
of Lender, that would be applicable to Lender in purchasing such shares of Common Stock and (y)
shall not be commercially impracticable, in the reasonable judgment of Borrower, in the time period
required by Section 4.
(b) If, upon the termination of any Loan pursuant to Section 4 and the purchase of Common
Stock in an amount equal to all or any portion of the Loaned Shares to be delivered to Lender by
Borrower in accordance with Section 4 of this Agreement (i) shall be prohibited by any law, rules
or regulation of any governmental authority to which it is or would be subject, (ii) shall violate,
or would upon such purchase likely violate, any order or prohibition of any court, tribunal or
other governmental authority, (iii) shall require the prior consent of any court, tribunal or
governmental authority prior to any such repurchase or (iv) would subject Borrower, in the
commercially reasonable judgment of Borrower, to any liability or potential liability under any
applicable federal securities laws (including, without limitation, Section 16 of the Exchange Act
or applicable banking regulations) (each of (i), (ii), (iii) and (iv), a Legal Obstacle), then,
in each case, Borrower shall immediately notify Lender of the Legal Obstacle and the basis
therefor, whereupon such Borrowers obligations under Section 4 shall be suspended until such time
as no Legal Obstacle with respect to such obligations shall exist (a Repayment Suspension).
Following the occurrence of and during the continuation of any Repayment Suspension, Borrower shall
use its reasonable best efforts to remove or cure the Legal
13
Obstacle as soon as
practicable and to deliver to Lender any Loaned Shares it actually acquires; provided that
Lender shall promptly reimburse all costs and expenses (including legal counsel to Borrower)
incurred or, at Borrowers election, provide reasonably adequate surety or guarantee for any such
costs and expenses that may be incurred by Borrower, in each case in removing or curing such Legal
Obstacle.
(c) If Borrower is unable to remove or cure any Legal Obstacle within 10 Business Days, Lender
may elect to require Borrower, upon five Business Days advance written notice, to pay to Lender in
lieu of the delivery of Loaned Shares otherwise required to be delivered, an amount in immediately
available funds (the Replacement Cash) equal to the product of (A) the average of the Relevant
Prices over the 40 consecutive Business Day period immediately preceding the termination date of
the Loan and (B) the number of Loaned Shares otherwise required to be delivered that Borrower
failed to deliver; provided that if any Business Day in the 40 consecutive Business Day averaging
period described in clause (A) above is a Disrupted Day in full or in part, (x) such averaging
period shall be extended by one Business Day for each such Disrupted Day, and (y) the Borrower
shall calculate the amount of Replacement Cash according to an appropriately weighted average of
the Relevant Prices over such averaging period (as extended).
(d) If Borrower shall fail to deliver to Lender on the Settlement Due Date the applicable
Loaned Shares relating to any portion of the Loan that has been terminated under Section 4 and
Borrower is unable to remove or cure any Legal Obstacle within 10 Business Days or Borrower shall
fail to pay the Replacement Cash to Lender in accordance with Section 10(c) above (to the extent
Borrower is required to pay Replacement Cash), then, in either case, Lender shall have the right
(upon prior written notice to Borrower) to purchase a like number of shares of Common Stock (and,
Non-Cash Distributions, if applicable pursuant to Section 5(b)) (Replacement Shares) in the
principal market for such securities in a commercially reasonable manner (and Lender shall promptly
notify Borrower of the aggregate purchase price of the Replacement Shares upon the exercise of such
right). To the extent Lender shall exercise such right, Borrowers obligation to return a like
amount of Loaned Shares or to pay the Replacement Cash, as applicable, shall terminate and Borrower
shall be liable to Lender for the purchase price of such Replacement Shares (plus all other
amounts, if any, due to Lender hereunder), all of which shall be due and payable within three
Business Days of notice to Borrower by Lender of the aggregate purchase price of the Replacement
Shares. The purchase price of Replacement Shares purchased under this Section 10 shall include
brokers fees and commissions and all other reasonable costs, fees and expenses related to such
purchase and sale.
14
Section 11. Transfers of Common Stock.
(a) The transfer of Loaned Shares to Borrower hereunder shall be made by the crediting by a
Clearing Organization of such Loaned Shares to Borrowers securities account (within the meaning
of Section 8-501 of the UCC) maintained with such Clearing Organization. All transfers of Loaned
Shares to Lender hereunder shall be made by the crediting of such Loaned Shares to Lenders
Designated Account (whereupon, for the avoidance of doubt, such Loaned Shares credited to Lenders
Designated Account shall become the property of Lender, and Borrower shall have no voting,
dispositive control or pecuniary interest with respect thereto). In every transfer of financial
assets (within the meaning of Section 8-102(a)(9) of the UCC) hereunder, the transferor shall take
all steps necessary (i) to effect a delivery of such financial assets to the transferee under
Section 8-301 of the UCC, or to cause the creation of a security entitlement in favor of the
transferee in such financial assets under Section 8-501 of the UCC, (ii) to enable the transferee
to obtain control (within the meaning of Section 8-106 of the UCC), and (iii) to provide the
transferee with comparable rights under any similar law or regulation of any other jurisdiction
that is applicable to such transfer.
(b) Except as otherwise provided herein, all transfers of cash hereunder to Borrower or Lender
shall be by wire transfer in immediately available, freely transferable funds.
(c) A transfer of securities or cash may be effected under this Section 11 on any Business Day
except (i) a Business Day on which the transferee is closed for business at its address set forth
in Section 17 or (ii) a Business Day on which a Clearing Organization or wire transfer system is
closed, if the facilities of such Clearing Organization or wire transfer system are required to
effect such transfer. Any transfer not effected because of this clause (c) shall be made on the
next following Business Day on which such transfer may be made.
Section 12. Indemnities.
(a) Lender hereby agrees to indemnify and hold harmless Borrower and its affiliates and its
former, present and future directors, officers, employees and other agents and representatives from
and against any and all liabilities, judgments, claims, settlements, losses, damages, fees, liens,
taxes, penalties, obligations and expenses (including, without limitation, any losses relating to
Borrowers market activities as a consequence of becoming, or of the risk of becoming, subject to
Section 16(b) of the Exchange Act, including, without limitation, any forbearance from market
activities or cessation of market activities and any losses in connection therewith) incurred or
suffered by any such person or entity directly or indirectly arising from, by reason of, or in
connection with, (i) any breach by Lender of any of its representations or warranties contained in
Section 7 or (ii) any breach by Lender of any of its covenants or agreements in this Agreement
(including, without limitation, Section 8(c)).
15
(b) Borrower hereby agrees to indemnify and hold harmless Lender and its affiliates and its
former, present and future directors, officers, employees and other agents and representatives from
and against any and all liabilities, judgments, claims, settlements, losses, damages, fees, liens,
taxes, penalties, obligations and expenses incurred or suffered by any such person or entity
directly or indirectly arising from, by reason of, or in connection with (i) any breach by Borrower
of any of its representations or warranties contained in Section 7 or (ii) any breach by Borrower
of any of its covenants or agreements in this Agreement.
(c) In case any claim or litigation which might give rise to any obligation of a party under
this Section 12 (each an Indemnifying Party) shall come to the attention of the party seeking
indemnification hereunder (the Indemnified Party), the Indemnified Party shall promptly notify
the Indemnifying Party in writing of the existence and amount thereof; provided that the failure of
the Indemnified Party to give such notice shall not adversely affect the right of the Indemnified
Party to indemnification under this Agreement, except to the extent the Indemnifying Party is
materially prejudiced thereby. The Indemnifying Party shall promptly notify the Indemnified Party
in writing if it accepts such claim or litigation as being within its indemnification obligations
under this Section 12. Such response shall be delivered no later than 30 days after the initial
notification from the Indemnified Party; provided that, if the Indemnifying Party reasonably cannot
respond to such notice within 30 days, the Indemnifying Party shall respond to the Indemnified
Party as soon thereafter as reasonably possible.
(d) An Indemnifying Party shall be entitled to participate in and, if (i) in the good faith
judgment of the Indemnified Party such claim can properly be resolved by money damages alone and
the Indemnifying Party has the financial resources to pay such damages and (ii) the Indemnifying
Party admits that this indemnity fully covers the claim or litigation, the Indemnifying Party shall
be entitled to direct the defense of any claim at its expense, but such defense shall be conducted
by legal counsel reasonably satisfactory to the Indemnified Party. An Indemnified Party shall not
make any settlement of any claim or litigation under this Section 12 without the written consent of
the Indemnifying Party.
Section 13. Termination of Agreement.
(a) This Agreement shall terminate upon the earliest of (i) the 45th Business Day following
the date as of which the entire principal amount of Convertible Notes ceases to be outstanding and
Lender has settled all payments or deliveries in respect of such Convertible Notes, whether as a
result of conversion, redemption, repurchase, cancellation, at maturity or otherwise, subject to
Section 10, (ii) the written agreement of Lender and Borrower to so terminate, (iii) August 24,
2010 (or such later date as Borrower and Lender shall have agreed which in no event shall be later
than September 7, 2010) (August 24, 2010 or such later date being the Early Unwind Date) if the
initial offering of the Convertible
16
Notes has not closed prior to such Early Unwind Date pursuant to the terms of the underwriting
agreement relating to the Convertible Notes, (iv) the occurrence of a Borrower Default, at the
option of Lender, as set forth in Section 9(a) and (v) the occurrence of a Lender Default, at the
option of Borrower, as set forth in Section 9(b).
(b) Unless otherwise agreed in writing by Borrower and Lender, the provisions of Section 12
shall survive the termination of this Agreement.
Section 14. Delegation. Neither party shall delegate its obligations under this Agreement
without the prior written consent of the other party, and any attempt to delegate obligations
arising under this Agreement without such consent shall be void; provided that notwithstanding the
foregoing and anything to the contrary herein, Borrower may designate any person to deliver or
receive Loaned Shares or cash to or from Lender when deliverable in accordance with this Agreement
and to otherwise perform Borrowers obligations in respect of this Agreement and any such designee
may assume such obligations. Borrower shall only be discharged of its obligations to Lender to the
extent of any such delivery or performance.
Section 15. Transfer and Assignment of the Agreement. Neither party shall transfer or assign
its rights or obligations under this Agreement without the prior written consent of the other
party, and any attempt to transfer or assign any rights or obligations arising under this Agreement
without such consent shall be void; provided that notwithstanding the foregoing and anything to the
contrary herein, Borrower shall have the right to assign its rights and obligations under this
Agreement to any of Borrowers affiliates or any other person of equal or better credit rating as
Borrower, or guaranteed by Borrower or an entity with equal or better credit rating as Borrower.
Section 16. Communications; Hedging. Lender acknowledges and agrees that (A) any purchases
or sales made by Borrower in respect of the Agreement shall be made in Borrowers sole judgment and
for Borrowers own account and (B) Lender does not have, and shall not attempt to exercise, any
influence over how, when or whether to effect such purchases or sales, including, without
limitation, the price paid or received per share pursuant to such transactions whether such
transactions are made on any securities exchange or privately. In addition, Lender shall not
communicate any material non-public information relating either to Lender or the Common Stock to
any employee of Borrower or its affiliates if Lender knows, or Borrower has notified Lender, that
such employee is involved in hedging Borrowers market and price risk with respect to the Agreement
until the fifth Business Day following the termination of the Agreement.
17
Section 17. Notices.
(a) All notices and other communications hereunder shall be in writing and shall be deemed to
have been duly given when received.
(b) All such notices and other communications shall be directed to the following address:
|
(i) |
|
If to Borrower to: |
|
|
|
|
Bank of America, N.A.
9 West 57th Street
New York, NY 10019
Attention: John Servidio |
|
|
(ii) |
|
If to Lender to: |
|
|
|
|
MannKind Corporation
28903 North Avenue Paine
Valencia, California 91355
Attn: David Thomson
Telephone: (661) 775-5350
Facsimile: (661) 755-2086 |
(c) In the case of any party, at such other address as may be designated by written notice to
the other parties.
Section 18. Governing Law; Submission To Jurisdiction; Severability.
(a) This Agreement, and each claim, controversy or dispute arising hereunder or relating
hereto, shall be governed by and construed in accordance with the laws of the State of New York,
but excluding any choice of law provisions that would require the application of the laws of a
jurisdiction other than New York.
(b) EACH PARTY HERETO IRREVOCABLY AND UNCONDITIONALLY (A) SUBMITS TO THE NON-EXCLUSIVE
JURISDICTION OF ANY UNITED STATES FEDERAL OR NEW YORK STATE COURT SITTING IN NEW YORK CITY, AND ANY
APPELLATE COURT FROM ANY SUCH COURT, SOLELY FOR THE PURPOSE OF ANY SUIT, ACTION OR PROCEEDING
BROUGHT TO ENFORCE ITS OBLIGATIONS HEREUNDER OR RELATING IN ANY WAY TO THIS AGREEMENT OR THE LOAN
HEREUNDER AND (B) WAIVES, TO THE FULLEST EXTENT IT MAY EFFECTIVELY DO SO, ANY DEFENSE OF AN
INCONVENIENT FORUM TO THE MAINTENANCE OF SUCH ACTION OR PROCEEDING IN ANY SUCH COURT AND ANY
18
RIGHT OF JURISDICTION ON ACCOUNT OF ITS PLACE OF RESIDENCE OR DOMICILE.
(c) EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES ANY RIGHT THAT IT MAY HAVE TO TRIAL BY JURY IN
ANY ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE
TRANSACTIONS CONTEMPLATED HEREBY.
(d) To the extent permitted by law, the unenforceability or invalidity of any provision or
provisions of this Agreement shall not render any other provision or provisions herein contained
unenforceable or invalid.
Section 19. Counterparts. This Agreement may be executed in any number of counterparts, and
all such counterparts taken together shall be deemed to constitute one and the same agreement.
Section 20. Amendments. No amendment or modification in respect of this Agreement shall be
effective unless it shall be in writing and signed by the parties hereto.
19
IN WITNESS WHEREOF, the parties hereto have executed this Share Lending Agreement as of the
date and year first above written.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
MANNKIND CORPORATION |
|
|
|
BANK OF AMERICA, N.A. |
|
|
as Lender |
|
|
|
as Borrower |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By: |
|
/s/ Matthew J. Pfeffer |
|
|
|
By: |
|
/s/ Charles J. Neslen |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Name:
|
|
Matthew J. Pfeffer
|
|
|
|
|
|
Name:
|
|
Charles J. Nelsen |
|
|
|
|
Title:
|
|
Chief Financial Officer
|
|
|
|
|
|
Title:
|
|
Director |
|
|
20
exv99w3
EXHIBIT 99.3
August 17, 2010
MannKind Corporation
28903 North Avenue Paine
Valencia, CA 91355
Re: The Mann Group LLC Revolving Loan Arrangement
Ladies and Gentlemen:
Reference is made to that certain Amended and Restated Promissory
Note made by MannKind Corporation (the Company) in favor of The Mann Group LLC, dated August 10, 2010 (the Loan). I hereby confirm by this letter that The Mann Group LLC shall not require the
Company to prepay amounts outstanding under the Loan prior to the maturity date of the Loan if such prepayment would require the use
by the Company of its working capital resources, including any proceeds from the current offering by the Company of convertible promissory notes due 2015.
|
|
|
|
|
Very truly yours,
THE MANN GROUP LLC
|
|
|
/s/ Alfred E. Mann
|
|
|
Alfred E. Mann, Managing Member |
|
|
|
|
|
|
|
|
|
|
Acknowledged and Agreed:
|
|
|
|
|
|
|
|
MANNKIND CORPORATION
|
|
|
|
By: |
/s/ David Thomson
|
|
|
|
David Thomson |
|
|
|
General Counsel |
|
|
|
|
Dated: August 18, 2010
exv99w4
EXHIBIT 99.4
Risk Factors
RISKS RELATED TO OUR BUSINESS
We depend heavily on the successful development and commercialization of our lead product
candidate, AFREZZA, which is not yet approved, and our other product candidates, which are in early
clinical or preclinical development.
To date, we have not commercialized any product candidates. In March 2009, we submitted an NDA
to the FDA requesting approval of AFREZZA for the treatment of adults with type 1 or type 2
diabetes for the control of hyperglycemia. In March 2010, we received a Complete Response letter
regarding this NDA from the FDA. A Complete Response letter is issued by the FDAs Center for Drug
Evaluation and Research when the review of a submitted file is completed and questions remain that
preclude the approval of the NDA in its current form. In July 2010, the FDA accepted our reply to
the Complete Response letter and set a target action date of December 29, 2010. There can be no
assurance that the FDA will find our proposed approach for addressing its questions acceptable. The
FDA could also request that we conduct additional clinical trials to provide sufficient data for
approval of the NDA. There can be no assurance that we will obtain approval of the NDA in a timely
manner or at all.
Our other product candidates are generally in early clinical or preclinical development. We
anticipate that in the near term, our ability to generate revenues will depend solely on the
successful development and commercialization of AFREZZA.
We have expended significant time, money and effort in the development of our lead product
candidate, AFREZZA, which has not yet received regulatory approval and which may not be approved by
the FDA in a timely manner, or at all. We must receive the necessary approvals from the FDA and
similar foreign regulatory agencies before AFREZZA can be marketed and sold in the United States or
elsewhere. Even if we were to receive regulatory approval, we ultimately may be unable to gain
market acceptance of AFREZZA for a variety of reasons, including the treatment and dosage regimen,
potential adverse effects, the availability of alternative treatments and cost effectiveness. If we
fail to commercialize AFREZZA, our business, financial condition and results of operations will be
materially and adversely affected.
We are seeking to develop and expand our portfolio of product candidates through our internal
research programs and through licensing or otherwise acquiring the rights to therapeutics in the
areas of cancer and other indications. All of these product candidates will require additional
research and development and significant preclinical, clinical and other testing prior to seeking
regulatory approval to market them. Accordingly, these product candidates will not be commercially
available for a number of years, if at all.
A significant portion of the research that we are conducting involves new and unproven
compounds and technologies, including AFREZZA, Technosphere platform technology and immunotherapy
product candidates. Research programs to identify new product candidates require substantial
technical, financial and human resources. Even if our research programs identify candidates that
initially show promise, these candidates may fail to progress to clinical development for any
number of reasons, including discovery upon further research that these candidates have adverse
effects or other characteristics that indicate they are unlikely to be effective. In addition, the
clinical results we obtain at one stage are not necessarily indicative of future testing results.
If we fail to successfully complete the development and commercialization of AFREZZA or develop or
expand our other product candidates, or are significantly delayed in doing so, our business and
results of operations will be harmed and the value of our stock could decline.
We have a history of operating losses, we expect to continue to incur losses and we may never
become profitable.
We are a development stage company with no commercial products. All of our product candidates
are still being developed, and all but AFREZZA are still in the early stages of development. Our
product candidates will require significant additional development, clinical trials, regulatory
clearances and additional investment before they can be commercialized. We cannot be certain when
AFREZZA may be approved, or if it will be approved.
We have never been profitable and, as of June 30, 2010, we had incurred a cumulative net loss
of $1.7 billion. The cumulative net loss has resulted principally from costs incurred in our
research and development programs, the write-off of goodwill and general operating expenses. We
expect to make substantial expenditures and to incur increasing operating losses in the future in
order to further develop and commercialize our product candidates, including costs and expenses to
complete clinical trials, seek regulatory approvals and market our product candidates, including
AFREZZA. This cumulative net loss may increase significantly as we continue development and
clinical trial efforts.
Our losses have had, and are expected to continue to have, an adverse impact on our working
capital, total assets and stockholders equity. As of June 30, 2010, we had a stockholders deficit
of $137.7 million. Our ability to achieve and sustain profitability depends upon obtaining
regulatory approvals for and successfully commercializing AFREZZA, either alone or with third
parties. We do not currently have the required approvals to market any of our product candidates,
and we may not receive them. We may not be profitable even if we succeed in commercializing any of
our product candidates. As a result, we cannot be sure when we will become profitable, if at all.
If we fail to raise additional capital our financial condition and business would suffer.
It is costly to develop therapeutic product candidates and conduct clinical trials for these
product candidates. Although we are currently focusing on AFREZZA as our lead product candidate, we
have begun to conduct clinical trials for additional product candidates. Our existing capital
resources will not be sufficient to support the expense of fully commercializing AFREZZA or
developing any of our product candidates.
Based upon our current expectations, we believe that our existing capital resources, including
the loan arrangement with The Mann Group LLC (an entity controlled by our principal stockholder)
but excluding the net proceeds from our recently-completed sale of our 5.75% convertible notes due
2015 and any proceeds to us from our share purchase arrangement with Seaside, will enable us to
continue planned operations through the first quarter of 2011. However, we cannot assure you that
our plans will not change or that changed circumstances will not result in the depletion of our
capital resources more rapidly than we currently anticipate. Accordingly, we may raise additional
funds through the sale of equity or debt securities, the entry into strategic business
collaborations, the establishment of other funding facilities, licensing arrangements and/or assets
sales, in order to continue the development and commercialization of AFREZZA and other product
candidates and to support our other ongoing activities. However, it may be difficult for us to
raise additional funds through the sale of equity or debt securities. As of June 30, 2010, we had a
stockholders deficit of $137.7 million which may raise concerns about our solvency and affect our
ability to raise additional funds. The amount of additional funds we need will depend on a number
of factors, including:
|
|
|
the rate of progress and costs of our clinical trials and research and development
activities, including costs of procuring clinical materials and expanding our own
manufacturing facilities; |
|
|
|
|
our success in establishing strategic business collaborations and the timing and amount of
any payments we might receive from any collaboration we are able to establish; |
|
|
|
|
actions taken by the FDA and other regulatory authorities affecting our products and
competitive products; |
|
|
|
|
our degree of success in commercializing AFREZZA; |
|
|
|
|
the emergence of competing technologies and products and other adverse market developments; |
|
|
|
|
the timing and amount of payments we might receive from potential licensees; |
|
|
|
|
the costs of preparing, filing, prosecuting, maintaining and enforcing patent claims and
other intellectual property rights or defending against claims of infringement by others; |
|
|
|
the costs of discontinuing projects and technologies or decommissioning existing
facilities, if we undertake those activities; and |
|
|
|
|
the costs of performing additional clinical trials to demonstrate safety and efficacy if
our current trials do not deliver results sufficient for FDA approval and
commercialization. |
We have raised capital in the past primarily through the sale of equity and debt securities.
We may in the future pursue the sale of additional equity and/or debt securities, or the
establishment of other funding facilities. For example, on August 10, 2010, we entered into the
Seaside purchase agreement and the Mann purchase agreement for the sale and issuance by us of up to
36,400,000 shares of our common stock over a period of approximately 50 weeks. Issuances of
additional debt or equity securities or the conversion of any of our currently outstanding
convertible debt securities into shares of our common stock could impact the rights of the holders
of our common stock and may dilute their ownership percentage. Moreover, the establishment of other
funding facilities may impose restrictions on our operations. These restrictions could include
limitations on additional borrowing and specific restrictions on the use of our assets, as well as
prohibitions on our ability to create liens, pay dividends, redeem our stock or make investments.
We also may seek to raise additional capital by pursuing opportunities for the licensing or
sale of certain intellectual property and other assets, including our Technosphere technology
platform. We cannot offer assurances, however, that any strategic collaborations, sales of
securities or sales or licenses of assets will be available to us on a timely basis or on
acceptable terms, if at all. We may be required to enter into relationships with third parties to
develop or commercialize products or technologies that we otherwise would have sought to develop
independently, and any such relationships may not be on terms as commercially favorable to us as
might otherwise be the case.
In the event that sufficient additional funds are not obtained through strategic collaboration
opportunities, sales of securities, credit facilities, licensing arrangements and/or asset sales on
a timely basis, we may be required to reduce expenses through the delay, reduction or curtailment
of our projects, including AFREZZA commercialization, or further reduction of costs for facilities
and administration. Moreover, if we do not obtain such additional funds, there will be substantial
doubt about our ability to continue as a going concern and increased risk of insolvency and loss of
investment to the holders of our securities. As of the date hereof, we have not obtained a solvency
opinion or otherwise conducted a valuation of our properties to determine whether our debts exceed
the fair value of our property within the meaning of applicable solvency laws. If we are or become
insolvent, investors in our stock may lose the entire value of their investment.
Deteriorating global economic conditions may have an adverse impact on the loan facility with an
entity controlled by our principal stockholder, which we currently cannot predict.
As widely reported, financial markets in the United States, Europe and Asia have been
experiencing a period of unprecedented turmoil and upheaval characterized by extreme volatility and
declines in security prices, severely diminished liquidity and credit availability, inability to
access capital markets, the bankruptcy, failure, collapse or sale of various financial institutions
and an unprecedented level of intervention from the United States federal government and other
governments. We cannot predict the impact of these events on the loan facility with an entity
controlled by our principal stockholder. If we are unable to draw on this financial resource, our
business and financial condition will be adversely affected.
If we do not achieve our projected development and commercialization goals in the timeframes we
announce and expect, our business would be harmed and the market price of our common stock could
decline.
For planning purposes, we estimate the timing of the accomplishment of various scientific,
clinical, regulatory and other product development goals, which we sometimes refer to as
milestones. These milestones may include the commencement or completion of scientific studies and
clinical trials and the submission of regulatory filings. From time to time, we publicly announce
the expected timing of some of these milestones. All of these milestones are based on a variety of
assumptions. The actual timing of the achievement of these milestones can vary dramatically from
our estimates, in many cases for reasons beyond our control, depending on numerous factors,
including:
|
|
|
the rate of progress, costs and results of our clinical trial and research and development
activities, which will be impacted by the level of proficiency and experience of our clinical
staff; |
|
|
|
|
our ability to identify and enroll patients who meet clinical trial eligibility criteria; |
|
|
|
|
our ability to access sufficient, reliable and affordable supplies of components used in the
manufacture of our product candidates, including insulin and other materials for AFREZZA; |
|
|
|
|
the costs of expanding and maintaining manufacturing operations, as necessary; |
|
|
|
|
the extent of scheduling conflicts with participating clinicians and clinical institutions; |
|
|
|
|
the receipt of approvals by our competitors and by us from the FDA and other regulatory agencies; |
|
|
|
|
our ability to enter into sales and marketing collaborations for AFREZZA; and |
|
|
|
|
other actions by regulators. |
In addition, if we do not obtain sufficient additional funds through sales of securities,
strategic collaborations or the license or sale of certain of our assets on a timely basis, we may
be required to reduce expenses by delaying, reducing or curtailing our development of AFREZZA or
other product development activities, which would impact our ability to meet milestones. If we fail
to commence or complete, or experience delays in or are forced to curtail, our proposed clinical
programs or otherwise fail to adhere to our projected development goals in the timeframes we
announce and expect (or within the timeframes expected by analysts or investors), our business and
results of operations will be harmed and the market price of our common stock may decline.
We face substantial competition in the development of our product candidates and may not be able to
compete successfully, and our product candidates may be rendered obsolete by rapid technological
change.
A number of established pharmaceutical companies have or are developing technologies for the
treatment of diabetes. We also face substantial competition for the development of our other
product candidates.
Many of our existing or potential competitors have, or have access to, substantially greater
financial, research and development, production, and sales and marketing resources than we do and
have a greater depth and number of experienced managers. As a result, our competitors may be better
equipped than we are to develop, manufacture, market and sell competing products. In addition,
gaining favorable reimbursement is critical to the success of AFREZZA. Many of our competitors have
existing infrastructure and relationships with managed care organizations and reimbursement
authorities which can be used to their advantage.
The rapid rate of scientific discoveries and technological changes could result in one or more
of our product candidates becoming obsolete or noncompetitive. Our competitors may develop or
introduce new products that render our technology and AFREZZA less competitive, uneconomical or
obsolete. Our future success will depend not only on our ability to develop our product candidates
but to improve them and keep pace with emerging industry developments. We cannot assure you that we
will be able to do so.
We also expect to face increasing competition from universities and other non-profit research
organizations. These institutions carry out a significant amount of research and development in the
areas of diabetes and cancer. These institutions are becoming increasingly aware of the commercial
value of their findings and are more active in seeking patent and other proprietary rights as well
as licensing revenues.
If we fail to enter into a strategic collaboration with respect to AFREZZA, we may not be able to
execute on our business model.
We have held extensive discussions with a number of pharmaceutical companies concerning a
potential strategic business collaboration for AFREZZA. To date we have not reached an agreement
with any of these
companies on a collaboration. We cannot predict when, if ever, we could conclude an agreement
with a partner. There can be no assurance that any such collaboration will be available to us on a
timely basis or on acceptable terms. If we are not able to enter into a collaboration on terms that
are favorable to us, we may be unable to undertake and fund product development, clinical trials,
manufacturing and marketing activities at our own expense. Accordingly, we may have to
substantially reduce our development efforts, which would delay or otherwise impede the
commercialization of AFREZZA.
We will face similar challenges as we seek to develop our other product candidates. Our
current strategy for developing, manufacturing and commercializing our other product candidates
includes evaluating the potential for collaborating with pharmaceutical and biotechnology companies
at some point in the drug development process and for these collaborators to undertake the advanced
clinical development and commercialization of our product candidates. It may be difficult for us to
find third parties that are willing to enter into collaborations on economic terms that are
favorable to us, or at all. Failure to enter into a collaboration with respect to any other product
candidate could substantially increase our requirements for capital and force us to substantially
reduce our development effort.
If we enter into collaborative agreements with respect to AFREZZA and if our third-party
collaborators do not perform satisfactorily or if our collaborations fail, development or
commercialization of AFREZZA may be delayed and our business could be harmed.
We may enter into license agreements, partnerships or other collaborative arrangements to
support the financing, development and marketing of AFREZZA. We may also license technology from
others to enhance or supplement our technologies. These various collaborators may enter into
arrangements that would make them potential competitors. These various collaborators also may
breach their agreements with us and delay our progress or fail to perform under their agreements,
which could harm our business.
If we enter into collaborative arrangements, we will have less control over the timing,
planning and other aspects of our clinical trials, and the sale and marketing of AFREZZA and our
other product candidates. We cannot offer assurances that we will be able to enter into
satisfactory arrangements with third parties as contemplated or that any of our existing or future
collaborations will be successful.
Continued testing of AFREZZA or our other product may not yield successful results, and even if it
does, we may still be unable to commercialize our product.
Our research and development programs are designed to test the safety and efficacy of AFREZZA
and our other product candidates through extensive nonclinical and clinical testing. We may
experience numerous unforeseen events during, or as a result of, the testing process that could
delay or prevent commercialization of AFREZZA or any of our other product candidates, including the
following:
|
|
|
safety and efficacy results obtained in our nonclinical and initial
clinical testing may be inconclusive or may not be predictive of
results obtained in later-stage clinical trials or following long-term
use, and we may as a result be forced to stop developing product
candidates that we currently believe are important to our future; |
|
|
|
|
the data collected from clinical trials of our product candidates may
not be sufficient to support FDA or other regulatory approval; |
|
|
|
|
after reviewing test results, we or any potential collaborators may
abandon projects that we previously believed were promising; and |
|
|
|
|
our product candidates may not produce the desired effects or may
result in adverse health effects or other characteristics that
preclude regulatory approval or limit their commercial use if
approved. |
Forecasts about the effects of the use of drugs, including AFREZZA, over terms longer than the
clinical trials or in much larger populations may not be consistent with the clinical results. If
use of AFREZZA results in
adverse health effects or reduced efficacy or both, the FDA or other regulatory agencies may
terminate our ability to market and sell AFREZZA, may narrow the approved indications for use or
otherwise require restrictive product labeling or marketing, or may require further clinical
trials, which may be time-consuming and expensive and may not produce favorable results.
As a result of any of these events, we, any collaborator, the FDA, or any other regulatory
authorities, may suspend or terminate clinical trials or marketing of AFREZZA at any time. Any
suspension or termination of our clinical trials or marketing activities may harm our business and
results of operations and the market price of our common stock may decline.
If we are unable to transition successfully from a development company to a company that
commercializes therapeutics, our business would suffer.
We require a well-structured plan to make the transition from the development stage to being a
company with commercial operations. In order to implement our commercialization strategy, we will
need to:
|
|
|
align our management structure to accommodate the increasing complexity of our operations; |
|
|
|
|
develop comprehensive and detailed commercialization, clinical
development and regulatory plans; and |
|
|
|
|
implement standard operating procedures. |
If we are unable to accomplish these measures in a timely manner, we would be at considerable
risk of failing to develop the capabilities necessary for commercial operations.
If our suppliers fail to deliver materials and services needed for the production of AFREZZA in a
timely and sufficient manner, or they fail to comply with applicable regulations, our business and
results of operations would be harmed and the market price of our common stock could decline.
For AFREZZA to be commercially viable, we need access to sufficient, reliable and affordable
supplies of insulin, our AFREZZA inhaler, the related cartridges and other materials. We have a
long-term agreement with N.V. Organon for the supply of insulin. In June 2009, we purchased from
Pfizer, a portion of its inventory of bulk insulin and acquired an option to purchase the remainder
of Pfizers insulin inventory, in whole or in part, at a specified price to the extent that Pfizer
has not otherwise disposed of or used the retained insulin.
We obtain FDKP, the precursor raw material for AFREZZA, from a major multinational chemical
manufacturer. We have completed a successful validation campaign of FDKP at commercial scale. We
can also utilize our in-house chemical manufacturing plant for supplemental capacity. We believe
our contract manufacturer has the capacity to supply our current and future commercial
requirements. We obtain our intended commercial AFREZZA inhaler and cartridges from a plastic
molding company located in the United States.
We must rely on our suppliers to comply with relevant regulatory and other legal requirements,
including the production of insulin in accordance with the FDAs current good manufacturing
practices, or cGMP for drug products, and the production of the AFREZZA inhaler and related
cartridges in accordance with Quality System Regulations, or QSR. The supply of any of these
materials may be limited or any of the manufacturers may not meet relevant regulatory requirements,
and if we are unable to obtain any of these materials in sufficient amounts, in a timely manner and
at reasonable prices, or if we should encounter delays or difficulties in our relationships with
manufacturers or suppliers, the development or manufacturing of AFREZZA may be delayed. Any such
events could delay market introduction and subsequent sales of AFREZZA and, if so, our business and
results of operations will be harmed and the market price of our common stock may decline.
We have never manufactured AFREZZA or any other product candidates in commercial quantities, and if
we fail to develop an effective manufacturing capability for our product candidates or to engage
third-party manufacturers with this capability, we may be unable to commercialize these products.
We use our Danbury facility to formulate AFREZZA, fill plastic cartridges with AFREZZA and
blister package the cartridges for use in our clinical trials. This facility has been fully
qualified and undergone inspection by the FDA. The manufacture of pharmaceutical products requires
significant expertise and capital investment, including the development of advanced manufacturing
techniques and process controls. Manufacturers of pharmaceutical products often encounter
difficulties in production, especially in scaling up initial production. These problems include
difficulties with production costs and yields, quality control and assurance and shortages of
qualified personnel, as well as compliance with strictly enforced federal, state and foreign
regulations. If we engage a third-party manufacturer, we would need to transfer our technology to
that third-party manufacturer and gain FDA approval, potentially causing delays in product
delivery. In addition, our third-party manufacturer may not perform as agreed or may terminate its
agreement with us.
Additionally, when we manufacture commercial material on a significantly larger production
scale than the production scale for clinical trial materials, we are required by the FDA to
establish that the results obtained from the clinical trials may reasonably be extrapolated to such
commercial material. We have submitted documentation to the FDA to show correlation to the
clinical-scale production materials but can provide no assurance that approval will be obtained.
Any of these factors could cause us to delay or suspend clinical trials, regulatory
submissions, required approvals or commercialization of our product candidates, entail higher costs
and result in our being unable to effectively commercialize our products. Furthermore, if we or a
third-party manufacturer fail to deliver the required commercial quantities of any product on a
timely basis, and at commercially reasonable prices and acceptable quality, and we were unable to
promptly find one or more replacement manufacturers capable of production at a substantially
equivalent cost, in substantially equivalent volume and quality on a timely basis, we would likely
be unable to meet demand for such products and we would lose potential revenues.
We deal with hazardous materials and must comply with environmental laws and regulations, which can
be expensive and restrict how we do business.
Our research and development work involves the controlled storage and use of hazardous
materials, including chemical, radioactive and biological materials. In addition, our manufacturing
operations involve the use of a chemical that is stable and non-hazardous under normal storage
conditions, but may form an explosive mixture under certain conditions. Our operations also produce
hazardous waste products. We are subject to federal, state and local laws and regulations governing
how we use, manufacture, store, handle and dispose of these materials. Moreover, the risk of
accidental contamination or injury from hazardous materials cannot be completely eliminated, and in
the event of an accident, we could be held liable for any damages that may result, and any
liability could fall outside the coverage or exceed the limits of our insurance. Currently, our
general liability policy provides coverage up to $1 million per occurrence and $2 million in the
aggregate and is supplemented by an umbrella policy that provides a further $4 million of coverage;
however, our insurance policy excludes pollution coverage and we do not carry a separate hazardous
materials policy. In addition, we could be required to incur significant costs to comply with
environmental laws and regulations in the future. Finally, current or future environmental laws and
regulations may impair our research, development or production efforts.
When we purchased the facilities located in Danbury, Connecticut in 2001, there was a soil
cleanup plan in process. As part of the purchase, we obtained an indemnification from the seller
related to the remediation of the soil for all known environmental conditions that existed at the
time the seller acquired the property. The seller is, in turn, indemnified for these known
environmental conditions by the previous owner. We also received an indemnification from the seller
for environmental conditions created during its ownership of the property and for environmental
problems unknown at the time that the seller acquired the property. These additional indemnities
are limited to the purchase price that we paid for the Danbury facilities.
During the construction of our expanded manufacturing facility, we completed the final stages
of the soil cleanup plan in the third quarter of 2008, at a cost of approximately $2.25 million. We
have reached an agreement
with the party responsible for their contribution to past clean-up costs and were reimbursed
$1.625 million in July 2010. The responsible party has agreed to pay for or indemnify us for any
future costs and expenses directly related to the final closure of the environmental remediation.
If we are unable to collect these future costs and expenses, if any, from the responsible party,
our business and results of operations may be harmed.
If we fail to enter into collaborations with third parties, we would be required to establish our
own sales, marketing and distribution capabilities, which could impact the commercialization of our
products and harm our business.
Our products are intended to be used by a large number of healthcare professionals who will
require substantial education and support. For example, a broad base of physicians, including
primary care physicians and endocrinologists, treat patients with diabetes. A large sales force
will be required in order to educate these physicians about the benefits and advantages of AFREZZA
and to provide adequate support for them. Therefore, we plan to enter into collaborations with one
or more pharmaceutical companies to market, distribute and sell AFREZZA, if it is approved. If we
fail to enter into collaborations, we would be required to establish our own direct sales,
marketing and distribution capabilities. Establishing these capabilities can be time-consuming and
expensive and would delay our ability to commercialize AFREZZA. Because we lack experience in
selling pharmaceutical products to the diabetes market, we would be at a disadvantage compared to
our potential competitors, all of whom have substantially more resources and experience than we do.
For example, several other companies selling products to treat diabetes have existing sales forces
in excess of 1,500 sales representatives. We, acting alone, would not initially be able to field a
sales force as large as our competitors or provide the same degree of marketing support. Also, we
would not be able to match our competitors spending levels for pre-launch marketing preparation,
including medical education. We cannot assure you that we will succeed in entering into acceptable
collaborations, that any such collaboration will be successful or, if not, that we will
successfully develop our own sales, marketing and distribution capabilities.
If any product that we may develop does not become widely accepted by physicians, patients,
third-party payers and the healthcare community, we may be unable to generate significant revenue,
if any.
AFREZZA and our other product candidates are new and unproven. Even if any of our product
candidates obtain regulatory approval, they may not gain market acceptance among physicians,
patients, third-party payers and the healthcare community. Failure to achieve market acceptance
would limit our ability to generate revenue and would adversely affect our results of operations.
The degree of market acceptance of AFREZZA and our other product candidates will depend on
many factors, including the:
|
|
|
claims for which FDA approval can be obtained, including superiority claims; |
|
|
|
|
perceived advantages and disadvantages of competitive products; |
|
|
|
|
willingness of the healthcare community and patients to adopt new technologies; |
|
|
|
|
ability to manufacture the product in sufficient quantities with acceptable quality and cost; |
|
|
|
|
perception of patients and the healthcare community, including third-party payers, regarding
the safety, efficacy and benefits compared to competing products or therapies; |
|
|
|
|
convenience and ease of administration relative to existing treatment methods; |
|
|
|
|
pricing and reimbursement relative to other treatment therapeutics and methods; and |
|
|
|
|
marketing and distribution support. |
Because of these and other factors, any product that we may develop may not gain market acceptance,
which would materially harm our business, financial condition and results of operations.
If third-party payers do not reimburse consumers for our products, our products might not be used
or purchased, which would adversely affect our revenues.
Our future revenues and potential for profitability may be affected by the continuing efforts
of governments and third-party payers to contain or reduce the costs of healthcare through various
means. For example, in certain foreign markets the pricing of prescription pharmaceuticals is
subject to governmental control. In the United States, there has been, and we expect that there
will continue to be, a number of federal and state proposals to implement similar governmental
controls. We cannot be certain what legislative proposals will be adopted or what actions federal,
state or private payers for healthcare goods and services may take in response to any drug pricing
reform proposals or legislation. Such reforms may make it difficult to complete the development and
testing of AFREZZA and our other product candidates, and therefore may limit our ability to
generate revenues from sales of our product candidates and achieve profitability. Further, to the
extent that such reforms have a material adverse effect on the business, financial condition and
profitability of other companies that are prospective collaborators for some of our product
candidates, our ability to commercialize our product candidates under development may be adversely
affected.
In the United States and elsewhere, sales of prescription pharmaceuticals still depend in
large part on the availability of reimbursement to the consumer from third-party payers, such as
governmental and private insurance plans. Third-party payers are increasingly challenging the
prices charged for medical products and services. In addition, because each third-party payer
individually approves reimbursement, obtaining these approvals is a time-consuming and costly
process. We would be required to provide scientific and clinical support for the use of any product
to each third-party payer separately with no assurance that approval would be obtained. This
process could delay the market acceptance of any product and could have a negative effect on our
future revenues and operating results. Even if we succeed in bringing one or more products to
market, we cannot be certain that any such products would be considered cost-effective or that
reimbursement to the consumer would be available, in which case our business and results of
operations would be harmed and the market price of our common stock could decline.
If product liability claims are brought against us, we may incur significant liabilities and suffer
damage to our reputation.
The testing, manufacturing, marketing and sale of AFREZZA and our other product candidates
expose us to potential product liability claims. A product liability claim may result in
substantial judgments as well as consume significant financial and management resources and result
in adverse publicity, decreased demand for a product, injury to our reputation, withdrawal of
clinical trial volunteers and loss of revenues. We currently carry worldwide liability insurance in
the amount of $10 million. We believe these limits are reasonable to cover us from potential
damages arising from current and previous clinical trials of AFREZZA. In addition, we carry local
policies per trial in each country in which we conduct clinical trials that require us to carry
coverage based on local statutory requirements. We intend to obtain product liability coverage for
commercial sales in the future if AFREZZA is approved. However, we may not be able to obtain
insurance coverage that will be adequate to satisfy any liability that may arise, and because
insurance coverage in our industry can be very expensive and difficult to obtain, we cannot assure
you that we will be able to obtain sufficient coverage at an acceptable cost, if at all. If losses
from such claims exceed our liability insurance coverage, we may ourselves incur substantial
liabilities. If we are required to pay a product liability claim our business and results of
operations would be harmed and the market price of our common stock may decline.
If we lose any key employees or scientific advisors, our operations and our ability to execute our
business strategy could be materially harmed.
In order to commercialize our product candidates successfully, we will be required to expand
our work force, particularly in the areas of manufacturing, clinical trials management, regulatory
affairs, business development, and sales and marketing. These activities will require the addition
of new personnel, including management, and the development of additional expertise by existing
personnel. We face intense competition for qualified employees among companies in the biotechnology
and biopharmaceutical industries. Our success depends
upon our ability to attract, retain and motivate highly skilled employees. We may be unable to
attract and retain these individuals on acceptable terms, if at all.
The loss of the services of any principal member of our management and scientific staff could
significantly delay or prevent the achievement of our scientific and business objectives. All of
our employees are at will and we currently do not have employment agreements with any of the
principal members of our management or scientific staff, and we do not have key person life
insurance to cover the loss of any of these individuals. Replacing key employees may be difficult
and time-consuming because of the limited number of individuals in our industry with the skills and
experience required to develop, gain regulatory approval of and commercialize our product
candidates successfully.
We have relationships with scientific advisors at academic and other institutions to conduct
research or assist us in formulating our research, development or clinical strategy. These
scientific advisors are not our employees and may have commitments to, and other obligations with,
other entities that may limit their availability to us. We have limited control over the activities
of these scientific advisors and can generally expect these individuals to devote only limited time
to our activities. Failure of any of these persons to devote sufficient time and resources to our
programs could harm our business. In addition, these advisors are not prohibited from, and may have
arrangements with, other companies to assist those companies in developing technologies that may
compete with our product candidates.
If our Chairman and Chief Executive Officer is unable to devote sufficient time and attention to
our business, our operations and our ability to execute our business strategy could be materially
harmed.
Alfred Mann, our Chairman and Chief Executive Officer, is involved in many other business and
charitable activities. As a result, the time and attention Mr. Mann devotes to the operation of our
business varies, and he may not expend the same time or focus on our activities as other, similarly
situated chief executive officers. If Mr. Mann is unable to devote the time and attention necessary
to running our business, we may not be able to execute our business strategy and our business could
be materially harmed.
If our internal controls over financial reporting are not considered effective, our business and
stock price could be adversely affected.
Section 404 of the Sarbanes-Oxley Act of 2002 requires us to evaluate the effectiveness of our
internal controls over financial reporting as of the end of each fiscal year, and to include a
management report assessing the effectiveness of our internal controls over financial reporting in
our annual report on Form 10-K for that fiscal year. Section 404 also requires our independent
registered public accounting firm to attest to, and report on, our internal controls over financial
reporting.
Our management, including our Chief Executive Officer and Chief Financial Officer, does not
expect that our internal controls over financial reporting will prevent all errors and all fraud. A
control system, no matter how well designed and operated, can provide only reasonable, not
absolute, assurance that the control systems objectives will be met. Further, the design of a
control system must reflect the fact that there are resource constraints, and the benefits of
controls must be considered relative to their costs. Because of the inherent limitations in all
control systems, no evaluation of controls can provide absolute assurance that all control issues
and instances of fraud involving a company have been, or will be, detected. The design of any
system of controls is based in part on certain assumptions about the likelihood of future events,
and we cannot assure you that any design will succeed in achieving its stated goals under all
potential future conditions. Over time, controls may become inadequate because of changes in
conditions or deterioration in the degree of compliance with policies or procedures. Because of the
inherent limitations in a cost-effective control system, misstatements due to error or fraud may
occur and not be detected. We cannot assure you that we or our independent registered public
accounting firm will not identify a material weakness in our internal controls in the future. A
material weakness in our internal controls over financial reporting would require management and
our independent registered public accounting firm to evaluate our internal controls as ineffective.
If our internal controls over financial reporting are not considered effective, we may experience a
loss of public confidence, which could have an adverse effect on our business and on the market
price of our common stock.
RISKS RELATED TO REGULATORY APPROVALS
Our product candidates must undergo rigorous nonclinical and clinical testing and we must obtain
regulatory approvals, which could be costly and time-consuming and subject us to unanticipated
delays or prevent us from marketing any products.
Our research and development activities, as well as the manufacturing and marketing of our
product candidates, including AFREZZA, are subject to regulation, including regulation for safety,
efficacy and quality, by the FDA in the United States and comparable authorities in other
countries. FDA regulations and the regulations of comparable foreign regulatory authorities are
wide-ranging and govern, among other things:
|
|
|
product design, development, manufacture and testing; |
|
|
|
|
product labeling; |
|
|
|
|
product storage and shipping; |
|
|
|
|
pre-market clearance or approval; |
|
|
|
|
advertising and promotion; and |
|
|
|
|
product sales and distribution. |
Clinical testing can be costly and take many years, and the outcome is uncertain and
susceptible to varying interpretations. We cannot be certain if or when the FDA might request
additional studies, under what conditions such studies might be requested, or what the size or
length of any such studies might be. The clinical trials of our product candidates may not be
completed on schedule, the FDA or foreign regulatory agencies may order us to stop or modify our
research, or these agencies may not ultimately approve any of our product candidates for commercial
sale. The data collected from our clinical trials may not be sufficient to support regulatory
approval of our various product candidates, including AFREZZA. Even if we believe the data
collected from our clinical trials are sufficient, the FDA has substantial discretion in the
approval process and may disagree with our interpretation of the data. Our failure to adequately
demonstrate the safety and efficacy of any of our product candidates would delay or prevent
regulatory approval of our product candidates, which could prevent us from achieving profitability.
The requirements governing the conduct of clinical trials and manufacturing and marketing of
our product candidates, including AFREZZA, outside the United States vary widely from country to
country. Foreign approvals may take longer to obtain than FDA approvals and can require, among
other things, additional testing and different clinical trial designs. Foreign regulatory approval
processes include essentially all of the risks associated with the FDA approval processes. Some of
those agencies also must approve prices of the products. Approval of a product by the FDA does not
ensure approval of the same product by the health authorities of other countries. In addition,
changes in regulatory policy in the United States or in foreign countries for product approval
during the period of product development and regulatory agency review of each submitted new
application may cause delays or rejections.
The process of obtaining FDA and other required regulatory approvals, including foreign
approvals, is expensive, often takes many years and can vary substantially based upon the type,
complexity and novelty of the products involved. We are not aware of any precedent for the
successful commercialization of products based on our technology. In January 2006, the FDA approved
the first pulmonary insulin product, Exubera. This approval has had an impact on and,
notwithstanding the voluntary withdrawal of the product from the market by its manufacturer, could
still impact the development and registration of AFREZZA in different ways. For example, Exubera
may be used as a reference for safety and efficacy evaluations of AFREZZA, and the approval
standards set for Exubera may be applied to other products that follow, including AFREZZA.
In March 2009, we submitted an NDA for AFREZZA. The FDA has advised us that it will regulate
AFREZZA as a combination product because of the complex nature of the system that includes the
combination
of a new drug (AFREZZA) and a new medical device (the AFREZZA inhaler used to administer the
insulin). The FDAs review of our NDA for AFREZZA involves several separate review groups of the
FDA including: (1) the Metabolic and Endocrine Drug Products Division; (2) the Pulmonary Drug
Products Division; and (3) the Center for Devices and Radiological Health, which reviews medical
devices. The Metabolic and Endocrine Drug Products Division is the lead group and obtains
consulting reviews from the other two FDA groups. We can make no assurances at this time about what
impact FDA review by multiple groups will have on the approvability of our product.
In March 2010, we received a Complete Response letter regarding this NDA from the FDA. A
Complete Response letter is issued by the FDAs Center for Drug Evaluation and Research when the
review of a submitted file is completed and questions remain that preclude the approval of the NDA
in its current form. In July 2010, the FDA accepted our reply to the Complete Response letter and
set a target action date of December 29, 2010. There can be no assurance that the FDA will find our
proposed approach for addressing its questions acceptable. The FDA could also request that we
conduct additional clinical trials to provide sufficient data for approval of the NDA. There can be
no assurance that we will obtain approval of the NDA in a timely manner or at all.
Also, questions that have been raised about the safety of marketed drugs generally, including
pertaining to the lack of adequate labeling, may result in increased cautiousness by the FDA in
reviewing new drugs based on safety, efficacy, or other regulatory considerations and may result in
significant delays in obtaining regulatory approvals. Such regulatory considerations may also
result in the imposition of more restrictive drug labeling or marketing requirements as conditions
of approval, which may significantly affect the marketability of our drug products. FDA review of
AFREZZA as a combination product may lengthen the product development and regulatory approval
process, increase our development costs and delay or prevent the commercialization of AFREZZA.
We are developing AFREZZA as a new treatment for diabetes utilizing unique, proprietary
components. As a combination product, any changes to either the AFREZZA inhaler, or AFREZZA,
including new suppliers, could possibly result in FDA requirements to repeat certain clinical
studies. For example, we plan to launch AFREZZA with our next-generation inhaler rather than the
device that was used in pivotal clinical studies, and in our July 2010 reply to the FDAs Complete
Response letter, we submitted information on the comparability of our next-generation inhaler to
the device that was used in pivotal clinical studies. As a result of our change to our
next-generation inhaler, the FDA could yet require us to undertake additional clinical trials and
other studies, which could significantly delay the development and commercialization of AFREZZA.
Our product candidates that are currently in development for the treatment of cancer also face
similar obstacles and costs.
We also must obtain final approval from the FDA for the trade name of our product. In
September 2009, we proposed AFREZZA as a trade name, which the FDA found conditionally acceptable
in December 2009.
We have only limited experience in filing and pursuing applications necessary to gain regulatory
approvals, which may impede our ability to obtain timely approvals from the FDA or foreign
regulatory agencies, if at all.
We will not be able to commercialize AFREZZA or any other product candidates until we have
obtained regulatory approval. Until we prepared and submitted our NDA for AFREZZA, we had no
experience as a company in late-stage regulatory filings, such as preparing and submitting NDAs,
which may place us at risk of delays, overspending and human resources inefficiencies. Any delay in
obtaining, or inability to obtain, regulatory approval could harm our business.
If we do not comply with regulatory requirements at any stage, whether before or after marketing
approval is obtained, we may be subject to criminal prosecution, fined or forced to remove a
product from the market or experience other adverse consequences, including restrictions or delays
in obtaining regulatory marketing approval.
Even if we comply with regulatory requirements, we may not be able to obtain the labeling
claims necessary or desirable for product promotion. We may also be required to undertake
post-marketing trials. In addition, if we or other parties identify adverse effects after any of
our products are on the market, or if manufacturing problems occur, regulatory approval may be
withdrawn and a reformulation of our products,
additional clinical trials, changes in labeling of, or indications of use for, our products
and/or additional marketing applications may be required. If we encounter any of the foregoing
problems, our business and results of operations will be harmed and the market price of our common
stock may decline.
Even if we obtain regulatory approval for our product candidates, such approval may be limited and
we will be subject to stringent, ongoing government regulation.
Even if regulatory authorities approve any of our product candidates, they could approve less
than the full scope of uses or labeling that we seek or otherwise require special warnings or other
restrictions on use or marketing or could require potentially costly post-marketing follow-up
clinical trials. Regulatory authorities may limit the segments of the diabetes population to which
we or others may market AFREZZA or limit the target population for our other product candidates.
Based on currently available clinical studies, we believe that AFREZZA may have certain advantages
over currently approved insulin products including its approximation of the natural early insulin
secretion normally seen in healthy individuals following the beginning of a meal. Nonetheless,
there are no assurances that these or any other advantages of AFREZZA will be agreed to by the FDA
or otherwise included in product labeling or advertising and, as a result, AFREZZA may not have our
expected competitive advantages when compared to other insulin products.
The manufacture, marketing and sale of any of our product candidates will be subject to
stringent and ongoing government regulation. The FDA may also withdraw product approvals if
problems concerning safety or efficacy of a product occurs following approval. We cannot be sure
that FDA and United States Congressional initiatives pertaining to ensuring the safety of marketed
drugs or other developments pertaining to the pharmaceutical industry will not adversely affect our
operations.
We also are required to register our establishments and list our products with the FDA and
certain state agencies. We and any third-party manufacturers or suppliers must continually adhere
to federal regulations setting forth requirements, known as cGMP (for drugs) and QSR (for medical
devices), and their foreign equivalents, which are enforced by the FDA and other national
regulatory bodies through their facilities inspection programs. If our facilities, or the
facilities of our manufacturers or suppliers, cannot pass a preapproval plant inspection, the FDA
will not approve the marketing of our product candidates. In complying with cGMP and foreign
regulatory requirements, we and any of our potential third-party manufacturers or suppliers will be
obligated to expend time, money and effort in production, record-keeping and quality control to
ensure that our products meet applicable specifications and other requirements. QSR requirements
also impose extensive testing, control and documentation requirements. State regulatory agencies
and the regulatory agencies of other countries have similar requirements. In addition, we will be
required to comply with regulatory requirements of the FDA, state regulatory agencies and the
regulatory agencies of other countries concerning the reporting of adverse events and device
malfunctions, corrections and removals (e.g., recalls), promotion and advertising and general
prohibitions against the manufacture and distribution of adulterated and misbranded devices.
Failure to comply with these regulatory requirements could result in civil fines, product seizures,
injunctions and/or criminal prosecution of responsible individuals and us. Any such actions would
have a material adverse effect on our business and results of operations.
Our insulin supplier does not yet supply human recombinant insulin for an FDA-approved product.
Our insulin supplier for purposes of the AFREZZA NDA sells its product outside of the United
States. The FDA has inspected this supplier and found it to be acceptable. If we were required to
find a new or additional supplier of insulin, we would be required to evaluate the new suppliers
ability to provide insulin that meets our specifications and quality requirements, which would
require significant time and expense and could delay the manufacturing and future commercialization
of AFREZZA. We also depend on suppliers for other materials that comprise AFREZZA, including our
AFREZZA inhaler and cartridges. Each device supplier must comply with relevant regulatory
requirements including QSR and is subject to inspection by the FDA. There can be no assurance, in
the conduct of an inspection of any of our suppliers, that the agency would find that the supplier
substantially complies with the QSR or cGMP requirements, where applicable. If we or any potential
third-party manufacturer or supplier fails to comply with these requirements or comparable
requirements in foreign countries, regulatory authorities may subject us to regulatory action,
including criminal prosecutions, fines and suspension of the manufacture of our products.
Reports of side effects or safety concerns in related technology fields or in other companies
clinical trials could delay or prevent us from obtaining regulatory approval or negatively impact
public perception of our product candidates.
At present, there are a number of clinical trials being conducted by us and other
pharmaceutical companies involving insulin delivery systems. If we discover that AFREZZA is
associated with a significantly increased frequency of adverse events, or if other pharmaceutical
companies announce that they observed frequent adverse events in their trials involving the
pulmonary delivery of insulin, we could encounter delays in the timing of our clinical trials or
difficulties in obtaining approval of AFREZZA. As well, the public perception of AFREZZA might be
adversely affected, which could harm our business and results of operations and cause the market
price of our common stock to decline, even if the concern relates to another companys products or
product candidates.
There are also a number of clinical trials being conducted by other pharmaceutical companies
involving compounds similar to, or competitive with, our other product candidates. Adverse results
reported by these other companies in their clinical trials could delay or prevent us from obtaining
regulatory approval or negatively impact public perception of our product candidates, which could
harm our business and results of operations and cause the market price of our common stock to
decline.
RISKS RELATED TO INTELLECTUAL PROPERTY
If we are unable to protect our proprietary rights, we may not be able to compete effectively, or
operate profitably.
Our commercial success depends, in large part, on our ability to obtain and maintain
intellectual property protection for our technology. Our ability to do so will depend on, among
other things, complex legal and factual questions, and it should be noted that the standards
regarding intellectual property rights in our fields are still evolving. We attempt to protect our
proprietary technology through a combination of patents, trade secrets and confidentiality
agreements. We own a number of domestic and international patents, have a number of domestic and
international patent applications pending and have licenses to additional patents. We cannot assure
you that our patents and licenses will successfully preclude others from using our technologies,
and we could incur substantial costs in seeking enforcement of our proprietary rights against
infringement. Even if issued, the patents may not give us an advantage over competitors with
similar alternative technologies.
Moreover, the issuance of a patent is not conclusive as to its validity or enforceability and
it is uncertain how much protection, if any, will be afforded by our patents. A third party may
challenge the validity or enforceability of a patent after its issuance by various proceedings such
as oppositions in foreign jurisdictions or re-examinations in the United States. If we attempt to
enforce our patents, they may be challenged in court where they could be held invalid,
unenforceable, or have their breadth narrowed to an extent that would destroy their value.
We also rely on unpatented technology, trade secrets, know-how and confidentiality agreements.
We require our officers, employees, consultants and advisors to execute proprietary information and
invention and assignment agreements upon commencement of their relationships with us. We also
execute confidentiality agreements with outside collaborators. There can be no assurance, however,
that these agreements will provide meaningful protection for our inventions, trade secrets,
know-how or other proprietary information in the event of unauthorized use or disclosure of such
information. If any trade secret, know-how or other technology not protected by a patent were to be
disclosed to or independently developed by a competitor, our business, results of operations and
financial condition could be adversely affected.
If we become involved in lawsuits to protect or enforce our patents or the patents of our
collaborators or licensors, we would be required to devote substantial time and resources to
prosecute or defend such proceedings.
Competitors may infringe our patents or the patents of our collaborators or licensors. To
counter infringement or unauthorized use, we may be required to file infringement claims, which can
be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide
that a patent of ours is not valid or is unenforceable, or may refuse to stop the other party from
using the technology at issue on the grounds that our patents do not cover its technology. A court
may also decide to award us a royalty from an infringing party instead of issuing an injunction
against the infringing activity. An adverse determination of any litigation or defense
proceedings could put one or more of our patents at risk of being invalidated or interpreted
narrowly and could put our patent applications at risk of not issuing.
Interference proceedings brought by the U.S. Patent and Trademark Office may be necessary to
determine the priority of inventions with respect to our patent applications or those of our
collaborators or licensors. Litigation or interference proceedings may fail and, even if
successful, may result in substantial costs and be a distraction to our management. We may not be
able, alone or with our collaborators and licensors, to prevent misappropriation of our proprietary
rights, particularly in countries where the laws may not protect such rights as fully as in the
United States. We may not prevail in any litigation or interference proceeding in which we are
involved. Even if we do prevail, these proceedings can be very expensive and distract our
management.
Furthermore, because of the substantial amount of discovery required in connection with
intellectual property litigation, there is a risk that some of our confidential information could
be compromised by disclosure during this type of litigation. In addition, during the course of this
kind of litigation, there could be public announcements of the results of hearings, motions or
other interim proceedings or developments. If securities analysts or investors perceive these
results to be negative, the market price of our common stock may decline.
If our technologies conflict with the proprietary rights of others, we may incur substantial costs
as a result of litigation or other proceedings and we could face substantial monetary damages and
be precluded from commercializing our products, which would materially harm our business.
Over the past three decades the number of patents issued to biotechnology companies has
expanded dramatically. As a result it is not always clear to industry participants, including us,
which patents cover the multitude of biotechnology product types. Ultimately, the courts must
determine the scope of coverage afforded by a patent and the courts do not always arrive at uniform
conclusions.
A patent owner may claim that we are making, using, selling or offering for sale an invention
covered by the owners patents and may go to court to stop us from engaging in such activities.
Such litigation is not uncommon in our industry.
Patent lawsuits can be expensive and would consume time and other resources. There is a risk
that a court would decide that we are infringing a third partys patents and would order us to stop
the activities covered by the patents, including the commercialization of our products. In
addition, there is a risk that we would have to pay the other party damages for having violated the
other partys patents (which damages may be increased, as well as attorneys fees ordered paid, if
infringement is found to be willful), or that we will be required to obtain a license from the
other party in order to continue to commercialize the affected products, or to design our products
in a manner that does not infringe a valid patent. We may not prevail in any legal action, and a
required license under the patent may not be available on acceptable terms or at all, requiring
cessation of activities that were found to infringe a valid patent. We also may not be able to
develop a non-infringing product design on commercially reasonable terms, or at all.
Moreover, certain components of AFREZZA and/or our cancer vaccines may be manufactured outside
the United States and imported into the United States. As such, third parties could file complaints
under 19 U.S.C. Section 337(a)(1)(B), or a 337 action, with the International Trade Commission, or
the ITC. A 337 action can be expensive and would consume time and other resources. There is a risk
that the ITC would decide that we are infringing a third partys patents and either enjoin us from
importing the infringing products or parts thereof into the United States or set a bond in an
amount that the ITC considers would offset our competitive advantage from the continued importation
during the statutory review period. The bond could be up to 100% of the value of the patented
products. We may not prevail in any legal action, and a required license under the patent may not
be available on acceptable terms, or at all, resulting in a permanent injunction preventing any
further importation of the infringing products or parts thereof into the United States. We also may
not be able to develop a non-infringing product design on commercially reasonable terms, or at all.
Although we own a number of domestic and foreign patents and patent applications relating to
AFREZZA and cancer vaccine products under development, we have identified certain third-party
patents having claims relating to pulmonary insulin delivery that may trigger an allegation of
infringement upon the commercial
manufacture and sale of AFREZZA as well as third-party patents disclosing methods of use and
compositions of matter related to cancer vaccines that also may trigger an allegation of
infringement upon the commercial manufacture and sale of our cancer immunotherapy. If a court were
to determine that our insulin products or cancer therapies were infringing any of these patent
rights, we would have to establish with the court that these patents were invalid or unenforceable
in order to avoid legal liability for infringement of these patents. However, proving patent
invalidity or unenforceability can be difficult because issued patents are presumed valid.
Therefore, in the event that we are unable to prevail in an infringement or invalidity action we
will have to either acquire the third-party patents outright or seek a royalty-bearing license.
Royalty-bearing licenses effectively increase production costs and therefore may materially affect
product profitability. Furthermore, should the patent holder refuse to either assign or license us
the infringed patents, it may be necessary to cease manufacturing the product entirely and/or
design around the patents, if possible. In either event, our business would be harmed and our
profitability could be materially adversely impacted.
Furthermore, because of the substantial amount of discovery required in connection with
intellectual property litigation, there is a risk that some of our confidential information could
be compromised by disclosure during this type of litigation. In addition, during the course of this
kind of litigation, there could be public announcements of the results of hearings, motions or
other interim proceedings or developments. If securities analysts or investors perceive these
results to be negative, the market price of our common stock may decline.
In addition, patent litigation may divert the attention of key personnel and we may not have
sufficient resources to bring these actions to a successful conclusion. At the same time, some of
our competitors may be able to sustain the costs of complex patent litigation more effectively than
we can because they have substantially greater resources. An adverse determination in a judicial or
administrative proceeding or failure to obtain necessary licenses could prevent us from
manufacturing and selling our products or result in substantial monetary damages, which would
adversely affect our business and results of operations and cause the market price of our common
stock to decline.
We may not obtain trademark registrations for our potential trade names.
We have not selected trade names for some of our product candidates; therefore, we have not
filed trademark registrations for our potential trade names for our product candidates in all
jurisdictions, nor can we assure that we will be granted registration of those potential trade
names for which we have filed. Although we intend to defend any opposition to our trademark
registrations, no assurance can be given that any of our trademarks will be registered in the
United States or elsewhere or that the use of any of our trademarks will confer a competitive
advantage in the marketplace. Furthermore, even if we are successful in our trademark
registrations, the FDA has its own process for drug nomenclature and its own views concerning
appropriate proprietary names. It also has the power, even after granting market approval, to
request a company to reconsider the name for a product because of evidence of confusion in the
marketplace. We cannot assure you that the FDA or any other regulatory authority will approve of
any of our trademarks or will not request reconsideration of one of our trademarks at some time in
the future.
RISKS RELATED TO OUR COMMON STOCK
Our stock price is volatile.
The stock market, particularly in recent years, has experienced significant volatility
particularly with respect to pharmaceutical and biotechnology stocks, and this trend may continue.
The volatility of pharmaceutical and biotechnology stocks often does not relate to the operating
performance of the companies represented by the stock. Our business and the market price of our
common stock may be influenced by a large variety of factors, including:
|
|
|
the progress and results of our clinical trials; |
|
|
|
|
general economic, political or stock market conditions; |
|
|
|
legislative developments; |
|
|
|
|
announcements by us or our competitors concerning clinical trial
results, acquisitions, strategic alliances, technological innovations,
newly approved commercial products, product discontinuations, or other
developments; |
|
|
|
|
the availability of critical materials used in developing and
manufacturing AFREZZA or other product candidates; |
|
|
|
|
developments or disputes concerning our patents or proprietary rights; |
|
|
|
|
the expense and time associated with, and the extent of our ultimate success in, securing
regulatory approvals; |
|
|
|
|
announcements by us concerning our financial condition or operating performance; |
|
|
|
|
changes in securities analysts estimates of our financial condition or operating performance; |
|
|
|
|
general market conditions and fluctuations for emerging growth and pharmaceutical market
sectors; |
|
|
|
|
the issuance and sale of our common stock pursuant to the Seaside purchase agreement and the
Mann purchase agreement over the terms of these agreements; |
|
|
|
|
sales of large blocks of our common stock, including sales by our executive officers,
directors and significant stockholders; |
|
|
|
|
the existence of, and the issuance of shares of our common stock pursuant to, the share
lending agreement and the short sales of our common stock effected in connection with the
recently-completed sale of our 5.75% convertible notes due 2015; and |
|
|
|
|
discussion of AFREZZA, our other product candidates, competitors products, or our stock
price by the financial and scientific press, the healthcare community and online investor
communities such as chat rooms. In particular, statements about us and our investigational
products that appear on interactive websites that permit users to generate content
anonymously or under a pseudonym may be difficult to verify and statements attributed to
company officials may, in fact, have originated elsewhere. |
Any of these risks, as well as other factors, could cause the market price of our common stock to
decline.
If other biotechnology and biopharmaceutical companies or the securities markets in general
encounter problems, the market price of our common stock could be adversely affected.
Public companies in general and companies included on the Nasdaq Global Market in particular
have experienced extreme price and volume fluctuations that have often been unrelated or
disproportionate to the operating performance of those companies. There has been particular
volatility in the market prices of securities of biotechnology and other life sciences companies,
and the market prices of these companies have often fluctuated because of problems or successes in
a given market segment or because investor interest has shifted to other segments. These broad
market and industry factors may cause the market price of our common stock to decline, regardless
of our operating performance. We have no control over this volatility and can only focus our
efforts on our own operations, and even these may be affected due to the state of the capital
markets.
In the past, following periods of large price declines in the public market price of a
companys securities, securities class action litigation has often been initiated against that
company. Litigation of this type could result in substantial costs and diversion of managements
attention and resources, which would hurt our business. Any adverse determination in litigation
could also subject us to significant liabilities.
Our Chairman and Chief Executive Officer and principal stockholder can individually control our
direction and policies, and his interests may be adverse to the interests of our other
stockholders. After his death, his stock will be left to his funding foundations for distribution
to various charities, and we cannot assure you of the manner in which those entities will manage
their holdings.
At July 23, 2010, Mr. Mann beneficially owned approximately 42.1% of our outstanding shares of
capital stock. After giving effect to our recently-completed issuance of 9,000,000 shares of our
common stock, at July 23, 2010 Mr. Mann would have beneficially owned approximately 39.0% of our
outstanding shares of capital stock. We believe members of Mr. Manns family beneficially owned
approximately an additional 1% of our outstanding shares of common stock, although Mr. Mann does
not have voting or investment power with respect to these shares. By virtue of his holdings, Mr.
Mann can and will continue to be able to effectively control the election of the members of our
board of directors, our management and our affairs and prevent corporate transactions such as
mergers, consolidations or the sale of all or substantially all of our assets that may be favorable
from our standpoint or that of our other stockholders or cause a transaction that we or our other
stockholders may view as unfavorable.
Subject to compliance with United States federal and state securities laws, and lockup
restrictions in connection with the recently-completed sale of our 5.75% convertible notes due
2015, Mr. Mann is free to sell the shares of our stock he holds at any time. Upon his death, we
have been advised by Mr. Mann that his shares of our capital stock will be left to the Alfred E.
Mann Medical Research Organization, or AEMMRO, and AEM Foundation for Biomedical Engineering, or
AEMFBE, not-for-profit medical research foundations that serve as funding organizations for Mr.
Manns various charities, including the Alfred Mann Foundation, or AMF, and the Alfred Mann
Institutes at the University of Southern California, the Technion-Israel Institute of Technology,
and Purdue University, and that may serve as funding organizations for any other charities that he
may establish. The AEMMRO is a membership foundation consisting of six members, including Mr. Mann,
his wife, three of his children and Dr. Joseph Schulman, the chief scientist of the AEMFBE. The
AEMFBE is a membership foundation consisting of five members, including Mr. Mann, his wife, and the
same three of his children. Although we understand that the members of AEMMRO and AEMFBE have been
advised of Mr. Manns objectives for these foundations, once Mr. Manns shares of our capital stock
become the property of the foundations, we cannot assure you as to how those shares will be
distributed or how they will be voted.
The future sale of our common stock or the conversion of our senior convertible notes into common
stock could negatively affect our stock price.
As of July 23, 2010, we had approximately 113,760,415 shares of common stock outstanding.
Substantially all of these shares are available for public sale, subject in some cases to volume
and other limitations or delivery of a prospectus. If our common stockholders sell substantial
amounts of common stock in the public market, or the market perceives that such sales may occur,
the market price of our common stock may decline. Likewise the issuance of additional shares of our
common stock upon the conversion of some or all of our senior convertible notes could adversely
affect the trading price of our common stock. In addition, the existence of these notes may
encourage short selling of our common stock by market participants. Furthermore, if we were to
include in a company-initiated registration statement shares held by our stockholders pursuant to
the exercise of their registration rights, the sale of those shares could impair our ability to
raise needed capital by depressing the price at which we could sell our common stock.
On August 10, 2010, we entered into the Seaside purchase agreement and the Mann purchase
agreement, which together provide for the sale and issuance by us of up to 36,400,000 shares of our
common stock over a period of approximately 50 weeks. The future issuance of shares of our common
stock pursuant to these two agreements, or the expectation that these issuances will occur, may
further depress the price of our common stock.
In addition, we will need to raise substantial additional capital in the future to fund our
operations. If we raise additional funds by issuing equity securities or additional convertible
debt, the market price of our common stock may decline and our existing stockholders may experience
significant dilution.
We have reserved for future issuance substantially all of our authorized but unissued shares of
common stock, which may impair our ability to conduct future financing and other transactions.
Our certificate of incorporation currently authorizes us to issue up to 200,000,000 shares of
common stock and 10,000,000 shares of preferred stock. As of June 30, 2010, we had a total of
86,325,779 shares of common stock that were authorized but unissued. In August 2010, we issued
9,000,000 shares pursuant to a share lending agreement with Bank of America, N.A. and we have
reserved substantially all of our remaining authorized but unissued shares for future issuance
pursuant to outstanding equity awards, our equity plans, our 3.75% senior convertible notes due
2013, our 5.75% senior convertible notes due 2015 and our common stock purchase agreements with
Seaside 88 and The Mann Group. As a result, our ability to issue shares of common stock other than
pursuant to existing arrangements will be limited until such time, if ever, that we are able to
amend our certificate of incorporation to further increase our authorized shares of common stock or
shares currently reserved for issuance otherwise become available (for example, due to the
termination of the underlying agreement to issue the shares).
If we are unable to enter into new arrangements to issue shares of our common stock or
securities convertible or exercisable into shares of our common stock, our ability to complete
equity-based financings or other transactions that involve the potential issuance of our common
stock or securities convertible or exercisable into our common stock, will be limited. In lieu of
issuing common stock or securities convertible into our common stock in any future equity financing
transactions, we may need to issue some or all of our authorized but unissued shares of preferred
stock, which would likely have superior rights, preferences and privileges to those of our common
stock, or we may need to issue debt that is not convertible into shares of our common stock, which
may require us to grant security interests in our assets and property and/or impose covenants upon
us that restrict our business. If we are unable to issue additional shares of common stock or
securities convertible or exercisable into our common stock, our ability to enter into strategic
transactions such as acquisitions of companies or technologies, may also be limited. If we propose
to amend our certificate of incorporation to increase our authorized shares of common stock, such a
proposal would require the approval by the holders of a majority of our outstanding shares of
common stock, and we cannot assure you that such a proposal would be adopted. If we are unable to
complete financing, strategic or other transactions due to our inability to issue additional shares
of common stock or securities convertible or exercisable into our common stock, our financial
condition and business prospects may be materially harmed.
Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition
of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our
stockholders to replace or remove our current management.
We are incorporated in Delaware. Certain anti-takeover provisions under Delaware law and in
our certificate of incorporation and amended and restated bylaws, as currently in effect, may make
a change of control of our company more difficult, even if a change in control would be beneficial
to our stockholders. Our anti-takeover provisions include provisions such as a prohibition on
stockholder actions by written consent, the authority of our board of directors to issue preferred
stock without stockholder approval, and supermajority voting requirements for specified actions. In
addition, we are governed by the provisions of Section 203 of the Delaware General Corporation Law,
which generally prohibits stockholders owning 15% or more of our outstanding voting stock from
merging or combining with us in certain circumstances. These provisions may delay or prevent an
acquisition of us, even if the acquisition may be considered beneficial by some of our
stockholders. In addition, they may frustrate or prevent any attempts by our stockholders to
replace or remove our current management by making it more difficult for stockholders to replace
members of our board of directors, which is responsible for appointing the members of our
management.
Because we do not expect to pay dividends in the foreseeable future, you must rely on stock
appreciation for any return on your investment.
We have paid no cash dividends on any of our capital stock to date, and we currently intend to
retain our future earnings, if any, to fund the development and growth of our business. As a
result, we do not expect to pay any cash dividends in the foreseeable future, and payment of cash
dividends, if any, will also depend on our financial condition, results of operations, capital
requirements and other factors and will be at the discretion of our board of directors.
Furthermore, we may in the future become subject to contractual restrictions on, or prohibitions
against, the payment of dividends. Accordingly, the success of your investment in our common stock
will likely depend
entirely upon any future appreciation. There is no guarantee that our common stock will
appreciate or maintain its current price. You could lose the entire value of your investment in our
common stock.
Description of Capital Stock
Our authorized capital stock consists of 200,000,000 shares of common stock, $0.01 par value,
and 10,000,000 shares of preferred stock, $0.01 par value. As of June 30, 2010, there were
113,674,221 shares of common stock outstanding and no shares of preferred stock outstanding.
Voting Rights
Each holder of our common stock is entitled to one vote for each share on all matters
submitted to a vote of our stockholders, including the election of our directors. Under our
certificate of incorporation and bylaws, our stockholders will not have cumulative voting rights.
Accordingly, the holders of a majority of our outstanding shares of common stock entitled to vote
in any election of directors can elect all of the directors standing for election, if they should
so choose.
Dividends
Subject to preferences that may be applicable to any outstanding shares of our preferred
stock, holders of our common stock are entitled to receive ratably any dividends our board of
directors declares out of funds legally available for that purpose.
Liquidation, Dissolution or Winding Up
If we liquidate, dissolve or wind up, the holders of our common stock are entitled to
share ratably in all assets legally available for distribution to our stockholders after the
payment of all of our debts and other liabilities and the satisfaction of any liquidation
preference granted to the holders of any outstanding shares of our preferred stock.
Rights and Preferences
Our common stock has no preemptive, conversion or subscription rights. There are no
redemption or sinking fund provisions applicable to our common stock. The rights, preferences and
privileges of the holders of our common stock are subject to, and may be adversely affected by, the
rights of the holders of any outstanding shares of our of preferred stock, which we may designate
and issue in the future.
Anti-Takeover Effects of Provisions of Delaware Law and Our Certificate of Incorporation and
Bylaws
Delaware takeover statute
We are subject to Section 203 of the Delaware General Corporation Law, or DGCL, which
regulates acquisitions of some Delaware corporations. In general, Section 203 prohibits, with some
exceptions, a publicly held Delaware corporation from engaging in a business combination with an
interested stockholder for a period of three years following the date of the transaction in which
the person became an interested stockholder, unless:
|
|
|
the board of directors of the corporation approved the
business combination or the other transaction in which the
person became an interested stockholder prior to the date
of the business combination or other transaction; |
|
|
|
|
upon consummation of the transaction that resulted in the
person becoming an interested stockholder, the person owned
at least 85% of the voting stock of the corporation
outstanding at the time the transaction commenced,
excluding shares owned by persons who are directors and
also officers of the corporation and shares issued under
employee stock plans under which employee participants do
not have the right to determine confidentially whether
shares held subject to the plan will be tendered in a
tender or exchange offer; or |
|
|
|
on or subsequent to the date the person became an
interested stockholder, the board of directors of the
corporation approved the business combination and the
stockholders of the corporation authorized the business
combination at an annual or special meeting of stockholders
by the affirmative vote of at least
662/3% of the outstanding stock of the
corporation not owned by the interested stockholder. |
Section 203 of the DGCL generally defines a business combination to include any of the
following:
|
|
|
any merger or consolidation involving the corporation and the interested stockholder; |
|
|
|
|
any sale, transfer, pledge or other disposition of 10% or more of the corporations
assets or outstanding stock involving the interested stockholder; |
|
|
|
|
in general, any transaction that results in the issuance or transfer by the
corporation of any of its stock to the interested stockholder; |
|
|
|
|
any transaction involving the corporation that has the effect of increasing the
proportionate share of its stock owned by the interested stockholder; or |
|
|
|
|
the receipt by the interested stockholder of the benefit of any loans, advances,
guarantees, pledges or other financial benefits provided by or through the
corporation. |
In general, Section 203 defines an interested stockholder as any person who, together
with the persons affiliates and associates, owns, or within three years prior to the determination
of interested stockholder status did own, 15% or more of a corporations voting stock.
Section 203 of the DGCL could depress our stock price and delay, discourage or prohibit
transactions not approved in advance by our board of directors, such as takeover attempts that
might otherwise involve the payment to our stockholders of a premium over the market price of our
common stock.
Certificate of incorporation and bylaw provisions
Our certificate of incorporation and bylaws include a number of provisions that may have
the effect of deterring hostile takeovers or delaying or preventing changes in our control or our
management, including, but not limited to the following:
|
|
|
Our board of directors can issue up to 10,000,000 shares of
preferred stock with any rights or preferences, including
the right to approve or not approve an acquisition or other
change in our control. |
|
|
|
|
Our certificate of incorporation and bylaws provide that
all stockholder actions must be effected at a duly called
meeting of holders and not by written consent. |
|
|
|
|
Our bylaws provide that special meetings of the
stockholders may be called only by the Chairman of our
board of directors, by our Chief Executive Officer, by our
board of directors upon a resolution adopted by a majority
of the total number of authorized directors or, under
certain limited circumstances, by the holders of at least
5% of our outstanding voting stock. |
|
|
|
|
Our bylaws provide that stockholders seeking to present
proposals before a meeting of stockholders or to nominate
candidates for election as directors at a meeting of
stockholders must provide timely
|
|
|
|
notice in writing and also
specify requirements as to the form and content of a
stockholders notice. These provisions may delay or
preclude stockholders from bringing matters before a
meeting of our stockholders or from making nominations for
directors at a meeting of stockholders, which could delay
or deter takeover attempts or changes in our management. |
|
|
|
|
Our certificate of incorporation provides that, subject to
the rights of the holders of any outstanding series of
preferred stock, all vacancies, including newly created
directorships, may, except as otherwise required by law, be
filled by the affirmative vote of a majority of directors
then in office, even if less than a quorum. In addition,
our certificate of incorporation provides that our board of
directors may fix the number of directors by resolution. |
|
|
|
|
Our certificate of incorporation does not provide for
cumulative voting for directors. The absence of cumulative
voting may make it more difficult for stockholders who own
an aggregate of less than a majority of our voting stock to
elect any directors to our board of directors. |
These and other provisions contained in our certificate of incorporation and bylaws are
expected to discourage coercive takeover practices and inadequate takeover bids. These provisions
are also designed to encourage persons seeking to acquire control of us to first negotiate with our
board of directors. However, these provisions could delay or discourage transactions involving an
actual or potential change in control of us or our management, including transactions in which our
stockholders might otherwise receive a premium for their shares over market price of our stock and
may limit the ability of stockholders to remove our current management or approve transactions that
our stockholders may deem to be in their best interests and, therefore, could adversely affect the
price of our common stock.
Transfer Agent and Registrar
The transfer agent and registrar for our common stock is BNY Mellon Shareowner Services,
LLC. Its address is 400 South Hope Street, Suite 400, Los Angeles, California 90071.